data_6jtf_residue ############################ # Computer software used # ############################ save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 6jtf _Structure_validation_residue.Date_analyzed 2020-04-10 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.62 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.53 126.1 74.5 Favored Pre-proline 0 N--CA 1.489 1.511 0 C-N-CA 123.453 0.701 . . . . 0.0 110.821 -178.14 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.59 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.806 0 C-N-CA 121.775 1.65 . . . . 0.0 112.97 -175.369 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' THR . . . . . 0.44 ' HA ' HE21 ' A' ' 44' ' ' GLN . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.608 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' GLN . . . . . 0.608 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.61 13.0 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -139.24 155.23 47.92 Favored 'General case' 0 CA--C 1.49 -1.346 0 N-CA-C 109.438 -0.578 . . . . 0.0 109.438 -179.313 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.41 -163.43 35.04 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 118.072 -2.013 . . . . 0.0 113.208 -179.736 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.38 179.97 46.24 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 119.724 -1.227 . . . . 0.0 113.298 -176.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 132.62 35.08 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . 0.266 0.3 OUTLIER -114.64 20.48 15.26 Favored 'General case' 0 C--N 1.317 -0.822 0 O-C-N 117.791 -3.068 . . . . 0.0 114.69 -176.029 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -55.34 -32.2 62.34 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 117.275 -1.77 . . . . 0.0 111.328 174.525 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.15 54.46 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -104.46 15.98 27.04 Favored 'General case' 0 N--CA 1.487 1.383 0 N-CA-C 114.49 1.293 . . . . 0.0 114.49 -176.45 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.01 124.19 22.96 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.484 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.45 16.11 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 2.5 m -84.81 -13.74 11.31 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.753 0 CA-C-N 118.634 0.652 . . . . 0.0 112.657 179.072 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.77 160.55 43.12 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.246 0.93 . . . . 0.0 112.471 -178.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 128.65 29.56 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -145.15 174.91 10.66 Favored 'General case' 0 CA--C 1.518 -0.285 0 CA-C-N 114.765 -1.107 . . . . 0.0 109.705 -175.92 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -135.01 165.06 26.22 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -179.46 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' HIS . . . . . 0.507 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.0 OUTLIER -144.47 154.15 56.27 Favored Pre-proline 0 N--CA 1.483 1.184 0 N-CA-C 106.993 -1.484 . . . . 0.0 106.993 172.714 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.29 3.08 7.97 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 C-N-CA 121.065 1.177 . . . . 0.0 114.61 -173.819 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 145.9 54.6 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 4.3 tt0 -128.62 128.11 43.53 Favored 'General case' 0 N--CA 1.479 1.011 0 O-C-N 124.479 1.112 . . . . 0.0 110.497 179.738 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -104.38 124.79 49.83 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.649 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . 0.782 ' HH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . 0.472 HD13 ' HA ' ' A' ' 86' ' ' LEU . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . 0.49 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 118.59 21.58 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 107' ' ' HIS . . . . . 0.782 ' CE1' ' HH ' ' A' ' 70' ' ' TYR . 1.2 p80 -149.42 170.24 19.02 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.949 0.88 . . . . 0.0 112.773 -176.889 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 108' ' ' CYS . . . . . 0.652 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -168.78 168.43 10.56 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 173.457 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.53 38.21 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -117.04 120.26 4.75 Favored Glycine 0 C--N 1.316 -0.569 0 N-CA-C 105.112 -3.195 . . . . 0.0 105.112 176.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.87 111.31 34.46 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.76 126.17 73.78 Favored Pre-proline 0 N--CA 1.489 1.483 0 C-N-CA 123.322 0.649 . . . . 0.0 110.881 -178.12 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.178 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' THR . . . . . 0.44 ' HA ' HE21 ' A' ' 44' ' ' GLN . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.608 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' GLN . . . . . 0.608 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.44 12.88 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.93 154.89 48.38 Favored 'General case' 0 CA--C 1.49 -1.346 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 -179.235 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.59 -163.4 35.13 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 118.059 -2.02 . . . . 0.0 113.208 -179.847 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.35 179.94 46.2 Favored Glycine 0 N--CA 1.444 -0.774 0 C-N-CA 119.67 -1.252 . . . . 0.0 113.27 -176.916 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.1 35.05 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -108.97 14.24 24.21 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 119.579 -1.95 . . . . 0.0 115.235 -175.545 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.28 -32.2 66.39 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.778 -1.969 . . . . 0.0 111.328 178.741 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.13 54.45 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.2 mp -104.32 15.75 27.62 Favored 'General case' 0 N--CA 1.486 1.371 0 N-CA-C 114.494 1.294 . . . . 0.0 114.494 -176.292 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.1 124.19 23.08 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.329 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.47 16.12 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 2.3 m -84.89 -13.68 11.29 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.781 0 O-C-N 123.766 0.667 . . . . 0.0 112.758 179.132 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.83 160.55 43.09 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.191 0.905 . . . . 0.0 112.471 -179.045 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 129.57 33.62 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' HIS . . . . . 0.455 ' CE1' ' NE2' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -147.89 175.47 10.93 Favored 'General case' 0 N--CA 1.446 -0.625 0 CA-C-N 114.785 -1.098 . . . . 0.0 110.259 -176.62 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' THR . . . . . 0.544 ' C ' ' ND1' ' A' ' 64' ' ' HIS . 28.7 p -134.83 163.2 30.35 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -177.49 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' HIS . . . . . 0.878 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -135.22 147.17 61.18 Favored Pre-proline 0 N--CA 1.492 1.641 0 C-N-CA 123.984 0.914 . . . . 0.0 108.876 177.864 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -79.32 3.08 7.79 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 N-CA-C 114.61 0.966 . . . . 0.0 114.61 178.869 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 144.69 55.67 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 6.9 tt0 -126.49 125.0 41.35 Favored 'General case' 0 CA--C 1.553 1.081 0 O-C-N 124.891 1.37 . . . . 0.0 110.378 -178.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.06 124.79 49.19 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.179 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . 0.897 ' HH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . 0.472 HD13 ' HA ' ' A' ' 86' ' ' LEU . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . 0.49 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 116.53 19.86 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 107' ' ' HIS . . . . . 0.897 ' CE1' ' HH ' ' A' ' 70' ' ' TYR . 0.0 OUTLIER -144.39 164.67 30.15 Favored 'General case' 0 C--N 1.341 0.222 0 N-CA-C 114.273 1.212 . . . . 0.0 114.273 -175.004 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 108' ' ' CYS . . . . . 0.745 ' N ' ' HD1' ' A' ' 107' ' ' HIS . 7.3 p -166.16 168.43 15.35 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 170.626 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 150.93 39.24 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.35 120.15 4.77 Favored Glycine 0 N--CA 1.448 -0.505 0 N-CA-C 104.911 -3.276 . . . . 0.0 104.911 176.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.6 111.31 34.31 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -179.104 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.7 126.18 73.9 Favored Pre-proline 0 N--CA 1.489 1.477 0 C-N-CA 123.359 0.664 . . . . 0.0 110.852 -178.126 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.57 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.778 0 C-N-CA 121.855 1.704 . . . . 0.0 112.97 -175.232 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' THR . . . . . 0.44 ' HA ' HE21 ' A' ' 44' ' ' GLN . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.608 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' GLN . . . . . 0.608 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.49 12.91 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.96 154.88 48.35 Favored 'General case' 0 CA--C 1.491 -1.301 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 -179.187 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.55 -163.4 35.1 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 118.014 -2.041 . . . . 0.0 113.208 -179.88 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.35 179.94 46.2 Favored Glycine 0 N--CA 1.444 -0.774 0 C-N-CA 119.67 -1.252 . . . . 0.0 113.27 -176.916 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.1 35.05 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -108.94 14.17 24.29 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 119.579 -1.95 . . . . 0.0 115.225 -175.501 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.29 -32.2 66.4 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.811 -1.955 . . . . 0.0 111.328 178.783 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.13 54.44 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.3 mp -104.25 15.71 27.75 Favored 'General case' 0 N--CA 1.486 1.351 0 N-CA-C 114.467 1.284 . . . . 0.0 114.467 -176.254 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.18 124.19 23.18 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.274 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.42 16.08 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 2.6 m -85.1 -13.47 11.26 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.829 0 CA-C-N 118.66 0.664 . . . . 0.0 112.707 179.222 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.74 160.55 43.13 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.205 0.911 . . . . 0.0 112.471 -179.195 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 129.64 33.92 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' HIS . . . . . 0.455 ' CE1' ' NE2' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -148.02 175.52 10.93 Favored 'General case' 0 N--CA 1.446 -0.655 0 CA-C-N 114.8 -1.091 . . . . 0.0 110.305 -176.644 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' THR . . . . . 0.547 ' C ' ' ND1' ' A' ' 64' ' ' HIS . 28.7 p -134.85 163.14 30.5 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -177.416 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' HIS . . . . . 0.877 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -135.11 147.06 60.95 Favored Pre-proline 0 N--CA 1.493 1.692 0 C-N-CA 123.985 0.914 . . . . 0.0 108.875 177.891 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -79.25 3.08 7.77 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 N-CA-C 114.61 0.966 . . . . 0.0 114.61 178.826 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 144.74 55.64 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 6.6 tt0 -126.52 124.88 41.04 Favored 'General case' 0 CA--C 1.553 1.096 0 O-C-N 124.936 1.398 . . . . 0.0 110.433 -178.862 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.06 124.79 49.2 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.214 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . 0.898 ' HH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . 0.472 HD13 ' HA ' ' A' ' 86' ' ' LEU . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . 0.49 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 116.41 19.78 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 107' ' ' HIS . . . . . 0.898 ' CE1' ' HH ' ' A' ' 70' ' ' TYR . 0.0 OUTLIER -144.15 164.28 31.14 Favored 'General case' 0 C--N 1.342 0.246 0 N-CA-C 114.291 1.219 . . . . 0.0 114.291 -174.882 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 108' ' ' CYS . . . . . 0.746 ' N ' ' HD1' ' A' ' 107' ' ' HIS . 7.3 p -165.96 168.43 15.73 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 170.501 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.02 39.1 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.6 120.41 4.84 Favored Glycine 0 N--CA 1.448 -0.525 0 N-CA-C 104.938 -3.265 . . . . 0.0 104.938 176.782 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.66 111.31 34.34 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -179.002 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.76 126.17 73.78 Favored Pre-proline 0 N--CA 1.489 1.483 0 C-N-CA 123.322 0.649 . . . . 0.0 110.881 -178.12 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.178 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' THR . . . . . 0.44 ' HA ' HE21 ' A' ' 44' ' ' GLN . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.608 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' GLN . . . . . 0.608 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.44 12.88 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.93 154.89 48.38 Favored 'General case' 0 CA--C 1.49 -1.346 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 -179.235 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.59 -163.4 35.13 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 118.059 -2.02 . . . . 0.0 113.208 -179.847 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.35 179.94 46.2 Favored Glycine 0 N--CA 1.444 -0.774 0 C-N-CA 119.67 -1.252 . . . . 0.0 113.27 -176.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.15 35.05 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -109.05 14.23 24.13 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 119.538 -1.976 . . . . 0.0 115.281 -175.559 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.24 -32.2 66.3 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.773 -1.971 . . . . 0.0 111.328 178.73 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.13 54.45 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.1 mp -104.41 15.88 27.29 Favored 'General case' 0 N--CA 1.487 1.386 0 N-CA-C 114.465 1.283 . . . . 0.0 114.465 -176.273 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.14 124.19 23.13 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.395 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.51 16.15 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 2.1 m -84.96 -13.72 11.26 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.794 0 CA-C-N 118.613 0.642 . . . . 0.0 112.707 179.16 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.74 160.55 43.13 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.166 0.893 . . . . 0.0 112.471 -179.025 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 129.57 33.62 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' HIS . . . . . 0.457 ' CE1' ' NE2' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -147.89 175.4 10.99 Favored 'General case' 0 N--CA 1.447 -0.596 0 CA-C-N 114.785 -1.098 . . . . 0.0 110.256 -176.587 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' THR . . . . . 0.546 ' C ' ' ND1' ' A' ' 64' ' ' HIS . 28.7 p -134.79 163.16 30.42 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -177.495 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' HIS . . . . . 0.878 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -135.19 147.04 60.69 Favored Pre-proline 0 N--CA 1.492 1.671 0 C-N-CA 123.987 0.915 . . . . 0.0 108.842 177.932 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -79.24 3.08 7.77 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 N-CA-C 114.61 0.966 . . . . 0.0 114.61 178.861 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 144.74 55.64 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 6.5 tt0 -126.45 124.88 41.13 Favored 'General case' 0 CA--C 1.553 1.096 0 O-C-N 124.917 1.385 . . . . 0.0 110.428 -178.854 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.09 124.79 49.21 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.157 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . 0.897 ' HH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . 0.472 HD13 ' HA ' ' A' ' 86' ' ' LEU . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . 0.49 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 116.51 19.84 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 107' ' ' HIS . . . . . 0.897 ' CE1' ' HH ' ' A' ' 70' ' ' TYR . 0.0 OUTLIER -144.35 164.57 30.41 Favored 'General case' 0 C--N 1.341 0.2 0 N-CA-C 114.23 1.196 . . . . 0.0 114.23 -174.956 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 108' ' ' CYS . . . . . 0.746 ' N ' ' HD1' ' A' ' 107' ' ' HIS . 7.3 p -166.11 168.43 15.44 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 170.599 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 150.93 39.24 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.35 120.15 4.77 Favored Glycine 0 N--CA 1.448 -0.505 0 N-CA-C 104.911 -3.276 . . . . 0.0 104.911 176.911 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.6 111.31 34.31 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -179.104 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.56 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.66 126.16 74.06 Favored Pre-proline 0 N--CA 1.488 1.469 0 C-N-CA 123.413 0.685 . . . . 0.0 110.925 -178.224 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.56 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.766 0 C-N-CA 121.759 1.639 . . . . 0.0 112.97 -175.215 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' THR . . . . . 0.44 ' HA ' HE21 ' A' ' 44' ' ' GLN . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.608 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' GLN . . . . . 0.608 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 125.24 11.94 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -135.8 152.1 50.75 Favored 'General case' 0 CA--C 1.494 -1.209 0 O-C-N 123.894 0.746 . . . . 0.0 110.059 -178.241 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 163.81 -163.46 35.82 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.502 -2.285 . . . . 0.0 113.208 178.453 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.43 179.98 46.29 Favored Glycine 0 N--CA 1.443 -0.886 0 C-N-CA 119.784 -1.198 . . . . 0.0 113.381 -176.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.28 35.04 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.532 -1.834 . . . . 0.0 107.908 -177.641 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -110.42 15.4 22.22 Favored 'General case' 0 N--CA 1.482 1.168 0 O-C-N 119.602 -1.936 . . . . 0.0 115.515 -175.456 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -56.98 -32.2 65.84 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 117.354 -1.739 . . . . 0.0 111.328 177.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.2 54.51 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.3 mp -104.69 16.06 26.76 Favored 'General case' 0 N--CA 1.486 1.337 0 N-CA-C 114.475 1.287 . . . . 0.0 114.475 -176.289 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.02 124.19 22.98 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.536 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.23 15.95 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 2.4 m -85.05 -13.51 11.27 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.906 0 CA-C-N 118.754 0.706 . . . . 0.0 112.498 179.237 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.48 160.55 43.24 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.402 1.001 . . . . 0.0 112.471 -179.223 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 126.35 21.06 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' HIS . . . . . 0.433 ' CE1' ' CD2' ' A' ' 64' ' ' HIS . 0.0 OUTLIER -139.94 169.29 17.99 Favored 'General case' 0 C--N 1.352 0.702 0 CA-C-N 113.504 -1.68 . . . . 0.0 110.459 -174.069 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -131.98 164.84 25.28 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 177.307 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' HIS . . . . . 0.572 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.0 OUTLIER -143.24 153.95 60.31 Favored Pre-proline 0 N--CA 1.485 1.312 0 N-CA-C 107.184 -1.413 . . . . 0.0 107.184 173.142 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.57 3.08 8.02 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 C-N-CA 120.772 0.981 . . . . 0.0 114.61 -174.869 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 145.15 55.36 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . 0.554 ' OE2' ' CE2' ' A' ' 70' ' ' TYR . 6.0 tt0 -127.92 128.01 44.36 Favored 'General case' 0 N--CA 1.485 1.304 0 O-C-N 124.277 0.985 . . . . 0.0 109.613 179.932 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.97 124.79 49.64 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.127 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . 0.767 ' HH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . 0.472 HD13 ' HA ' ' A' ' 86' ' ' LEU . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . 0.49 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 119.21 22.24 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 107' ' ' HIS . . . . . 0.767 ' CE1' ' HH ' ' A' ' 70' ' ' TYR . 1.5 p80 -150.74 171.43 17.18 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 122.148 0.975 . . . . 0.0 112.529 -177.37 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 108' ' ' CYS . . . . . 0.658 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -169.38 168.43 9.55 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 174.213 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.44 38.35 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.96 120.32 4.77 Favored Glycine 0 N--CA 1.447 -0.608 0 N-CA-C 105.19 -3.164 . . . . 0.0 105.19 176.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.88 111.31 34.46 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.856 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.63 126.28 73.84 Favored Pre-proline 0 N--CA 1.489 1.476 0 C-N-CA 123.354 0.662 . . . . 0.0 110.86 -178.172 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.65 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.801 0 C-N-CA 121.832 1.688 . . . . 0.0 112.97 -175.286 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' THR . . . . . 0.44 ' HA ' HE21 ' A' ' 44' ' ' GLN . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.608 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' GLN . . . . . 0.608 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 125.51 12.15 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -136.69 152.67 50.64 Favored 'General case' 0 CA--C 1.492 -1.258 0 O-C-N 123.741 0.651 . . . . 0.0 109.9 -178.447 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 163.62 -163.43 35.7 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.728 -2.177 . . . . 0.0 113.208 178.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.38 179.97 46.24 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 119.724 -1.227 . . . . 0.0 113.298 -176.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 132.74 35.07 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . 0.263 0.3 OUTLIER -114.71 20.36 15.3 Favored 'General case' 0 N--CA 1.477 0.908 0 O-C-N 117.712 -3.117 . . . . 0.0 114.69 -176.107 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -55.24 -32.2 62.11 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 117.133 -1.827 . . . . 0.0 111.328 174.548 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 -0.15 54.19 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -103.1 14.9 30.76 Favored 'General case' 0 N--CA 1.49 1.565 0 N-CA-C 114.478 1.288 . . . . 0.0 114.478 -176.366 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.44 124.19 23.5 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -177.753 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.79 16.34 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -81.43 -17.27 11.98 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.906 0 O-C-N 125.025 1.453 . . . . 0.0 112.908 178.981 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -154.67 160.55 41.47 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 118.659 0.663 . . . . 0.0 112.471 -176.632 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 131.26 41.5 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -151.13 -179.79 7.62 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.784 -0.644 . . . . 0.0 109.575 -178.404 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -137.62 164.42 28.83 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -175.411 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' HIS . . . . . 0.579 ' CE1' ' CD ' ' A' ' 68' ' ' GLU . 0.0 OUTLIER -141.47 151.93 62.22 Favored Pre-proline 0 N--CA 1.496 1.835 0 N-CA-C 106.959 -1.497 . . . . 0.0 106.959 174.678 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -79.88 3.08 7.89 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 C-N-CA 120.77 0.98 . . . . 0.0 114.61 -176.587 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 147.9 52.31 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . 0.579 ' CD ' ' CE1' ' A' ' 64' ' ' HIS . 14.0 pt-20 -136.06 135.12 39.12 Favored 'General case' 0 N--CA 1.47 0.554 0 N-CA-C 108.909 -0.775 . . . . 0.0 108.909 176.664 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -105.76 124.79 50.13 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 -178.162 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . 0.756 ' HH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . 0.472 HD13 ' HA ' ' A' ' 86' ' ' LEU . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . 0.49 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 119.79 23.05 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 107' ' ' HIS . . . . . 0.756 ' CE1' ' HH ' ' A' ' 70' ' ' TYR . 3.4 p80 -151.82 172.51 16.05 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-O 122.15 0.976 . . . . 0.0 112.223 -177.616 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 108' ' ' CYS . . . . . 0.605 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -170.04 168.43 8.49 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 174.755 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.78 37.78 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -117.98 121.23 5.0 Favored Glycine 0 C--N 1.313 -0.737 0 N-CA-C 104.952 -3.259 . . . . 0.0 104.952 176.712 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -106.09 111.31 34.59 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.607 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 124' ' ' LEU . . . . . 0.412 HD23 ' OE1' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.76 126.17 73.78 Favored Pre-proline 0 N--CA 1.489 1.483 0 C-N-CA 123.322 0.649 . . . . 0.0 110.881 -178.12 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.178 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' THR . . . . . 0.44 ' HA ' HE21 ' A' ' 44' ' ' GLN . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.608 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' GLN . . . . . 0.608 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.46 12.89 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.93 154.93 48.39 Favored 'General case' 0 CA--C 1.491 -1.316 0 N-CA-C 109.571 -0.529 . . . . 0.0 109.571 -179.235 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.55 -163.43 35.12 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 118.07 -2.014 . . . . 0.0 113.208 -179.851 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.38 179.97 46.24 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 119.724 -1.227 . . . . 0.0 113.298 -176.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.15 35.05 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -109.14 14.34 23.96 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 119.504 -1.998 . . . . 0.0 115.235 -175.56 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.24 -32.2 66.3 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.773 -1.971 . . . . 0.0 111.328 178.645 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.1 54.42 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.2 mp -104.3 15.8 27.52 Favored 'General case' 0 N--CA 1.486 1.339 0 N-CA-C 114.497 1.295 . . . . 0.0 114.497 -176.321 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.12 124.19 23.11 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.343 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.48 16.13 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 2.2 m -84.94 -13.64 11.29 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.777 0 CA-C-N 118.631 0.651 . . . . 0.0 112.719 179.124 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.83 160.55 43.09 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.183 0.901 . . . . 0.0 112.471 -179.052 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 129.6 33.75 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' HIS . . . . . 0.456 ' CE1' ' NE2' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -147.97 175.5 10.93 Favored 'General case' 0 N--CA 1.446 -0.655 0 CA-C-N 114.811 -1.086 . . . . 0.0 110.263 -176.649 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' THR . . . . . 0.546 ' C ' ' ND1' ' A' ' 64' ' ' HIS . 28.7 p -134.83 163.15 30.46 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -177.435 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' HIS . . . . . 0.877 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -135.09 147.05 60.92 Favored Pre-proline 0 N--CA 1.493 1.676 0 C-N-CA 123.965 0.906 . . . . 0.0 108.857 177.954 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -79.28 3.08 7.78 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 N-CA-C 114.61 0.966 . . . . 0.0 114.61 178.782 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 144.74 55.64 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 6.7 tt0 -126.52 124.92 41.14 Favored 'General case' 0 CA--C 1.553 1.073 0 O-C-N 124.917 1.385 . . . . 0.0 110.392 -178.869 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.06 124.79 49.19 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.179 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . 0.897 ' HH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . 0.472 HD13 ' HA ' ' A' ' 86' ' ' LEU . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . 0.49 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 116.53 19.86 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 107' ' ' HIS . . . . . 0.897 ' CE1' ' HH ' ' A' ' 70' ' ' TYR . 0.0 OUTLIER -144.43 164.59 30.39 Favored 'General case' 0 C--N 1.341 0.222 0 N-CA-C 114.194 1.183 . . . . 0.0 114.194 -174.946 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 108' ' ' CYS . . . . . 0.746 ' N ' ' HD1' ' A' ' 107' ' ' HIS . 7.3 p -166.11 168.43 15.44 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 170.633 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 150.93 39.24 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.36 120.17 4.77 Favored Glycine 0 N--CA 1.448 -0.543 0 N-CA-C 104.982 -3.247 . . . . 0.0 104.982 176.852 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.6 111.31 34.31 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -179.057 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.56 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.67 126.1 74.18 Favored Pre-proline 0 N--CA 1.489 1.521 0 C-N-CA 123.428 0.691 . . . . 0.0 110.853 -178.135 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.234 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' THR . . . . . 0.44 ' HA ' HE21 ' A' ' 44' ' ' GLN . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.608 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' GLN . . . . . 0.608 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.32 12.78 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.68 154.7 48.62 Favored 'General case' 0 CA--C 1.491 -1.295 0 N-CA-C 109.524 -0.547 . . . . 0.0 109.524 -179.151 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.69 -163.39 35.18 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 118.029 -2.034 . . . . 0.0 113.208 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.34 -179.94 46.27 Favored Glycine 0 N--CA 1.445 -0.703 0 C-N-CA 119.668 -1.254 . . . . 0.0 113.289 -176.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.22 133.29 35.01 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.48 -1.86 . . . . 0.0 107.908 -177.599 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -109.08 14.05 24.2 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 119.618 -1.926 . . . . 0.0 115.383 -175.627 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.18 -32.2 66.2 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.782 -1.967 . . . . 0.0 111.328 178.775 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.19 54.5 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.2 mp -104.59 15.98 26.96 Favored 'General case' 0 N--CA 1.486 1.353 0 N-CA-C 114.488 1.292 . . . . 0.0 114.488 -176.284 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.06 124.19 23.03 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.468 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.54 16.17 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 2.1 m -85.07 -13.58 11.25 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.793 0 N-CA-C 112.816 0.673 . . . . 0.0 112.816 179.223 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.91 160.55 43.06 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.094 0.861 . . . . 0.0 112.471 -179.176 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 128.06 27.25 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -143.66 173.57 11.55 Favored 'General case' 0 CA--C 1.513 -0.471 0 CA-C-N 114.44 -1.255 . . . . 0.0 109.906 -175.516 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -134.3 165.5 24.98 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 179.569 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' HIS . . . . . 0.578 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.0 OUTLIER -145.43 154.39 52.98 Favored Pre-proline 0 N--CA 1.481 1.099 0 N-CA-C 107.255 -1.387 . . . . 0.0 107.255 172.404 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.33 3.08 7.97 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 C-N-CA 120.946 1.097 . . . . 0.0 114.61 -173.161 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 145.02 55.49 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 40.1 tt0 -128.36 128.5 44.64 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 123.766 0.666 . . . . 0.0 109.463 179.311 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.58 124.79 49.45 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.315 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . 0.832 ' HH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . 0.472 HD13 ' HA ' ' A' ' 86' ' ' LEU . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . 0.49 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 118.75 21.72 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 107' ' ' HIS . . . . . 0.832 ' CE1' ' HH ' ' A' ' 70' ' ' TYR . 1.0 OUTLIER -149.16 170.15 19.1 Favored 'General case' 0 CA--C 1.518 -0.252 0 CA-C-O 122.108 0.956 . . . . 0.0 113.213 -176.9 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 108' ' ' CYS . . . . . 0.654 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -168.97 168.43 10.21 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 173.215 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.05 39.04 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.48 119.89 4.67 Favored Glycine 0 N--CA 1.451 -0.357 0 N-CA-C 104.924 -3.27 . . . . 0.0 104.924 176.915 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.33 111.31 34.15 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -179.104 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.76 126.17 73.78 Favored Pre-proline 0 N--CA 1.489 1.483 0 C-N-CA 123.322 0.649 . . . . 0.0 110.881 -178.12 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.178 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' THR . . . . . 0.44 ' HA ' HE21 ' A' ' 44' ' ' GLN . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.608 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' GLN . . . . . 0.608 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 125.59 12.22 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -136.81 152.82 50.72 Favored 'General case' 0 CA--C 1.493 -1.239 0 O-C-N 123.731 0.644 . . . . 0.0 109.904 -178.486 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 163.51 -163.43 35.64 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.685 -2.198 . . . . 0.0 113.208 179.012 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.4 179.94 46.25 Favored Glycine 0 N--CA 1.444 -0.812 0 C-N-CA 119.745 -1.217 . . . . 0.0 113.343 -176.912 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.15 35.05 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.506 -1.847 . . . . 0.0 107.908 -177.646 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -109.06 14.27 24.09 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 119.573 -1.955 . . . . 0.0 115.238 -175.519 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.28 -32.2 66.39 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.778 -1.969 . . . . 0.0 111.328 178.731 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 -0.04 54.29 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -103.75 15.44 28.77 Favored 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 114.438 1.273 . . . . 0.0 114.438 -176.428 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.15 124.19 23.14 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.135 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.61 16.22 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -82.23 -16.41 11.8 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.923 0 O-C-N 124.729 1.268 . . . . 0.0 112.874 179.103 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -154.24 160.55 41.86 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 118.833 0.742 . . . . 0.0 112.471 -177.258 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 128.09 27.37 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -143.84 173.58 11.57 Favored 'General case' 0 CA--C 1.516 -0.347 0 CA-C-N 114.512 -1.222 . . . . 0.0 109.911 -175.468 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -134.3 164.67 26.88 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 179.701 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' HIS . . . . . 0.536 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.0 OUTLIER -143.77 153.54 57.93 Favored Pre-proline 0 N--CA 1.484 1.272 0 N-CA-C 106.906 -1.516 . . . . 0.0 106.906 173.051 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -79.96 3.08 7.9 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 C-N-CA 121.104 1.203 . . . . 0.0 114.61 -174.226 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 143.61 56.24 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . 0.558 ' HG3' HD23 ' A' ' 124' ' ' LEU . 0.1 OUTLIER -120.15 120.81 37.26 Favored 'General case' 0 N--CA 1.506 2.342 0 O-C-N 125.931 2.019 . . . . 0.0 111.397 -178.3 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -102.4 124.79 48.6 Favored 'General case' 0 N--CA 1.498 1.961 0 CA-C-N 120.735 1.607 . . . . 0.0 107.536 175.528 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . 0.746 ' HH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . 0.472 HD13 ' HA ' ' A' ' 86' ' ' LEU . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . 0.49 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . 0.431 ' HB ' ' HB3' ' A' ' 68' ' ' GLU . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 118.89 21.85 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 107' ' ' HIS . . . . . 0.746 ' CE1' ' HH ' ' A' ' 70' ' ' TYR . 1.4 p80 -150.2 170.72 18.3 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 121.961 0.886 . . . . 0.0 112.554 -177.01 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 108' ' ' CYS . . . . . 0.65 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -168.97 168.43 10.21 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 173.904 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.6 38.08 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -117.43 120.76 4.89 Favored Glycine 0 C--N 1.315 -0.629 0 N-CA-C 105.009 -3.236 . . . . 0.0 105.009 176.833 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.97 111.31 34.52 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.793 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 124' ' ' LEU . . . . . 0.558 HD23 ' HG3' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.56 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.82 126.18 73.62 Favored Pre-proline 0 N--CA 1.489 1.484 0 C-N-CA 123.354 0.661 . . . . 0.0 110.825 -178.075 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.171 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' THR . . . . . 0.44 ' HA ' HE21 ' A' ' 44' ' ' GLN . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.608 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' GLN . . . . . 0.608 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.09 12.6 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.11 154.15 49.23 Favored 'General case' 0 CA--C 1.492 -1.281 0 N-CA-C 109.654 -0.498 . . . . 0.0 109.654 -178.96 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.94 -163.4 35.32 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.941 -2.076 . . . . 0.0 113.208 179.714 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.35 179.94 46.2 Favored Glycine 0 N--CA 1.444 -0.774 0 C-N-CA 119.67 -1.252 . . . . 0.0 113.27 -176.916 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.08 35.05 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -108.89 14.16 24.37 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 119.555 -1.966 . . . . 0.0 115.229 -175.541 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.28 -32.2 66.39 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.778 -1.969 . . . . 0.0 111.328 178.794 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.16 54.47 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.3 mp -104.44 15.87 27.29 Favored 'General case' 0 N--CA 1.486 1.354 0 N-CA-C 114.482 1.29 . . . . 0.0 114.482 -176.296 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.1 124.19 23.08 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.397 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.56 16.18 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 2.4 m -85.24 -13.51 11.2 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.816 0 CA-C-N 118.648 0.658 . . . . 0.0 112.73 179.236 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.71 160.55 43.14 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.153 0.888 . . . . 0.0 112.471 -179.217 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 129.84 34.88 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -148.38 177.23 9.62 Favored 'General case' 0 CA--C 1.515 -0.366 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.712 -177.238 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -135.89 164.81 27.09 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -177.116 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -142.68 153.29 61.41 Favored Pre-proline 0 N--CA 1.495 1.808 0 N-CA-C 106.896 -1.52 . . . . 0.0 106.896 173.65 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.28 3.08 7.97 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 C-N-CA 120.818 1.012 . . . . 0.0 114.61 -175.614 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 145.11 55.39 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . 0.546 ' CG ' HD23 ' A' ' 124' ' ' LEU . 0.3 OUTLIER -121.19 122.63 40.4 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 126.751 2.532 . . . . 0.0 112.971 -178.906 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -104.57 124.79 49.93 Favored 'General case' 0 N--CA 1.498 1.961 0 CA-C-N 120.444 1.475 . . . . 0.0 107.536 176.102 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . 0.803 ' HH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . 0.472 HD13 ' HA ' ' A' ' 86' ' ' LEU . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . 0.49 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 118.97 21.93 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 107' ' ' HIS . . . . . 0.803 ' CE1' ' HH ' ' A' ' 70' ' ' TYR . 2.0 p80 -150.04 171.35 16.99 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 122.181 0.991 . . . . 0.0 112.555 -177.34 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 108' ' ' CYS . . . . . 0.663 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -169.44 168.43 9.46 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 173.792 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.23 38.73 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.69 120.21 4.76 Favored Glycine 0 N--CA 1.448 -0.539 0 N-CA-C 105.034 -3.226 . . . . 0.0 105.034 176.925 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.71 111.31 34.37 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 124' ' ' LEU . . . . . 0.546 HD23 ' CG ' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.7 126.13 74.03 Favored Pre-proline 0 N--CA 1.489 1.477 0 C-N-CA 123.359 0.664 . . . . 0.0 110.886 -178.126 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.2 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' THR . . . . . 0.44 ' HA ' HE21 ' A' ' 44' ' ' GLN . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.608 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' GLN . . . . . 0.608 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.64 13.03 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -139.18 155.29 47.94 Favored 'General case' 0 CA--C 1.49 -1.356 0 N-CA-C 109.514 -0.551 . . . . 0.0 109.514 -179.329 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.33 -163.43 35.0 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 118.037 -2.03 . . . . 0.0 113.208 -179.801 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.4 179.93 46.24 Favored Glycine 0 N--CA 1.444 -0.812 0 C-N-CA 119.745 -1.217 . . . . 0.0 113.368 -176.912 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.14 132.47 35.09 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.514 -1.843 . . . . 0.0 107.908 -177.643 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . 0.263 0.3 OUTLIER -114.5 20.2 15.57 Favored 'General case' 0 C--N 1.312 -1.04 0 O-C-N 117.72 -3.112 . . . . 0.0 114.683 -175.974 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -55.07 -32.2 61.75 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 117.366 -1.734 . . . . 0.0 111.328 174.57 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 6.42 49.09 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -111.5 10.79 21.33 Favored 'General case' 2 N--CA 1.62 8.062 0 O-C-N 124.811 1.319 . . . . 0.0 111.199 -170.476 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.04 124.19 23.01 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.244 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.34 16.03 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 1.9 m -83.93 -14.51 11.51 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.919 0 O-C-N 124.134 0.896 . . . . 0.0 112.816 179.222 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -153.33 160.55 42.71 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.095 0.861 . . . . 0.0 112.471 -178.52 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 128.37 28.47 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -144.64 174.11 11.25 Favored 'General case' 0 CA--C 1.518 -0.274 0 CA-C-N 114.684 -1.144 . . . . 0.0 109.829 -175.619 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -134.54 164.89 26.46 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -179.772 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' HIS . . . . . 0.468 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.0 OUTLIER -144.39 154.07 56.44 Favored Pre-proline 0 N--CA 1.484 1.254 0 N-CA-C 106.895 -1.52 . . . . 0.0 106.895 172.617 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.09 3.08 7.93 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 C-N-CA 121.146 1.231 . . . . 0.0 114.61 -173.75 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 145.68 54.82 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 23.6 tt0 -128.93 128.44 43.76 Favored 'General case' 0 N--CA 1.478 0.945 0 O-C-N 124.052 0.845 . . . . 0.0 110.103 179.599 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -104.22 124.79 49.75 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.742 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . 0.805 ' HH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 142.11 29.27 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 14.6 tp -132.36 121.37 23.39 Favored 'General case' 2 C--N 1.468 5.722 0 N-CA-C 102.143 -3.28 . . . . 0.0 102.143 179.921 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . 0.472 HD13 ' HA ' ' A' ' 86' ' ' LEU . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . 0.49 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 118.46 21.46 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 107' ' ' HIS . . . . . 0.805 ' CE1' ' HH ' ' A' ' 70' ' ' TYR . 0.7 OUTLIER -148.91 169.35 20.75 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 122.042 0.925 . . . . 0.0 113.172 -176.556 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 108' ' ' CYS . . . . . 0.645 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -168.41 168.43 11.25 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 173.111 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.49 38.28 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -117.19 120.96 4.98 Favored Glycine 0 N--CA 1.446 -0.684 0 N-CA-C 104.99 -3.244 . . . . 0.0 104.99 176.779 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -106.12 111.31 34.6 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.882 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.56 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.73 126.13 73.94 Favored Pre-proline 0 N--CA 1.489 1.477 0 C-N-CA 123.386 0.674 . . . . 0.0 110.882 -178.127 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.178 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' THR . . . . . 0.44 ' HA ' HE21 ' A' ' 44' ' ' GLN . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.608 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' GLN . . . . . 0.608 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.48 12.9 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.96 154.88 48.35 Favored 'General case' 0 CA--C 1.491 -1.316 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 -179.202 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.58 -163.43 35.14 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 118.041 -2.028 . . . . 0.0 113.208 -179.852 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.38 179.97 46.24 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 119.724 -1.227 . . . . 0.0 113.298 -176.946 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.1 35.05 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -108.52 13.92 25.0 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 119.751 -1.843 . . . . 0.0 115.39 -175.544 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.57 -32.2 66.9 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.774 -1.97 . . . . 0.0 111.328 179.044 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.19 54.5 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.6 mp -103.85 15.22 29.2 Favored 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 114.517 1.303 . . . . 0.0 114.517 -176.223 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.35 124.19 23.39 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -177.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.47 16.12 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 2.2 m -84.85 -13.76 11.29 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.812 0 O-C-N 123.766 0.667 . . . . 0.0 112.705 179.169 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.83 160.55 43.09 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.198 0.908 . . . . 0.0 112.471 -178.996 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 129.44 33.01 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' HIS . . . . . 0.469 ' CE1' ' NE2' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -147.65 175.15 11.11 Favored 'General case' 0 N--CA 1.447 -0.607 0 CA-C-N 114.756 -1.111 . . . . 0.0 110.303 -176.527 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' THR . . . . . 0.553 ' C ' ' ND1' ' A' ' 64' ' ' HIS . 28.7 p -134.64 163.1 30.51 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -177.615 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' HIS . . . . . 0.878 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -135.12 147.07 60.94 Favored Pre-proline 0 N--CA 1.492 1.666 0 C-N-CA 123.931 0.892 . . . . 0.0 108.831 177.9 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -79.23 3.08 7.77 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 CA-C-N 119.819 0.971 . . . . 0.0 114.61 178.861 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 144.74 55.64 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 6.9 tt0 -126.59 125.11 41.42 Favored 'General case' 0 CA--C 1.553 1.088 0 O-C-N 124.879 1.362 . . . . 0.0 110.342 -178.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.13 124.79 49.23 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.18 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . 0.899 ' HH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . 0.472 HD13 ' HA ' ' A' ' 86' ' ' LEU . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . 0.49 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 116.39 19.77 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 107' ' ' HIS . . . . . 0.899 ' CE1' ' HH ' ' A' ' 70' ' ' TYR . 0.0 OUTLIER -144.06 164.24 31.21 Favored 'General case' 0 C--N 1.341 0.224 0 N-CA-C 114.331 1.234 . . . . 0.0 114.331 -174.866 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 108' ' ' CYS . . . . . 0.748 ' N ' ' HD1' ' A' ' 107' ' ' HIS . 7.3 p -165.96 168.43 15.73 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 170.457 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 150.81 39.44 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.25 120.12 4.77 Favored Glycine 0 N--CA 1.448 -0.509 0 N-CA-C 104.894 -3.282 . . . . 0.0 104.894 176.863 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.52 111.31 34.26 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -179.107 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.61 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.8 126.03 74.01 Favored Pre-proline 0 N--CA 1.488 1.428 0 C-N-CA 123.358 0.663 . . . . 0.0 110.963 -178.117 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.46 107.32 2.36 Favored 'Trans proline' 0 C--N 1.323 -0.799 0 C-N-CA 121.836 1.691 . . . . 0.0 112.97 -175.1 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' THR . . . . . 0.44 ' HA ' HE21 ' A' ' 44' ' ' GLN . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.608 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' GLN . . . . . 0.608 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.13 12.63 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.2 153.95 49.14 Favored 'General case' 0 CA--C 1.493 -1.233 0 O-C-N 123.524 0.515 . . . . 0.0 109.729 -178.841 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.99 -163.46 35.39 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.965 -2.064 . . . . 0.0 113.208 179.792 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.45 179.97 46.3 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 119.699 -1.239 . . . . 0.0 113.319 -176.95 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 132.53 35.08 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.506 -1.847 . . . . 0.0 107.908 -177.646 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . 0.266 0.3 OUTLIER -114.53 20.49 15.32 Favored 'General case' 0 C--N 1.316 -0.849 0 O-C-N 117.804 -3.06 . . . . 0.0 114.774 -175.974 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -55.47 -32.2 62.62 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 117.33 -1.748 . . . . 0.0 111.328 174.542 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.2 54.51 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.2 mp -104.2 15.71 27.79 Favored 'General case' 0 N--CA 1.488 1.448 0 N-CA-C 114.529 1.307 . . . . 0.0 114.529 -176.419 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.17 124.19 23.17 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.249 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.71 16.28 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 1.6 m -84.97 -13.94 11.21 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.668 0 CA-C-N 118.669 0.668 . . . . 0.0 112.787 179.043 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.69 160.55 43.15 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.086 0.857 . . . . 0.0 112.471 -178.93 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 127.14 23.68 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -141.7 171.22 14.36 Favored 'General case' 0 C--N 1.351 0.634 0 CA-C-N 114.027 -1.442 . . . . 0.0 110.184 -174.718 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -133.0 165.53 24.52 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 178.347 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' HIS . . . . . 0.604 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.0 OUTLIER -145.55 154.04 52.07 Favored Pre-proline 0 N--CA 1.48 1.052 0 N-CA-C 107.208 -1.404 . . . . 0.0 107.208 172.63 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.17 3.08 7.94 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 C-N-CA 121.04 1.16 . . . . 0.0 114.61 -173.122 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 144.3 55.87 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 33.1 tt0 -126.3 127.34 45.42 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 124.286 0.991 . . . . 0.0 109.456 179.857 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.4 124.79 49.36 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 177.428 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . 0.816 ' HH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . 0.472 HD13 ' HA ' ' A' ' 86' ' ' LEU . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . 0.49 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 119.08 22.07 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 107' ' ' HIS . . . . . 0.816 ' CE1' ' HH ' ' A' ' 70' ' ' TYR . 1.0 OUTLIER -150.21 171.04 17.58 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 122.16 0.981 . . . . 0.0 112.737 -177.18 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 108' ' ' CYS . . . . . 0.669 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -169.29 168.43 9.69 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 173.848 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 150.76 39.53 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.2 120.04 4.74 Favored Glycine 0 N--CA 1.448 -0.509 0 N-CA-C 104.947 -3.261 . . . . 0.0 104.947 176.857 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.46 111.31 34.22 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -179.058 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.76 126.17 73.78 Favored Pre-proline 0 N--CA 1.489 1.483 0 C-N-CA 123.322 0.649 . . . . 0.0 110.881 -178.12 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.178 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' THR . . . . . 0.44 ' HA ' HE21 ' A' ' 44' ' ' GLN . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.608 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' GLN . . . . . 0.608 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.44 12.88 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.93 154.89 48.38 Favored 'General case' 0 CA--C 1.49 -1.346 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 -179.235 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.59 -163.4 35.13 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 118.059 -2.02 . . . . 0.0 113.208 -179.847 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.35 179.94 46.2 Favored Glycine 0 N--CA 1.444 -0.774 0 C-N-CA 119.67 -1.252 . . . . 0.0 113.27 -176.916 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 132.59 35.08 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . 0.268 0.3 OUTLIER -114.57 20.43 15.34 Favored 'General case' 0 C--N 1.316 -0.869 0 O-C-N 117.821 -3.049 . . . . 0.0 114.791 -176.067 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -55.34 -32.2 62.34 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 117.275 -1.77 . . . . 0.0 111.328 174.557 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.09 54.41 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.2 mp -104.13 15.67 27.92 Favored 'General case' 0 N--CA 1.486 1.357 0 N-CA-C 114.559 1.318 . . . . 0.0 114.559 -176.327 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.23 124.19 23.24 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.237 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.51 16.15 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 2.2 m -84.97 -13.68 11.27 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.781 0 CA-C-N 118.613 0.642 . . . . 0.0 112.73 179.168 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.8 160.55 43.11 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.161 0.892 . . . . 0.0 112.471 -179.046 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 129.57 33.62 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' HIS . . . . . 0.456 ' CE1' ' NE2' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -147.89 175.47 10.93 Favored 'General case' 0 N--CA 1.446 -0.625 0 CA-C-N 114.785 -1.098 . . . . 0.0 110.259 -176.62 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' THR . . . . . 0.546 ' C ' ' ND1' ' A' ' 64' ' ' HIS . 28.7 p -134.83 163.16 30.44 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -177.49 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' HIS . . . . . 0.877 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -135.18 147.04 60.72 Favored Pre-proline 0 N--CA 1.492 1.646 0 C-N-CA 124.013 0.925 . . . . 0.0 108.925 177.879 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -79.24 3.08 7.77 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 CA-C-N 119.809 0.968 . . . . 0.0 114.61 178.894 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 144.74 55.64 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 6.7 tt0 -126.52 124.92 41.14 Favored 'General case' 0 CA--C 1.553 1.073 0 O-C-N 124.917 1.385 . . . . 0.0 110.392 -178.869 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.06 124.79 49.19 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.179 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . 0.897 ' HH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . 0.472 HD13 ' HA ' ' A' ' 86' ' ' LEU . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . 0.49 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 116.51 19.84 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 107' ' ' HIS . . . . . 0.897 ' CE1' ' HH ' ' A' ' 70' ' ' TYR . 0.0 OUTLIER -144.39 164.61 30.32 Favored 'General case' 0 C--N 1.341 0.2 0 N-CA-C 114.211 1.189 . . . . 0.0 114.211 -174.976 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 108' ' ' CYS . . . . . 0.745 ' N ' ' HD1' ' A' ' 107' ' ' HIS . 7.3 p -166.11 168.43 15.44 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 170.633 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 150.93 39.24 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.34 120.12 4.76 Favored Glycine 0 N--CA 1.447 -0.596 0 N-CA-C 104.976 -3.249 . . . . 0.0 104.976 176.901 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.6 111.31 34.31 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -179.055 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.75 126.23 73.65 Favored Pre-proline 0 N--CA 1.489 1.483 0 C-N-CA 123.322 0.649 . . . . 0.0 110.847 -178.12 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.57 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.778 0 C-N-CA 121.855 1.704 . . . . 0.0 112.97 -175.211 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' THR . . . . . 0.44 ' HA ' HE21 ' A' ' 44' ' ' GLN . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.608 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' GLN . . . . . 0.608 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 125.32 12.0 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -136.32 152.39 50.62 Favored 'General case' 0 CA--C 1.497 -1.084 0 O-C-N 123.731 0.644 . . . . 0.0 109.833 -178.296 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 163.75 -163.4 35.75 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.651 -2.214 . . . . 0.0 113.208 178.775 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.35 179.94 46.2 Favored Glycine 0 N--CA 1.444 -0.774 0 C-N-CA 119.67 -1.252 . . . . 0.0 113.27 -176.916 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 132.45 35.08 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -106.74 13.12 28.36 Favored 'General case' 0 N--CA 1.492 1.664 0 N-CA-C 115.597 1.702 . . . . 0.0 115.597 -175.034 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -58.91 -32.2 69.32 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 117.26 -1.776 . . . . 0.0 111.328 179.714 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 -0.23 54.12 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 47.9 mt -104.23 16.42 26.23 Favored 'General case' 0 C--N 1.364 1.224 0 N-CA-C 114.879 1.437 . . . . 0.0 114.879 -177.065 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -67.69 124.19 22.56 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.726 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.93 16.44 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -86.5 -12.96 10.91 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.621 0 CA-C-N 119.548 1.067 . . . . 0.0 112.281 178.766 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -151.41 160.55 43.69 Favored 'General case' 0 C--O 1.281 2.733 0 C-N-CA 119.023 -1.071 . . . . 0.0 112.471 -179.581 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 130.62 38.49 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -150.02 178.87 8.54 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.613 -0.721 . . . . 0.0 109.6 -177.933 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -136.78 164.82 27.38 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -176.04 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' HIS . . . . . 0.58 ' CE1' ' CD ' ' A' ' 68' ' ' GLU . 0.0 OUTLIER -142.21 152.38 61.0 Favored Pre-proline 0 N--CA 1.495 1.78 0 N-CA-C 107.12 -1.437 . . . . 0.0 107.12 174.393 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.1 3.08 7.93 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 N-CA-C 114.61 0.966 . . . . 0.0 114.61 -176.145 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 148.11 52.04 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . 0.58 ' CD ' ' CE1' ' A' ' 64' ' ' HIS . 16.9 pt-20 -136.47 136.21 39.26 Favored 'General case' 0 CA--C 1.517 -0.304 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 176.452 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -106.53 124.79 50.13 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 -177.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . 0.776 ' HH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . 0.472 HD13 ' HA ' ' A' ' 86' ' ' LEU . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . 0.49 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 119.69 22.91 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 107' ' ' HIS . . . . . 0.776 ' CE1' ' HH ' ' A' ' 70' ' ' TYR . 3.5 p80 -151.42 172.49 15.86 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 122.176 0.988 . . . . 0.0 112.399 -177.665 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 108' ' ' CYS . . . . . 0.61 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -170.1 168.43 8.39 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 174.521 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.5 38.26 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -117.01 120.25 4.75 Favored Glycine 0 N--CA 1.447 -0.627 0 N-CA-C 105.152 -3.179 . . . . 0.0 105.152 176.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.85 111.31 34.45 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.856 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 124' ' ' LEU . . . . . 0.425 HD23 ' OE1' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.56 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.73 126.13 73.94 Favored Pre-proline 0 N--CA 1.489 1.477 0 C-N-CA 123.386 0.674 . . . . 0.0 110.882 -178.127 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.178 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' THR . . . . . 0.44 ' HA ' HE21 ' A' ' 44' ' ' GLN . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.608 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' GLN . . . . . 0.608 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 125.55 12.18 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -136.67 152.65 50.64 Favored 'General case' 0 CA--C 1.493 -1.217 0 O-C-N 123.773 0.67 . . . . 0.0 109.94 -178.401 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 163.58 -163.46 35.7 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.683 -2.198 . . . . 0.0 113.208 178.939 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.45 179.97 46.3 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 119.699 -1.239 . . . . 0.0 113.319 -176.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.12 35.05 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.506 -1.847 . . . . 0.0 107.908 -177.646 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -108.96 14.19 24.26 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 119.604 -1.935 . . . . 0.0 115.302 -175.559 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.27 -32.2 66.37 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.805 -1.958 . . . . 0.0 111.328 178.773 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 -0.02 54.31 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -103.65 15.28 29.23 Favored 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 114.449 1.278 . . . . 0.0 114.449 -176.38 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.21 124.19 23.22 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.031 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.64 16.24 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -81.89 -16.77 11.88 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.958 0 O-C-N 124.906 1.379 . . . . 0.0 112.928 179.114 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -154.43 160.55 41.69 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 118.758 0.708 . . . . 0.0 112.471 -177.057 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 128.2 27.82 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -144.13 173.83 11.4 Favored 'General case' 0 CA--C 1.516 -0.334 0 CA-C-N 114.575 -1.193 . . . . 0.0 109.86 -175.556 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -134.43 164.77 26.69 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 179.886 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' HIS . . . . . 0.538 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.0 OUTLIER -143.85 153.6 57.73 Favored Pre-proline 0 N--CA 1.483 1.182 0 N-CA-C 106.989 -1.486 . . . . 0.0 106.989 173.042 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.04 3.08 7.92 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 C-N-CA 121.075 1.183 . . . . 0.0 114.61 -174.215 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 143.69 56.19 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . 0.54 ' HG3' HD23 ' A' ' 124' ' ' LEU . 0.1 OUTLIER -120.08 120.78 37.25 Favored 'General case' 0 N--CA 1.507 2.385 0 O-C-N 125.999 2.062 . . . . 0.0 111.502 -178.315 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -102.49 124.79 48.68 Favored 'General case' 0 N--CA 1.498 1.961 0 CA-C-N 120.76 1.618 . . . . 0.0 107.536 175.493 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . 0.747 ' HH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . 0.472 HD13 ' HA ' ' A' ' 86' ' ' LEU . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . 0.49 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . 0.42 ' HB ' ' HB3' ' A' ' 68' ' ' GLU . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 118.89 21.85 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 107' ' ' HIS . . . . . 0.747 ' CE1' ' HH ' ' A' ' 70' ' ' TYR . 1.4 p80 -150.23 170.75 18.23 Favored 'General case' 0 C--N 1.322 -0.597 0 C-N-CA 119.462 -0.895 . . . . 0.0 112.54 -177.031 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 108' ' ' CYS . . . . . 0.65 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -168.96 168.43 10.23 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 173.932 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.6 38.08 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -117.43 120.76 4.89 Favored Glycine 0 C--N 1.315 -0.629 0 N-CA-C 105.009 -3.236 . . . . 0.0 105.009 176.833 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.97 111.31 34.52 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.793 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 124' ' ' LEU . . . . . 0.54 HD23 ' HG3' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.76 126.17 73.78 Favored Pre-proline 0 N--CA 1.489 1.483 0 C-N-CA 123.322 0.649 . . . . 0.0 110.881 -178.12 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.178 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' THR . . . . . 0.44 ' HA ' HE21 ' A' ' 44' ' ' GLN . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.608 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' GLN . . . . . 0.608 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.44 12.88 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.93 154.88 48.38 Favored 'General case' 0 CA--C 1.49 -1.33 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 -179.204 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.59 -163.43 35.14 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 118.059 -2.02 . . . . 0.0 113.208 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.38 179.97 46.24 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 119.724 -1.227 . . . . 0.0 113.298 -176.946 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 132.99 35.06 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -108.8 14.19 24.46 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 119.569 -1.957 . . . . 0.0 115.265 -175.538 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.35 -32.2 66.5 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.789 -1.965 . . . . 0.0 111.328 178.784 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.08 54.4 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.2 mp -104.43 15.98 27.07 Favored 'General case' 0 N--CA 1.487 1.389 0 N-CA-C 114.396 1.258 . . . . 0.0 114.396 -176.322 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.06 124.19 23.03 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.467 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.53 16.16 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 2.5 m -85.06 -13.6 11.25 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.787 0 O-C-N 123.801 0.688 . . . . 0.0 112.737 179.241 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.86 160.55 43.08 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.187 0.903 . . . . 0.0 112.471 -179.11 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 129.64 33.92 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' HIS . . . . . 0.452 ' CE1' ' NE2' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -148.05 175.55 10.91 Favored 'General case' 0 N--CA 1.447 -0.601 0 CA-C-N 114.8 -1.091 . . . . 0.0 110.244 -176.666 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' THR . . . . . 0.544 ' C ' ' ND1' ' A' ' 64' ' ' HIS . 28.7 p -134.85 163.16 30.44 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -177.385 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' HIS . . . . . 0.875 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -135.14 147.03 60.76 Favored Pre-proline 0 N--CA 1.492 1.631 0 C-N-CA 124.031 0.932 . . . . 0.0 108.869 177.939 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -79.27 3.08 7.78 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 N-CA-C 114.61 0.966 . . . . 0.0 114.61 178.825 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 144.74 55.64 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 6.7 tt0 -126.52 124.92 41.14 Favored 'General case' 0 CA--C 1.553 1.073 0 O-C-N 124.917 1.385 . . . . 0.0 110.392 -178.869 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.06 124.79 49.19 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.179 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . 0.898 ' HH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . 0.472 HD13 ' HA ' ' A' ' 86' ' ' LEU . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . 0.49 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 116.51 19.84 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 107' ' ' HIS . . . . . 0.898 ' CE1' ' HH ' ' A' ' 70' ' ' TYR . 0.0 OUTLIER -144.35 164.57 30.41 Favored 'General case' 0 C--N 1.341 0.2 0 N-CA-C 114.23 1.196 . . . . 0.0 114.23 -174.956 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 108' ' ' CYS . . . . . 0.746 ' N ' ' HD1' ' A' ' 107' ' ' HIS . 7.3 p -166.11 168.43 15.44 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 170.599 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 150.99 39.15 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.52 120.47 4.86 Favored Glycine 0 N--CA 1.447 -0.616 0 N-CA-C 104.946 -3.261 . . . . 0.0 104.946 176.766 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.72 111.31 34.37 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -179.023 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.77 126.21 73.66 Favored Pre-proline 0 N--CA 1.49 1.534 0 C-N-CA 123.364 0.665 . . . . 0.0 110.762 -178.076 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.261 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' THR . . . . . 0.44 ' HA ' HE21 ' A' ' 44' ' ' GLN . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.608 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' GLN . . . . . 0.608 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.24 12.72 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.28 154.41 49.04 Favored 'General case' 0 CA--C 1.488 -1.434 0 N-CA-C 109.662 -0.496 . . . . 0.0 109.662 -179.056 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.76 -163.46 35.26 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.972 -2.061 . . . . 0.0 113.208 179.738 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.47 179.82 46.22 Favored Glycine 0 N--CA 1.444 -0.785 0 C-N-CA 119.66 -1.257 . . . . 0.0 113.27 -176.858 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.07 133.07 35.09 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.494 -1.853 . . . . 0.0 107.908 -177.692 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . 0.286 0.3 OUTLIER -114.63 20.64 15.15 Favored 'General case' 0 N--CA 1.473 0.716 0 O-C-N 118.281 -2.762 . . . . 0.0 115.226 -176.201 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -56.19 -32.2 64.14 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 117.243 -1.783 . . . . 0.0 111.328 174.709 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 -1.17 53.11 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 59.6 mt -102.74 15.85 28.16 Favored 'General case' 0 CA--C 1.558 1.278 0 N-CA-C 114.876 1.436 . . . . 0.0 114.876 -176.903 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.13 124.19 23.12 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.321 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.76 16.32 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -86.07 -13.03 11.04 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.535 0 CA-C-N 119.284 0.947 . . . . 0.0 112.389 178.863 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -151.82 160.55 43.52 Favored 'General case' 0 C--O 1.281 2.733 0 C-N-CA 119.206 -0.998 . . . . 0.0 112.471 -179.452 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 128.16 27.67 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -144.0 173.81 11.39 Favored 'General case' 0 CA--C 1.519 -0.235 0 CA-C-N 114.543 -1.208 . . . . 0.0 109.778 -175.395 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -134.5 165.14 25.88 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 179.752 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' HIS . . . . . 0.543 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.0 OUTLIER -144.3 154.34 57.08 Favored Pre-proline 0 N--CA 1.484 1.248 0 N-CA-C 107.151 -1.425 . . . . 0.0 107.151 172.704 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.53 3.08 8.01 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 C-N-CA 120.901 1.068 . . . . 0.0 114.61 -174.026 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 145.57 54.93 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 33.2 tt0 -128.57 128.22 43.82 Favored 'General case' 0 N--CA 1.486 1.372 0 O-C-N 124.232 0.958 . . . . 0.0 110.037 179.554 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.93 124.79 49.62 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.509 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . 0.795 ' HH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . 0.472 HD13 ' HA ' ' A' ' 86' ' ' LEU . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . 0.49 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 118.88 21.84 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 107' ' ' HIS . . . . . 0.795 ' CE1' ' HH ' ' A' ' 70' ' ' TYR . 1.0 OUTLIER -150.11 170.67 18.35 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 121.949 0.88 . . . . 0.0 112.691 -177.034 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 108' ' ' CYS . . . . . 0.652 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -168.98 168.43 10.2 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 173.863 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.49 38.28 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -117.11 120.24 4.74 Favored Glycine 0 N--CA 1.448 -0.562 0 N-CA-C 105.047 -3.221 . . . . 0.0 105.047 177.018 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.77 111.31 34.4 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.86 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.76 126.17 73.78 Favored Pre-proline 0 N--CA 1.489 1.483 0 C-N-CA 123.322 0.649 . . . . 0.0 110.881 -178.12 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.178 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' THR . . . . . 0.44 ' HA ' HE21 ' A' ' 44' ' ' GLN . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.608 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' GLN . . . . . 0.608 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 125.51 12.15 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -136.66 152.8 50.81 Favored 'General case' 0 CA--C 1.493 -1.213 0 O-C-N 123.686 0.616 . . . . 0.0 109.894 -178.491 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 163.54 -163.43 35.66 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.694 -2.193 . . . . 0.0 113.208 178.947 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.4 179.94 46.25 Favored Glycine 0 N--CA 1.444 -0.812 0 C-N-CA 119.745 -1.217 . . . . 0.0 113.343 -176.912 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.25 35.05 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.506 -1.847 . . . . 0.0 107.908 -177.646 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -108.54 13.92 24.97 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 119.879 -1.763 . . . . 0.0 115.585 -175.579 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.79 -32.2 67.3 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.792 -1.963 . . . . 0.0 111.328 179.09 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.15 54.46 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 22.9 mt -104.76 16.14 26.57 Favored 'General case' 0 N--CA 1.484 1.251 0 N-CA-C 114.602 1.334 . . . . 0.0 114.602 -176.64 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -67.5 124.19 22.34 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.652 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.8 16.35 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -86.39 -12.79 10.97 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 CA-C-N 119.446 1.021 . . . . 0.0 112.251 178.85 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -151.62 160.55 43.6 Favored 'General case' 0 C--O 1.281 2.733 0 C-N-CA 119.128 -1.029 . . . . 0.0 112.471 -179.574 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 130.57 38.27 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -149.99 178.85 8.55 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.541 -177.928 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -136.76 164.81 27.4 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -176.03 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' HIS . . . . . 0.582 ' CE1' ' CD ' ' A' ' 68' ' ' GLU . 0.0 OUTLIER -142.03 152.23 61.21 Favored Pre-proline 0 N--CA 1.495 1.807 0 N-CA-C 107.161 -1.422 . . . . 0.0 107.161 174.534 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.1 3.08 7.93 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 N-CA-C 114.61 0.966 . . . . 0.0 114.61 -176.321 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 148.0 52.18 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . 0.582 ' CD ' ' CE1' ' A' ' 64' ' ' HIS . 17.1 pt-20 -136.31 135.83 39.23 Favored 'General case' 0 N--CA 1.465 0.319 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 176.593 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -106.28 124.79 50.13 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 -178.014 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . 0.782 ' HH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . 0.472 HD13 ' HA ' ' A' ' 86' ' ' LEU . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . 0.49 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 119.69 22.91 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 107' ' ' HIS . . . . . 0.782 ' CE1' ' HH ' ' A' ' 70' ' ' TYR . 3.5 p80 -151.3 172.43 15.89 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 122.202 1.001 . . . . 0.0 112.503 -177.633 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 108' ' ' CYS . . . . . 0.603 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -170.13 168.43 8.35 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 174.428 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.41 38.42 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.93 120.24 4.75 Favored Glycine 0 N--CA 1.448 -0.535 0 N-CA-C 105.058 -3.217 . . . . 0.0 105.058 176.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.79 111.31 34.42 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.931 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 124' ' ' LEU . . . . . 0.421 HD23 ' OE1' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.56 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.48 126.15 74.53 Favored Pre-proline 0 N--CA 1.489 1.511 0 C-N-CA 123.444 0.698 . . . . 0.0 110.821 -178.148 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.65 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.801 0 C-N-CA 121.832 1.688 . . . . 0.0 112.97 -175.364 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' THR . . . . . 0.44 ' HA ' HE21 ' A' ' 44' ' ' GLN . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' ALA . . . . . 0.608 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' GLN . . . . . 0.608 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 125.25 11.95 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -136.03 152.2 50.66 Favored 'General case' 0 CA--C 1.494 -1.177 0 O-C-N 123.809 0.693 . . . . 0.0 109.948 -178.28 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 163.82 -163.43 35.81 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.594 -2.241 . . . . 0.0 113.208 178.618 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.4 179.94 46.25 Favored Glycine 0 N--CA 1.444 -0.812 0 C-N-CA 119.745 -1.217 . . . . 0.0 113.343 -176.912 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.42 35.04 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.506 -1.847 . . . . 0.0 107.908 -177.646 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -108.8 14.11 24.51 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 119.907 -1.746 . . . . 0.0 115.637 -175.622 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.87 -32.2 67.44 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.796 -1.962 . . . . 0.0 111.328 178.98 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 -0.38 54.0 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 67.1 mt -104.03 16.1 27.03 Favored 'General case' 0 C--N 1.363 1.188 0 N-CA-C 114.868 1.433 . . . . 0.0 114.868 -177.309 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -67.16 124.19 21.91 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.773 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.89 16.41 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -86.37 -13.02 10.94 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.765 0 CA-C-N 119.652 1.115 . . . . 0.0 112.087 178.734 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -151.4 160.55 43.69 Favored 'General case' 0 C--O 1.281 2.733 0 C-N-CA 118.903 -1.119 . . . . 0.0 112.471 -179.428 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 131.24 41.38 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -151.05 -179.95 7.74 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.762 -0.653 . . . . 0.0 109.636 -178.348 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -137.54 165.17 26.95 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -175.479 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' HIS . . . . . 0.561 ' CE1' ' CD ' ' A' ' 68' ' ' GLU . 0.0 OUTLIER -143.25 153.01 59.08 Favored Pre-proline 0 N--CA 1.495 1.79 0 N-CA-C 106.942 -1.503 . . . . 0.0 106.942 173.967 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.25 3.08 7.96 Favored 'Trans proline' 0 C--N 1.278 -3.17 0 C-N-CA 120.841 1.027 . . . . 0.0 114.61 -175.432 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 148.14 52.0 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' GLU . . . . . 0.561 ' CD ' ' CE1' ' A' ' 64' ' ' HIS . 18.0 pt-20 -136.76 135.93 38.48 Favored 'General case' 0 N--CA 1.468 0.457 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 176.473 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -106.18 124.79 50.13 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 -177.833 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' TYR . . . . . 0.77 ' HH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . 0.472 HD13 ' HA ' ' A' ' 86' ' ' LEU . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . 0.49 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 119.42 22.54 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 107' ' ' HIS . . . . . 0.77 ' CE1' ' HH ' ' A' ' 70' ' ' TYR . 3.7 p80 -150.77 172.2 15.99 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 122.184 0.992 . . . . 0.0 112.514 -177.549 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 108' ' ' CYS . . . . . 0.614 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -170.01 168.43 8.55 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 174.154 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.53 38.21 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -117.01 120.38 4.79 Favored Glycine 0 N--CA 1.447 -0.627 0 N-CA-C 105.094 -3.202 . . . . 0.0 105.094 176.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.96 111.31 34.51 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 124' ' ' LEU . . . . . 0.447 HD23 ' OE1' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.62 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.53 126.1 74.5 Favored Pre-proline 0 N--CA 1.489 1.511 0 C-N-CA 123.453 0.701 . . . . 0.0 110.821 -178.14 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.59 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.806 0 C-N-CA 121.775 1.65 . . . . 0.0 112.97 -175.369 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' THR . . . . . 0.44 ' HA ' HE21 ' A' ' 44' ' ' GLN . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.608 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . 0.608 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.61 13.0 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -139.24 155.23 47.92 Favored 'General case' 0 CA--C 1.49 -1.346 0 N-CA-C 109.438 -0.578 . . . . 0.0 109.438 -179.313 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.41 -163.43 35.04 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 118.072 -2.013 . . . . 0.0 113.208 -179.736 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.38 179.97 46.24 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 119.724 -1.227 . . . . 0.0 113.298 -176.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 132.62 35.08 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . 0.266 0.3 OUTLIER -114.64 20.48 15.26 Favored 'General case' 0 C--N 1.317 -0.822 0 O-C-N 117.791 -3.068 . . . . 0.0 114.69 -176.029 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -55.34 -32.2 62.34 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 117.275 -1.77 . . . . 0.0 111.328 174.525 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.15 54.46 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -104.46 15.98 27.04 Favored 'General case' 0 N--CA 1.487 1.383 0 N-CA-C 114.49 1.293 . . . . 0.0 114.49 -176.45 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.01 124.19 22.96 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.484 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.45 16.11 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 2.5 m -84.81 -13.74 11.31 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.753 0 CA-C-N 118.634 0.652 . . . . 0.0 112.657 179.072 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.77 160.55 43.12 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.246 0.93 . . . . 0.0 112.471 -178.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 128.65 29.56 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -145.15 174.91 10.66 Favored 'General case' 0 CA--C 1.518 -0.285 0 CA-C-N 114.765 -1.107 . . . . 0.0 109.705 -175.92 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -135.01 165.06 26.22 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -179.46 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' HIS . . . . . 0.507 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.0 OUTLIER -144.47 154.15 56.27 Favored Pre-proline 0 N--CA 1.483 1.184 0 N-CA-C 106.993 -1.484 . . . . 0.0 106.993 172.714 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.29 3.08 7.97 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 C-N-CA 121.065 1.177 . . . . 0.0 114.61 -173.819 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 145.9 54.6 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 4.3 tt0 -128.62 128.11 43.53 Favored 'General case' 0 N--CA 1.479 1.011 0 O-C-N 124.479 1.112 . . . . 0.0 110.497 179.738 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -104.38 124.79 49.83 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.649 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . 0.782 ' HH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . 0.472 HD13 ' HA ' ' A' ' 86' ' ' LEU . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . 0.49 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 118.59 21.58 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' HIS . . . . . 0.782 ' CE1' ' HH ' ' A' ' 70' ' ' TYR . 1.2 p80 -149.42 170.24 19.02 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.949 0.88 . . . . 0.0 112.773 -176.889 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' CYS . . . . . 0.652 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -168.78 168.43 10.56 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 173.457 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.53 38.21 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -117.04 120.26 4.75 Favored Glycine 0 C--N 1.316 -0.569 0 N-CA-C 105.112 -3.195 . . . . 0.0 105.112 176.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.87 111.31 34.46 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 202' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.68 0 CA-C-O 117.878 -1.058 . . . . 0.0 108.451 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.76 126.17 73.78 Favored Pre-proline 0 N--CA 1.489 1.483 0 C-N-CA 123.322 0.649 . . . . 0.0 110.881 -178.12 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.178 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' THR . . . . . 0.44 ' HA ' HE21 ' A' ' 44' ' ' GLN . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.608 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . 0.608 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.44 12.88 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.93 154.89 48.38 Favored 'General case' 0 CA--C 1.49 -1.346 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 -179.235 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.59 -163.4 35.13 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 118.059 -2.02 . . . . 0.0 113.208 -179.847 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.35 179.94 46.2 Favored Glycine 0 N--CA 1.444 -0.774 0 C-N-CA 119.67 -1.252 . . . . 0.0 113.27 -176.916 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.1 35.05 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -108.97 14.24 24.21 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 119.579 -1.95 . . . . 0.0 115.235 -175.545 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.28 -32.2 66.39 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.778 -1.969 . . . . 0.0 111.328 178.741 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.13 54.45 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.2 mp -104.32 15.75 27.62 Favored 'General case' 0 N--CA 1.486 1.371 0 N-CA-C 114.494 1.294 . . . . 0.0 114.494 -176.292 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.1 124.19 23.08 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.329 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.47 16.12 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 2.3 m -84.89 -13.68 11.29 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.781 0 O-C-N 123.766 0.667 . . . . 0.0 112.758 179.132 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.83 160.55 43.09 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.191 0.905 . . . . 0.0 112.471 -179.045 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 129.57 33.62 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' HIS . . . . . 0.455 ' CE1' ' NE2' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -147.89 175.47 10.93 Favored 'General case' 0 N--CA 1.446 -0.625 0 CA-C-N 114.785 -1.098 . . . . 0.0 110.259 -176.62 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' THR . . . . . 0.544 ' C ' ' ND1' ' A' ' 64' ' ' HIS . 28.7 p -134.83 163.2 30.35 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -177.49 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' HIS . . . . . 0.878 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -135.22 147.17 61.18 Favored Pre-proline 0 N--CA 1.492 1.641 0 C-N-CA 123.984 0.914 . . . . 0.0 108.876 177.864 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -79.32 3.08 7.79 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 N-CA-C 114.61 0.966 . . . . 0.0 114.61 178.869 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 144.69 55.67 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 6.9 tt0 -126.49 125.0 41.35 Favored 'General case' 0 CA--C 1.553 1.081 0 O-C-N 124.891 1.37 . . . . 0.0 110.378 -178.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.06 124.79 49.19 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.179 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . 0.897 ' HH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . 0.472 HD13 ' HA ' ' A' ' 86' ' ' LEU . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . 0.49 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 116.53 19.86 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' HIS . . . . . 0.897 ' CE1' ' HH ' ' A' ' 70' ' ' TYR . 0.0 OUTLIER -144.39 164.67 30.15 Favored 'General case' 0 C--N 1.341 0.222 0 N-CA-C 114.273 1.212 . . . . 0.0 114.273 -175.004 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' CYS . . . . . 0.745 ' N ' ' HD1' ' A' ' 107' ' ' HIS . 7.3 p -166.16 168.43 15.35 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 170.626 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 150.93 39.24 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.35 120.15 4.77 Favored Glycine 0 N--CA 1.448 -0.505 0 N-CA-C 104.911 -3.276 . . . . 0.0 104.911 176.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.6 111.31 34.31 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -179.104 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 202' ' ' TRP . . . . . . . . . . . . . 1.3 m0 . . . . . 0 N--CA 1.49 1.561 0 CA-C-O 118.158 -0.925 . . . . 0.0 109.388 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.7 126.18 73.9 Favored Pre-proline 0 N--CA 1.489 1.477 0 C-N-CA 123.359 0.664 . . . . 0.0 110.852 -178.126 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.57 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.778 0 C-N-CA 121.855 1.704 . . . . 0.0 112.97 -175.232 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' THR . . . . . 0.44 ' HA ' HE21 ' A' ' 44' ' ' GLN . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.608 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . 0.608 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.49 12.91 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.96 154.88 48.35 Favored 'General case' 0 CA--C 1.491 -1.301 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 -179.187 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.55 -163.4 35.1 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 118.014 -2.041 . . . . 0.0 113.208 -179.88 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.35 179.94 46.2 Favored Glycine 0 N--CA 1.444 -0.774 0 C-N-CA 119.67 -1.252 . . . . 0.0 113.27 -176.916 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.1 35.05 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -108.94 14.17 24.29 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 119.579 -1.95 . . . . 0.0 115.225 -175.501 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.29 -32.2 66.4 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.811 -1.955 . . . . 0.0 111.328 178.783 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.13 54.44 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.3 mp -104.25 15.71 27.75 Favored 'General case' 0 N--CA 1.486 1.351 0 N-CA-C 114.467 1.284 . . . . 0.0 114.467 -176.254 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.18 124.19 23.18 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.274 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.42 16.08 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 2.6 m -85.1 -13.47 11.26 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.829 0 CA-C-N 118.66 0.664 . . . . 0.0 112.707 179.222 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.74 160.55 43.13 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.205 0.911 . . . . 0.0 112.471 -179.195 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 129.64 33.92 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' HIS . . . . . 0.455 ' CE1' ' NE2' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -148.02 175.52 10.93 Favored 'General case' 0 N--CA 1.446 -0.655 0 CA-C-N 114.8 -1.091 . . . . 0.0 110.305 -176.644 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' THR . . . . . 0.547 ' C ' ' ND1' ' A' ' 64' ' ' HIS . 28.7 p -134.85 163.14 30.5 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -177.416 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' HIS . . . . . 0.877 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -135.11 147.06 60.95 Favored Pre-proline 0 N--CA 1.493 1.692 0 C-N-CA 123.985 0.914 . . . . 0.0 108.875 177.891 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -79.25 3.08 7.77 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 N-CA-C 114.61 0.966 . . . . 0.0 114.61 178.826 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 144.74 55.64 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 6.6 tt0 -126.52 124.88 41.04 Favored 'General case' 0 CA--C 1.553 1.096 0 O-C-N 124.936 1.398 . . . . 0.0 110.433 -178.862 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.06 124.79 49.2 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.214 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . 0.898 ' HH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . 0.472 HD13 ' HA ' ' A' ' 86' ' ' LEU . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . 0.49 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 116.41 19.78 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' HIS . . . . . 0.898 ' CE1' ' HH ' ' A' ' 70' ' ' TYR . 0.0 OUTLIER -144.15 164.28 31.14 Favored 'General case' 0 C--N 1.342 0.246 0 N-CA-C 114.291 1.219 . . . . 0.0 114.291 -174.882 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' CYS . . . . . 0.746 ' N ' ' HD1' ' A' ' 107' ' ' HIS . 7.3 p -165.96 168.43 15.73 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 170.501 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.02 39.1 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . 0.404 ' HA3' ' H2 ' ' A' ' 202' ' ' TRP . . . -116.6 120.41 4.84 Favored Glycine 0 N--CA 1.448 -0.525 0 N-CA-C 104.938 -3.265 . . . . 0.0 104.938 176.782 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.66 111.31 34.34 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -179.002 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 202' ' ' TRP . . . . . 0.404 ' H2 ' ' HA3' ' A' ' 122' ' ' GLY . 1.5 m0 . . . . . 0 N--CA 1.488 1.436 0 CA-C-O 118.168 -0.92 . . . . 0.0 109.424 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.76 126.17 73.78 Favored Pre-proline 0 N--CA 1.489 1.483 0 C-N-CA 123.322 0.649 . . . . 0.0 110.881 -178.12 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.178 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' THR . . . . . 0.44 ' HA ' HE21 ' A' ' 44' ' ' GLN . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.608 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . 0.608 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.44 12.88 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.93 154.89 48.38 Favored 'General case' 0 CA--C 1.49 -1.346 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 -179.235 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.59 -163.4 35.13 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 118.059 -2.02 . . . . 0.0 113.208 -179.847 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.35 179.94 46.2 Favored Glycine 0 N--CA 1.444 -0.774 0 C-N-CA 119.67 -1.252 . . . . 0.0 113.27 -176.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.15 35.05 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -109.05 14.23 24.13 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 119.538 -1.976 . . . . 0.0 115.281 -175.559 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.24 -32.2 66.3 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.773 -1.971 . . . . 0.0 111.328 178.73 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.13 54.45 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.1 mp -104.41 15.88 27.29 Favored 'General case' 0 N--CA 1.487 1.386 0 N-CA-C 114.465 1.283 . . . . 0.0 114.465 -176.273 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.14 124.19 23.13 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.395 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.51 16.15 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 2.1 m -84.96 -13.72 11.26 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.794 0 CA-C-N 118.613 0.642 . . . . 0.0 112.707 179.16 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.74 160.55 43.13 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.166 0.893 . . . . 0.0 112.471 -179.025 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 129.57 33.62 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' HIS . . . . . 0.457 ' CE1' ' NE2' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -147.89 175.4 10.99 Favored 'General case' 0 N--CA 1.447 -0.596 0 CA-C-N 114.785 -1.098 . . . . 0.0 110.256 -176.587 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' THR . . . . . 0.546 ' C ' ' ND1' ' A' ' 64' ' ' HIS . 28.7 p -134.79 163.16 30.42 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -177.495 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' HIS . . . . . 0.878 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -135.19 147.04 60.69 Favored Pre-proline 0 N--CA 1.492 1.671 0 C-N-CA 123.987 0.915 . . . . 0.0 108.842 177.932 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -79.24 3.08 7.77 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 N-CA-C 114.61 0.966 . . . . 0.0 114.61 178.861 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 144.74 55.64 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 6.5 tt0 -126.45 124.88 41.13 Favored 'General case' 0 CA--C 1.553 1.096 0 O-C-N 124.917 1.385 . . . . 0.0 110.428 -178.854 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.09 124.79 49.21 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.157 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . 0.897 ' HH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . 0.472 HD13 ' HA ' ' A' ' 86' ' ' LEU . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . 0.49 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 116.51 19.84 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' HIS . . . . . 0.897 ' CE1' ' HH ' ' A' ' 70' ' ' TYR . 0.0 OUTLIER -144.35 164.57 30.41 Favored 'General case' 0 C--N 1.341 0.2 0 N-CA-C 114.23 1.196 . . . . 0.0 114.23 -174.956 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' CYS . . . . . 0.746 ' N ' ' HD1' ' A' ' 107' ' ' HIS . 7.3 p -166.11 168.43 15.44 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 170.599 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 150.93 39.24 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.35 120.15 4.77 Favored Glycine 0 N--CA 1.448 -0.505 0 N-CA-C 104.911 -3.276 . . . . 0.0 104.911 176.911 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.6 111.31 34.31 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -179.104 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 202' ' ' TRP . . . . . . . . . . . . . 1.2 m0 . . . . . 0 N--CA 1.489 1.525 0 CA-C-O 118.193 -0.908 . . . . 0.0 109.332 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.56 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.66 126.16 74.06 Favored Pre-proline 0 N--CA 1.488 1.469 0 C-N-CA 123.413 0.685 . . . . 0.0 110.925 -178.224 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.56 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.766 0 C-N-CA 121.759 1.639 . . . . 0.0 112.97 -175.215 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' THR . . . . . 0.44 ' HA ' HE21 ' A' ' 44' ' ' GLN . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.608 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . 0.608 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 125.24 11.94 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -135.8 152.1 50.75 Favored 'General case' 0 CA--C 1.494 -1.209 0 O-C-N 123.894 0.746 . . . . 0.0 110.059 -178.241 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 163.81 -163.46 35.82 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.502 -2.285 . . . . 0.0 113.208 178.453 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.43 179.98 46.29 Favored Glycine 0 N--CA 1.443 -0.886 0 C-N-CA 119.784 -1.198 . . . . 0.0 113.381 -176.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.28 35.04 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.532 -1.834 . . . . 0.0 107.908 -177.641 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -110.42 15.4 22.22 Favored 'General case' 0 N--CA 1.482 1.168 0 O-C-N 119.602 -1.936 . . . . 0.0 115.515 -175.456 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -56.98 -32.2 65.84 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 117.354 -1.739 . . . . 0.0 111.328 177.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.2 54.51 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.3 mp -104.69 16.06 26.76 Favored 'General case' 0 N--CA 1.486 1.337 0 N-CA-C 114.475 1.287 . . . . 0.0 114.475 -176.289 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.02 124.19 22.98 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.536 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.23 15.95 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 2.4 m -85.05 -13.51 11.27 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.906 0 CA-C-N 118.754 0.706 . . . . 0.0 112.498 179.237 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.48 160.55 43.24 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.402 1.001 . . . . 0.0 112.471 -179.223 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 126.35 21.06 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' HIS . . . . . 0.433 ' CE1' ' CD2' ' A' ' 64' ' ' HIS . 0.0 OUTLIER -139.94 169.29 17.99 Favored 'General case' 0 C--N 1.352 0.702 0 CA-C-N 113.504 -1.68 . . . . 0.0 110.459 -174.069 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -131.98 164.84 25.28 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 177.307 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' HIS . . . . . 0.572 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.0 OUTLIER -143.24 153.95 60.31 Favored Pre-proline 0 N--CA 1.485 1.312 0 N-CA-C 107.184 -1.413 . . . . 0.0 107.184 173.142 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.57 3.08 8.02 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 C-N-CA 120.772 0.981 . . . . 0.0 114.61 -174.869 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 145.15 55.36 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . 0.554 ' OE2' ' CE2' ' A' ' 70' ' ' TYR . 6.0 tt0 -127.92 128.01 44.36 Favored 'General case' 0 N--CA 1.485 1.304 0 O-C-N 124.277 0.985 . . . . 0.0 109.613 179.932 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.97 124.79 49.64 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.127 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . 0.767 ' HH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . 0.472 HD13 ' HA ' ' A' ' 86' ' ' LEU . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . 0.49 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 119.21 22.24 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' HIS . . . . . 0.767 ' CE1' ' HH ' ' A' ' 70' ' ' TYR . 1.5 p80 -150.74 171.43 17.18 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 122.148 0.975 . . . . 0.0 112.529 -177.37 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' CYS . . . . . 0.658 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -169.38 168.43 9.55 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 174.213 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.44 38.35 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.96 120.32 4.77 Favored Glycine 0 N--CA 1.447 -0.608 0 N-CA-C 105.19 -3.164 . . . . 0.0 105.19 176.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.88 111.31 34.46 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.856 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 202' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.558 0 CA-C-O 117.596 -1.192 . . . . 0.0 108.238 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.63 126.28 73.84 Favored Pre-proline 0 N--CA 1.489 1.476 0 C-N-CA 123.354 0.662 . . . . 0.0 110.86 -178.172 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.65 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.801 0 C-N-CA 121.832 1.688 . . . . 0.0 112.97 -175.286 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' THR . . . . . 0.44 ' HA ' HE21 ' A' ' 44' ' ' GLN . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.608 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . 0.608 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 125.51 12.15 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -136.69 152.67 50.64 Favored 'General case' 0 CA--C 1.492 -1.258 0 O-C-N 123.741 0.651 . . . . 0.0 109.9 -178.447 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 163.62 -163.43 35.7 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.728 -2.177 . . . . 0.0 113.208 178.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.38 179.97 46.24 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 119.724 -1.227 . . . . 0.0 113.298 -176.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 132.74 35.07 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . 0.263 0.3 OUTLIER -114.71 20.36 15.3 Favored 'General case' 0 N--CA 1.477 0.908 0 O-C-N 117.712 -3.117 . . . . 0.0 114.69 -176.107 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -55.24 -32.2 62.11 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 117.133 -1.827 . . . . 0.0 111.328 174.548 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 -0.15 54.19 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -103.1 14.9 30.76 Favored 'General case' 0 N--CA 1.49 1.565 0 N-CA-C 114.478 1.288 . . . . 0.0 114.478 -176.366 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.44 124.19 23.5 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -177.753 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.79 16.34 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -81.43 -17.27 11.98 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.906 0 O-C-N 125.025 1.453 . . . . 0.0 112.908 178.981 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -154.67 160.55 41.47 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 118.659 0.663 . . . . 0.0 112.471 -176.632 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 131.26 41.5 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -151.13 -179.79 7.62 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.784 -0.644 . . . . 0.0 109.575 -178.404 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -137.62 164.42 28.83 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -175.411 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' HIS . . . . . 0.579 ' CE1' ' CD ' ' A' ' 68' ' ' GLU . 0.0 OUTLIER -141.47 151.93 62.22 Favored Pre-proline 0 N--CA 1.496 1.835 0 N-CA-C 106.959 -1.497 . . . . 0.0 106.959 174.678 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -79.88 3.08 7.89 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 C-N-CA 120.77 0.98 . . . . 0.0 114.61 -176.587 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 147.9 52.31 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . 0.579 ' CD ' ' CE1' ' A' ' 64' ' ' HIS . 14.0 pt-20 -136.06 135.12 39.12 Favored 'General case' 0 N--CA 1.47 0.554 0 N-CA-C 108.909 -0.775 . . . . 0.0 108.909 176.664 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -105.76 124.79 50.13 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 -178.162 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . 0.756 ' HH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . 0.472 HD13 ' HA ' ' A' ' 86' ' ' LEU . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . 0.49 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 119.79 23.05 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' HIS . . . . . 0.756 ' CE1' ' HH ' ' A' ' 70' ' ' TYR . 3.4 p80 -151.82 172.51 16.05 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-O 122.15 0.976 . . . . 0.0 112.223 -177.616 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' CYS . . . . . 0.605 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -170.04 168.43 8.49 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 174.755 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.78 37.78 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -117.98 121.23 5.0 Favored Glycine 0 C--N 1.313 -0.737 0 N-CA-C 104.952 -3.259 . . . . 0.0 104.952 176.712 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -106.09 111.31 34.59 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.607 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 124' ' ' LEU . . . . . 0.412 HD23 ' OE1' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 202' ' ' TRP . . . . . . . . . . . . . 40.8 m0 . . . . . 0 N--CA 1.49 1.553 0 CA-C-O 117.123 -1.417 . . . . 0.0 109.469 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.76 126.17 73.78 Favored Pre-proline 0 N--CA 1.489 1.483 0 C-N-CA 123.322 0.649 . . . . 0.0 110.881 -178.12 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.178 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' THR . . . . . 0.44 ' HA ' HE21 ' A' ' 44' ' ' GLN . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.608 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . 0.608 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.46 12.89 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.93 154.93 48.39 Favored 'General case' 0 CA--C 1.491 -1.316 0 N-CA-C 109.571 -0.529 . . . . 0.0 109.571 -179.235 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.55 -163.43 35.12 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 118.07 -2.014 . . . . 0.0 113.208 -179.851 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.38 179.97 46.24 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 119.724 -1.227 . . . . 0.0 113.298 -176.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.15 35.05 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -109.14 14.34 23.96 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 119.504 -1.998 . . . . 0.0 115.235 -175.56 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.24 -32.2 66.3 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.773 -1.971 . . . . 0.0 111.328 178.645 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.1 54.42 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.2 mp -104.3 15.8 27.52 Favored 'General case' 0 N--CA 1.486 1.339 0 N-CA-C 114.497 1.295 . . . . 0.0 114.497 -176.321 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.12 124.19 23.11 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.343 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.48 16.13 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 2.2 m -84.94 -13.64 11.29 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.777 0 CA-C-N 118.631 0.651 . . . . 0.0 112.719 179.124 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.83 160.55 43.09 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.183 0.901 . . . . 0.0 112.471 -179.052 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 129.6 33.75 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' HIS . . . . . 0.456 ' CE1' ' NE2' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -147.97 175.5 10.93 Favored 'General case' 0 N--CA 1.446 -0.655 0 CA-C-N 114.811 -1.086 . . . . 0.0 110.263 -176.649 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' THR . . . . . 0.546 ' C ' ' ND1' ' A' ' 64' ' ' HIS . 28.7 p -134.83 163.15 30.46 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -177.435 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' HIS . . . . . 0.877 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -135.09 147.05 60.92 Favored Pre-proline 0 N--CA 1.493 1.676 0 C-N-CA 123.965 0.906 . . . . 0.0 108.857 177.954 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -79.28 3.08 7.78 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 N-CA-C 114.61 0.966 . . . . 0.0 114.61 178.782 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 144.74 55.64 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 6.7 tt0 -126.52 124.92 41.14 Favored 'General case' 0 CA--C 1.553 1.073 0 O-C-N 124.917 1.385 . . . . 0.0 110.392 -178.869 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.06 124.79 49.19 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.179 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . 0.897 ' HH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . 0.472 HD13 ' HA ' ' A' ' 86' ' ' LEU . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . 0.49 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 116.53 19.86 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' HIS . . . . . 0.897 ' CE1' ' HH ' ' A' ' 70' ' ' TYR . 0.0 OUTLIER -144.43 164.59 30.39 Favored 'General case' 0 C--N 1.341 0.222 0 N-CA-C 114.194 1.183 . . . . 0.0 114.194 -174.946 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' CYS . . . . . 0.746 ' N ' ' HD1' ' A' ' 107' ' ' HIS . 7.3 p -166.11 168.43 15.44 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 170.633 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 150.93 39.24 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.36 120.17 4.77 Favored Glycine 0 N--CA 1.448 -0.543 0 N-CA-C 104.982 -3.247 . . . . 0.0 104.982 176.852 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.6 111.31 34.31 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -179.057 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 202' ' ' TRP . . . . . . . . . . . . . 1.2 m0 . . . . . 0 N--CA 1.49 1.529 0 CA-C-O 118.114 -0.946 . . . . 0.0 109.31 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.56 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.67 126.1 74.18 Favored Pre-proline 0 N--CA 1.489 1.521 0 C-N-CA 123.428 0.691 . . . . 0.0 110.853 -178.135 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.234 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' THR . . . . . 0.44 ' HA ' HE21 ' A' ' 44' ' ' GLN . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.608 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . 0.608 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.32 12.78 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.68 154.7 48.62 Favored 'General case' 0 CA--C 1.491 -1.295 0 N-CA-C 109.524 -0.547 . . . . 0.0 109.524 -179.151 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.69 -163.39 35.18 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 118.029 -2.034 . . . . 0.0 113.208 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.34 -179.94 46.27 Favored Glycine 0 N--CA 1.445 -0.703 0 C-N-CA 119.668 -1.254 . . . . 0.0 113.289 -176.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.22 133.29 35.01 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.48 -1.86 . . . . 0.0 107.908 -177.599 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -109.08 14.05 24.2 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 119.618 -1.926 . . . . 0.0 115.383 -175.627 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.18 -32.2 66.2 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.782 -1.967 . . . . 0.0 111.328 178.775 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.19 54.5 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.2 mp -104.59 15.98 26.96 Favored 'General case' 0 N--CA 1.486 1.353 0 N-CA-C 114.488 1.292 . . . . 0.0 114.488 -176.284 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.06 124.19 23.03 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.468 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.54 16.17 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 2.1 m -85.07 -13.58 11.25 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.793 0 N-CA-C 112.816 0.673 . . . . 0.0 112.816 179.223 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.91 160.55 43.06 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.094 0.861 . . . . 0.0 112.471 -179.176 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 128.06 27.25 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -143.66 173.57 11.55 Favored 'General case' 0 CA--C 1.513 -0.471 0 CA-C-N 114.44 -1.255 . . . . 0.0 109.906 -175.516 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -134.3 165.5 24.98 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 179.569 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' HIS . . . . . 0.578 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.0 OUTLIER -145.43 154.39 52.98 Favored Pre-proline 0 N--CA 1.481 1.099 0 N-CA-C 107.255 -1.387 . . . . 0.0 107.255 172.404 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.33 3.08 7.97 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 C-N-CA 120.946 1.097 . . . . 0.0 114.61 -173.161 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 145.02 55.49 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 40.1 tt0 -128.36 128.5 44.64 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 123.766 0.666 . . . . 0.0 109.463 179.311 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.58 124.79 49.45 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.315 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . 0.832 ' HH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . 0.472 HD13 ' HA ' ' A' ' 86' ' ' LEU . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . 0.49 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 118.75 21.72 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' HIS . . . . . 0.832 ' CE1' ' HH ' ' A' ' 70' ' ' TYR . 1.0 OUTLIER -149.16 170.15 19.1 Favored 'General case' 0 CA--C 1.518 -0.252 0 CA-C-O 122.108 0.956 . . . . 0.0 113.213 -176.9 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' CYS . . . . . 0.654 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -168.97 168.43 10.21 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 173.215 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.05 39.04 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.48 119.89 4.67 Favored Glycine 0 N--CA 1.451 -0.357 0 N-CA-C 104.924 -3.27 . . . . 0.0 104.924 176.915 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.33 111.31 34.15 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -179.104 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 202' ' ' TRP . . . . . . . . . . . . . 8.6 m0 . . . . . 0 N--CA 1.489 1.507 0 CA-C-O 118.571 -0.728 . . . . 0.0 110.004 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.76 126.17 73.78 Favored Pre-proline 0 N--CA 1.489 1.483 0 C-N-CA 123.322 0.649 . . . . 0.0 110.881 -178.12 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.178 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' THR . . . . . 0.44 ' HA ' HE21 ' A' ' 44' ' ' GLN . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.608 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . 0.608 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 125.59 12.22 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -136.81 152.82 50.72 Favored 'General case' 0 CA--C 1.493 -1.239 0 O-C-N 123.731 0.644 . . . . 0.0 109.904 -178.486 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 163.51 -163.43 35.64 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.685 -2.198 . . . . 0.0 113.208 179.012 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.4 179.94 46.25 Favored Glycine 0 N--CA 1.444 -0.812 0 C-N-CA 119.745 -1.217 . . . . 0.0 113.343 -176.912 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.15 35.05 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.506 -1.847 . . . . 0.0 107.908 -177.646 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -109.06 14.27 24.09 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 119.573 -1.955 . . . . 0.0 115.238 -175.519 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.28 -32.2 66.39 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.778 -1.969 . . . . 0.0 111.328 178.731 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 -0.04 54.29 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -103.75 15.44 28.77 Favored 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 114.438 1.273 . . . . 0.0 114.438 -176.428 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.15 124.19 23.14 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.135 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.61 16.22 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -82.23 -16.41 11.8 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.923 0 O-C-N 124.729 1.268 . . . . 0.0 112.874 179.103 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -154.24 160.55 41.86 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 118.833 0.742 . . . . 0.0 112.471 -177.258 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 128.09 27.37 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -143.84 173.58 11.57 Favored 'General case' 0 CA--C 1.516 -0.347 0 CA-C-N 114.512 -1.222 . . . . 0.0 109.911 -175.468 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -134.3 164.67 26.88 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 179.701 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' HIS . . . . . 0.536 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.0 OUTLIER -143.77 153.54 57.93 Favored Pre-proline 0 N--CA 1.484 1.272 0 N-CA-C 106.906 -1.516 . . . . 0.0 106.906 173.051 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -79.96 3.08 7.9 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 C-N-CA 121.104 1.203 . . . . 0.0 114.61 -174.226 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 143.61 56.24 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . 0.558 ' HG3' HD23 ' A' ' 124' ' ' LEU . 0.1 OUTLIER -120.15 120.81 37.26 Favored 'General case' 0 N--CA 1.506 2.342 0 O-C-N 125.931 2.019 . . . . 0.0 111.397 -178.3 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -102.4 124.79 48.6 Favored 'General case' 0 N--CA 1.498 1.961 0 CA-C-N 120.735 1.607 . . . . 0.0 107.536 175.528 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . 0.746 ' HH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . 0.472 HD13 ' HA ' ' A' ' 86' ' ' LEU . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . 0.49 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . 0.431 ' HB ' ' HB3' ' A' ' 68' ' ' GLU . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 118.89 21.85 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' HIS . . . . . 0.746 ' CE1' ' HH ' ' A' ' 70' ' ' TYR . 1.4 p80 -150.2 170.72 18.3 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 121.961 0.886 . . . . 0.0 112.554 -177.01 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' CYS . . . . . 0.65 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -168.97 168.43 10.21 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 173.904 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.6 38.08 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -117.43 120.76 4.89 Favored Glycine 0 C--N 1.315 -0.629 0 N-CA-C 105.009 -3.236 . . . . 0.0 105.009 176.833 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.97 111.31 34.52 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.793 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 124' ' ' LEU . . . . . 0.558 HD23 ' HG3' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 202' ' ' TRP . . . . . . . . . . . . . 41.0 m0 . . . . . 0 N--CA 1.491 1.59 0 CA-C-O 117.526 -1.226 . . . . 0.0 109.664 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.56 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.82 126.18 73.62 Favored Pre-proline 0 N--CA 1.489 1.484 0 C-N-CA 123.354 0.661 . . . . 0.0 110.825 -178.075 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.171 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' THR . . . . . 0.44 ' HA ' HE21 ' A' ' 44' ' ' GLN . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.608 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . 0.608 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.09 12.6 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.11 154.15 49.23 Favored 'General case' 0 CA--C 1.492 -1.281 0 N-CA-C 109.654 -0.498 . . . . 0.0 109.654 -178.96 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . 0.425 ' HA2' ' CE2' ' A' ' 202' ' ' TRP . . . 162.94 -163.4 35.32 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.941 -2.076 . . . . 0.0 113.208 179.714 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.35 179.94 46.2 Favored Glycine 0 N--CA 1.444 -0.774 0 C-N-CA 119.67 -1.252 . . . . 0.0 113.27 -176.916 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.08 35.05 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -108.89 14.16 24.37 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 119.555 -1.966 . . . . 0.0 115.229 -175.541 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.28 -32.2 66.39 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.778 -1.969 . . . . 0.0 111.328 178.794 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.16 54.47 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.3 mp -104.44 15.87 27.29 Favored 'General case' 0 N--CA 1.486 1.354 0 N-CA-C 114.482 1.29 . . . . 0.0 114.482 -176.296 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.1 124.19 23.08 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.397 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.56 16.18 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 2.4 m -85.24 -13.51 11.2 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.816 0 CA-C-N 118.648 0.658 . . . . 0.0 112.73 179.236 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.71 160.55 43.14 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.153 0.888 . . . . 0.0 112.471 -179.217 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 129.84 34.88 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -148.38 177.23 9.62 Favored 'General case' 0 CA--C 1.515 -0.366 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.712 -177.238 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -135.89 164.81 27.09 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -177.116 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -142.68 153.29 61.41 Favored Pre-proline 0 N--CA 1.495 1.808 0 N-CA-C 106.896 -1.52 . . . . 0.0 106.896 173.65 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.28 3.08 7.97 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 C-N-CA 120.818 1.012 . . . . 0.0 114.61 -175.614 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 145.11 55.39 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . 0.546 ' CG ' HD23 ' A' ' 124' ' ' LEU . 0.3 OUTLIER -121.19 122.63 40.4 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 126.751 2.532 . . . . 0.0 112.971 -178.906 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -104.57 124.79 49.93 Favored 'General case' 0 N--CA 1.498 1.961 0 CA-C-N 120.444 1.475 . . . . 0.0 107.536 176.102 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . 0.803 ' HH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . 0.472 HD13 ' HA ' ' A' ' 86' ' ' LEU . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . 0.49 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 118.97 21.93 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' HIS . . . . . 0.803 ' CE1' ' HH ' ' A' ' 70' ' ' TYR . 2.0 p80 -150.04 171.35 16.99 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 122.181 0.991 . . . . 0.0 112.555 -177.34 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' CYS . . . . . 0.663 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -169.44 168.43 9.46 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 173.792 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.23 38.73 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.69 120.21 4.76 Favored Glycine 0 N--CA 1.448 -0.539 0 N-CA-C 105.034 -3.226 . . . . 0.0 105.034 176.925 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.71 111.31 34.37 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 124' ' ' LEU . . . . . 0.546 HD23 ' CG ' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 202' ' ' TRP . . . . . 0.425 ' CE2' ' HA2' ' A' ' 47' ' ' GLY . 13.1 m0 . . . . . 0 N--CA 1.491 1.575 0 CA-C-O 117.229 -1.367 . . . . 0.0 109.439 . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.7 126.13 74.03 Favored Pre-proline 0 N--CA 1.489 1.477 0 C-N-CA 123.359 0.664 . . . . 0.0 110.886 -178.126 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.2 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' THR . . . . . 0.44 ' HA ' HE21 ' A' ' 44' ' ' GLN . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.608 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . 0.608 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.64 13.03 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -139.18 155.29 47.94 Favored 'General case' 0 CA--C 1.49 -1.356 0 N-CA-C 109.514 -0.551 . . . . 0.0 109.514 -179.329 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.33 -163.43 35.0 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 118.037 -2.03 . . . . 0.0 113.208 -179.801 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.4 179.93 46.24 Favored Glycine 0 N--CA 1.444 -0.812 0 C-N-CA 119.745 -1.217 . . . . 0.0 113.368 -176.912 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.14 132.47 35.09 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.514 -1.843 . . . . 0.0 107.908 -177.643 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . 0.263 0.3 OUTLIER -114.5 20.2 15.57 Favored 'General case' 0 C--N 1.312 -1.04 0 O-C-N 117.72 -3.112 . . . . 0.0 114.683 -175.974 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -55.07 -32.2 61.75 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 117.366 -1.734 . . . . 0.0 111.328 174.57 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 6.42 49.09 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -111.5 10.79 21.33 Favored 'General case' 2 N--CA 1.62 8.062 0 O-C-N 124.811 1.319 . . . . 0.0 111.199 -170.476 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.04 124.19 23.01 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.244 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.34 16.03 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 1.9 m -83.93 -14.51 11.51 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.919 0 O-C-N 124.134 0.896 . . . . 0.0 112.816 179.222 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -153.33 160.55 42.71 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.095 0.861 . . . . 0.0 112.471 -178.52 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 128.37 28.47 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -144.64 174.11 11.25 Favored 'General case' 0 CA--C 1.518 -0.274 0 CA-C-N 114.684 -1.144 . . . . 0.0 109.829 -175.619 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -134.54 164.89 26.46 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -179.772 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' HIS . . . . . 0.468 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.0 OUTLIER -144.39 154.07 56.44 Favored Pre-proline 0 N--CA 1.484 1.254 0 N-CA-C 106.895 -1.52 . . . . 0.0 106.895 172.617 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.09 3.08 7.93 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 C-N-CA 121.146 1.231 . . . . 0.0 114.61 -173.75 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 145.68 54.82 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 23.6 tt0 -128.93 128.44 43.76 Favored 'General case' 0 N--CA 1.478 0.945 0 O-C-N 124.052 0.845 . . . . 0.0 110.103 179.599 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -104.22 124.79 49.75 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.742 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . 0.805 ' HH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 142.11 29.27 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 14.6 tp -132.36 121.37 23.39 Favored 'General case' 2 C--N 1.468 5.722 0 N-CA-C 102.143 -3.28 . . . . 0.0 102.143 179.921 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . 0.472 HD13 ' HA ' ' A' ' 86' ' ' LEU . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . 0.49 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 118.46 21.46 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' HIS . . . . . 0.805 ' CE1' ' HH ' ' A' ' 70' ' ' TYR . 0.7 OUTLIER -148.91 169.35 20.75 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 122.042 0.925 . . . . 0.0 113.172 -176.556 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' CYS . . . . . 0.645 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -168.41 168.43 11.25 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 173.111 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.49 38.28 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -117.19 120.96 4.98 Favored Glycine 0 N--CA 1.446 -0.684 0 N-CA-C 104.99 -3.244 . . . . 0.0 104.99 176.779 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -106.12 111.31 34.6 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.882 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 202' ' ' TRP . . . . . . . . . . . . . 3.3 m0 . . . . . 0 N--CA 1.487 1.386 0 CA-C-O 118.209 -0.901 . . . . 0.0 109.111 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.56 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.73 126.13 73.94 Favored Pre-proline 0 N--CA 1.489 1.477 0 C-N-CA 123.386 0.674 . . . . 0.0 110.882 -178.127 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.178 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' THR . . . . . 0.44 ' HA ' HE21 ' A' ' 44' ' ' GLN . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.608 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . 0.608 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.48 12.9 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.96 154.88 48.35 Favored 'General case' 0 CA--C 1.491 -1.316 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 -179.202 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.58 -163.43 35.14 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 118.041 -2.028 . . . . 0.0 113.208 -179.852 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.38 179.97 46.24 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 119.724 -1.227 . . . . 0.0 113.298 -176.946 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.1 35.05 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -108.52 13.92 25.0 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 119.751 -1.843 . . . . 0.0 115.39 -175.544 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.57 -32.2 66.9 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.774 -1.97 . . . . 0.0 111.328 179.044 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.19 54.5 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.6 mp -103.85 15.22 29.2 Favored 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 114.517 1.303 . . . . 0.0 114.517 -176.223 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.35 124.19 23.39 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -177.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.47 16.12 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 2.2 m -84.85 -13.76 11.29 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.812 0 O-C-N 123.766 0.667 . . . . 0.0 112.705 179.169 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.83 160.55 43.09 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.198 0.908 . . . . 0.0 112.471 -178.996 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 129.44 33.01 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' HIS . . . . . 0.469 ' CE1' ' NE2' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -147.65 175.15 11.11 Favored 'General case' 0 N--CA 1.447 -0.607 0 CA-C-N 114.756 -1.111 . . . . 0.0 110.303 -176.527 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' THR . . . . . 0.553 ' C ' ' ND1' ' A' ' 64' ' ' HIS . 28.7 p -134.64 163.1 30.51 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -177.615 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' HIS . . . . . 0.878 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -135.12 147.07 60.94 Favored Pre-proline 0 N--CA 1.492 1.666 0 C-N-CA 123.931 0.892 . . . . 0.0 108.831 177.9 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -79.23 3.08 7.77 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 CA-C-N 119.819 0.971 . . . . 0.0 114.61 178.861 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 144.74 55.64 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 6.9 tt0 -126.59 125.11 41.42 Favored 'General case' 0 CA--C 1.553 1.088 0 O-C-N 124.879 1.362 . . . . 0.0 110.342 -178.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.13 124.79 49.23 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.18 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . 0.899 ' HH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . 0.472 HD13 ' HA ' ' A' ' 86' ' ' LEU . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . 0.49 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 116.39 19.77 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' HIS . . . . . 0.899 ' CE1' ' HH ' ' A' ' 70' ' ' TYR . 0.0 OUTLIER -144.06 164.24 31.21 Favored 'General case' 0 C--N 1.341 0.224 0 N-CA-C 114.331 1.234 . . . . 0.0 114.331 -174.866 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' CYS . . . . . 0.748 ' N ' ' HD1' ' A' ' 107' ' ' HIS . 7.3 p -165.96 168.43 15.73 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 170.457 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 150.81 39.44 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.25 120.12 4.77 Favored Glycine 0 N--CA 1.448 -0.509 0 N-CA-C 104.894 -3.282 . . . . 0.0 104.894 176.863 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.52 111.31 34.26 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -179.107 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 202' ' ' TRP . . . . . . . . . . . . . 1.3 m0 . . . . . 0 N--CA 1.489 1.501 0 CA-C-O 118.272 -0.87 . . . . 0.0 109.396 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.61 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.8 126.03 74.01 Favored Pre-proline 0 N--CA 1.488 1.428 0 C-N-CA 123.358 0.663 . . . . 0.0 110.963 -178.117 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.46 107.32 2.36 Favored 'Trans proline' 0 C--N 1.323 -0.799 0 C-N-CA 121.836 1.691 . . . . 0.0 112.97 -175.1 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' THR . . . . . 0.44 ' HA ' HE21 ' A' ' 44' ' ' GLN . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.608 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . 0.608 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.13 12.63 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.2 153.95 49.14 Favored 'General case' 0 CA--C 1.493 -1.233 0 O-C-N 123.524 0.515 . . . . 0.0 109.729 -178.841 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.99 -163.46 35.39 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.965 -2.064 . . . . 0.0 113.208 179.792 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.45 179.97 46.3 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 119.699 -1.239 . . . . 0.0 113.319 -176.95 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 132.53 35.08 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.506 -1.847 . . . . 0.0 107.908 -177.646 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . 0.266 0.3 OUTLIER -114.53 20.49 15.32 Favored 'General case' 0 C--N 1.316 -0.849 0 O-C-N 117.804 -3.06 . . . . 0.0 114.774 -175.974 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -55.47 -32.2 62.62 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 117.33 -1.748 . . . . 0.0 111.328 174.542 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.2 54.51 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.2 mp -104.2 15.71 27.79 Favored 'General case' 0 N--CA 1.488 1.448 0 N-CA-C 114.529 1.307 . . . . 0.0 114.529 -176.419 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.17 124.19 23.17 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.249 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.71 16.28 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 1.6 m -84.97 -13.94 11.21 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.668 0 CA-C-N 118.669 0.668 . . . . 0.0 112.787 179.043 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.69 160.55 43.15 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.086 0.857 . . . . 0.0 112.471 -178.93 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 127.14 23.68 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -141.7 171.22 14.36 Favored 'General case' 0 C--N 1.351 0.634 0 CA-C-N 114.027 -1.442 . . . . 0.0 110.184 -174.718 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -133.0 165.53 24.52 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 178.347 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' HIS . . . . . 0.604 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.0 OUTLIER -145.55 154.04 52.07 Favored Pre-proline 0 N--CA 1.48 1.052 0 N-CA-C 107.208 -1.404 . . . . 0.0 107.208 172.63 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.17 3.08 7.94 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 C-N-CA 121.04 1.16 . . . . 0.0 114.61 -173.122 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 144.3 55.87 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 33.1 tt0 -126.3 127.34 45.42 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 124.286 0.991 . . . . 0.0 109.456 179.857 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.4 124.79 49.36 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 177.428 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . 0.816 ' HH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . 0.472 HD13 ' HA ' ' A' ' 86' ' ' LEU . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . 0.49 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 119.08 22.07 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' HIS . . . . . 0.816 ' CE1' ' HH ' ' A' ' 70' ' ' TYR . 1.0 OUTLIER -150.21 171.04 17.58 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 122.16 0.981 . . . . 0.0 112.737 -177.18 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' CYS . . . . . 0.669 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -169.29 168.43 9.69 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 173.848 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 150.76 39.53 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.2 120.04 4.74 Favored Glycine 0 N--CA 1.448 -0.509 0 N-CA-C 104.947 -3.261 . . . . 0.0 104.947 176.857 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.46 111.31 34.22 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -179.058 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 202' ' ' TRP . . . . . . . . . . . . . 11.6 m0 . . . . . 0 N--CA 1.488 1.449 0 CA-C-O 118.012 -0.994 . . . . 0.0 109.683 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.76 126.17 73.78 Favored Pre-proline 0 N--CA 1.489 1.483 0 C-N-CA 123.322 0.649 . . . . 0.0 110.881 -178.12 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.178 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' THR . . . . . 0.44 ' HA ' HE21 ' A' ' 44' ' ' GLN . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.608 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . 0.608 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.44 12.88 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.93 154.89 48.38 Favored 'General case' 0 CA--C 1.49 -1.346 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 -179.235 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.59 -163.4 35.13 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 118.059 -2.02 . . . . 0.0 113.208 -179.847 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.35 179.94 46.2 Favored Glycine 0 N--CA 1.444 -0.774 0 C-N-CA 119.67 -1.252 . . . . 0.0 113.27 -176.916 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 132.59 35.08 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . 0.268 0.3 OUTLIER -114.57 20.43 15.34 Favored 'General case' 0 C--N 1.316 -0.869 0 O-C-N 117.821 -3.049 . . . . 0.0 114.791 -176.067 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -55.34 -32.2 62.34 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 117.275 -1.77 . . . . 0.0 111.328 174.557 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.09 54.41 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.2 mp -104.13 15.67 27.92 Favored 'General case' 0 N--CA 1.486 1.357 0 N-CA-C 114.559 1.318 . . . . 0.0 114.559 -176.327 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.23 124.19 23.24 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.237 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.51 16.15 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 2.2 m -84.97 -13.68 11.27 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.781 0 CA-C-N 118.613 0.642 . . . . 0.0 112.73 179.168 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.8 160.55 43.11 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.161 0.892 . . . . 0.0 112.471 -179.046 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 129.57 33.62 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' HIS . . . . . 0.456 ' CE1' ' NE2' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -147.89 175.47 10.93 Favored 'General case' 0 N--CA 1.446 -0.625 0 CA-C-N 114.785 -1.098 . . . . 0.0 110.259 -176.62 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' THR . . . . . 0.546 ' C ' ' ND1' ' A' ' 64' ' ' HIS . 28.7 p -134.83 163.16 30.44 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -177.49 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' HIS . . . . . 0.877 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -135.18 147.04 60.72 Favored Pre-proline 0 N--CA 1.492 1.646 0 C-N-CA 124.013 0.925 . . . . 0.0 108.925 177.879 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -79.24 3.08 7.77 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 CA-C-N 119.809 0.968 . . . . 0.0 114.61 178.894 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 144.74 55.64 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 6.7 tt0 -126.52 124.92 41.14 Favored 'General case' 0 CA--C 1.553 1.073 0 O-C-N 124.917 1.385 . . . . 0.0 110.392 -178.869 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.06 124.79 49.19 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.179 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . 0.897 ' HH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . 0.472 HD13 ' HA ' ' A' ' 86' ' ' LEU . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . 0.49 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 116.51 19.84 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' HIS . . . . . 0.897 ' CE1' ' HH ' ' A' ' 70' ' ' TYR . 0.0 OUTLIER -144.39 164.61 30.32 Favored 'General case' 0 C--N 1.341 0.2 0 N-CA-C 114.211 1.189 . . . . 0.0 114.211 -174.976 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' CYS . . . . . 0.745 ' N ' ' HD1' ' A' ' 107' ' ' HIS . 7.3 p -166.11 168.43 15.44 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 170.633 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 150.93 39.24 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.34 120.12 4.76 Favored Glycine 0 N--CA 1.447 -0.596 0 N-CA-C 104.976 -3.249 . . . . 0.0 104.976 176.901 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.6 111.31 34.31 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -179.055 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 202' ' ' TRP . . . . . . . . . . . . . 1.3 m0 . . . . . 0 N--CA 1.49 1.557 0 CA-C-O 118.232 -0.89 . . . . 0.0 109.367 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.75 126.23 73.65 Favored Pre-proline 0 N--CA 1.489 1.483 0 C-N-CA 123.322 0.649 . . . . 0.0 110.847 -178.12 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.57 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.778 0 C-N-CA 121.855 1.704 . . . . 0.0 112.97 -175.211 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' THR . . . . . 0.44 ' HA ' HE21 ' A' ' 44' ' ' GLN . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.608 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . 0.608 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 125.32 12.0 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -136.32 152.39 50.62 Favored 'General case' 0 CA--C 1.497 -1.084 0 O-C-N 123.731 0.644 . . . . 0.0 109.833 -178.296 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . 0.452 ' HA2' ' CE2' ' A' ' 202' ' ' TRP . . . 163.75 -163.4 35.75 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.651 -2.214 . . . . 0.0 113.208 178.775 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.35 179.94 46.2 Favored Glycine 0 N--CA 1.444 -0.774 0 C-N-CA 119.67 -1.252 . . . . 0.0 113.27 -176.916 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 132.45 35.08 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -106.74 13.12 28.36 Favored 'General case' 0 N--CA 1.492 1.664 0 N-CA-C 115.597 1.702 . . . . 0.0 115.597 -175.034 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -58.91 -32.2 69.32 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 117.26 -1.776 . . . . 0.0 111.328 179.714 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 -0.23 54.12 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 47.9 mt -104.23 16.42 26.23 Favored 'General case' 0 C--N 1.364 1.224 0 N-CA-C 114.879 1.437 . . . . 0.0 114.879 -177.065 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -67.69 124.19 22.56 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.726 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.93 16.44 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -86.5 -12.96 10.91 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.621 0 CA-C-N 119.548 1.067 . . . . 0.0 112.281 178.766 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -151.41 160.55 43.69 Favored 'General case' 0 C--O 1.281 2.733 0 C-N-CA 119.023 -1.071 . . . . 0.0 112.471 -179.581 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 130.62 38.49 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -150.02 178.87 8.54 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.613 -0.721 . . . . 0.0 109.6 -177.933 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -136.78 164.82 27.38 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -176.04 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' HIS . . . . . 0.58 ' CE1' ' CD ' ' A' ' 68' ' ' GLU . 0.0 OUTLIER -142.21 152.38 61.0 Favored Pre-proline 0 N--CA 1.495 1.78 0 N-CA-C 107.12 -1.437 . . . . 0.0 107.12 174.393 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.1 3.08 7.93 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 N-CA-C 114.61 0.966 . . . . 0.0 114.61 -176.145 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 148.11 52.04 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . 0.58 ' CD ' ' CE1' ' A' ' 64' ' ' HIS . 16.9 pt-20 -136.47 136.21 39.26 Favored 'General case' 0 CA--C 1.517 -0.304 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 176.452 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -106.53 124.79 50.13 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 -177.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . 0.776 ' HH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . 0.472 HD13 ' HA ' ' A' ' 86' ' ' LEU . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . 0.49 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 119.69 22.91 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' HIS . . . . . 0.776 ' CE1' ' HH ' ' A' ' 70' ' ' TYR . 3.5 p80 -151.42 172.49 15.86 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 122.176 0.988 . . . . 0.0 112.399 -177.665 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' CYS . . . . . 0.61 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -170.1 168.43 8.39 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 174.521 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.5 38.26 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -117.01 120.25 4.75 Favored Glycine 0 N--CA 1.447 -0.627 0 N-CA-C 105.152 -3.179 . . . . 0.0 105.152 176.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.85 111.31 34.45 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.856 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 124' ' ' LEU . . . . . 0.425 HD23 ' OE1' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 202' ' ' TRP . . . . . 0.452 ' CE2' ' HA2' ' A' ' 47' ' ' GLY . 9.5 m0 . . . . . 0 N--CA 1.49 1.542 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.289 . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.56 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.73 126.13 73.94 Favored Pre-proline 0 N--CA 1.489 1.477 0 C-N-CA 123.386 0.674 . . . . 0.0 110.882 -178.127 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.178 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' THR . . . . . 0.44 ' HA ' HE21 ' A' ' 44' ' ' GLN . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.608 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . 0.608 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 125.55 12.18 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -136.67 152.65 50.64 Favored 'General case' 0 CA--C 1.493 -1.217 0 O-C-N 123.773 0.67 . . . . 0.0 109.94 -178.401 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 163.58 -163.46 35.7 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.683 -2.198 . . . . 0.0 113.208 178.939 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.45 179.97 46.3 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 119.699 -1.239 . . . . 0.0 113.319 -176.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.12 35.05 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.506 -1.847 . . . . 0.0 107.908 -177.646 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -108.96 14.19 24.26 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 119.604 -1.935 . . . . 0.0 115.302 -175.559 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.27 -32.2 66.37 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.805 -1.958 . . . . 0.0 111.328 178.773 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 -0.02 54.31 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -103.65 15.28 29.23 Favored 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 114.449 1.278 . . . . 0.0 114.449 -176.38 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.21 124.19 23.22 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.031 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.64 16.24 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -81.89 -16.77 11.88 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.958 0 O-C-N 124.906 1.379 . . . . 0.0 112.928 179.114 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -154.43 160.55 41.69 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 118.758 0.708 . . . . 0.0 112.471 -177.057 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 128.2 27.82 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -144.13 173.83 11.4 Favored 'General case' 0 CA--C 1.516 -0.334 0 CA-C-N 114.575 -1.193 . . . . 0.0 109.86 -175.556 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -134.43 164.77 26.69 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 179.886 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' HIS . . . . . 0.538 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.0 OUTLIER -143.85 153.6 57.73 Favored Pre-proline 0 N--CA 1.483 1.182 0 N-CA-C 106.989 -1.486 . . . . 0.0 106.989 173.042 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.04 3.08 7.92 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 C-N-CA 121.075 1.183 . . . . 0.0 114.61 -174.215 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 143.69 56.19 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . 0.54 ' HG3' HD23 ' A' ' 124' ' ' LEU . 0.1 OUTLIER -120.08 120.78 37.25 Favored 'General case' 0 N--CA 1.507 2.385 0 O-C-N 125.999 2.062 . . . . 0.0 111.502 -178.315 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -102.49 124.79 48.68 Favored 'General case' 0 N--CA 1.498 1.961 0 CA-C-N 120.76 1.618 . . . . 0.0 107.536 175.493 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . 0.747 ' HH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . 0.472 HD13 ' HA ' ' A' ' 86' ' ' LEU . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . 0.49 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . 0.42 ' HB ' ' HB3' ' A' ' 68' ' ' GLU . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 118.89 21.85 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' HIS . . . . . 0.747 ' CE1' ' HH ' ' A' ' 70' ' ' TYR . 1.4 p80 -150.23 170.75 18.23 Favored 'General case' 0 C--N 1.322 -0.597 0 C-N-CA 119.462 -0.895 . . . . 0.0 112.54 -177.031 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' CYS . . . . . 0.65 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -168.96 168.43 10.23 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 173.932 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.6 38.08 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -117.43 120.76 4.89 Favored Glycine 0 C--N 1.315 -0.629 0 N-CA-C 105.009 -3.236 . . . . 0.0 105.009 176.833 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.97 111.31 34.52 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.793 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 124' ' ' LEU . . . . . 0.54 HD23 ' HG3' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 202' ' ' TRP . . . . . . . . . . . . . 41.6 m0 . . . . . 0 N--CA 1.491 1.586 0 CA-C-O 117.459 -1.258 . . . . 0.0 109.754 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.76 126.17 73.78 Favored Pre-proline 0 N--CA 1.489 1.483 0 C-N-CA 123.322 0.649 . . . . 0.0 110.881 -178.12 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.178 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' THR . . . . . 0.44 ' HA ' HE21 ' A' ' 44' ' ' GLN . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.608 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . 0.608 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.44 12.88 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.93 154.88 48.38 Favored 'General case' 0 CA--C 1.49 -1.33 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 -179.204 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.59 -163.43 35.14 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 118.059 -2.02 . . . . 0.0 113.208 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.38 179.97 46.24 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 119.724 -1.227 . . . . 0.0 113.298 -176.946 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 132.99 35.06 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -108.8 14.19 24.46 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 119.569 -1.957 . . . . 0.0 115.265 -175.538 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.35 -32.2 66.5 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.789 -1.965 . . . . 0.0 111.328 178.784 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.08 54.4 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.2 mp -104.43 15.98 27.07 Favored 'General case' 0 N--CA 1.487 1.389 0 N-CA-C 114.396 1.258 . . . . 0.0 114.396 -176.322 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.06 124.19 23.03 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.467 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.53 16.16 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 2.5 m -85.06 -13.6 11.25 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.787 0 O-C-N 123.801 0.688 . . . . 0.0 112.737 179.241 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.86 160.55 43.08 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.187 0.903 . . . . 0.0 112.471 -179.11 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 129.64 33.92 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' HIS . . . . . 0.452 ' CE1' ' NE2' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -148.05 175.55 10.91 Favored 'General case' 0 N--CA 1.447 -0.601 0 CA-C-N 114.8 -1.091 . . . . 0.0 110.244 -176.666 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' THR . . . . . 0.544 ' C ' ' ND1' ' A' ' 64' ' ' HIS . 28.7 p -134.85 163.16 30.44 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -177.385 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' HIS . . . . . 0.875 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -135.14 147.03 60.76 Favored Pre-proline 0 N--CA 1.492 1.631 0 C-N-CA 124.031 0.932 . . . . 0.0 108.869 177.939 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -79.27 3.08 7.78 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 N-CA-C 114.61 0.966 . . . . 0.0 114.61 178.825 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 144.74 55.64 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 6.7 tt0 -126.52 124.92 41.14 Favored 'General case' 0 CA--C 1.553 1.073 0 O-C-N 124.917 1.385 . . . . 0.0 110.392 -178.869 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.06 124.79 49.19 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.179 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . 0.898 ' HH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . 0.472 HD13 ' HA ' ' A' ' 86' ' ' LEU . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . 0.49 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 116.51 19.84 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 107' ' ' HIS . . . . . 0.898 ' CE1' ' HH ' ' A' ' 70' ' ' TYR . 0.0 OUTLIER -144.35 164.57 30.41 Favored 'General case' 0 C--N 1.341 0.2 0 N-CA-C 114.23 1.196 . . . . 0.0 114.23 -174.956 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 108' ' ' CYS . . . . . 0.746 ' N ' ' HD1' ' A' ' 107' ' ' HIS . 7.3 p -166.11 168.43 15.44 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 170.599 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 150.99 39.15 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.52 120.47 4.86 Favored Glycine 0 N--CA 1.447 -0.616 0 N-CA-C 104.946 -3.261 . . . . 0.0 104.946 176.766 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.72 111.31 34.37 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -179.023 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 202' ' ' TRP . . . . . . . . . . . . . 1.7 m0 . . . . . 0 N--CA 1.487 1.416 0 CA-C-O 118.167 -0.921 . . . . 0.0 109.419 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.77 126.21 73.66 Favored Pre-proline 0 N--CA 1.49 1.534 0 C-N-CA 123.364 0.665 . . . . 0.0 110.762 -178.076 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.261 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' THR . . . . . 0.44 ' HA ' HE21 ' A' ' 44' ' ' GLN . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.608 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . 0.608 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.24 12.72 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.28 154.41 49.04 Favored 'General case' 0 CA--C 1.488 -1.434 0 N-CA-C 109.662 -0.496 . . . . 0.0 109.662 -179.056 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.76 -163.46 35.26 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.972 -2.061 . . . . 0.0 113.208 179.738 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.47 179.82 46.22 Favored Glycine 0 N--CA 1.444 -0.785 0 C-N-CA 119.66 -1.257 . . . . 0.0 113.27 -176.858 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.07 133.07 35.09 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.494 -1.853 . . . . 0.0 107.908 -177.692 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . 0.286 0.3 OUTLIER -114.63 20.64 15.15 Favored 'General case' 0 N--CA 1.473 0.716 0 O-C-N 118.281 -2.762 . . . . 0.0 115.226 -176.201 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -56.19 -32.2 64.14 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 117.243 -1.783 . . . . 0.0 111.328 174.709 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 -1.17 53.11 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 59.6 mt -102.74 15.85 28.16 Favored 'General case' 0 CA--C 1.558 1.278 0 N-CA-C 114.876 1.436 . . . . 0.0 114.876 -176.903 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.13 124.19 23.12 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.321 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.76 16.32 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -86.07 -13.03 11.04 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.535 0 CA-C-N 119.284 0.947 . . . . 0.0 112.389 178.863 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -151.82 160.55 43.52 Favored 'General case' 0 C--O 1.281 2.733 0 C-N-CA 119.206 -0.998 . . . . 0.0 112.471 -179.452 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 128.16 27.67 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -144.0 173.81 11.39 Favored 'General case' 0 CA--C 1.519 -0.235 0 CA-C-N 114.543 -1.208 . . . . 0.0 109.778 -175.395 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -134.5 165.14 25.88 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 179.752 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' HIS . . . . . 0.543 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.0 OUTLIER -144.3 154.34 57.08 Favored Pre-proline 0 N--CA 1.484 1.248 0 N-CA-C 107.151 -1.425 . . . . 0.0 107.151 172.704 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.53 3.08 8.01 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 C-N-CA 120.901 1.068 . . . . 0.0 114.61 -174.026 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 145.57 54.93 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 33.2 tt0 -128.57 128.22 43.82 Favored 'General case' 0 N--CA 1.486 1.372 0 O-C-N 124.232 0.958 . . . . 0.0 110.037 179.554 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.93 124.79 49.62 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.509 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . 0.795 ' HH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . 0.472 HD13 ' HA ' ' A' ' 86' ' ' LEU . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . 0.49 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 118.88 21.84 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 107' ' ' HIS . . . . . 0.795 ' CE1' ' HH ' ' A' ' 70' ' ' TYR . 1.0 OUTLIER -150.11 170.67 18.35 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 121.949 0.88 . . . . 0.0 112.691 -177.034 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 108' ' ' CYS . . . . . 0.652 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -168.98 168.43 10.2 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 173.863 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.49 38.28 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -117.11 120.24 4.74 Favored Glycine 0 N--CA 1.448 -0.562 0 N-CA-C 105.047 -3.221 . . . . 0.0 105.047 177.018 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.77 111.31 34.4 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.86 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 202' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.488 1.45 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 . . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.76 126.17 73.78 Favored Pre-proline 0 N--CA 1.489 1.483 0 C-N-CA 123.322 0.649 . . . . 0.0 110.881 -178.12 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.178 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' THR . . . . . 0.44 ' HA ' HE21 ' A' ' 44' ' ' GLN . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.608 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . 0.608 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 125.51 12.15 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -136.66 152.8 50.81 Favored 'General case' 0 CA--C 1.493 -1.213 0 O-C-N 123.686 0.616 . . . . 0.0 109.894 -178.491 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . 0.462 ' HA2' ' CE2' ' A' ' 202' ' ' TRP . . . 163.54 -163.43 35.66 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.694 -2.193 . . . . 0.0 113.208 178.947 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.4 179.94 46.25 Favored Glycine 0 N--CA 1.444 -0.812 0 C-N-CA 119.745 -1.217 . . . . 0.0 113.343 -176.912 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.25 35.05 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.506 -1.847 . . . . 0.0 107.908 -177.646 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -108.54 13.92 24.97 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 119.879 -1.763 . . . . 0.0 115.585 -175.579 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.79 -32.2 67.3 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.792 -1.963 . . . . 0.0 111.328 179.09 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.15 54.46 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 22.9 mt -104.76 16.14 26.57 Favored 'General case' 0 N--CA 1.484 1.251 0 N-CA-C 114.602 1.334 . . . . 0.0 114.602 -176.64 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -67.5 124.19 22.34 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.652 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.8 16.35 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -86.39 -12.79 10.97 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 CA-C-N 119.446 1.021 . . . . 0.0 112.251 178.85 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -151.62 160.55 43.6 Favored 'General case' 0 C--O 1.281 2.733 0 C-N-CA 119.128 -1.029 . . . . 0.0 112.471 -179.574 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 130.57 38.27 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -149.99 178.85 8.55 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.541 -177.928 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -136.76 164.81 27.4 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -176.03 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' HIS . . . . . 0.582 ' CE1' ' CD ' ' A' ' 68' ' ' GLU . 0.0 OUTLIER -142.03 152.23 61.21 Favored Pre-proline 0 N--CA 1.495 1.807 0 N-CA-C 107.161 -1.422 . . . . 0.0 107.161 174.534 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.1 3.08 7.93 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 N-CA-C 114.61 0.966 . . . . 0.0 114.61 -176.321 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 148.0 52.18 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . 0.582 ' CD ' ' CE1' ' A' ' 64' ' ' HIS . 17.1 pt-20 -136.31 135.83 39.23 Favored 'General case' 0 N--CA 1.465 0.319 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 176.593 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -106.28 124.79 50.13 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 -178.014 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . 0.782 ' HH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . 0.472 HD13 ' HA ' ' A' ' 86' ' ' LEU . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . 0.49 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 119.69 22.91 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 107' ' ' HIS . . . . . 0.782 ' CE1' ' HH ' ' A' ' 70' ' ' TYR . 3.5 p80 -151.3 172.43 15.89 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 122.202 1.001 . . . . 0.0 112.503 -177.633 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 108' ' ' CYS . . . . . 0.603 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -170.13 168.43 8.35 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 174.428 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.41 38.42 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.93 120.24 4.75 Favored Glycine 0 N--CA 1.448 -0.535 0 N-CA-C 105.058 -3.217 . . . . 0.0 105.058 176.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.79 111.31 34.42 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.931 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 124' ' ' LEU . . . . . 0.421 HD23 ' OE1' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 202' ' ' TRP . . . . . 0.462 ' CE2' ' HA2' ' A' ' 47' ' ' GLY . 11.4 m0 . . . . . 0 N--CA 1.49 1.554 0 CA-C-O 117.175 -1.393 . . . . 0.0 109.408 . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.56 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.48 126.15 74.53 Favored Pre-proline 0 N--CA 1.489 1.511 0 C-N-CA 123.444 0.698 . . . . 0.0 110.821 -178.148 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.65 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.801 0 C-N-CA 121.832 1.688 . . . . 0.0 112.97 -175.364 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' THR . . . . . 0.44 ' HA ' HE21 ' A' ' 44' ' ' GLN . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' ALA . . . . . 0.608 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' GLN . . . . . 0.608 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 125.25 11.95 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -136.03 152.2 50.66 Favored 'General case' 0 CA--C 1.494 -1.177 0 O-C-N 123.809 0.693 . . . . 0.0 109.948 -178.28 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . 0.443 ' HA2' ' CE2' ' A' ' 202' ' ' TRP . . . 163.82 -163.43 35.81 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.594 -2.241 . . . . 0.0 113.208 178.618 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.4 179.94 46.25 Favored Glycine 0 N--CA 1.444 -0.812 0 C-N-CA 119.745 -1.217 . . . . 0.0 113.343 -176.912 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.42 35.04 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.506 -1.847 . . . . 0.0 107.908 -177.646 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -108.8 14.11 24.51 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 119.907 -1.746 . . . . 0.0 115.637 -175.622 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.87 -32.2 67.44 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.796 -1.962 . . . . 0.0 111.328 178.98 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 -0.38 54.0 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 67.1 mt -104.03 16.1 27.03 Favored 'General case' 0 C--N 1.363 1.188 0 N-CA-C 114.868 1.433 . . . . 0.0 114.868 -177.309 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -67.16 124.19 21.91 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.773 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.89 16.41 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -86.37 -13.02 10.94 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.765 0 CA-C-N 119.652 1.115 . . . . 0.0 112.087 178.734 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -151.4 160.55 43.69 Favored 'General case' 0 C--O 1.281 2.733 0 C-N-CA 118.903 -1.119 . . . . 0.0 112.471 -179.428 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 131.24 41.38 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -151.05 -179.95 7.74 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.762 -0.653 . . . . 0.0 109.636 -178.348 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -137.54 165.17 26.95 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -175.479 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' HIS . . . . . 0.561 ' CE1' ' CD ' ' A' ' 68' ' ' GLU . 0.0 OUTLIER -143.25 153.01 59.08 Favored Pre-proline 0 N--CA 1.495 1.79 0 N-CA-C 106.942 -1.503 . . . . 0.0 106.942 173.967 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.25 3.08 7.96 Favored 'Trans proline' 0 C--N 1.278 -3.17 0 C-N-CA 120.841 1.027 . . . . 0.0 114.61 -175.432 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 148.14 52.0 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . 0.561 ' CD ' ' CE1' ' A' ' 64' ' ' HIS . 18.0 pt-20 -136.76 135.93 38.48 Favored 'General case' 0 N--CA 1.468 0.457 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 176.473 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -106.18 124.79 50.13 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 -177.833 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' TYR . . . . . 0.77 ' HH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . 0.472 HD13 ' HA ' ' A' ' 86' ' ' LEU . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . 0.49 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 119.42 22.54 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 107' ' ' HIS . . . . . 0.77 ' CE1' ' HH ' ' A' ' 70' ' ' TYR . 3.7 p80 -150.77 172.2 15.99 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 122.184 0.992 . . . . 0.0 112.514 -177.549 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 108' ' ' CYS . . . . . 0.614 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -170.01 168.43 8.55 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 174.154 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.53 38.21 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -117.01 120.38 4.79 Favored Glycine 0 N--CA 1.447 -0.627 0 N-CA-C 105.094 -3.202 . . . . 0.0 105.094 176.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.96 111.31 34.51 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 124' ' ' LEU . . . . . 0.447 HD23 ' OE1' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 202' ' ' TRP . . . . . 0.443 ' CE2' ' HA2' ' A' ' 47' ' ' GLY . 8.7 m0 . . . . . 0 N--CA 1.49 1.531 0 CA-C-O 117.146 -1.407 . . . . 0.0 109.176 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.62 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.53 126.1 74.5 Favored Pre-proline 0 N--CA 1.489 1.511 0 C-N-CA 123.453 0.701 . . . . 0.0 110.821 -178.14 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.59 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.806 0 C-N-CA 121.775 1.65 . . . . 0.0 112.97 -175.369 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 34.0 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.61 13.0 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -139.24 155.23 47.92 Favored 'General case' 0 CA--C 1.49 -1.346 0 N-CA-C 109.438 -0.578 . . . . 0.0 109.438 -179.313 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.41 -163.43 35.04 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 118.072 -2.013 . . . . 0.0 113.208 -179.736 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.38 179.97 46.24 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 119.724 -1.227 . . . . 0.0 113.298 -176.946 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 132.62 35.08 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . 0.266 0.3 OUTLIER -114.64 20.48 15.26 Favored 'General case' 0 C--N 1.317 -0.822 0 O-C-N 117.791 -3.068 . . . . 0.0 114.69 -176.029 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -55.34 -32.2 62.34 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 117.275 -1.77 . . . . 0.0 111.328 174.525 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.15 54.46 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -104.46 15.98 27.04 Favored 'General case' 0 N--CA 1.487 1.383 0 N-CA-C 114.49 1.293 . . . . 0.0 114.49 -176.45 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.01 124.19 22.96 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.484 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.45 16.11 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 2.5 m -84.81 -13.74 11.31 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.753 0 CA-C-N 118.634 0.652 . . . . 0.0 112.657 179.072 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.77 160.55 43.12 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.246 0.93 . . . . 0.0 112.471 -178.941 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 128.65 29.56 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -145.15 174.91 10.66 Favored 'General case' 0 CA--C 1.518 -0.285 0 CA-C-N 114.765 -1.107 . . . . 0.0 109.705 -175.92 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -135.01 165.06 26.22 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -179.46 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 64' ' ' HIS . . . . . 0.507 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.0 OUTLIER -144.47 154.15 56.27 Favored Pre-proline 0 N--CA 1.483 1.184 0 N-CA-C 106.993 -1.484 . . . . 0.0 106.993 172.714 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.29 3.08 7.97 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 C-N-CA 121.065 1.177 . . . . 0.0 114.61 -173.819 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 145.9 54.6 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 68' ' ' GLU . . . . . 0.472 ' HB2' HD23 ' A' ' 124' ' ' LEU . 4.3 tt0 -128.62 128.11 43.53 Favored 'General case' 0 N--CA 1.479 1.011 0 O-C-N 124.479 1.112 . . . . 0.0 110.497 179.738 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -104.38 124.79 49.83 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.649 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 70' ' ' TYR . . . . . 0.676 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 118.59 21.58 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 107' ' ' HIS . . . . . 0.677 ' ND1' ' C ' ' A' ' 107' ' ' HIS . 1.2 p80 -149.42 170.24 19.02 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.949 0.88 . . . . 0.0 112.773 -176.889 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 108' ' ' CYS . . . . . 0.652 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -168.78 168.43 10.56 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 173.457 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.53 38.21 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -117.04 120.26 4.75 Favored Glycine 0 C--N 1.316 -0.569 0 N-CA-C 105.112 -3.195 . . . . 0.0 105.112 176.998 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.87 111.31 34.46 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.904 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 124' ' ' LEU . . . . . 0.472 HD23 ' HB2' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.76 126.17 73.78 Favored Pre-proline 0 N--CA 1.489 1.483 0 C-N-CA 123.322 0.649 . . . . 0.0 110.881 -178.12 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.178 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 34.0 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.44 12.88 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.93 154.89 48.38 Favored 'General case' 0 CA--C 1.49 -1.346 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 -179.235 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.59 -163.4 35.13 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 118.059 -2.02 . . . . 0.0 113.208 -179.847 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.35 179.94 46.2 Favored Glycine 0 N--CA 1.444 -0.774 0 C-N-CA 119.67 -1.252 . . . . 0.0 113.27 -176.916 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.1 35.05 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 50' ' ' LEU . . . . . 0.479 ' H ' HD12 ' A' ' 50' ' ' LEU . 0.0 OUTLIER -108.97 14.24 24.21 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 119.579 -1.95 . . . . 0.0 115.235 -175.545 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.28 -32.2 66.39 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.778 -1.969 . . . . 0.0 111.328 178.741 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.13 54.45 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.2 mp -104.32 15.75 27.62 Favored 'General case' 0 N--CA 1.486 1.371 0 N-CA-C 114.494 1.294 . . . . 0.0 114.494 -176.292 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.1 124.19 23.08 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.329 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.47 16.12 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 2.3 m -84.89 -13.68 11.29 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.781 0 O-C-N 123.766 0.667 . . . . 0.0 112.758 179.132 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.83 160.55 43.09 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.191 0.905 . . . . 0.0 112.471 -179.045 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 129.57 33.62 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 62' ' ' HIS . . . . . 0.612 ' CE1' ' HE2' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -147.89 175.47 10.93 Favored 'General case' 0 N--CA 1.446 -0.625 0 CA-C-N 114.785 -1.098 . . . . 0.0 110.259 -176.62 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 63' ' ' THR . . . . . 0.544 ' C ' ' ND1' ' A' ' 64' ' ' HIS . 28.7 p -134.83 163.2 30.35 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -177.49 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 64' ' ' HIS . . . . . 0.878 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -135.22 147.17 61.18 Favored Pre-proline 0 N--CA 1.492 1.641 0 C-N-CA 123.984 0.914 . . . . 0.0 108.876 177.864 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -79.32 3.08 7.79 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 N-CA-C 114.61 0.966 . . . . 0.0 114.61 178.869 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 144.69 55.67 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 68' ' ' GLU . . . . . 0.436 ' HB2' HD23 ' A' ' 124' ' ' LEU . 6.9 tt0 -126.49 125.0 41.35 Favored 'General case' 0 CA--C 1.553 1.081 0 O-C-N 124.891 1.37 . . . . 0.0 110.378 -178.93 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.06 124.79 49.19 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.179 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 70' ' ' TYR . . . . . 0.761 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 116.53 19.86 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 107' ' ' HIS . . . . . 0.761 ' CE1' ' OH ' ' A' ' 70' ' ' TYR . 0.0 OUTLIER -144.39 164.67 30.15 Favored 'General case' 0 C--N 1.341 0.222 0 N-CA-C 114.273 1.212 . . . . 0.0 114.273 -175.004 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 108' ' ' CYS . . . . . 0.637 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -166.16 168.43 15.35 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 170.626 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 118' ' ' SER . . . . . 0.467 ' O ' HD12 ' A' ' 50' ' ' LEU . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 150.93 39.24 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.35 120.15 4.77 Favored Glycine 0 N--CA 1.448 -0.505 0 N-CA-C 104.911 -3.276 . . . . 0.0 104.911 176.911 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.6 111.31 34.31 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -179.104 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 124' ' ' LEU . . . . . 0.436 HD23 ' HB2' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.7 126.18 73.9 Favored Pre-proline 0 N--CA 1.489 1.477 0 C-N-CA 123.359 0.664 . . . . 0.0 110.852 -178.126 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.57 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.778 0 C-N-CA 121.855 1.704 . . . . 0.0 112.97 -175.232 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 34.0 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.49 12.91 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.96 154.88 48.35 Favored 'General case' 0 CA--C 1.491 -1.301 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 -179.187 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.55 -163.4 35.1 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 118.014 -2.041 . . . . 0.0 113.208 -179.88 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.35 179.94 46.2 Favored Glycine 0 N--CA 1.444 -0.774 0 C-N-CA 119.67 -1.252 . . . . 0.0 113.27 -176.916 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.1 35.05 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 50' ' ' LEU . . . . . 0.475 ' H ' HD12 ' A' ' 50' ' ' LEU . 0.0 OUTLIER -108.94 14.17 24.29 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 119.579 -1.95 . . . . 0.0 115.225 -175.501 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.29 -32.2 66.4 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.811 -1.955 . . . . 0.0 111.328 178.783 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.13 54.44 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.3 mp -104.25 15.71 27.75 Favored 'General case' 0 N--CA 1.486 1.351 0 N-CA-C 114.467 1.284 . . . . 0.0 114.467 -176.254 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.18 124.19 23.18 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.274 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.42 16.08 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 2.6 m -85.1 -13.47 11.26 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.829 0 CA-C-N 118.66 0.664 . . . . 0.0 112.707 179.222 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.74 160.55 43.13 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.205 0.911 . . . . 0.0 112.471 -179.195 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 129.64 33.92 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 62' ' ' HIS . . . . . 0.605 ' CE1' ' HE2' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -148.02 175.52 10.93 Favored 'General case' 0 N--CA 1.446 -0.655 0 CA-C-N 114.8 -1.091 . . . . 0.0 110.305 -176.644 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 63' ' ' THR . . . . . 0.547 ' C ' ' ND1' ' A' ' 64' ' ' HIS . 28.7 p -134.85 163.14 30.5 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -177.416 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 64' ' ' HIS . . . . . 0.877 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -135.11 147.06 60.95 Favored Pre-proline 0 N--CA 1.493 1.692 0 C-N-CA 123.985 0.914 . . . . 0.0 108.875 177.891 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -79.25 3.08 7.77 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 N-CA-C 114.61 0.966 . . . . 0.0 114.61 178.826 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 144.74 55.64 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 68' ' ' GLU . . . . . 0.438 ' HB2' HD23 ' A' ' 124' ' ' LEU . 6.6 tt0 -126.52 124.88 41.04 Favored 'General case' 0 CA--C 1.553 1.096 0 O-C-N 124.936 1.398 . . . . 0.0 110.433 -178.862 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.06 124.79 49.2 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.214 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 70' ' ' TYR . . . . . 0.762 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 116.41 19.78 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 107' ' ' HIS . . . . . 0.762 ' CE1' ' OH ' ' A' ' 70' ' ' TYR . 0.0 OUTLIER -144.15 164.28 31.14 Favored 'General case' 0 C--N 1.342 0.246 0 N-CA-C 114.291 1.219 . . . . 0.0 114.291 -174.882 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 108' ' ' CYS . . . . . 0.634 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -165.96 168.43 15.73 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 170.501 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 118' ' ' SER . . . . . 0.464 ' O ' HD12 ' A' ' 50' ' ' LEU . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.02 39.1 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.6 120.41 4.84 Favored Glycine 0 N--CA 1.448 -0.525 0 N-CA-C 104.938 -3.265 . . . . 0.0 104.938 176.782 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.66 111.31 34.34 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -179.002 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 124' ' ' LEU . . . . . 0.438 HD23 ' HB2' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.76 126.17 73.78 Favored Pre-proline 0 N--CA 1.489 1.483 0 C-N-CA 123.322 0.649 . . . . 0.0 110.881 -178.12 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.178 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 34.0 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.44 12.88 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.93 154.89 48.38 Favored 'General case' 0 CA--C 1.49 -1.346 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 -179.235 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.59 -163.4 35.13 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 118.059 -2.02 . . . . 0.0 113.208 -179.847 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.35 179.94 46.2 Favored Glycine 0 N--CA 1.444 -0.774 0 C-N-CA 119.67 -1.252 . . . . 0.0 113.27 -176.916 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.15 35.05 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' LEU . . . . . 0.48 ' H ' HD12 ' A' ' 50' ' ' LEU . 0.0 OUTLIER -109.05 14.23 24.13 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 119.538 -1.976 . . . . 0.0 115.281 -175.559 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.24 -32.2 66.3 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.773 -1.971 . . . . 0.0 111.328 178.73 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.13 54.45 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.1 mp -104.41 15.88 27.29 Favored 'General case' 0 N--CA 1.487 1.386 0 N-CA-C 114.465 1.283 . . . . 0.0 114.465 -176.273 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.14 124.19 23.13 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.395 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.51 16.15 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 2.1 m -84.96 -13.72 11.26 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.794 0 CA-C-N 118.613 0.642 . . . . 0.0 112.707 179.16 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.74 160.55 43.13 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.166 0.893 . . . . 0.0 112.471 -179.025 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 129.57 33.62 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 62' ' ' HIS . . . . . 0.608 ' CE1' ' HE2' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -147.89 175.4 10.99 Favored 'General case' 0 N--CA 1.447 -0.596 0 CA-C-N 114.785 -1.098 . . . . 0.0 110.256 -176.587 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 63' ' ' THR . . . . . 0.546 ' C ' ' ND1' ' A' ' 64' ' ' HIS . 28.7 p -134.79 163.16 30.42 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -177.495 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 64' ' ' HIS . . . . . 0.878 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -135.19 147.04 60.69 Favored Pre-proline 0 N--CA 1.492 1.671 0 C-N-CA 123.987 0.915 . . . . 0.0 108.842 177.932 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -79.24 3.08 7.77 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 N-CA-C 114.61 0.966 . . . . 0.0 114.61 178.861 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 144.74 55.64 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 68' ' ' GLU . . . . . 0.434 ' HB2' HD23 ' A' ' 124' ' ' LEU . 6.5 tt0 -126.45 124.88 41.13 Favored 'General case' 0 CA--C 1.553 1.096 0 O-C-N 124.917 1.385 . . . . 0.0 110.428 -178.854 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.09 124.79 49.21 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.157 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 70' ' ' TYR . . . . . 0.763 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 116.51 19.84 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 107' ' ' HIS . . . . . 0.763 ' CE1' ' OH ' ' A' ' 70' ' ' TYR . 0.0 OUTLIER -144.35 164.57 30.41 Favored 'General case' 0 C--N 1.341 0.2 0 N-CA-C 114.23 1.196 . . . . 0.0 114.23 -174.956 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 108' ' ' CYS . . . . . 0.637 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -166.11 168.43 15.44 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 170.599 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 118' ' ' SER . . . . . 0.468 ' O ' HD12 ' A' ' 50' ' ' LEU . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 150.93 39.24 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.35 120.15 4.77 Favored Glycine 0 N--CA 1.448 -0.505 0 N-CA-C 104.911 -3.276 . . . . 0.0 104.911 176.911 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.6 111.31 34.31 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -179.104 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 124' ' ' LEU . . . . . 0.434 HD23 ' HB2' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.56 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.66 126.16 74.06 Favored Pre-proline 0 N--CA 1.488 1.469 0 C-N-CA 123.413 0.685 . . . . 0.0 110.925 -178.224 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.56 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.766 0 C-N-CA 121.759 1.639 . . . . 0.0 112.97 -175.215 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 34.0 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 125.24 11.94 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -135.8 152.1 50.75 Favored 'General case' 0 CA--C 1.494 -1.209 0 O-C-N 123.894 0.746 . . . . 0.0 110.059 -178.241 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 163.81 -163.46 35.82 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.502 -2.285 . . . . 0.0 113.208 178.453 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.43 179.98 46.29 Favored Glycine 0 N--CA 1.443 -0.886 0 C-N-CA 119.784 -1.198 . . . . 0.0 113.381 -176.95 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.28 35.04 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.532 -1.834 . . . . 0.0 107.908 -177.641 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' LEU . . . . . 0.46 ' H ' HD12 ' A' ' 50' ' ' LEU . 0.0 OUTLIER -110.42 15.4 22.22 Favored 'General case' 0 N--CA 1.482 1.168 0 O-C-N 119.602 -1.936 . . . . 0.0 115.515 -175.456 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -56.98 -32.2 65.84 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 117.354 -1.739 . . . . 0.0 111.328 177.972 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.2 54.51 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.3 mp -104.69 16.06 26.76 Favored 'General case' 0 N--CA 1.486 1.337 0 N-CA-C 114.475 1.287 . . . . 0.0 114.475 -176.289 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.02 124.19 22.98 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.536 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.23 15.95 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 2.4 m -85.05 -13.51 11.27 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.906 0 CA-C-N 118.754 0.706 . . . . 0.0 112.498 179.237 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.48 160.55 43.24 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.402 1.001 . . . . 0.0 112.471 -179.223 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 126.35 21.06 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' HIS . . . . . 0.433 ' CE1' ' CD2' ' A' ' 64' ' ' HIS . 0.0 OUTLIER -139.94 169.29 17.99 Favored 'General case' 0 C--N 1.352 0.702 0 CA-C-N 113.504 -1.68 . . . . 0.0 110.459 -174.069 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -131.98 164.84 25.28 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 177.307 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 64' ' ' HIS . . . . . 0.572 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.0 OUTLIER -143.24 153.95 60.31 Favored Pre-proline 0 N--CA 1.485 1.312 0 N-CA-C 107.184 -1.413 . . . . 0.0 107.184 173.142 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.57 3.08 8.02 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 C-N-CA 120.772 0.981 . . . . 0.0 114.61 -174.869 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 145.15 55.36 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 68' ' ' GLU . . . . . 0.554 ' OE2' ' CE2' ' A' ' 70' ' ' TYR . 6.0 tt0 -127.92 128.01 44.36 Favored 'General case' 0 N--CA 1.485 1.304 0 O-C-N 124.277 0.985 . . . . 0.0 109.613 179.932 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.97 124.79 49.64 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.127 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 70' ' ' TYR . . . . . 0.654 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 119.21 22.24 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 107' ' ' HIS . . . . . 0.685 ' ND1' ' C ' ' A' ' 107' ' ' HIS . 1.5 p80 -150.74 171.43 17.18 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 122.148 0.975 . . . . 0.0 112.529 -177.37 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 108' ' ' CYS . . . . . 0.658 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -169.38 168.43 9.55 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 174.213 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 118' ' ' SER . . . . . 0.44 ' O ' HD12 ' A' ' 50' ' ' LEU . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 120' ' ' CYS . . . . . 0.407 ' HB3' HD21 ' A' ' 50' ' ' LEU . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.44 38.35 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.96 120.32 4.77 Favored Glycine 0 N--CA 1.447 -0.608 0 N-CA-C 105.19 -3.164 . . . . 0.0 105.19 176.9 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.88 111.31 34.46 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.856 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.63 126.28 73.84 Favored Pre-proline 0 N--CA 1.489 1.476 0 C-N-CA 123.354 0.662 . . . . 0.0 110.86 -178.172 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.65 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.801 0 C-N-CA 121.832 1.688 . . . . 0.0 112.97 -175.286 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 34.0 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 125.51 12.15 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -136.69 152.67 50.64 Favored 'General case' 0 CA--C 1.492 -1.258 0 O-C-N 123.741 0.651 . . . . 0.0 109.9 -178.447 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 163.62 -163.43 35.7 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.728 -2.177 . . . . 0.0 113.208 178.978 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.38 179.97 46.24 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 119.724 -1.227 . . . . 0.0 113.298 -176.946 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 132.74 35.07 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . 0.263 0.3 OUTLIER -114.71 20.36 15.3 Favored 'General case' 0 N--CA 1.477 0.908 0 O-C-N 117.712 -3.117 . . . . 0.0 114.69 -176.107 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -55.24 -32.2 62.11 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 117.133 -1.827 . . . . 0.0 111.328 174.548 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 -0.15 54.19 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -103.1 14.9 30.76 Favored 'General case' 0 N--CA 1.49 1.565 0 N-CA-C 114.478 1.288 . . . . 0.0 114.478 -176.366 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.44 124.19 23.5 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -177.753 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.79 16.34 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.457 HG22 ' H ' ' A' ' 58' ' ' VAL . 0.1 OUTLIER -81.43 -17.27 11.98 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.906 0 O-C-N 125.025 1.453 . . . . 0.0 112.908 178.981 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -154.67 160.55 41.47 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 118.659 0.663 . . . . 0.0 112.471 -176.632 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 131.26 41.5 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -151.13 -179.79 7.62 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.784 -0.644 . . . . 0.0 109.575 -178.404 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -137.62 164.42 28.83 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -175.411 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 64' ' ' HIS . . . . . 0.579 ' CE1' ' CD ' ' A' ' 68' ' ' GLU . 0.0 OUTLIER -141.47 151.93 62.22 Favored Pre-proline 0 N--CA 1.496 1.835 0 N-CA-C 106.959 -1.497 . . . . 0.0 106.959 174.678 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -79.88 3.08 7.89 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 C-N-CA 120.77 0.98 . . . . 0.0 114.61 -176.587 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 147.9 52.31 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 68' ' ' GLU . . . . . 0.762 ' HB3' HD23 ' A' ' 124' ' ' LEU . 14.0 pt-20 -136.06 135.12 39.12 Favored 'General case' 0 N--CA 1.47 0.554 0 N-CA-C 108.909 -0.775 . . . . 0.0 108.909 176.664 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -105.76 124.79 50.13 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 -178.162 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 70' ' ' TYR . . . . . 0.715 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 119.79 23.05 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 107' ' ' HIS . . . . . 0.715 ' CE1' ' OH ' ' A' ' 70' ' ' TYR . 3.4 p80 -151.82 172.51 16.05 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-O 122.15 0.976 . . . . 0.0 112.223 -177.616 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 108' ' ' CYS . . . . . 0.605 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -170.04 168.43 8.49 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 174.755 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.78 37.78 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -117.98 121.23 5.0 Favored Glycine 0 C--N 1.313 -0.737 0 N-CA-C 104.952 -3.259 . . . . 0.0 104.952 176.712 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -106.09 111.31 34.59 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.607 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 124' ' ' LEU . . . . . 0.762 HD23 ' HB3' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.76 126.17 73.78 Favored Pre-proline 0 N--CA 1.489 1.483 0 C-N-CA 123.322 0.649 . . . . 0.0 110.881 -178.12 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.178 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 34.0 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.46 12.89 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.93 154.93 48.39 Favored 'General case' 0 CA--C 1.491 -1.316 0 N-CA-C 109.571 -0.529 . . . . 0.0 109.571 -179.235 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.55 -163.43 35.12 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 118.07 -2.014 . . . . 0.0 113.208 -179.851 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.38 179.97 46.24 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 119.724 -1.227 . . . . 0.0 113.298 -176.946 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.15 35.05 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 50' ' ' LEU . . . . . 0.481 ' H ' HD12 ' A' ' 50' ' ' LEU . 0.0 OUTLIER -109.14 14.34 23.96 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 119.504 -1.998 . . . . 0.0 115.235 -175.56 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.24 -32.2 66.3 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.773 -1.971 . . . . 0.0 111.328 178.645 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.1 54.42 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.2 mp -104.3 15.8 27.52 Favored 'General case' 0 N--CA 1.486 1.339 0 N-CA-C 114.497 1.295 . . . . 0.0 114.497 -176.321 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.12 124.19 23.11 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.343 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.48 16.13 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 2.2 m -84.94 -13.64 11.29 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.777 0 CA-C-N 118.631 0.651 . . . . 0.0 112.719 179.124 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.83 160.55 43.09 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.183 0.901 . . . . 0.0 112.471 -179.052 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 129.6 33.75 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 62' ' ' HIS . . . . . 0.61 ' CE1' ' HE2' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -147.97 175.5 10.93 Favored 'General case' 0 N--CA 1.446 -0.655 0 CA-C-N 114.811 -1.086 . . . . 0.0 110.263 -176.649 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 63' ' ' THR . . . . . 0.546 ' C ' ' ND1' ' A' ' 64' ' ' HIS . 28.7 p -134.83 163.15 30.46 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -177.435 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 64' ' ' HIS . . . . . 0.877 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -135.09 147.05 60.92 Favored Pre-proline 0 N--CA 1.493 1.676 0 C-N-CA 123.965 0.906 . . . . 0.0 108.857 177.954 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -79.28 3.08 7.78 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 N-CA-C 114.61 0.966 . . . . 0.0 114.61 178.782 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 144.74 55.64 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 68' ' ' GLU . . . . . 0.436 ' HB2' HD23 ' A' ' 124' ' ' LEU . 6.7 tt0 -126.52 124.92 41.14 Favored 'General case' 0 CA--C 1.553 1.073 0 O-C-N 124.917 1.385 . . . . 0.0 110.392 -178.869 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.06 124.79 49.19 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.179 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 70' ' ' TYR . . . . . 0.763 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 116.53 19.86 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 107' ' ' HIS . . . . . 0.763 ' CE1' ' OH ' ' A' ' 70' ' ' TYR . 0.0 OUTLIER -144.43 164.59 30.39 Favored 'General case' 0 C--N 1.341 0.222 0 N-CA-C 114.194 1.183 . . . . 0.0 114.194 -174.946 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 108' ' ' CYS . . . . . 0.637 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -166.11 168.43 15.44 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 170.633 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 118' ' ' SER . . . . . 0.466 ' O ' HD12 ' A' ' 50' ' ' LEU . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 150.93 39.24 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.36 120.17 4.77 Favored Glycine 0 N--CA 1.448 -0.543 0 N-CA-C 104.982 -3.247 . . . . 0.0 104.982 176.852 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.6 111.31 34.31 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -179.057 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 124' ' ' LEU . . . . . 0.436 HD23 ' HB2' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.56 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.67 126.1 74.18 Favored Pre-proline 0 N--CA 1.489 1.521 0 C-N-CA 123.428 0.691 . . . . 0.0 110.853 -178.135 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.234 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 34.0 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.32 12.78 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.68 154.7 48.62 Favored 'General case' 0 CA--C 1.491 -1.295 0 N-CA-C 109.524 -0.547 . . . . 0.0 109.524 -179.151 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.69 -163.39 35.18 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 118.029 -2.034 . . . . 0.0 113.208 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.34 -179.94 46.27 Favored Glycine 0 N--CA 1.445 -0.703 0 C-N-CA 119.668 -1.254 . . . . 0.0 113.289 -176.972 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.22 133.29 35.01 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.48 -1.86 . . . . 0.0 107.908 -177.599 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' LEU . . . . . 0.52 ' H ' HD12 ' A' ' 50' ' ' LEU . 0.0 OUTLIER -109.08 14.05 24.2 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 119.618 -1.926 . . . . 0.0 115.383 -175.627 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.18 -32.2 66.2 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.782 -1.967 . . . . 0.0 111.328 178.775 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.19 54.5 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.2 mp -104.59 15.98 26.96 Favored 'General case' 0 N--CA 1.486 1.353 0 N-CA-C 114.488 1.292 . . . . 0.0 114.488 -176.284 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.06 124.19 23.03 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.468 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.54 16.17 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.418 ' H ' HG22 ' A' ' 58' ' ' VAL . 2.1 m -85.07 -13.58 11.25 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.793 0 N-CA-C 112.816 0.673 . . . . 0.0 112.816 179.223 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.91 160.55 43.06 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.094 0.861 . . . . 0.0 112.471 -179.176 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 128.06 27.25 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -143.66 173.57 11.55 Favored 'General case' 0 CA--C 1.513 -0.471 0 CA-C-N 114.44 -1.255 . . . . 0.0 109.906 -175.516 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -134.3 165.5 24.98 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 179.569 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 64' ' ' HIS . . . . . 0.578 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.0 OUTLIER -145.43 154.39 52.98 Favored Pre-proline 0 N--CA 1.481 1.099 0 N-CA-C 107.255 -1.387 . . . . 0.0 107.255 172.404 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.33 3.08 7.97 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 C-N-CA 120.946 1.097 . . . . 0.0 114.61 -173.161 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 145.02 55.49 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 68' ' ' GLU . . . . . 0.42 ' HB2' HD23 ' A' ' 124' ' ' LEU . 40.1 tt0 -128.36 128.5 44.64 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 123.766 0.666 . . . . 0.0 109.463 179.311 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.58 124.79 49.45 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.315 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 70' ' ' TYR . . . . . 0.725 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 118.75 21.72 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 107' ' ' HIS . . . . . 0.725 ' CE1' ' OH ' ' A' ' 70' ' ' TYR . 1.0 OUTLIER -149.16 170.15 19.1 Favored 'General case' 0 CA--C 1.518 -0.252 0 CA-C-O 122.108 0.956 . . . . 0.0 113.213 -176.9 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 108' ' ' CYS . . . . . 0.654 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -168.97 168.43 10.21 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 173.215 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 118' ' ' SER . . . . . 0.503 ' O ' HD12 ' A' ' 50' ' ' LEU . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 120' ' ' CYS . . . . . 0.409 ' CB ' HD21 ' A' ' 50' ' ' LEU . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.05 39.04 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.48 119.89 4.67 Favored Glycine 0 N--CA 1.451 -0.357 0 N-CA-C 104.924 -3.27 . . . . 0.0 104.924 176.915 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.33 111.31 34.15 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -179.104 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 124' ' ' LEU . . . . . 0.42 HD23 ' HB2' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.76 126.17 73.78 Favored Pre-proline 0 N--CA 1.489 1.483 0 C-N-CA 123.322 0.649 . . . . 0.0 110.881 -178.12 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.178 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 34.0 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 125.59 12.22 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -136.81 152.82 50.72 Favored 'General case' 0 CA--C 1.493 -1.239 0 O-C-N 123.731 0.644 . . . . 0.0 109.904 -178.486 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 163.51 -163.43 35.64 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.685 -2.198 . . . . 0.0 113.208 179.012 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.4 179.94 46.25 Favored Glycine 0 N--CA 1.444 -0.812 0 C-N-CA 119.745 -1.217 . . . . 0.0 113.343 -176.912 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.15 35.05 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.506 -1.847 . . . . 0.0 107.908 -177.646 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' LEU . . . . . 0.48 ' H ' HD12 ' A' ' 50' ' ' LEU . 0.0 OUTLIER -109.06 14.27 24.09 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 119.573 -1.955 . . . . 0.0 115.238 -175.519 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.28 -32.2 66.39 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.778 -1.969 . . . . 0.0 111.328 178.731 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 -0.04 54.29 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -103.75 15.44 28.77 Favored 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 114.438 1.273 . . . . 0.0 114.438 -176.428 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.15 124.19 23.14 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.135 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.61 16.22 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.46 HG22 ' H ' ' A' ' 58' ' ' VAL . 0.3 OUTLIER -82.23 -16.41 11.8 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.923 0 O-C-N 124.729 1.268 . . . . 0.0 112.874 179.103 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -154.24 160.55 41.86 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 118.833 0.742 . . . . 0.0 112.471 -177.258 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 128.09 27.37 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -143.84 173.58 11.57 Favored 'General case' 0 CA--C 1.516 -0.347 0 CA-C-N 114.512 -1.222 . . . . 0.0 109.911 -175.468 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -134.3 164.67 26.88 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 179.701 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 64' ' ' HIS . . . . . 0.536 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.0 OUTLIER -143.77 153.54 57.93 Favored Pre-proline 0 N--CA 1.484 1.272 0 N-CA-C 106.906 -1.516 . . . . 0.0 106.906 173.051 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -79.96 3.08 7.9 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 C-N-CA 121.104 1.203 . . . . 0.0 114.61 -174.226 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 143.61 56.24 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 68' ' ' GLU . . . . . 0.511 ' HB3' ' HB ' ' A' ' 101' ' ' ILE . 0.1 OUTLIER -120.15 120.81 37.26 Favored 'General case' 0 N--CA 1.506 2.342 0 O-C-N 125.931 2.019 . . . . 0.0 111.397 -178.3 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -102.4 124.79 48.6 Favored 'General case' 0 N--CA 1.498 1.961 0 CA-C-N 120.735 1.607 . . . . 0.0 107.536 175.528 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 70' ' ' TYR . . . . . 0.65 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 101' ' ' ILE . . . . . 0.511 ' HB ' ' HB3' ' A' ' 68' ' ' GLU . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 118.89 21.85 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 107' ' ' HIS . . . . . 0.678 ' ND1' ' C ' ' A' ' 107' ' ' HIS . 1.4 p80 -150.2 170.72 18.3 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 121.961 0.886 . . . . 0.0 112.554 -177.01 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 108' ' ' CYS . . . . . 0.65 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -168.97 168.43 10.21 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 173.904 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 118' ' ' SER . . . . . 0.469 ' O ' HD12 ' A' ' 50' ' ' LEU . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.6 38.08 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -117.43 120.76 4.89 Favored Glycine 0 C--N 1.315 -0.629 0 N-CA-C 105.009 -3.236 . . . . 0.0 105.009 176.833 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.97 111.31 34.52 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.793 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.56 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.82 126.18 73.62 Favored Pre-proline 0 N--CA 1.489 1.484 0 C-N-CA 123.354 0.661 . . . . 0.0 110.825 -178.075 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.171 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 34.0 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.09 12.6 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.11 154.15 49.23 Favored 'General case' 0 CA--C 1.492 -1.281 0 N-CA-C 109.654 -0.498 . . . . 0.0 109.654 -178.96 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.94 -163.4 35.32 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.941 -2.076 . . . . 0.0 113.208 179.714 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.35 179.94 46.2 Favored Glycine 0 N--CA 1.444 -0.774 0 C-N-CA 119.67 -1.252 . . . . 0.0 113.27 -176.916 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.08 35.05 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' LEU . . . . . 0.479 ' H ' HD12 ' A' ' 50' ' ' LEU . 0.0 OUTLIER -108.89 14.16 24.37 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 119.555 -1.966 . . . . 0.0 115.229 -175.541 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.28 -32.2 66.39 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.778 -1.969 . . . . 0.0 111.328 178.794 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.16 54.47 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.3 mp -104.44 15.87 27.29 Favored 'General case' 0 N--CA 1.486 1.354 0 N-CA-C 114.482 1.29 . . . . 0.0 114.482 -176.296 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.1 124.19 23.08 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.397 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.56 16.18 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 2.4 m -85.24 -13.51 11.2 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.816 0 CA-C-N 118.648 0.658 . . . . 0.0 112.73 179.236 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.71 160.55 43.14 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.153 0.888 . . . . 0.0 112.471 -179.217 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 129.84 34.88 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -148.38 177.23 9.62 Favored 'General case' 0 CA--C 1.515 -0.366 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.712 -177.238 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -135.89 164.81 27.09 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -177.116 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 64' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -142.68 153.29 61.41 Favored Pre-proline 0 N--CA 1.495 1.808 0 N-CA-C 106.896 -1.52 . . . . 0.0 106.896 173.65 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.28 3.08 7.97 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 C-N-CA 120.818 1.012 . . . . 0.0 114.61 -175.614 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 145.11 55.39 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 68' ' ' GLU . . . . . 0.427 ' HG3' HD23 ' A' ' 124' ' ' LEU . 0.3 OUTLIER -121.19 122.63 40.4 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 126.751 2.532 . . . . 0.0 112.971 -178.906 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -104.57 124.79 49.93 Favored 'General case' 0 N--CA 1.498 1.961 0 CA-C-N 120.444 1.475 . . . . 0.0 107.536 176.102 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 70' ' ' TYR . . . . . 0.704 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 118.97 21.93 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 107' ' ' HIS . . . . . 0.704 ' CE1' ' OH ' ' A' ' 70' ' ' TYR . 2.0 p80 -150.04 171.35 16.99 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 122.181 0.991 . . . . 0.0 112.555 -177.34 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 108' ' ' CYS . . . . . 0.663 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -169.44 168.43 9.46 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 173.792 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 118' ' ' SER . . . . . 0.47 ' O ' HD12 ' A' ' 50' ' ' LEU . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.23 38.73 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.69 120.21 4.76 Favored Glycine 0 N--CA 1.448 -0.539 0 N-CA-C 105.034 -3.226 . . . . 0.0 105.034 176.925 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.71 111.31 34.37 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.984 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 124' ' ' LEU . . . . . 0.427 HD23 ' HG3' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.7 126.13 74.03 Favored Pre-proline 0 N--CA 1.489 1.477 0 C-N-CA 123.359 0.664 . . . . 0.0 110.886 -178.126 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.2 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 34.0 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.64 13.03 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -139.18 155.29 47.94 Favored 'General case' 0 CA--C 1.49 -1.356 0 N-CA-C 109.514 -0.551 . . . . 0.0 109.514 -179.329 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.33 -163.43 35.0 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 118.037 -2.03 . . . . 0.0 113.208 -179.801 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.4 179.93 46.24 Favored Glycine 0 N--CA 1.444 -0.812 0 C-N-CA 119.745 -1.217 . . . . 0.0 113.368 -176.912 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.14 132.47 35.09 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.514 -1.843 . . . . 0.0 107.908 -177.643 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . 0.263 0.3 OUTLIER -114.5 20.2 15.57 Favored 'General case' 0 C--N 1.312 -1.04 0 O-C-N 117.72 -3.112 . . . . 0.0 114.683 -175.974 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -55.07 -32.2 61.75 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 117.366 -1.734 . . . . 0.0 111.328 174.57 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 6.42 49.09 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 53' ' ' LEU . . . . . 0.424 ' HA ' HD12 ' A' ' 53' ' ' LEU . 1.0 OUTLIER -111.5 10.79 21.33 Favored 'General case' 2 N--CA 1.62 8.062 0 O-C-N 124.811 1.319 . . . . 0.0 111.199 -170.476 . . . . . . . . 4 4 . 1 . 011 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.04 124.19 23.01 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.244 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.34 16.03 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.432 ' H ' HG22 ' A' ' 58' ' ' VAL . 1.9 m -83.93 -14.51 11.51 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.919 0 O-C-N 124.134 0.896 . . . . 0.0 112.816 179.222 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -153.33 160.55 42.71 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.095 0.861 . . . . 0.0 112.471 -178.52 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 128.37 28.47 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -144.64 174.11 11.25 Favored 'General case' 0 CA--C 1.518 -0.274 0 CA-C-N 114.684 -1.144 . . . . 0.0 109.829 -175.619 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -134.54 164.89 26.46 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -179.772 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 64' ' ' HIS . . . . . 0.468 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.0 OUTLIER -144.39 154.07 56.44 Favored Pre-proline 0 N--CA 1.484 1.254 0 N-CA-C 106.895 -1.52 . . . . 0.0 106.895 172.617 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.09 3.08 7.93 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 C-N-CA 121.146 1.231 . . . . 0.0 114.61 -173.75 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 145.68 54.82 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 68' ' ' GLU . . . . . 0.483 ' HB2' HD23 ' A' ' 124' ' ' LEU . 23.6 tt0 -128.93 128.44 43.76 Favored 'General case' 0 N--CA 1.478 0.945 0 O-C-N 124.052 0.845 . . . . 0.0 110.103 179.599 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -104.22 124.79 49.75 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.742 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 70' ' ' TYR . . . . . 0.695 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 142.11 29.27 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 14.6 tp -132.36 121.37 23.39 Favored 'General case' 2 C--N 1.468 5.722 0 N-CA-C 102.143 -3.28 . . . . 0.0 102.143 179.921 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 118.46 21.46 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 107' ' ' HIS . . . . . 0.695 ' CE1' ' OH ' ' A' ' 70' ' ' TYR . 0.7 OUTLIER -148.91 169.35 20.75 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 122.042 0.925 . . . . 0.0 113.172 -176.556 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 108' ' ' CYS . . . . . 0.645 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -168.41 168.43 11.25 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 173.111 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.49 38.28 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -117.19 120.96 4.98 Favored Glycine 0 N--CA 1.446 -0.684 0 N-CA-C 104.99 -3.244 . . . . 0.0 104.99 176.779 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -106.12 111.31 34.6 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.882 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 124' ' ' LEU . . . . . 0.483 HD23 ' HB2' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.56 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.73 126.13 73.94 Favored Pre-proline 0 N--CA 1.489 1.477 0 C-N-CA 123.386 0.674 . . . . 0.0 110.882 -178.127 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.178 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 34.0 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.48 12.9 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.96 154.88 48.35 Favored 'General case' 0 CA--C 1.491 -1.316 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 -179.202 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.58 -163.43 35.14 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 118.041 -2.028 . . . . 0.0 113.208 -179.852 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.38 179.97 46.24 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 119.724 -1.227 . . . . 0.0 113.298 -176.946 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.1 35.05 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 50' ' ' LEU . . . . . 0.48 HD12 ' O ' ' A' ' 118' ' ' SER . 0.0 OUTLIER -108.52 13.92 25.0 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 119.751 -1.843 . . . . 0.0 115.39 -175.544 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.57 -32.2 66.9 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.774 -1.97 . . . . 0.0 111.328 179.044 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.19 54.5 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.6 mp -103.85 15.22 29.2 Favored 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 114.517 1.303 . . . . 0.0 114.517 -176.223 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.35 124.19 23.39 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -177.955 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.47 16.12 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 2.2 m -84.85 -13.76 11.29 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.812 0 O-C-N 123.766 0.667 . . . . 0.0 112.705 179.169 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.83 160.55 43.09 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.198 0.908 . . . . 0.0 112.471 -178.996 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 129.44 33.01 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 62' ' ' HIS . . . . . 0.615 ' CE1' ' HE2' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -147.65 175.15 11.11 Favored 'General case' 0 N--CA 1.447 -0.607 0 CA-C-N 114.756 -1.111 . . . . 0.0 110.303 -176.527 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 63' ' ' THR . . . . . 0.553 ' C ' ' ND1' ' A' ' 64' ' ' HIS . 28.7 p -134.64 163.1 30.51 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -177.615 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 64' ' ' HIS . . . . . 0.878 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -135.12 147.07 60.94 Favored Pre-proline 0 N--CA 1.492 1.666 0 C-N-CA 123.931 0.892 . . . . 0.0 108.831 177.9 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -79.23 3.08 7.77 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 CA-C-N 119.819 0.971 . . . . 0.0 114.61 178.861 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 144.74 55.64 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 68' ' ' GLU . . . . . 0.44 ' HB2' HD23 ' A' ' 124' ' ' LEU . 6.9 tt0 -126.59 125.11 41.42 Favored 'General case' 0 CA--C 1.553 1.088 0 O-C-N 124.879 1.362 . . . . 0.0 110.342 -178.928 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.13 124.79 49.23 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.18 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 70' ' ' TYR . . . . . 0.762 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 116.39 19.77 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 107' ' ' HIS . . . . . 0.762 ' CE1' ' OH ' ' A' ' 70' ' ' TYR . 0.0 OUTLIER -144.06 164.24 31.21 Favored 'General case' 0 C--N 1.341 0.224 0 N-CA-C 114.331 1.234 . . . . 0.0 114.331 -174.866 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 108' ' ' CYS . . . . . 0.634 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -165.96 168.43 15.73 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 170.457 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 118' ' ' SER . . . . . 0.48 ' O ' HD12 ' A' ' 50' ' ' LEU . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 150.81 39.44 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.25 120.12 4.77 Favored Glycine 0 N--CA 1.448 -0.509 0 N-CA-C 104.894 -3.282 . . . . 0.0 104.894 176.863 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.52 111.31 34.26 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -179.107 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 124' ' ' LEU . . . . . 0.44 HD23 ' HB2' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.61 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.8 126.03 74.01 Favored Pre-proline 0 N--CA 1.488 1.428 0 C-N-CA 123.358 0.663 . . . . 0.0 110.963 -178.117 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.46 107.32 2.36 Favored 'Trans proline' 0 C--N 1.323 -0.799 0 C-N-CA 121.836 1.691 . . . . 0.0 112.97 -175.1 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 34.0 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.13 12.63 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.2 153.95 49.14 Favored 'General case' 0 CA--C 1.493 -1.233 0 O-C-N 123.524 0.515 . . . . 0.0 109.729 -178.841 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.99 -163.46 35.39 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.965 -2.064 . . . . 0.0 113.208 179.792 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.45 179.97 46.3 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 119.699 -1.239 . . . . 0.0 113.319 -176.95 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 132.53 35.08 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.506 -1.847 . . . . 0.0 107.908 -177.646 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . 0.266 0.3 OUTLIER -114.53 20.49 15.32 Favored 'General case' 0 C--N 1.316 -0.849 0 O-C-N 117.804 -3.06 . . . . 0.0 114.774 -175.974 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -55.47 -32.2 62.62 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 117.33 -1.748 . . . . 0.0 111.328 174.542 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.2 54.51 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.2 mp -104.2 15.71 27.79 Favored 'General case' 0 N--CA 1.488 1.448 0 N-CA-C 114.529 1.307 . . . . 0.0 114.529 -176.419 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.17 124.19 23.17 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.249 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.71 16.28 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.418 ' H ' HG22 ' A' ' 58' ' ' VAL . 1.6 m -84.97 -13.94 11.21 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.668 0 CA-C-N 118.669 0.668 . . . . 0.0 112.787 179.043 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.69 160.55 43.15 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.086 0.857 . . . . 0.0 112.471 -178.93 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 127.14 23.68 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -141.7 171.22 14.36 Favored 'General case' 0 C--N 1.351 0.634 0 CA-C-N 114.027 -1.442 . . . . 0.0 110.184 -174.718 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -133.0 165.53 24.52 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 178.347 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 64' ' ' HIS . . . . . 0.604 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.0 OUTLIER -145.55 154.04 52.07 Favored Pre-proline 0 N--CA 1.48 1.052 0 N-CA-C 107.208 -1.404 . . . . 0.0 107.208 172.63 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.17 3.08 7.94 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 C-N-CA 121.04 1.16 . . . . 0.0 114.61 -173.122 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 144.3 55.87 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 33.1 tt0 -126.3 127.34 45.42 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 124.286 0.991 . . . . 0.0 109.456 179.857 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.4 124.79 49.36 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 177.428 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 70' ' ' TYR . . . . . 0.713 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 119.08 22.07 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 107' ' ' HIS . . . . . 0.713 ' CE1' ' OH ' ' A' ' 70' ' ' TYR . 1.0 OUTLIER -150.21 171.04 17.58 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 122.16 0.981 . . . . 0.0 112.737 -177.18 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 108' ' ' CYS . . . . . 0.669 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -169.29 168.43 9.69 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 173.848 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 150.76 39.53 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.2 120.04 4.74 Favored Glycine 0 N--CA 1.448 -0.509 0 N-CA-C 104.947 -3.261 . . . . 0.0 104.947 176.857 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.46 111.31 34.22 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -179.058 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.76 126.17 73.78 Favored Pre-proline 0 N--CA 1.489 1.483 0 C-N-CA 123.322 0.649 . . . . 0.0 110.881 -178.12 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.178 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 34.0 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.44 12.88 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.93 154.89 48.38 Favored 'General case' 0 CA--C 1.49 -1.346 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 -179.235 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.59 -163.4 35.13 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 118.059 -2.02 . . . . 0.0 113.208 -179.847 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.35 179.94 46.2 Favored Glycine 0 N--CA 1.444 -0.774 0 C-N-CA 119.67 -1.252 . . . . 0.0 113.27 -176.916 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 132.59 35.08 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . 0.268 0.3 OUTLIER -114.57 20.43 15.34 Favored 'General case' 0 C--N 1.316 -0.869 0 O-C-N 117.821 -3.049 . . . . 0.0 114.791 -176.067 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -55.34 -32.2 62.34 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 117.275 -1.77 . . . . 0.0 111.328 174.557 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.09 54.41 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.2 mp -104.13 15.67 27.92 Favored 'General case' 0 N--CA 1.486 1.357 0 N-CA-C 114.559 1.318 . . . . 0.0 114.559 -176.327 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.23 124.19 23.24 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.237 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.51 16.15 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 2.2 m -84.97 -13.68 11.27 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.781 0 CA-C-N 118.613 0.642 . . . . 0.0 112.73 179.168 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.8 160.55 43.11 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.161 0.892 . . . . 0.0 112.471 -179.046 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 129.57 33.62 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 62' ' ' HIS . . . . . 0.609 ' CE1' ' HE2' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -147.89 175.47 10.93 Favored 'General case' 0 N--CA 1.446 -0.625 0 CA-C-N 114.785 -1.098 . . . . 0.0 110.259 -176.62 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 63' ' ' THR . . . . . 0.546 ' C ' ' ND1' ' A' ' 64' ' ' HIS . 28.7 p -134.83 163.16 30.44 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -177.49 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 64' ' ' HIS . . . . . 0.877 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -135.18 147.04 60.72 Favored Pre-proline 0 N--CA 1.492 1.646 0 C-N-CA 124.013 0.925 . . . . 0.0 108.925 177.879 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -79.24 3.08 7.77 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 CA-C-N 119.809 0.968 . . . . 0.0 114.61 178.894 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 144.74 55.64 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 68' ' ' GLU . . . . . 0.436 ' HB2' HD23 ' A' ' 124' ' ' LEU . 6.7 tt0 -126.52 124.92 41.14 Favored 'General case' 0 CA--C 1.553 1.073 0 O-C-N 124.917 1.385 . . . . 0.0 110.392 -178.869 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.06 124.79 49.19 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.179 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 70' ' ' TYR . . . . . 0.762 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 116.51 19.84 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 107' ' ' HIS . . . . . 0.762 ' CE1' ' OH ' ' A' ' 70' ' ' TYR . 0.0 OUTLIER -144.39 164.61 30.32 Favored 'General case' 0 C--N 1.341 0.2 0 N-CA-C 114.211 1.189 . . . . 0.0 114.211 -174.976 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 108' ' ' CYS . . . . . 0.636 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -166.11 168.43 15.44 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 170.633 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 150.93 39.24 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.34 120.12 4.76 Favored Glycine 0 N--CA 1.447 -0.596 0 N-CA-C 104.976 -3.249 . . . . 0.0 104.976 176.901 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.6 111.31 34.31 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -179.055 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 124' ' ' LEU . . . . . 0.436 HD23 ' HB2' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.75 126.23 73.65 Favored Pre-proline 0 N--CA 1.489 1.483 0 C-N-CA 123.322 0.649 . . . . 0.0 110.847 -178.12 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.57 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.778 0 C-N-CA 121.855 1.704 . . . . 0.0 112.97 -175.211 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 34.0 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 125.32 12.0 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -136.32 152.39 50.62 Favored 'General case' 0 CA--C 1.497 -1.084 0 O-C-N 123.731 0.644 . . . . 0.0 109.833 -178.296 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 163.75 -163.4 35.75 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.651 -2.214 . . . . 0.0 113.208 178.775 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.35 179.94 46.2 Favored Glycine 0 N--CA 1.444 -0.774 0 C-N-CA 119.67 -1.252 . . . . 0.0 113.27 -176.916 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 132.45 35.08 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 50' ' ' LEU . . . . . 0.577 HD12 ' O ' ' A' ' 118' ' ' SER . 0.0 OUTLIER -106.74 13.12 28.36 Favored 'General case' 0 N--CA 1.492 1.664 0 N-CA-C 115.597 1.702 . . . . 0.0 115.597 -175.034 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -58.91 -32.2 69.32 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 117.26 -1.776 . . . . 0.0 111.328 179.714 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 -0.23 54.12 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 47.9 mt -104.23 16.42 26.23 Favored 'General case' 0 C--N 1.364 1.224 0 N-CA-C 114.879 1.437 . . . . 0.0 114.879 -177.065 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -67.69 124.19 22.56 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.726 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.93 16.44 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -86.5 -12.96 10.91 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.621 0 CA-C-N 119.548 1.067 . . . . 0.0 112.281 178.766 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -151.41 160.55 43.69 Favored 'General case' 0 C--O 1.281 2.733 0 C-N-CA 119.023 -1.071 . . . . 0.0 112.471 -179.581 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 130.62 38.49 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -150.02 178.87 8.54 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.613 -0.721 . . . . 0.0 109.6 -177.933 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -136.78 164.82 27.38 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -176.04 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 64' ' ' HIS . . . . . 0.58 ' CE1' ' CD ' ' A' ' 68' ' ' GLU . 0.0 OUTLIER -142.21 152.38 61.0 Favored Pre-proline 0 N--CA 1.495 1.78 0 N-CA-C 107.12 -1.437 . . . . 0.0 107.12 174.393 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.1 3.08 7.93 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 N-CA-C 114.61 0.966 . . . . 0.0 114.61 -176.145 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 148.11 52.04 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 68' ' ' GLU . . . . . 0.744 ' HB3' HD23 ' A' ' 124' ' ' LEU . 16.9 pt-20 -136.47 136.21 39.26 Favored 'General case' 0 CA--C 1.517 -0.304 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 176.452 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -106.53 124.79 50.13 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 -177.955 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 70' ' ' TYR . . . . . 0.71 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 119.69 22.91 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 107' ' ' HIS . . . . . 0.71 ' CE1' ' OH ' ' A' ' 70' ' ' TYR . 3.5 p80 -151.42 172.49 15.86 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 122.176 0.988 . . . . 0.0 112.399 -177.665 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 108' ' ' CYS . . . . . 0.61 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -170.1 168.43 8.39 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 174.521 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 118' ' ' SER . . . . . 0.577 ' O ' HD12 ' A' ' 50' ' ' LEU . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 120' ' ' CYS . . . . . 0.57 ' HB2' HD21 ' A' ' 50' ' ' LEU . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.5 38.26 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -117.01 120.25 4.75 Favored Glycine 0 N--CA 1.447 -0.627 0 N-CA-C 105.152 -3.179 . . . . 0.0 105.152 176.987 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.85 111.31 34.45 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.856 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 124' ' ' LEU . . . . . 0.744 HD23 ' HB3' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.56 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.73 126.13 73.94 Favored Pre-proline 0 N--CA 1.489 1.477 0 C-N-CA 123.386 0.674 . . . . 0.0 110.882 -178.127 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.178 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 34.0 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 125.55 12.18 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -136.67 152.65 50.64 Favored 'General case' 0 CA--C 1.493 -1.217 0 O-C-N 123.773 0.67 . . . . 0.0 109.94 -178.401 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 163.58 -163.46 35.7 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.683 -2.198 . . . . 0.0 113.208 178.939 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.45 179.97 46.3 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 119.699 -1.239 . . . . 0.0 113.319 -176.95 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.12 35.05 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.506 -1.847 . . . . 0.0 107.908 -177.646 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 50' ' ' LEU . . . . . 0.478 ' H ' HD12 ' A' ' 50' ' ' LEU . 0.0 OUTLIER -108.96 14.19 24.26 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 119.604 -1.935 . . . . 0.0 115.302 -175.559 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.27 -32.2 66.37 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.805 -1.958 . . . . 0.0 111.328 178.773 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 -0.02 54.31 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -103.65 15.28 29.23 Favored 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 114.449 1.278 . . . . 0.0 114.449 -176.38 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.21 124.19 23.22 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.031 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.64 16.24 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.464 HG22 ' H ' ' A' ' 58' ' ' VAL . 0.2 OUTLIER -81.89 -16.77 11.88 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.958 0 O-C-N 124.906 1.379 . . . . 0.0 112.928 179.114 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -154.43 160.55 41.69 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 118.758 0.708 . . . . 0.0 112.471 -177.057 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 128.2 27.82 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -144.13 173.83 11.4 Favored 'General case' 0 CA--C 1.516 -0.334 0 CA-C-N 114.575 -1.193 . . . . 0.0 109.86 -175.556 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -134.43 164.77 26.69 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 179.886 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 64' ' ' HIS . . . . . 0.538 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.0 OUTLIER -143.85 153.6 57.73 Favored Pre-proline 0 N--CA 1.483 1.182 0 N-CA-C 106.989 -1.486 . . . . 0.0 106.989 173.042 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.04 3.08 7.92 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 C-N-CA 121.075 1.183 . . . . 0.0 114.61 -174.215 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 143.69 56.19 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 68' ' ' GLU . . . . . 0.495 ' HB3' ' HB ' ' A' ' 101' ' ' ILE . 0.1 OUTLIER -120.08 120.78 37.25 Favored 'General case' 0 N--CA 1.507 2.385 0 O-C-N 125.999 2.062 . . . . 0.0 111.502 -178.315 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -102.49 124.79 48.68 Favored 'General case' 0 N--CA 1.498 1.961 0 CA-C-N 120.76 1.618 . . . . 0.0 107.536 175.493 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 70' ' ' TYR . . . . . 0.653 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 101' ' ' ILE . . . . . 0.495 ' HB ' ' HB3' ' A' ' 68' ' ' GLU . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 118.89 21.85 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 107' ' ' HIS . . . . . 0.677 ' ND1' ' C ' ' A' ' 107' ' ' HIS . 1.4 p80 -150.23 170.75 18.23 Favored 'General case' 0 C--N 1.322 -0.597 0 C-N-CA 119.462 -0.895 . . . . 0.0 112.54 -177.031 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 108' ' ' CYS . . . . . 0.65 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -168.96 168.43 10.23 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 173.932 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 118' ' ' SER . . . . . 0.468 ' O ' HD12 ' A' ' 50' ' ' LEU . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.6 38.08 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -117.43 120.76 4.89 Favored Glycine 0 C--N 1.315 -0.629 0 N-CA-C 105.009 -3.236 . . . . 0.0 105.009 176.833 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.97 111.31 34.52 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.793 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.76 126.17 73.78 Favored Pre-proline 0 N--CA 1.489 1.483 0 C-N-CA 123.322 0.649 . . . . 0.0 110.881 -178.12 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.178 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 34.0 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.44 12.88 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.93 154.88 48.38 Favored 'General case' 0 CA--C 1.49 -1.33 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 -179.204 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.59 -163.43 35.14 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 118.059 -2.02 . . . . 0.0 113.208 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.38 179.97 46.24 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 119.724 -1.227 . . . . 0.0 113.298 -176.946 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 132.99 35.06 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 50' ' ' LEU . . . . . 0.478 ' H ' HD12 ' A' ' 50' ' ' LEU . 0.0 OUTLIER -108.8 14.19 24.46 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 119.569 -1.957 . . . . 0.0 115.265 -175.538 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.35 -32.2 66.5 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.789 -1.965 . . . . 0.0 111.328 178.784 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.08 54.4 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.2 mp -104.43 15.98 27.07 Favored 'General case' 0 N--CA 1.487 1.389 0 N-CA-C 114.396 1.258 . . . . 0.0 114.396 -176.322 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.06 124.19 23.03 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.467 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.53 16.16 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 2.5 m -85.06 -13.6 11.25 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.787 0 O-C-N 123.801 0.688 . . . . 0.0 112.737 179.241 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.86 160.55 43.08 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.187 0.903 . . . . 0.0 112.471 -179.11 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 129.64 33.92 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 62' ' ' HIS . . . . . 0.606 ' CE1' ' HE2' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -148.05 175.55 10.91 Favored 'General case' 0 N--CA 1.447 -0.601 0 CA-C-N 114.8 -1.091 . . . . 0.0 110.244 -176.666 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 63' ' ' THR . . . . . 0.544 ' C ' ' ND1' ' A' ' 64' ' ' HIS . 28.7 p -134.85 163.16 30.44 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -177.385 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 64' ' ' HIS . . . . . 0.875 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -135.14 147.03 60.76 Favored Pre-proline 0 N--CA 1.492 1.631 0 C-N-CA 124.031 0.932 . . . . 0.0 108.869 177.939 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -79.27 3.08 7.78 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 N-CA-C 114.61 0.966 . . . . 0.0 114.61 178.825 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 144.74 55.64 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 68' ' ' GLU . . . . . 0.437 ' HB2' HD23 ' A' ' 124' ' ' LEU . 6.7 tt0 -126.52 124.92 41.14 Favored 'General case' 0 CA--C 1.553 1.073 0 O-C-N 124.917 1.385 . . . . 0.0 110.392 -178.869 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.06 124.79 49.19 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.179 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 70' ' ' TYR . . . . . 0.763 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 116.51 19.84 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 107' ' ' HIS . . . . . 0.763 ' CE1' ' OH ' ' A' ' 70' ' ' TYR . 0.0 OUTLIER -144.35 164.57 30.41 Favored 'General case' 0 C--N 1.341 0.2 0 N-CA-C 114.23 1.196 . . . . 0.0 114.23 -174.956 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 108' ' ' CYS . . . . . 0.637 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -166.11 168.43 15.44 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 170.599 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 118' ' ' SER . . . . . 0.466 ' O ' HD12 ' A' ' 50' ' ' LEU . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 120' ' ' CYS . . . . . 0.4 ' CB ' HD21 ' A' ' 50' ' ' LEU . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 150.99 39.15 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.52 120.47 4.86 Favored Glycine 0 N--CA 1.447 -0.616 0 N-CA-C 104.946 -3.261 . . . . 0.0 104.946 176.766 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.72 111.31 34.37 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -179.023 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 124' ' ' LEU . . . . . 0.437 HD23 ' HB2' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.77 126.21 73.66 Favored Pre-proline 0 N--CA 1.49 1.534 0 C-N-CA 123.364 0.665 . . . . 0.0 110.762 -178.076 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.261 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 34.0 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.24 12.72 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.28 154.41 49.04 Favored 'General case' 0 CA--C 1.488 -1.434 0 N-CA-C 109.662 -0.496 . . . . 0.0 109.662 -179.056 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.76 -163.46 35.26 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.972 -2.061 . . . . 0.0 113.208 179.738 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.47 179.82 46.22 Favored Glycine 0 N--CA 1.444 -0.785 0 C-N-CA 119.66 -1.257 . . . . 0.0 113.27 -176.858 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.07 133.07 35.09 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.494 -1.853 . . . . 0.0 107.908 -177.692 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 50' ' ' LEU . . . . . 0.624 ' HB3' HD12 ' A' ' 53' ' ' LEU 0.286 0.3 OUTLIER -114.63 20.64 15.15 Favored 'General case' 0 N--CA 1.473 0.716 0 O-C-N 118.281 -2.762 . . . . 0.0 115.226 -176.201 . . . . . . . . 4 4 . 1 . 018 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -56.19 -32.2 64.14 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 117.243 -1.783 . . . . 0.0 111.328 174.709 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 -1.17 53.11 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 53' ' ' LEU . . . . . 0.624 HD12 ' HB3' ' A' ' 50' ' ' LEU . 59.6 mt -102.74 15.85 28.16 Favored 'General case' 0 CA--C 1.558 1.278 0 N-CA-C 114.876 1.436 . . . . 0.0 114.876 -176.903 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.13 124.19 23.12 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.321 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.76 16.32 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -86.07 -13.03 11.04 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.535 0 CA-C-N 119.284 0.947 . . . . 0.0 112.389 178.863 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -151.82 160.55 43.52 Favored 'General case' 0 C--O 1.281 2.733 0 C-N-CA 119.206 -0.998 . . . . 0.0 112.471 -179.452 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 128.16 27.67 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -144.0 173.81 11.39 Favored 'General case' 0 CA--C 1.519 -0.235 0 CA-C-N 114.543 -1.208 . . . . 0.0 109.778 -175.395 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -134.5 165.14 25.88 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 179.752 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 64' ' ' HIS . . . . . 0.543 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.0 OUTLIER -144.3 154.34 57.08 Favored Pre-proline 0 N--CA 1.484 1.248 0 N-CA-C 107.151 -1.425 . . . . 0.0 107.151 172.704 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.53 3.08 8.01 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 C-N-CA 120.901 1.068 . . . . 0.0 114.61 -174.026 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 145.57 54.93 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 68' ' ' GLU . . . . . 0.438 ' HB2' HD23 ' A' ' 124' ' ' LEU . 33.2 tt0 -128.57 128.22 43.82 Favored 'General case' 0 N--CA 1.486 1.372 0 O-C-N 124.232 0.958 . . . . 0.0 110.037 179.554 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.93 124.79 49.62 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.509 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 70' ' ' TYR . . . . . 0.694 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 118.88 21.84 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 107' ' ' HIS . . . . . 0.694 ' CE1' ' OH ' ' A' ' 70' ' ' TYR . 1.0 OUTLIER -150.11 170.67 18.35 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 121.949 0.88 . . . . 0.0 112.691 -177.034 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 108' ' ' CYS . . . . . 0.652 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -168.98 168.43 10.2 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 173.863 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.49 38.28 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -117.11 120.24 4.74 Favored Glycine 0 N--CA 1.448 -0.562 0 N-CA-C 105.047 -3.221 . . . . 0.0 105.047 177.018 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.77 111.31 34.4 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.86 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 124' ' ' LEU . . . . . 0.438 HD23 ' HB2' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.76 126.17 73.78 Favored Pre-proline 0 N--CA 1.489 1.483 0 C-N-CA 123.322 0.649 . . . . 0.0 110.881 -178.12 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.178 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 34.0 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 125.51 12.15 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -136.66 152.8 50.81 Favored 'General case' 0 CA--C 1.493 -1.213 0 O-C-N 123.686 0.616 . . . . 0.0 109.894 -178.491 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 163.54 -163.43 35.66 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.694 -2.193 . . . . 0.0 113.208 178.947 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.4 179.94 46.25 Favored Glycine 0 N--CA 1.444 -0.812 0 C-N-CA 119.745 -1.217 . . . . 0.0 113.343 -176.912 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.25 35.05 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.506 -1.847 . . . . 0.0 107.908 -177.646 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 50' ' ' LEU . . . . . 0.485 HD12 ' O ' ' A' ' 118' ' ' SER . 0.0 OUTLIER -108.54 13.92 24.97 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 119.879 -1.763 . . . . 0.0 115.585 -175.579 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.79 -32.2 67.3 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.792 -1.963 . . . . 0.0 111.328 179.09 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.15 54.46 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 22.9 mt -104.76 16.14 26.57 Favored 'General case' 0 N--CA 1.484 1.251 0 N-CA-C 114.602 1.334 . . . . 0.0 114.602 -176.64 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -67.5 124.19 22.34 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.652 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.8 16.35 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -86.39 -12.79 10.97 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 CA-C-N 119.446 1.021 . . . . 0.0 112.251 178.85 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -151.62 160.55 43.6 Favored 'General case' 0 C--O 1.281 2.733 0 C-N-CA 119.128 -1.029 . . . . 0.0 112.471 -179.574 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 130.57 38.27 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -149.99 178.85 8.55 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.541 -177.928 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -136.76 164.81 27.4 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -176.03 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 64' ' ' HIS . . . . . 0.582 ' CE1' ' CD ' ' A' ' 68' ' ' GLU . 0.0 OUTLIER -142.03 152.23 61.21 Favored Pre-proline 0 N--CA 1.495 1.807 0 N-CA-C 107.161 -1.422 . . . . 0.0 107.161 174.534 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.1 3.08 7.93 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 N-CA-C 114.61 0.966 . . . . 0.0 114.61 -176.321 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 148.0 52.18 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 68' ' ' GLU . . . . . 0.744 ' HB3' HD23 ' A' ' 124' ' ' LEU . 17.1 pt-20 -136.31 135.83 39.23 Favored 'General case' 0 N--CA 1.465 0.319 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 176.593 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -106.28 124.79 50.13 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 -178.014 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 70' ' ' TYR . . . . . 0.709 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 119.69 22.91 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 107' ' ' HIS . . . . . 0.709 ' CE1' ' OH ' ' A' ' 70' ' ' TYR . 3.5 p80 -151.3 172.43 15.89 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 122.202 1.001 . . . . 0.0 112.503 -177.633 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 108' ' ' CYS . . . . . 0.603 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -170.13 168.43 8.35 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 174.428 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 118' ' ' SER . . . . . 0.485 ' O ' HD12 ' A' ' 50' ' ' LEU . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 120' ' ' CYS . . . . . 0.402 ' CB ' HD21 ' A' ' 50' ' ' LEU . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.41 38.42 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.93 120.24 4.75 Favored Glycine 0 N--CA 1.448 -0.535 0 N-CA-C 105.058 -3.217 . . . . 0.0 105.058 176.982 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.79 111.31 34.42 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.931 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 124' ' ' LEU . . . . . 0.744 HD23 ' HB3' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.56 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.48 126.15 74.53 Favored Pre-proline 0 N--CA 1.489 1.511 0 C-N-CA 123.444 0.698 . . . . 0.0 110.821 -178.148 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.65 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.801 0 C-N-CA 121.832 1.688 . . . . 0.0 112.97 -175.364 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 34.0 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 125.25 11.95 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -136.03 152.2 50.66 Favored 'General case' 0 CA--C 1.494 -1.177 0 O-C-N 123.809 0.693 . . . . 0.0 109.948 -178.28 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 163.82 -163.43 35.81 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.594 -2.241 . . . . 0.0 113.208 178.618 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.4 179.94 46.25 Favored Glycine 0 N--CA 1.444 -0.812 0 C-N-CA 119.745 -1.217 . . . . 0.0 113.343 -176.912 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.42 35.04 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.506 -1.847 . . . . 0.0 107.908 -177.646 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 50' ' ' LEU . . . . . 0.481 HD12 ' O ' ' A' ' 118' ' ' SER . 0.0 OUTLIER -108.8 14.11 24.51 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 119.907 -1.746 . . . . 0.0 115.637 -175.622 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.87 -32.2 67.44 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.796 -1.962 . . . . 0.0 111.328 178.98 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 -0.38 54.0 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 67.1 mt -104.03 16.1 27.03 Favored 'General case' 0 C--N 1.363 1.188 0 N-CA-C 114.868 1.433 . . . . 0.0 114.868 -177.309 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -67.16 124.19 21.91 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.773 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.89 16.41 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -86.37 -13.02 10.94 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.765 0 CA-C-N 119.652 1.115 . . . . 0.0 112.087 178.734 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -151.4 160.55 43.69 Favored 'General case' 0 C--O 1.281 2.733 0 C-N-CA 118.903 -1.119 . . . . 0.0 112.471 -179.428 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 131.24 41.38 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -151.05 -179.95 7.74 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.762 -0.653 . . . . 0.0 109.636 -178.348 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -137.54 165.17 26.95 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -175.479 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 64' ' ' HIS . . . . . 0.561 ' CE1' ' CD ' ' A' ' 68' ' ' GLU . 0.0 OUTLIER -143.25 153.01 59.08 Favored Pre-proline 0 N--CA 1.495 1.79 0 N-CA-C 106.942 -1.503 . . . . 0.0 106.942 173.967 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.25 3.08 7.96 Favored 'Trans proline' 0 C--N 1.278 -3.17 0 C-N-CA 120.841 1.027 . . . . 0.0 114.61 -175.432 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 148.14 52.0 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 68' ' ' GLU . . . . . 0.74 ' HB3' HD23 ' A' ' 124' ' ' LEU . 18.0 pt-20 -136.76 135.93 38.48 Favored 'General case' 0 N--CA 1.468 0.457 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 176.473 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -106.18 124.79 50.13 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 -177.833 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 70' ' ' TYR . . . . . 0.685 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 101' ' ' ILE . . . . . 0.422 ' HB ' ' HG2' ' A' ' 68' ' ' GLU . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 119.42 22.54 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 107' ' ' HIS . . . . . 0.685 ' CE1' ' OH ' ' A' ' 70' ' ' TYR . 3.7 p80 -150.77 172.2 15.99 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 122.184 0.992 . . . . 0.0 112.514 -177.549 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 108' ' ' CYS . . . . . 0.614 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -170.01 168.43 8.55 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 174.154 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 118' ' ' SER . . . . . 0.481 ' O ' HD12 ' A' ' 50' ' ' LEU . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.53 38.21 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -117.01 120.38 4.79 Favored Glycine 0 N--CA 1.447 -0.627 0 N-CA-C 105.094 -3.202 . . . . 0.0 105.094 176.992 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.96 111.31 34.51 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.924 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 124' ' ' LEU . . . . . 0.74 HD23 ' HB3' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.62 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.53 126.1 74.5 Favored Pre-proline 0 N--CA 1.489 1.511 0 C-N-CA 123.453 0.701 . . . . 0.0 110.821 -178.14 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.59 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.806 0 C-N-CA 121.775 1.65 . . . . 0.0 112.97 -175.369 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 34.0 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.61 13.0 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -139.24 155.23 47.92 Favored 'General case' 0 CA--C 1.49 -1.346 0 N-CA-C 109.438 -0.578 . . . . 0.0 109.438 -179.313 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.41 -163.43 35.04 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 118.072 -2.013 . . . . 0.0 113.208 -179.736 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.38 179.97 46.24 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 119.724 -1.227 . . . . 0.0 113.298 -176.946 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 132.62 35.08 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . 0.266 0.3 OUTLIER -114.64 20.48 15.26 Favored 'General case' 0 C--N 1.317 -0.822 0 O-C-N 117.791 -3.068 . . . . 0.0 114.69 -176.029 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -55.34 -32.2 62.34 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 117.275 -1.77 . . . . 0.0 111.328 174.525 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.15 54.46 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -104.46 15.98 27.04 Favored 'General case' 0 N--CA 1.487 1.383 0 N-CA-C 114.49 1.293 . . . . 0.0 114.49 -176.45 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.01 124.19 22.96 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.484 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.45 16.11 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 2.5 m -84.81 -13.74 11.31 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.753 0 CA-C-N 118.634 0.652 . . . . 0.0 112.657 179.072 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.77 160.55 43.12 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.246 0.93 . . . . 0.0 112.471 -178.941 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 128.65 29.56 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -145.15 174.91 10.66 Favored 'General case' 0 CA--C 1.518 -0.285 0 CA-C-N 114.765 -1.107 . . . . 0.0 109.705 -175.92 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -135.01 165.06 26.22 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -179.46 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' HIS . . . . . 0.507 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.0 OUTLIER -144.47 154.15 56.27 Favored Pre-proline 0 N--CA 1.483 1.184 0 N-CA-C 106.993 -1.484 . . . . 0.0 106.993 172.714 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.29 3.08 7.97 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 C-N-CA 121.065 1.177 . . . . 0.0 114.61 -173.819 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 145.9 54.6 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.472 ' HB2' HD23 ' A' ' 124' ' ' LEU . 4.3 tt0 -128.62 128.11 43.53 Favored 'General case' 0 N--CA 1.479 1.011 0 O-C-N 124.479 1.112 . . . . 0.0 110.497 179.738 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -104.38 124.79 49.83 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.649 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' TYR . . . . . 0.676 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 118.59 21.58 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 107' ' ' HIS . . . . . 0.677 ' ND1' ' C ' ' A' ' 107' ' ' HIS . 1.2 p80 -149.42 170.24 19.02 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.949 0.88 . . . . 0.0 112.773 -176.889 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 108' ' ' CYS . . . . . 0.652 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -168.78 168.43 10.56 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 173.457 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.53 38.21 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -117.04 120.26 4.75 Favored Glycine 0 C--N 1.316 -0.569 0 N-CA-C 105.112 -3.195 . . . . 0.0 105.112 176.998 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.87 111.31 34.46 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.904 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 124' ' ' LEU . . . . . 0.472 HD23 ' HB2' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 202' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.68 0 CA-C-O 117.878 -1.058 . . . . 0.0 108.451 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.76 126.17 73.78 Favored Pre-proline 0 N--CA 1.489 1.483 0 C-N-CA 123.322 0.649 . . . . 0.0 110.881 -178.12 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.178 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 34.0 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.44 12.88 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.93 154.89 48.38 Favored 'General case' 0 CA--C 1.49 -1.346 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 -179.235 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.59 -163.4 35.13 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 118.059 -2.02 . . . . 0.0 113.208 -179.847 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.35 179.94 46.2 Favored Glycine 0 N--CA 1.444 -0.774 0 C-N-CA 119.67 -1.252 . . . . 0.0 113.27 -176.916 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.1 35.05 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.479 ' H ' HD12 ' A' ' 50' ' ' LEU . 0.0 OUTLIER -108.97 14.24 24.21 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 119.579 -1.95 . . . . 0.0 115.235 -175.545 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.28 -32.2 66.39 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.778 -1.969 . . . . 0.0 111.328 178.741 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.13 54.45 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.2 mp -104.32 15.75 27.62 Favored 'General case' 0 N--CA 1.486 1.371 0 N-CA-C 114.494 1.294 . . . . 0.0 114.494 -176.292 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.1 124.19 23.08 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.329 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.47 16.12 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.425 HG11 ' CZ3' ' A' ' 202' ' ' TRP . 2.3 m -84.89 -13.68 11.29 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.781 0 O-C-N 123.766 0.667 . . . . 0.0 112.758 179.132 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.83 160.55 43.09 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.191 0.905 . . . . 0.0 112.471 -179.045 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 129.57 33.62 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' HIS . . . . . 0.455 ' CE1' ' NE2' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -147.89 175.47 10.93 Favored 'General case' 0 N--CA 1.446 -0.625 0 CA-C-N 114.785 -1.098 . . . . 0.0 110.259 -176.62 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 63' ' ' THR . . . . . 0.544 ' C ' ' ND1' ' A' ' 64' ' ' HIS . 28.7 p -134.83 163.2 30.35 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -177.49 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 64' ' ' HIS . . . . . 0.878 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -135.22 147.17 61.18 Favored Pre-proline 0 N--CA 1.492 1.641 0 C-N-CA 123.984 0.914 . . . . 0.0 108.876 177.864 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -79.32 3.08 7.79 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 N-CA-C 114.61 0.966 . . . . 0.0 114.61 178.869 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 144.69 55.67 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.436 ' HB2' HD23 ' A' ' 124' ' ' LEU . 6.9 tt0 -126.49 125.0 41.35 Favored 'General case' 0 CA--C 1.553 1.081 0 O-C-N 124.891 1.37 . . . . 0.0 110.378 -178.93 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.06 124.79 49.19 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.179 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 70' ' ' TYR . . . . . 0.761 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 116.53 19.86 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 107' ' ' HIS . . . . . 0.796 ' HD1' ' N ' ' A' ' 108' ' ' CYS . 0.0 OUTLIER -144.39 164.67 30.15 Favored 'General case' 0 C--N 1.341 0.222 0 N-CA-C 114.273 1.212 . . . . 0.0 114.273 -175.004 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 108' ' ' CYS . . . . . 0.796 ' N ' ' HD1' ' A' ' 107' ' ' HIS . 7.3 p -166.16 168.43 15.35 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 170.626 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 118' ' ' SER . . . . . 0.467 ' O ' HD12 ' A' ' 50' ' ' LEU . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 150.93 39.24 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.35 120.15 4.77 Favored Glycine 0 N--CA 1.448 -0.505 0 N-CA-C 104.911 -3.276 . . . . 0.0 104.911 176.911 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.6 111.31 34.31 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -179.104 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 124' ' ' LEU . . . . . 0.436 HD23 ' HB2' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 202' ' ' TRP . . . . . 0.425 ' CZ3' HG11 ' A' ' 58' ' ' VAL . 1.3 m0 . . . . . 0 N--CA 1.49 1.561 0 CA-C-O 118.158 -0.925 . . . . 0.0 109.388 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.7 126.18 73.9 Favored Pre-proline 0 N--CA 1.489 1.477 0 C-N-CA 123.359 0.664 . . . . 0.0 110.852 -178.126 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.57 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.778 0 C-N-CA 121.855 1.704 . . . . 0.0 112.97 -175.232 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 34.0 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.49 12.91 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.96 154.88 48.35 Favored 'General case' 0 CA--C 1.491 -1.301 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 -179.187 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.55 -163.4 35.1 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 118.014 -2.041 . . . . 0.0 113.208 -179.88 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.35 179.94 46.2 Favored Glycine 0 N--CA 1.444 -0.774 0 C-N-CA 119.67 -1.252 . . . . 0.0 113.27 -176.916 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.1 35.05 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.475 ' H ' HD12 ' A' ' 50' ' ' LEU . 0.0 OUTLIER -108.94 14.17 24.29 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 119.579 -1.95 . . . . 0.0 115.225 -175.501 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.29 -32.2 66.4 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.811 -1.955 . . . . 0.0 111.328 178.783 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.13 54.44 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.3 mp -104.25 15.71 27.75 Favored 'General case' 0 N--CA 1.486 1.351 0 N-CA-C 114.467 1.284 . . . . 0.0 114.467 -176.254 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.18 124.19 23.18 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.274 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.42 16.08 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 2.6 m -85.1 -13.47 11.26 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.829 0 CA-C-N 118.66 0.664 . . . . 0.0 112.707 179.222 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.74 160.55 43.13 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.205 0.911 . . . . 0.0 112.471 -179.195 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 129.64 33.92 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' HIS . . . . . 0.455 ' CE1' ' NE2' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -148.02 175.52 10.93 Favored 'General case' 0 N--CA 1.446 -0.655 0 CA-C-N 114.8 -1.091 . . . . 0.0 110.305 -176.644 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 63' ' ' THR . . . . . 0.547 ' C ' ' ND1' ' A' ' 64' ' ' HIS . 28.7 p -134.85 163.14 30.5 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -177.416 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 64' ' ' HIS . . . . . 0.877 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -135.11 147.06 60.95 Favored Pre-proline 0 N--CA 1.493 1.692 0 C-N-CA 123.985 0.914 . . . . 0.0 108.875 177.891 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -79.25 3.08 7.77 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 N-CA-C 114.61 0.966 . . . . 0.0 114.61 178.826 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 144.74 55.64 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.438 ' HB2' HD23 ' A' ' 124' ' ' LEU . 6.6 tt0 -126.52 124.88 41.04 Favored 'General case' 0 CA--C 1.553 1.096 0 O-C-N 124.936 1.398 . . . . 0.0 110.433 -178.862 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.06 124.79 49.2 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.214 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' TYR . . . . . 0.762 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 116.41 19.78 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 107' ' ' HIS . . . . . 0.798 ' HD1' ' N ' ' A' ' 108' ' ' CYS . 0.0 OUTLIER -144.15 164.28 31.14 Favored 'General case' 0 C--N 1.342 0.246 0 N-CA-C 114.291 1.219 . . . . 0.0 114.291 -174.882 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 108' ' ' CYS . . . . . 0.798 ' N ' ' HD1' ' A' ' 107' ' ' HIS . 7.3 p -165.96 168.43 15.73 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 170.501 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 118' ' ' SER . . . . . 0.464 ' O ' HD12 ' A' ' 50' ' ' LEU . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.02 39.1 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.6 120.41 4.84 Favored Glycine 0 N--CA 1.448 -0.525 0 N-CA-C 104.938 -3.265 . . . . 0.0 104.938 176.782 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.66 111.31 34.34 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -179.002 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 124' ' ' LEU . . . . . 0.438 HD23 ' HB2' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 202' ' ' TRP . . . . . . . . . . . . . 1.5 m0 . . . . . 0 N--CA 1.488 1.436 0 CA-C-O 118.168 -0.92 . . . . 0.0 109.424 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.76 126.17 73.78 Favored Pre-proline 0 N--CA 1.489 1.483 0 C-N-CA 123.322 0.649 . . . . 0.0 110.881 -178.12 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.178 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 34.0 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.44 12.88 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.93 154.89 48.38 Favored 'General case' 0 CA--C 1.49 -1.346 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 -179.235 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.59 -163.4 35.13 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 118.059 -2.02 . . . . 0.0 113.208 -179.847 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.35 179.94 46.2 Favored Glycine 0 N--CA 1.444 -0.774 0 C-N-CA 119.67 -1.252 . . . . 0.0 113.27 -176.916 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.15 35.05 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.48 ' H ' HD12 ' A' ' 50' ' ' LEU . 0.0 OUTLIER -109.05 14.23 24.13 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 119.538 -1.976 . . . . 0.0 115.281 -175.559 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.24 -32.2 66.3 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.773 -1.971 . . . . 0.0 111.328 178.73 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.13 54.45 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.1 mp -104.41 15.88 27.29 Favored 'General case' 0 N--CA 1.487 1.386 0 N-CA-C 114.465 1.283 . . . . 0.0 114.465 -176.273 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.14 124.19 23.13 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.395 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.51 16.15 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.447 HG11 ' CZ3' ' A' ' 202' ' ' TRP . 2.1 m -84.96 -13.72 11.26 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.794 0 CA-C-N 118.613 0.642 . . . . 0.0 112.707 179.16 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.74 160.55 43.13 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.166 0.893 . . . . 0.0 112.471 -179.025 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 129.57 33.62 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' HIS . . . . . 0.457 ' CE1' ' NE2' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -147.89 175.4 10.99 Favored 'General case' 0 N--CA 1.447 -0.596 0 CA-C-N 114.785 -1.098 . . . . 0.0 110.256 -176.587 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 63' ' ' THR . . . . . 0.546 ' C ' ' ND1' ' A' ' 64' ' ' HIS . 28.7 p -134.79 163.16 30.42 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -177.495 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 64' ' ' HIS . . . . . 0.878 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -135.19 147.04 60.69 Favored Pre-proline 0 N--CA 1.492 1.671 0 C-N-CA 123.987 0.915 . . . . 0.0 108.842 177.932 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -79.24 3.08 7.77 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 N-CA-C 114.61 0.966 . . . . 0.0 114.61 178.861 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 144.74 55.64 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.434 ' HB2' HD23 ' A' ' 124' ' ' LEU . 6.5 tt0 -126.45 124.88 41.13 Favored 'General case' 0 CA--C 1.553 1.096 0 O-C-N 124.917 1.385 . . . . 0.0 110.428 -178.854 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.09 124.79 49.21 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.157 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 70' ' ' TYR . . . . . 0.763 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 116.51 19.84 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 107' ' ' HIS . . . . . 0.797 ' HD1' ' N ' ' A' ' 108' ' ' CYS . 0.0 OUTLIER -144.35 164.57 30.41 Favored 'General case' 0 C--N 1.341 0.2 0 N-CA-C 114.23 1.196 . . . . 0.0 114.23 -174.956 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 108' ' ' CYS . . . . . 0.797 ' N ' ' HD1' ' A' ' 107' ' ' HIS . 7.3 p -166.11 168.43 15.44 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 170.599 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 118' ' ' SER . . . . . 0.468 ' O ' HD12 ' A' ' 50' ' ' LEU . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 150.93 39.24 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.35 120.15 4.77 Favored Glycine 0 N--CA 1.448 -0.505 0 N-CA-C 104.911 -3.276 . . . . 0.0 104.911 176.911 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.6 111.31 34.31 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -179.104 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 124' ' ' LEU . . . . . 0.434 HD23 ' HB2' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 202' ' ' TRP . . . . . 0.447 ' CZ3' HG11 ' A' ' 58' ' ' VAL . 1.2 m0 . . . . . 0 N--CA 1.489 1.525 0 CA-C-O 118.193 -0.908 . . . . 0.0 109.332 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.56 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.66 126.16 74.06 Favored Pre-proline 0 N--CA 1.488 1.469 0 C-N-CA 123.413 0.685 . . . . 0.0 110.925 -178.224 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.56 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.766 0 C-N-CA 121.759 1.639 . . . . 0.0 112.97 -175.215 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 34.0 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 125.24 11.94 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -135.8 152.1 50.75 Favored 'General case' 0 CA--C 1.494 -1.209 0 O-C-N 123.894 0.746 . . . . 0.0 110.059 -178.241 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 163.81 -163.46 35.82 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.502 -2.285 . . . . 0.0 113.208 178.453 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.43 179.98 46.29 Favored Glycine 0 N--CA 1.443 -0.886 0 C-N-CA 119.784 -1.198 . . . . 0.0 113.381 -176.95 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.28 35.04 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.532 -1.834 . . . . 0.0 107.908 -177.641 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.46 ' H ' HD12 ' A' ' 50' ' ' LEU . 0.0 OUTLIER -110.42 15.4 22.22 Favored 'General case' 0 N--CA 1.482 1.168 0 O-C-N 119.602 -1.936 . . . . 0.0 115.515 -175.456 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -56.98 -32.2 65.84 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 117.354 -1.739 . . . . 0.0 111.328 177.972 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.2 54.51 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.3 mp -104.69 16.06 26.76 Favored 'General case' 0 N--CA 1.486 1.337 0 N-CA-C 114.475 1.287 . . . . 0.0 114.475 -176.289 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.02 124.19 22.98 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.536 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.23 15.95 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 2.4 m -85.05 -13.51 11.27 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.906 0 CA-C-N 118.754 0.706 . . . . 0.0 112.498 179.237 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.48 160.55 43.24 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.402 1.001 . . . . 0.0 112.471 -179.223 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 126.35 21.06 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' HIS . . . . . 0.433 ' CE1' ' CD2' ' A' ' 64' ' ' HIS . 0.0 OUTLIER -139.94 169.29 17.99 Favored 'General case' 0 C--N 1.352 0.702 0 CA-C-N 113.504 -1.68 . . . . 0.0 110.459 -174.069 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -131.98 164.84 25.28 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 177.307 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 64' ' ' HIS . . . . . 0.572 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.0 OUTLIER -143.24 153.95 60.31 Favored Pre-proline 0 N--CA 1.485 1.312 0 N-CA-C 107.184 -1.413 . . . . 0.0 107.184 173.142 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.57 3.08 8.02 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 C-N-CA 120.772 0.981 . . . . 0.0 114.61 -174.869 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 145.15 55.36 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.554 ' OE2' ' CE2' ' A' ' 70' ' ' TYR . 6.0 tt0 -127.92 128.01 44.36 Favored 'General case' 0 N--CA 1.485 1.304 0 O-C-N 124.277 0.985 . . . . 0.0 109.613 179.932 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.97 124.79 49.64 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.127 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 70' ' ' TYR . . . . . 0.654 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 119.21 22.24 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 107' ' ' HIS . . . . . 0.685 ' ND1' ' C ' ' A' ' 107' ' ' HIS . 1.5 p80 -150.74 171.43 17.18 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 122.148 0.975 . . . . 0.0 112.529 -177.37 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 108' ' ' CYS . . . . . 0.658 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -169.38 168.43 9.55 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 174.213 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 118' ' ' SER . . . . . 0.44 ' O ' HD12 ' A' ' 50' ' ' LEU . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 120' ' ' CYS . . . . . 0.407 ' HB3' HD21 ' A' ' 50' ' ' LEU . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.44 38.35 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.96 120.32 4.77 Favored Glycine 0 N--CA 1.447 -0.608 0 N-CA-C 105.19 -3.164 . . . . 0.0 105.19 176.9 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.88 111.31 34.46 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.856 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 202' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.558 0 CA-C-O 117.596 -1.192 . . . . 0.0 108.238 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.63 126.28 73.84 Favored Pre-proline 0 N--CA 1.489 1.476 0 C-N-CA 123.354 0.662 . . . . 0.0 110.86 -178.172 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.65 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.801 0 C-N-CA 121.832 1.688 . . . . 0.0 112.97 -175.286 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 34.0 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 125.51 12.15 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -136.69 152.67 50.64 Favored 'General case' 0 CA--C 1.492 -1.258 0 O-C-N 123.741 0.651 . . . . 0.0 109.9 -178.447 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 163.62 -163.43 35.7 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.728 -2.177 . . . . 0.0 113.208 178.978 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.38 179.97 46.24 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 119.724 -1.227 . . . . 0.0 113.298 -176.946 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 132.74 35.07 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . 0.263 0.3 OUTLIER -114.71 20.36 15.3 Favored 'General case' 0 N--CA 1.477 0.908 0 O-C-N 117.712 -3.117 . . . . 0.0 114.69 -176.107 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -55.24 -32.2 62.11 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 117.133 -1.827 . . . . 0.0 111.328 174.548 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 -0.15 54.19 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -103.1 14.9 30.76 Favored 'General case' 0 N--CA 1.49 1.565 0 N-CA-C 114.478 1.288 . . . . 0.0 114.478 -176.366 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.44 124.19 23.5 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -177.753 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.79 16.34 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.576 HG11 ' CZ3' ' A' ' 202' ' ' TRP . 0.1 OUTLIER -81.43 -17.27 11.98 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.906 0 O-C-N 125.025 1.453 . . . . 0.0 112.908 178.981 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -154.67 160.55 41.47 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 118.659 0.663 . . . . 0.0 112.471 -176.632 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 131.26 41.5 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -151.13 -179.79 7.62 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.784 -0.644 . . . . 0.0 109.575 -178.404 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -137.62 164.42 28.83 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -175.411 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' HIS . . . . . 0.579 ' CE1' ' CD ' ' A' ' 68' ' ' GLU . 0.0 OUTLIER -141.47 151.93 62.22 Favored Pre-proline 0 N--CA 1.496 1.835 0 N-CA-C 106.959 -1.497 . . . . 0.0 106.959 174.678 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -79.88 3.08 7.89 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 C-N-CA 120.77 0.98 . . . . 0.0 114.61 -176.587 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 147.9 52.31 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.762 ' HB3' HD23 ' A' ' 124' ' ' LEU . 14.0 pt-20 -136.06 135.12 39.12 Favored 'General case' 0 N--CA 1.47 0.554 0 N-CA-C 108.909 -0.775 . . . . 0.0 108.909 176.664 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -105.76 124.79 50.13 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 -178.162 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' TYR . . . . . 0.715 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 119.79 23.05 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 107' ' ' HIS . . . . . 0.715 ' CE1' ' OH ' ' A' ' 70' ' ' TYR . 3.4 p80 -151.82 172.51 16.05 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-O 122.15 0.976 . . . . 0.0 112.223 -177.616 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 108' ' ' CYS . . . . . 0.605 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -170.04 168.43 8.49 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 174.755 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.78 37.78 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -117.98 121.23 5.0 Favored Glycine 0 C--N 1.313 -0.737 0 N-CA-C 104.952 -3.259 . . . . 0.0 104.952 176.712 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -106.09 111.31 34.59 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.607 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 124' ' ' LEU . . . . . 0.762 HD23 ' HB3' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 202' ' ' TRP . . . . . 0.576 ' CZ3' HG11 ' A' ' 58' ' ' VAL . 40.8 m0 . . . . . 0 N--CA 1.49 1.553 0 CA-C-O 117.123 -1.417 . . . . 0.0 109.469 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.76 126.17 73.78 Favored Pre-proline 0 N--CA 1.489 1.483 0 C-N-CA 123.322 0.649 . . . . 0.0 110.881 -178.12 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.178 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 34.0 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.46 12.89 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.93 154.93 48.39 Favored 'General case' 0 CA--C 1.491 -1.316 0 N-CA-C 109.571 -0.529 . . . . 0.0 109.571 -179.235 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.55 -163.43 35.12 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 118.07 -2.014 . . . . 0.0 113.208 -179.851 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.38 179.97 46.24 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 119.724 -1.227 . . . . 0.0 113.298 -176.946 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.15 35.05 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.481 ' H ' HD12 ' A' ' 50' ' ' LEU . 0.0 OUTLIER -109.14 14.34 23.96 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 119.504 -1.998 . . . . 0.0 115.235 -175.56 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.24 -32.2 66.3 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.773 -1.971 . . . . 0.0 111.328 178.645 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.1 54.42 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.2 mp -104.3 15.8 27.52 Favored 'General case' 0 N--CA 1.486 1.339 0 N-CA-C 114.497 1.295 . . . . 0.0 114.497 -176.321 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.12 124.19 23.11 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.343 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.48 16.13 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.462 HG11 ' CZ3' ' A' ' 202' ' ' TRP . 2.2 m -84.94 -13.64 11.29 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.777 0 CA-C-N 118.631 0.651 . . . . 0.0 112.719 179.124 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.83 160.55 43.09 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.183 0.901 . . . . 0.0 112.471 -179.052 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 129.6 33.75 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' HIS . . . . . 0.456 ' CE1' ' NE2' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -147.97 175.5 10.93 Favored 'General case' 0 N--CA 1.446 -0.655 0 CA-C-N 114.811 -1.086 . . . . 0.0 110.263 -176.649 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 63' ' ' THR . . . . . 0.546 ' C ' ' ND1' ' A' ' 64' ' ' HIS . 28.7 p -134.83 163.15 30.46 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -177.435 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 64' ' ' HIS . . . . . 0.877 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -135.09 147.05 60.92 Favored Pre-proline 0 N--CA 1.493 1.676 0 C-N-CA 123.965 0.906 . . . . 0.0 108.857 177.954 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -79.28 3.08 7.78 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 N-CA-C 114.61 0.966 . . . . 0.0 114.61 178.782 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 144.74 55.64 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.436 ' HB2' HD23 ' A' ' 124' ' ' LEU . 6.7 tt0 -126.52 124.92 41.14 Favored 'General case' 0 CA--C 1.553 1.073 0 O-C-N 124.917 1.385 . . . . 0.0 110.392 -178.869 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.06 124.79 49.19 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.179 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' TYR . . . . . 0.763 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 116.53 19.86 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 107' ' ' HIS . . . . . 0.797 ' HD1' ' N ' ' A' ' 108' ' ' CYS . 0.0 OUTLIER -144.43 164.59 30.39 Favored 'General case' 0 C--N 1.341 0.222 0 N-CA-C 114.194 1.183 . . . . 0.0 114.194 -174.946 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 108' ' ' CYS . . . . . 0.797 ' N ' ' HD1' ' A' ' 107' ' ' HIS . 7.3 p -166.11 168.43 15.44 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 170.633 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 118' ' ' SER . . . . . 0.466 ' O ' HD12 ' A' ' 50' ' ' LEU . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 150.93 39.24 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.36 120.17 4.77 Favored Glycine 0 N--CA 1.448 -0.543 0 N-CA-C 104.982 -3.247 . . . . 0.0 104.982 176.852 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.6 111.31 34.31 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -179.057 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 124' ' ' LEU . . . . . 0.436 HD23 ' HB2' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 202' ' ' TRP . . . . . 0.462 ' CZ3' HG11 ' A' ' 58' ' ' VAL . 1.2 m0 . . . . . 0 N--CA 1.49 1.529 0 CA-C-O 118.114 -0.946 . . . . 0.0 109.31 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.56 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.67 126.1 74.18 Favored Pre-proline 0 N--CA 1.489 1.521 0 C-N-CA 123.428 0.691 . . . . 0.0 110.853 -178.135 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.234 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 34.0 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.32 12.78 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.68 154.7 48.62 Favored 'General case' 0 CA--C 1.491 -1.295 0 N-CA-C 109.524 -0.547 . . . . 0.0 109.524 -179.151 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.69 -163.39 35.18 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 118.029 -2.034 . . . . 0.0 113.208 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.34 -179.94 46.27 Favored Glycine 0 N--CA 1.445 -0.703 0 C-N-CA 119.668 -1.254 . . . . 0.0 113.289 -176.972 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.22 133.29 35.01 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.48 -1.86 . . . . 0.0 107.908 -177.599 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.52 ' H ' HD12 ' A' ' 50' ' ' LEU . 0.0 OUTLIER -109.08 14.05 24.2 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 119.618 -1.926 . . . . 0.0 115.383 -175.627 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.18 -32.2 66.2 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.782 -1.967 . . . . 0.0 111.328 178.775 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.19 54.5 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.2 mp -104.59 15.98 26.96 Favored 'General case' 0 N--CA 1.486 1.353 0 N-CA-C 114.488 1.292 . . . . 0.0 114.488 -176.284 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.06 124.19 23.03 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.468 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.54 16.17 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.666 HG11 ' CZ3' ' A' ' 202' ' ' TRP . 2.1 m -85.07 -13.58 11.25 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.793 0 N-CA-C 112.816 0.673 . . . . 0.0 112.816 179.223 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.91 160.55 43.06 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.094 0.861 . . . . 0.0 112.471 -179.176 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 128.06 27.25 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -143.66 173.57 11.55 Favored 'General case' 0 CA--C 1.513 -0.471 0 CA-C-N 114.44 -1.255 . . . . 0.0 109.906 -175.516 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -134.3 165.5 24.98 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 179.569 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' HIS . . . . . 0.578 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.0 OUTLIER -145.43 154.39 52.98 Favored Pre-proline 0 N--CA 1.481 1.099 0 N-CA-C 107.255 -1.387 . . . . 0.0 107.255 172.404 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.33 3.08 7.97 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 C-N-CA 120.946 1.097 . . . . 0.0 114.61 -173.161 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 145.02 55.49 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.42 ' HB2' HD23 ' A' ' 124' ' ' LEU . 40.1 tt0 -128.36 128.5 44.64 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 123.766 0.666 . . . . 0.0 109.463 179.311 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.58 124.79 49.45 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.315 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 70' ' ' TYR . . . . . 0.725 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 118.75 21.72 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 107' ' ' HIS . . . . . 0.725 ' CE1' ' OH ' ' A' ' 70' ' ' TYR . 1.0 OUTLIER -149.16 170.15 19.1 Favored 'General case' 0 CA--C 1.518 -0.252 0 CA-C-O 122.108 0.956 . . . . 0.0 113.213 -176.9 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 108' ' ' CYS . . . . . 0.666 ' N ' ' HD1' ' A' ' 107' ' ' HIS . 7.3 p -168.97 168.43 10.21 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 173.215 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 118' ' ' SER . . . . . 0.503 ' O ' HD12 ' A' ' 50' ' ' LEU . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 120' ' ' CYS . . . . . 0.409 ' CB ' HD21 ' A' ' 50' ' ' LEU . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.05 39.04 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.48 119.89 4.67 Favored Glycine 0 N--CA 1.451 -0.357 0 N-CA-C 104.924 -3.27 . . . . 0.0 104.924 176.915 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.33 111.31 34.15 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -179.104 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 124' ' ' LEU . . . . . 0.42 HD23 ' HB2' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 202' ' ' TRP . . . . . 0.666 ' CZ3' HG11 ' A' ' 58' ' ' VAL . 8.6 m0 . . . . . 0 N--CA 1.489 1.507 0 CA-C-O 118.571 -0.728 . . . . 0.0 110.004 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.76 126.17 73.78 Favored Pre-proline 0 N--CA 1.489 1.483 0 C-N-CA 123.322 0.649 . . . . 0.0 110.881 -178.12 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.178 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 34.0 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 125.59 12.22 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -136.81 152.82 50.72 Favored 'General case' 0 CA--C 1.493 -1.239 0 O-C-N 123.731 0.644 . . . . 0.0 109.904 -178.486 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 163.51 -163.43 35.64 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.685 -2.198 . . . . 0.0 113.208 179.012 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.4 179.94 46.25 Favored Glycine 0 N--CA 1.444 -0.812 0 C-N-CA 119.745 -1.217 . . . . 0.0 113.343 -176.912 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.15 35.05 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.506 -1.847 . . . . 0.0 107.908 -177.646 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.48 ' H ' HD12 ' A' ' 50' ' ' LEU . 0.0 OUTLIER -109.06 14.27 24.09 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 119.573 -1.955 . . . . 0.0 115.238 -175.519 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.28 -32.2 66.39 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.778 -1.969 . . . . 0.0 111.328 178.731 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 -0.04 54.29 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -103.75 15.44 28.77 Favored 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 114.438 1.273 . . . . 0.0 114.438 -176.428 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.15 124.19 23.14 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.135 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.61 16.22 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.601 HG11 ' CZ3' ' A' ' 202' ' ' TRP . 0.3 OUTLIER -82.23 -16.41 11.8 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.923 0 O-C-N 124.729 1.268 . . . . 0.0 112.874 179.103 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -154.24 160.55 41.86 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 118.833 0.742 . . . . 0.0 112.471 -177.258 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 128.09 27.37 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -143.84 173.58 11.57 Favored 'General case' 0 CA--C 1.516 -0.347 0 CA-C-N 114.512 -1.222 . . . . 0.0 109.911 -175.468 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -134.3 164.67 26.88 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 179.701 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 64' ' ' HIS . . . . . 0.536 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.0 OUTLIER -143.77 153.54 57.93 Favored Pre-proline 0 N--CA 1.484 1.272 0 N-CA-C 106.906 -1.516 . . . . 0.0 106.906 173.051 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -79.96 3.08 7.9 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 C-N-CA 121.104 1.203 . . . . 0.0 114.61 -174.226 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 143.61 56.24 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.511 ' HB3' ' HB ' ' A' ' 101' ' ' ILE . 0.1 OUTLIER -120.15 120.81 37.26 Favored 'General case' 0 N--CA 1.506 2.342 0 O-C-N 125.931 2.019 . . . . 0.0 111.397 -178.3 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -102.4 124.79 48.6 Favored 'General case' 0 N--CA 1.498 1.961 0 CA-C-N 120.735 1.607 . . . . 0.0 107.536 175.528 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' TYR . . . . . 0.65 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 101' ' ' ILE . . . . . 0.511 ' HB ' ' HB3' ' A' ' 68' ' ' GLU . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 118.89 21.85 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 107' ' ' HIS . . . . . 0.678 ' ND1' ' C ' ' A' ' 107' ' ' HIS . 1.4 p80 -150.2 170.72 18.3 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 121.961 0.886 . . . . 0.0 112.554 -177.01 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 108' ' ' CYS . . . . . 0.65 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -168.97 168.43 10.21 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 173.904 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 118' ' ' SER . . . . . 0.469 ' O ' HD12 ' A' ' 50' ' ' LEU . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.6 38.08 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -117.43 120.76 4.89 Favored Glycine 0 C--N 1.315 -0.629 0 N-CA-C 105.009 -3.236 . . . . 0.0 105.009 176.833 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.97 111.31 34.52 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.793 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 202' ' ' TRP . . . . . 0.601 ' CZ3' HG11 ' A' ' 58' ' ' VAL . 41.0 m0 . . . . . 0 N--CA 1.491 1.59 0 CA-C-O 117.526 -1.226 . . . . 0.0 109.664 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.56 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.82 126.18 73.62 Favored Pre-proline 0 N--CA 1.489 1.484 0 C-N-CA 123.354 0.661 . . . . 0.0 110.825 -178.075 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.171 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 34.0 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.09 12.6 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.11 154.15 49.23 Favored 'General case' 0 CA--C 1.492 -1.281 0 N-CA-C 109.654 -0.498 . . . . 0.0 109.654 -178.96 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' GLY . . . . . 0.429 ' HA2' ' CE2' ' A' ' 202' ' ' TRP . . . 162.94 -163.4 35.32 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.941 -2.076 . . . . 0.0 113.208 179.714 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.35 179.94 46.2 Favored Glycine 0 N--CA 1.444 -0.774 0 C-N-CA 119.67 -1.252 . . . . 0.0 113.27 -176.916 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.08 35.05 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.479 ' H ' HD12 ' A' ' 50' ' ' LEU . 0.0 OUTLIER -108.89 14.16 24.37 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 119.555 -1.966 . . . . 0.0 115.229 -175.541 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.28 -32.2 66.39 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.778 -1.969 . . . . 0.0 111.328 178.794 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.16 54.47 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.3 mp -104.44 15.87 27.29 Favored 'General case' 0 N--CA 1.486 1.354 0 N-CA-C 114.482 1.29 . . . . 0.0 114.482 -176.296 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.1 124.19 23.08 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.397 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.56 16.18 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 2.4 m -85.24 -13.51 11.2 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.816 0 CA-C-N 118.648 0.658 . . . . 0.0 112.73 179.236 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.71 160.55 43.14 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.153 0.888 . . . . 0.0 112.471 -179.217 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 129.84 34.88 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -148.38 177.23 9.62 Favored 'General case' 0 CA--C 1.515 -0.366 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.712 -177.238 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -135.89 164.81 27.09 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -177.116 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -142.68 153.29 61.41 Favored Pre-proline 0 N--CA 1.495 1.808 0 N-CA-C 106.896 -1.52 . . . . 0.0 106.896 173.65 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.28 3.08 7.97 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 C-N-CA 120.818 1.012 . . . . 0.0 114.61 -175.614 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 145.11 55.39 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.427 ' HG3' HD23 ' A' ' 124' ' ' LEU . 0.3 OUTLIER -121.19 122.63 40.4 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 126.751 2.532 . . . . 0.0 112.971 -178.906 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -104.57 124.79 49.93 Favored 'General case' 0 N--CA 1.498 1.961 0 CA-C-N 120.444 1.475 . . . . 0.0 107.536 176.102 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' TYR . . . . . 0.704 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 118.97 21.93 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 107' ' ' HIS . . . . . 0.704 ' CE1' ' OH ' ' A' ' 70' ' ' TYR . 2.0 p80 -150.04 171.35 16.99 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 122.181 0.991 . . . . 0.0 112.555 -177.34 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 108' ' ' CYS . . . . . 0.663 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -169.44 168.43 9.46 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 173.792 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 118' ' ' SER . . . . . 0.47 ' O ' HD12 ' A' ' 50' ' ' LEU . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.23 38.73 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.69 120.21 4.76 Favored Glycine 0 N--CA 1.448 -0.539 0 N-CA-C 105.034 -3.226 . . . . 0.0 105.034 176.925 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.71 111.31 34.37 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.984 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 124' ' ' LEU . . . . . 0.427 HD23 ' HG3' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 202' ' ' TRP . . . . . 0.429 ' CE2' ' HA2' ' A' ' 47' ' ' GLY . 13.1 m0 . . . . . 0 N--CA 1.491 1.575 0 CA-C-O 117.229 -1.367 . . . . 0.0 109.439 . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.7 126.13 74.03 Favored Pre-proline 0 N--CA 1.489 1.477 0 C-N-CA 123.359 0.664 . . . . 0.0 110.886 -178.126 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.2 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 34.0 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.64 13.03 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -139.18 155.29 47.94 Favored 'General case' 0 CA--C 1.49 -1.356 0 N-CA-C 109.514 -0.551 . . . . 0.0 109.514 -179.329 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.33 -163.43 35.0 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 118.037 -2.03 . . . . 0.0 113.208 -179.801 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.4 179.93 46.24 Favored Glycine 0 N--CA 1.444 -0.812 0 C-N-CA 119.745 -1.217 . . . . 0.0 113.368 -176.912 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.14 132.47 35.09 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.514 -1.843 . . . . 0.0 107.908 -177.643 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . 0.263 0.3 OUTLIER -114.5 20.2 15.57 Favored 'General case' 0 C--N 1.312 -1.04 0 O-C-N 117.72 -3.112 . . . . 0.0 114.683 -175.974 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -55.07 -32.2 61.75 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 117.366 -1.734 . . . . 0.0 111.328 174.57 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 6.42 49.09 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 53' ' ' LEU . . . . . 0.424 ' HA ' HD12 ' A' ' 53' ' ' LEU . 1.0 OUTLIER -111.5 10.79 21.33 Favored 'General case' 2 N--CA 1.62 8.062 0 O-C-N 124.811 1.319 . . . . 0.0 111.199 -170.476 . . . . . . . . 4 4 . 1 . 011 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.04 124.19 23.01 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.244 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.34 16.03 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.594 HG11 ' CZ3' ' A' ' 202' ' ' TRP . 1.9 m -83.93 -14.51 11.51 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.919 0 O-C-N 124.134 0.896 . . . . 0.0 112.816 179.222 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -153.33 160.55 42.71 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.095 0.861 . . . . 0.0 112.471 -178.52 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 128.37 28.47 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -144.64 174.11 11.25 Favored 'General case' 0 CA--C 1.518 -0.274 0 CA-C-N 114.684 -1.144 . . . . 0.0 109.829 -175.619 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -134.54 164.89 26.46 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -179.772 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 64' ' ' HIS . . . . . 0.468 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.0 OUTLIER -144.39 154.07 56.44 Favored Pre-proline 0 N--CA 1.484 1.254 0 N-CA-C 106.895 -1.52 . . . . 0.0 106.895 172.617 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.09 3.08 7.93 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 C-N-CA 121.146 1.231 . . . . 0.0 114.61 -173.75 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 145.68 54.82 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.483 ' HB2' HD23 ' A' ' 124' ' ' LEU . 23.6 tt0 -128.93 128.44 43.76 Favored 'General case' 0 N--CA 1.478 0.945 0 O-C-N 124.052 0.845 . . . . 0.0 110.103 179.599 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -104.22 124.79 49.75 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.742 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 70' ' ' TYR . . . . . 0.695 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 142.11 29.27 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 14.6 tp -132.36 121.37 23.39 Favored 'General case' 2 C--N 1.468 5.722 0 N-CA-C 102.143 -3.28 . . . . 0.0 102.143 179.921 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 118.46 21.46 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 107' ' ' HIS . . . . . 0.695 ' CE1' ' OH ' ' A' ' 70' ' ' TYR . 0.7 OUTLIER -148.91 169.35 20.75 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 122.042 0.925 . . . . 0.0 113.172 -176.556 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 108' ' ' CYS . . . . . 0.645 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -168.41 168.43 11.25 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 173.111 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.49 38.28 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -117.19 120.96 4.98 Favored Glycine 0 N--CA 1.446 -0.684 0 N-CA-C 104.99 -3.244 . . . . 0.0 104.99 176.779 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -106.12 111.31 34.6 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.882 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 124' ' ' LEU . . . . . 0.483 HD23 ' HB2' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 202' ' ' TRP . . . . . 0.594 ' CZ3' HG11 ' A' ' 58' ' ' VAL . 3.3 m0 . . . . . 0 N--CA 1.487 1.386 0 CA-C-O 118.209 -0.901 . . . . 0.0 109.111 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.56 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.73 126.13 73.94 Favored Pre-proline 0 N--CA 1.489 1.477 0 C-N-CA 123.386 0.674 . . . . 0.0 110.882 -178.127 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.178 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 34.0 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.48 12.9 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.96 154.88 48.35 Favored 'General case' 0 CA--C 1.491 -1.316 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 -179.202 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.58 -163.43 35.14 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 118.041 -2.028 . . . . 0.0 113.208 -179.852 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.38 179.97 46.24 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 119.724 -1.227 . . . . 0.0 113.298 -176.946 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.1 35.05 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.48 HD12 ' O ' ' A' ' 118' ' ' SER . 0.0 OUTLIER -108.52 13.92 25.0 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 119.751 -1.843 . . . . 0.0 115.39 -175.544 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.57 -32.2 66.9 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.774 -1.97 . . . . 0.0 111.328 179.044 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.19 54.5 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.6 mp -103.85 15.22 29.2 Favored 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 114.517 1.303 . . . . 0.0 114.517 -176.223 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.35 124.19 23.39 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -177.955 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.47 16.12 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.463 HG11 ' CZ3' ' A' ' 202' ' ' TRP . 2.2 m -84.85 -13.76 11.29 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.812 0 O-C-N 123.766 0.667 . . . . 0.0 112.705 179.169 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.83 160.55 43.09 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.198 0.908 . . . . 0.0 112.471 -178.996 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 129.44 33.01 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' HIS . . . . . 0.469 ' CE1' ' NE2' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -147.65 175.15 11.11 Favored 'General case' 0 N--CA 1.447 -0.607 0 CA-C-N 114.756 -1.111 . . . . 0.0 110.303 -176.527 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 63' ' ' THR . . . . . 0.553 ' C ' ' ND1' ' A' ' 64' ' ' HIS . 28.7 p -134.64 163.1 30.51 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -177.615 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 64' ' ' HIS . . . . . 0.878 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -135.12 147.07 60.94 Favored Pre-proline 0 N--CA 1.492 1.666 0 C-N-CA 123.931 0.892 . . . . 0.0 108.831 177.9 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -79.23 3.08 7.77 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 CA-C-N 119.819 0.971 . . . . 0.0 114.61 178.861 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 144.74 55.64 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.44 ' HB2' HD23 ' A' ' 124' ' ' LEU . 6.9 tt0 -126.59 125.11 41.42 Favored 'General case' 0 CA--C 1.553 1.088 0 O-C-N 124.879 1.362 . . . . 0.0 110.342 -178.928 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.13 124.79 49.23 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.18 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 70' ' ' TYR . . . . . 0.762 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 116.39 19.77 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 107' ' ' HIS . . . . . 0.8 ' HD1' ' N ' ' A' ' 108' ' ' CYS . 0.0 OUTLIER -144.06 164.24 31.21 Favored 'General case' 0 C--N 1.341 0.224 0 N-CA-C 114.331 1.234 . . . . 0.0 114.331 -174.866 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 108' ' ' CYS . . . . . 0.8 ' N ' ' HD1' ' A' ' 107' ' ' HIS . 7.3 p -165.96 168.43 15.73 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 170.457 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 118' ' ' SER . . . . . 0.48 ' O ' HD12 ' A' ' 50' ' ' LEU . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 150.81 39.44 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.25 120.12 4.77 Favored Glycine 0 N--CA 1.448 -0.509 0 N-CA-C 104.894 -3.282 . . . . 0.0 104.894 176.863 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.52 111.31 34.26 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -179.107 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 124' ' ' LEU . . . . . 0.44 HD23 ' HB2' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 202' ' ' TRP . . . . . 0.463 ' CZ3' HG11 ' A' ' 58' ' ' VAL . 1.3 m0 . . . . . 0 N--CA 1.489 1.501 0 CA-C-O 118.272 -0.87 . . . . 0.0 109.396 . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.61 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.8 126.03 74.01 Favored Pre-proline 0 N--CA 1.488 1.428 0 C-N-CA 123.358 0.663 . . . . 0.0 110.963 -178.117 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.46 107.32 2.36 Favored 'Trans proline' 0 C--N 1.323 -0.799 0 C-N-CA 121.836 1.691 . . . . 0.0 112.97 -175.1 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 34.0 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.13 12.63 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.2 153.95 49.14 Favored 'General case' 0 CA--C 1.493 -1.233 0 O-C-N 123.524 0.515 . . . . 0.0 109.729 -178.841 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.99 -163.46 35.39 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.965 -2.064 . . . . 0.0 113.208 179.792 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.45 179.97 46.3 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 119.699 -1.239 . . . . 0.0 113.319 -176.95 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 132.53 35.08 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.506 -1.847 . . . . 0.0 107.908 -177.646 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . 0.266 0.3 OUTLIER -114.53 20.49 15.32 Favored 'General case' 0 C--N 1.316 -0.849 0 O-C-N 117.804 -3.06 . . . . 0.0 114.774 -175.974 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -55.47 -32.2 62.62 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 117.33 -1.748 . . . . 0.0 111.328 174.542 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.2 54.51 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.2 mp -104.2 15.71 27.79 Favored 'General case' 0 N--CA 1.488 1.448 0 N-CA-C 114.529 1.307 . . . . 0.0 114.529 -176.419 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.17 124.19 23.17 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.249 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.71 16.28 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.678 HG11 ' CZ3' ' A' ' 202' ' ' TRP . 1.6 m -84.97 -13.94 11.21 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.668 0 CA-C-N 118.669 0.668 . . . . 0.0 112.787 179.043 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.69 160.55 43.15 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.086 0.857 . . . . 0.0 112.471 -178.93 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 127.14 23.68 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -141.7 171.22 14.36 Favored 'General case' 0 C--N 1.351 0.634 0 CA-C-N 114.027 -1.442 . . . . 0.0 110.184 -174.718 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -133.0 165.53 24.52 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 178.347 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 64' ' ' HIS . . . . . 0.604 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.0 OUTLIER -145.55 154.04 52.07 Favored Pre-proline 0 N--CA 1.48 1.052 0 N-CA-C 107.208 -1.404 . . . . 0.0 107.208 172.63 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.17 3.08 7.94 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 C-N-CA 121.04 1.16 . . . . 0.0 114.61 -173.122 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 144.3 55.87 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 33.1 tt0 -126.3 127.34 45.42 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 124.286 0.991 . . . . 0.0 109.456 179.857 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.4 124.79 49.36 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 177.428 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 70' ' ' TYR . . . . . 0.713 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 119.08 22.07 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 107' ' ' HIS . . . . . 0.713 ' CE1' ' OH ' ' A' ' 70' ' ' TYR . 1.0 OUTLIER -150.21 171.04 17.58 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 122.16 0.981 . . . . 0.0 112.737 -177.18 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 108' ' ' CYS . . . . . 0.669 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -169.29 168.43 9.69 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 173.848 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 150.76 39.53 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.2 120.04 4.74 Favored Glycine 0 N--CA 1.448 -0.509 0 N-CA-C 104.947 -3.261 . . . . 0.0 104.947 176.857 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.46 111.31 34.22 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -179.058 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 202' ' ' TRP . . . . . 0.678 ' CZ3' HG11 ' A' ' 58' ' ' VAL . 11.6 m0 . . . . . 0 N--CA 1.488 1.449 0 CA-C-O 118.012 -0.994 . . . . 0.0 109.683 . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.76 126.17 73.78 Favored Pre-proline 0 N--CA 1.489 1.483 0 C-N-CA 123.322 0.649 . . . . 0.0 110.881 -178.12 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.178 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 34.0 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.44 12.88 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.93 154.89 48.38 Favored 'General case' 0 CA--C 1.49 -1.346 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 -179.235 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.59 -163.4 35.13 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 118.059 -2.02 . . . . 0.0 113.208 -179.847 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.35 179.94 46.2 Favored Glycine 0 N--CA 1.444 -0.774 0 C-N-CA 119.67 -1.252 . . . . 0.0 113.27 -176.916 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 132.59 35.08 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . 0.268 0.3 OUTLIER -114.57 20.43 15.34 Favored 'General case' 0 C--N 1.316 -0.869 0 O-C-N 117.821 -3.049 . . . . 0.0 114.791 -176.067 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -55.34 -32.2 62.34 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 117.275 -1.77 . . . . 0.0 111.328 174.557 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.09 54.41 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.2 mp -104.13 15.67 27.92 Favored 'General case' 0 N--CA 1.486 1.357 0 N-CA-C 114.559 1.318 . . . . 0.0 114.559 -176.327 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.23 124.19 23.24 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.237 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.51 16.15 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.442 HG11 ' CZ3' ' A' ' 202' ' ' TRP . 2.2 m -84.97 -13.68 11.27 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.781 0 CA-C-N 118.613 0.642 . . . . 0.0 112.73 179.168 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.8 160.55 43.11 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.161 0.892 . . . . 0.0 112.471 -179.046 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 129.57 33.62 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 62' ' ' HIS . . . . . 0.456 ' CE1' ' NE2' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -147.89 175.47 10.93 Favored 'General case' 0 N--CA 1.446 -0.625 0 CA-C-N 114.785 -1.098 . . . . 0.0 110.259 -176.62 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 63' ' ' THR . . . . . 0.546 ' C ' ' ND1' ' A' ' 64' ' ' HIS . 28.7 p -134.83 163.16 30.44 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -177.49 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 64' ' ' HIS . . . . . 0.877 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -135.18 147.04 60.72 Favored Pre-proline 0 N--CA 1.492 1.646 0 C-N-CA 124.013 0.925 . . . . 0.0 108.925 177.879 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -79.24 3.08 7.77 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 CA-C-N 119.809 0.968 . . . . 0.0 114.61 178.894 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 144.74 55.64 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.436 ' HB2' HD23 ' A' ' 124' ' ' LEU . 6.7 tt0 -126.52 124.92 41.14 Favored 'General case' 0 CA--C 1.553 1.073 0 O-C-N 124.917 1.385 . . . . 0.0 110.392 -178.869 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.06 124.79 49.19 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.179 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 70' ' ' TYR . . . . . 0.762 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 116.51 19.84 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 107' ' ' HIS . . . . . 0.796 ' HD1' ' N ' ' A' ' 108' ' ' CYS . 0.0 OUTLIER -144.39 164.61 30.32 Favored 'General case' 0 C--N 1.341 0.2 0 N-CA-C 114.211 1.189 . . . . 0.0 114.211 -174.976 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 108' ' ' CYS . . . . . 0.796 ' N ' ' HD1' ' A' ' 107' ' ' HIS . 7.3 p -166.11 168.43 15.44 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 170.633 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 150.93 39.24 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.34 120.12 4.76 Favored Glycine 0 N--CA 1.447 -0.596 0 N-CA-C 104.976 -3.249 . . . . 0.0 104.976 176.901 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.6 111.31 34.31 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -179.055 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 124' ' ' LEU . . . . . 0.436 HD23 ' HB2' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 202' ' ' TRP . . . . . 0.442 ' CZ3' HG11 ' A' ' 58' ' ' VAL . 1.3 m0 . . . . . 0 N--CA 1.49 1.557 0 CA-C-O 118.232 -0.89 . . . . 0.0 109.367 . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.75 126.23 73.65 Favored Pre-proline 0 N--CA 1.489 1.483 0 C-N-CA 123.322 0.649 . . . . 0.0 110.847 -178.12 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.57 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.778 0 C-N-CA 121.855 1.704 . . . . 0.0 112.97 -175.211 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 34.0 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 125.32 12.0 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -136.32 152.39 50.62 Favored 'General case' 0 CA--C 1.497 -1.084 0 O-C-N 123.731 0.644 . . . . 0.0 109.833 -178.296 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' GLY . . . . . 0.456 ' HA2' ' CE2' ' A' ' 202' ' ' TRP . . . 163.75 -163.4 35.75 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.651 -2.214 . . . . 0.0 113.208 178.775 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.35 179.94 46.2 Favored Glycine 0 N--CA 1.444 -0.774 0 C-N-CA 119.67 -1.252 . . . . 0.0 113.27 -176.916 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 132.45 35.08 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.577 HD12 ' O ' ' A' ' 118' ' ' SER . 0.0 OUTLIER -106.74 13.12 28.36 Favored 'General case' 0 N--CA 1.492 1.664 0 N-CA-C 115.597 1.702 . . . . 0.0 115.597 -175.034 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -58.91 -32.2 69.32 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 117.26 -1.776 . . . . 0.0 111.328 179.714 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 -0.23 54.12 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 47.9 mt -104.23 16.42 26.23 Favored 'General case' 0 C--N 1.364 1.224 0 N-CA-C 114.879 1.437 . . . . 0.0 114.879 -177.065 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -67.69 124.19 22.56 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.726 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.93 16.44 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.404 HG21 ' CZ3' ' A' ' 202' ' ' TRP . 0.1 OUTLIER -86.5 -12.96 10.91 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.621 0 CA-C-N 119.548 1.067 . . . . 0.0 112.281 178.766 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -151.41 160.55 43.69 Favored 'General case' 0 C--O 1.281 2.733 0 C-N-CA 119.023 -1.071 . . . . 0.0 112.471 -179.581 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 130.62 38.49 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -150.02 178.87 8.54 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.613 -0.721 . . . . 0.0 109.6 -177.933 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -136.78 164.82 27.38 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -176.04 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 64' ' ' HIS . . . . . 0.58 ' CE1' ' CD ' ' A' ' 68' ' ' GLU . 0.0 OUTLIER -142.21 152.38 61.0 Favored Pre-proline 0 N--CA 1.495 1.78 0 N-CA-C 107.12 -1.437 . . . . 0.0 107.12 174.393 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.1 3.08 7.93 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 N-CA-C 114.61 0.966 . . . . 0.0 114.61 -176.145 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 148.11 52.04 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.744 ' HB3' HD23 ' A' ' 124' ' ' LEU . 16.9 pt-20 -136.47 136.21 39.26 Favored 'General case' 0 CA--C 1.517 -0.304 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 176.452 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -106.53 124.79 50.13 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 -177.955 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 70' ' ' TYR . . . . . 0.71 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 119.69 22.91 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 107' ' ' HIS . . . . . 0.71 ' CE1' ' OH ' ' A' ' 70' ' ' TYR . 3.5 p80 -151.42 172.49 15.86 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 122.176 0.988 . . . . 0.0 112.399 -177.665 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 108' ' ' CYS . . . . . 0.61 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -170.1 168.43 8.39 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 174.521 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 118' ' ' SER . . . . . 0.577 ' O ' HD12 ' A' ' 50' ' ' LEU . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 120' ' ' CYS . . . . . 0.57 ' HB2' HD21 ' A' ' 50' ' ' LEU . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.5 38.26 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -117.01 120.25 4.75 Favored Glycine 0 N--CA 1.447 -0.627 0 N-CA-C 105.152 -3.179 . . . . 0.0 105.152 176.987 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.85 111.31 34.45 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.856 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 124' ' ' LEU . . . . . 0.744 HD23 ' HB3' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 202' ' ' TRP . . . . . 0.456 ' CE2' ' HA2' ' A' ' 47' ' ' GLY . 9.5 m0 . . . . . 0 N--CA 1.49 1.542 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.289 . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.56 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.73 126.13 73.94 Favored Pre-proline 0 N--CA 1.489 1.477 0 C-N-CA 123.386 0.674 . . . . 0.0 110.882 -178.127 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.178 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 34.0 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 125.55 12.18 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -136.67 152.65 50.64 Favored 'General case' 0 CA--C 1.493 -1.217 0 O-C-N 123.773 0.67 . . . . 0.0 109.94 -178.401 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 163.58 -163.46 35.7 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.683 -2.198 . . . . 0.0 113.208 178.939 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.45 179.97 46.3 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 119.699 -1.239 . . . . 0.0 113.319 -176.95 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.12 35.05 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.506 -1.847 . . . . 0.0 107.908 -177.646 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.478 ' H ' HD12 ' A' ' 50' ' ' LEU . 0.0 OUTLIER -108.96 14.19 24.26 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 119.604 -1.935 . . . . 0.0 115.302 -175.559 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.27 -32.2 66.37 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.805 -1.958 . . . . 0.0 111.328 178.773 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 -0.02 54.31 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -103.65 15.28 29.23 Favored 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 114.449 1.278 . . . . 0.0 114.449 -176.38 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.21 124.19 23.22 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.031 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.64 16.24 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.636 HG11 ' CZ3' ' A' ' 202' ' ' TRP . 0.2 OUTLIER -81.89 -16.77 11.88 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.958 0 O-C-N 124.906 1.379 . . . . 0.0 112.928 179.114 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -154.43 160.55 41.69 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 118.758 0.708 . . . . 0.0 112.471 -177.057 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 128.2 27.82 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -144.13 173.83 11.4 Favored 'General case' 0 CA--C 1.516 -0.334 0 CA-C-N 114.575 -1.193 . . . . 0.0 109.86 -175.556 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -134.43 164.77 26.69 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 179.886 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 64' ' ' HIS . . . . . 0.538 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.0 OUTLIER -143.85 153.6 57.73 Favored Pre-proline 0 N--CA 1.483 1.182 0 N-CA-C 106.989 -1.486 . . . . 0.0 106.989 173.042 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.04 3.08 7.92 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 C-N-CA 121.075 1.183 . . . . 0.0 114.61 -174.215 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 143.69 56.19 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.495 ' HB3' ' HB ' ' A' ' 101' ' ' ILE . 0.1 OUTLIER -120.08 120.78 37.25 Favored 'General case' 0 N--CA 1.507 2.385 0 O-C-N 125.999 2.062 . . . . 0.0 111.502 -178.315 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -102.49 124.79 48.68 Favored 'General case' 0 N--CA 1.498 1.961 0 CA-C-N 120.76 1.618 . . . . 0.0 107.536 175.493 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 70' ' ' TYR . . . . . 0.653 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 101' ' ' ILE . . . . . 0.495 ' HB ' ' HB3' ' A' ' 68' ' ' GLU . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 118.89 21.85 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 107' ' ' HIS . . . . . 0.677 ' ND1' ' C ' ' A' ' 107' ' ' HIS . 1.4 p80 -150.23 170.75 18.23 Favored 'General case' 0 C--N 1.322 -0.597 0 C-N-CA 119.462 -0.895 . . . . 0.0 112.54 -177.031 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 108' ' ' CYS . . . . . 0.65 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -168.96 168.43 10.23 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 173.932 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 118' ' ' SER . . . . . 0.468 ' O ' HD12 ' A' ' 50' ' ' LEU . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.6 38.08 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -117.43 120.76 4.89 Favored Glycine 0 C--N 1.315 -0.629 0 N-CA-C 105.009 -3.236 . . . . 0.0 105.009 176.833 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.97 111.31 34.52 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.793 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 202' ' ' TRP . . . . . 0.636 ' CZ3' HG11 ' A' ' 58' ' ' VAL . 41.6 m0 . . . . . 0 N--CA 1.491 1.586 0 CA-C-O 117.459 -1.258 . . . . 0.0 109.754 . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.76 126.17 73.78 Favored Pre-proline 0 N--CA 1.489 1.483 0 C-N-CA 123.322 0.649 . . . . 0.0 110.881 -178.12 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.178 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 34.0 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.44 12.88 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.93 154.88 48.38 Favored 'General case' 0 CA--C 1.49 -1.33 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 -179.204 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.59 -163.43 35.14 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 118.059 -2.02 . . . . 0.0 113.208 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.38 179.97 46.24 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 119.724 -1.227 . . . . 0.0 113.298 -176.946 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 132.99 35.06 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.478 ' H ' HD12 ' A' ' 50' ' ' LEU . 0.0 OUTLIER -108.8 14.19 24.46 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 119.569 -1.957 . . . . 0.0 115.265 -175.538 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.35 -32.2 66.5 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.789 -1.965 . . . . 0.0 111.328 178.784 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.08 54.4 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.2 mp -104.43 15.98 27.07 Favored 'General case' 0 N--CA 1.487 1.389 0 N-CA-C 114.396 1.258 . . . . 0.0 114.396 -176.322 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.06 124.19 23.03 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.467 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.53 16.16 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.4 HG11 ' CZ3' ' A' ' 202' ' ' TRP . 2.5 m -85.06 -13.6 11.25 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.787 0 O-C-N 123.801 0.688 . . . . 0.0 112.737 179.241 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.86 160.55 43.08 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.187 0.903 . . . . 0.0 112.471 -179.11 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 129.64 33.92 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 62' ' ' HIS . . . . . 0.452 ' CE1' ' NE2' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -148.05 175.55 10.91 Favored 'General case' 0 N--CA 1.447 -0.601 0 CA-C-N 114.8 -1.091 . . . . 0.0 110.244 -176.666 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 63' ' ' THR . . . . . 0.544 ' C ' ' ND1' ' A' ' 64' ' ' HIS . 28.7 p -134.85 163.16 30.44 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -177.385 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 64' ' ' HIS . . . . . 0.875 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -135.14 147.03 60.76 Favored Pre-proline 0 N--CA 1.492 1.631 0 C-N-CA 124.031 0.932 . . . . 0.0 108.869 177.939 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -79.27 3.08 7.78 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 N-CA-C 114.61 0.966 . . . . 0.0 114.61 178.825 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 144.74 55.64 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.437 ' HB2' HD23 ' A' ' 124' ' ' LEU . 6.7 tt0 -126.52 124.92 41.14 Favored 'General case' 0 CA--C 1.553 1.073 0 O-C-N 124.917 1.385 . . . . 0.0 110.392 -178.869 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.06 124.79 49.19 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.179 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 70' ' ' TYR . . . . . 0.763 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 116.51 19.84 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 107' ' ' HIS . . . . . 0.797 ' HD1' ' N ' ' A' ' 108' ' ' CYS . 0.0 OUTLIER -144.35 164.57 30.41 Favored 'General case' 0 C--N 1.341 0.2 0 N-CA-C 114.23 1.196 . . . . 0.0 114.23 -174.956 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 108' ' ' CYS . . . . . 0.797 ' N ' ' HD1' ' A' ' 107' ' ' HIS . 7.3 p -166.11 168.43 15.44 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 170.599 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 118' ' ' SER . . . . . 0.466 ' O ' HD12 ' A' ' 50' ' ' LEU . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 120' ' ' CYS . . . . . 0.4 ' CB ' HD21 ' A' ' 50' ' ' LEU . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 150.99 39.15 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.52 120.47 4.86 Favored Glycine 0 N--CA 1.447 -0.616 0 N-CA-C 104.946 -3.261 . . . . 0.0 104.946 176.766 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.72 111.31 34.37 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -179.023 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 124' ' ' LEU . . . . . 0.437 HD23 ' HB2' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 202' ' ' TRP . . . . . 0.4 ' CZ3' HG11 ' A' ' 58' ' ' VAL . 1.7 m0 . . . . . 0 N--CA 1.487 1.416 0 CA-C-O 118.167 -0.921 . . . . 0.0 109.419 . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.77 126.21 73.66 Favored Pre-proline 0 N--CA 1.49 1.534 0 C-N-CA 123.364 0.665 . . . . 0.0 110.762 -178.076 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.261 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 34.0 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.24 12.72 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.28 154.41 49.04 Favored 'General case' 0 CA--C 1.488 -1.434 0 N-CA-C 109.662 -0.496 . . . . 0.0 109.662 -179.056 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.76 -163.46 35.26 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.972 -2.061 . . . . 0.0 113.208 179.738 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.47 179.82 46.22 Favored Glycine 0 N--CA 1.444 -0.785 0 C-N-CA 119.66 -1.257 . . . . 0.0 113.27 -176.858 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.07 133.07 35.09 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.494 -1.853 . . . . 0.0 107.908 -177.692 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.624 ' HB3' HD12 ' A' ' 53' ' ' LEU 0.286 0.3 OUTLIER -114.63 20.64 15.15 Favored 'General case' 0 N--CA 1.473 0.716 0 O-C-N 118.281 -2.762 . . . . 0.0 115.226 -176.201 . . . . . . . . 4 4 . 1 . 018 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -56.19 -32.2 64.14 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 117.243 -1.783 . . . . 0.0 111.328 174.709 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 -1.17 53.11 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 53' ' ' LEU . . . . . 0.624 HD12 ' HB3' ' A' ' 50' ' ' LEU . 59.6 mt -102.74 15.85 28.16 Favored 'General case' 0 CA--C 1.558 1.278 0 N-CA-C 114.876 1.436 . . . . 0.0 114.876 -176.903 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.13 124.19 23.12 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.321 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.76 16.32 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -86.07 -13.03 11.04 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.535 0 CA-C-N 119.284 0.947 . . . . 0.0 112.389 178.863 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -151.82 160.55 43.52 Favored 'General case' 0 C--O 1.281 2.733 0 C-N-CA 119.206 -0.998 . . . . 0.0 112.471 -179.452 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 128.16 27.67 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -144.0 173.81 11.39 Favored 'General case' 0 CA--C 1.519 -0.235 0 CA-C-N 114.543 -1.208 . . . . 0.0 109.778 -175.395 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -134.5 165.14 25.88 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 179.752 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 64' ' ' HIS . . . . . 0.543 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.0 OUTLIER -144.3 154.34 57.08 Favored Pre-proline 0 N--CA 1.484 1.248 0 N-CA-C 107.151 -1.425 . . . . 0.0 107.151 172.704 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.53 3.08 8.01 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 C-N-CA 120.901 1.068 . . . . 0.0 114.61 -174.026 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 145.57 54.93 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.438 ' HB2' HD23 ' A' ' 124' ' ' LEU . 33.2 tt0 -128.57 128.22 43.82 Favored 'General case' 0 N--CA 1.486 1.372 0 O-C-N 124.232 0.958 . . . . 0.0 110.037 179.554 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.93 124.79 49.62 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.509 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 70' ' ' TYR . . . . . 0.694 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 118.88 21.84 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 107' ' ' HIS . . . . . 0.694 ' CE1' ' OH ' ' A' ' 70' ' ' TYR . 1.0 OUTLIER -150.11 170.67 18.35 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 121.949 0.88 . . . . 0.0 112.691 -177.034 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 108' ' ' CYS . . . . . 0.652 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -168.98 168.43 10.2 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 173.863 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.49 38.28 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -117.11 120.24 4.74 Favored Glycine 0 N--CA 1.448 -0.562 0 N-CA-C 105.047 -3.221 . . . . 0.0 105.047 177.018 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.77 111.31 34.4 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.86 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 124' ' ' LEU . . . . . 0.438 HD23 ' HB2' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 202' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.488 1.45 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 . . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.76 126.17 73.78 Favored Pre-proline 0 N--CA 1.489 1.483 0 C-N-CA 123.322 0.649 . . . . 0.0 110.881 -178.12 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.178 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 34.0 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 125.51 12.15 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -136.66 152.8 50.81 Favored 'General case' 0 CA--C 1.493 -1.213 0 O-C-N 123.686 0.616 . . . . 0.0 109.894 -178.491 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 47' ' ' GLY . . . . . 0.466 ' HA2' ' CE2' ' A' ' 202' ' ' TRP . . . 163.54 -163.43 35.66 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.694 -2.193 . . . . 0.0 113.208 178.947 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.4 179.94 46.25 Favored Glycine 0 N--CA 1.444 -0.812 0 C-N-CA 119.745 -1.217 . . . . 0.0 113.343 -176.912 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.25 35.05 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.506 -1.847 . . . . 0.0 107.908 -177.646 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.485 HD12 ' O ' ' A' ' 118' ' ' SER . 0.0 OUTLIER -108.54 13.92 24.97 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 119.879 -1.763 . . . . 0.0 115.585 -175.579 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.79 -32.2 67.3 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.792 -1.963 . . . . 0.0 111.328 179.09 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.15 54.46 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 22.9 mt -104.76 16.14 26.57 Favored 'General case' 0 N--CA 1.484 1.251 0 N-CA-C 114.602 1.334 . . . . 0.0 114.602 -176.64 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -67.5 124.19 22.34 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.652 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.8 16.35 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.406 HG21 ' CZ3' ' A' ' 202' ' ' TRP . 0.0 OUTLIER -86.39 -12.79 10.97 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 CA-C-N 119.446 1.021 . . . . 0.0 112.251 178.85 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -151.62 160.55 43.6 Favored 'General case' 0 C--O 1.281 2.733 0 C-N-CA 119.128 -1.029 . . . . 0.0 112.471 -179.574 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 130.57 38.27 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -149.99 178.85 8.55 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.541 -177.928 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -136.76 164.81 27.4 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -176.03 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 64' ' ' HIS . . . . . 0.582 ' CE1' ' CD ' ' A' ' 68' ' ' GLU . 0.0 OUTLIER -142.03 152.23 61.21 Favored Pre-proline 0 N--CA 1.495 1.807 0 N-CA-C 107.161 -1.422 . . . . 0.0 107.161 174.534 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.1 3.08 7.93 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 N-CA-C 114.61 0.966 . . . . 0.0 114.61 -176.321 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 148.0 52.18 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.744 ' HB3' HD23 ' A' ' 124' ' ' LEU . 17.1 pt-20 -136.31 135.83 39.23 Favored 'General case' 0 N--CA 1.465 0.319 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 176.593 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -106.28 124.79 50.13 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 -178.014 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 70' ' ' TYR . . . . . 0.709 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 119.69 22.91 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 107' ' ' HIS . . . . . 0.709 ' CE1' ' OH ' ' A' ' 70' ' ' TYR . 3.5 p80 -151.3 172.43 15.89 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 122.202 1.001 . . . . 0.0 112.503 -177.633 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 108' ' ' CYS . . . . . 0.603 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -170.13 168.43 8.35 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 174.428 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 118' ' ' SER . . . . . 0.485 ' O ' HD12 ' A' ' 50' ' ' LEU . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 120' ' ' CYS . . . . . 0.402 ' CB ' HD21 ' A' ' 50' ' ' LEU . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.41 38.42 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.93 120.24 4.75 Favored Glycine 0 N--CA 1.448 -0.535 0 N-CA-C 105.058 -3.217 . . . . 0.0 105.058 176.982 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.79 111.31 34.42 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.931 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 124' ' ' LEU . . . . . 0.744 HD23 ' HB3' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 202' ' ' TRP . . . . . 0.466 ' CE2' ' HA2' ' A' ' 47' ' ' GLY . 11.4 m0 . . . . . 0 N--CA 1.49 1.554 0 CA-C-O 117.175 -1.393 . . . . 0.0 109.408 . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.56 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.48 126.15 74.53 Favored Pre-proline 0 N--CA 1.489 1.511 0 C-N-CA 123.444 0.698 . . . . 0.0 110.821 -178.148 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.65 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.801 0 C-N-CA 121.832 1.688 . . . . 0.0 112.97 -175.364 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 35' ' ' ALA . . . . . . . . . . . . . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 44' ' ' GLN . . . . . . . . . . . . . 34.0 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 125.25 11.95 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -136.03 152.2 50.66 Favored 'General case' 0 CA--C 1.494 -1.177 0 O-C-N 123.809 0.693 . . . . 0.0 109.948 -178.28 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 47' ' ' GLY . . . . . 0.447 ' HA2' ' CE2' ' A' ' 202' ' ' TRP . . . 163.82 -163.43 35.81 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.594 -2.241 . . . . 0.0 113.208 178.618 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.4 179.94 46.25 Favored Glycine 0 N--CA 1.444 -0.812 0 C-N-CA 119.745 -1.217 . . . . 0.0 113.343 -176.912 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.42 35.04 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.506 -1.847 . . . . 0.0 107.908 -177.646 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.481 HD12 ' O ' ' A' ' 118' ' ' SER . 0.0 OUTLIER -108.8 14.11 24.51 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 119.907 -1.746 . . . . 0.0 115.637 -175.622 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.87 -32.2 67.44 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.796 -1.962 . . . . 0.0 111.328 178.98 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 -0.38 54.0 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 67.1 mt -104.03 16.1 27.03 Favored 'General case' 0 C--N 1.363 1.188 0 N-CA-C 114.868 1.433 . . . . 0.0 114.868 -177.309 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -67.16 124.19 21.91 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.773 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.89 16.41 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -86.37 -13.02 10.94 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.765 0 CA-C-N 119.652 1.115 . . . . 0.0 112.087 178.734 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -151.4 160.55 43.69 Favored 'General case' 0 C--O 1.281 2.733 0 C-N-CA 118.903 -1.119 . . . . 0.0 112.471 -179.428 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 131.24 41.38 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -151.05 -179.95 7.74 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.762 -0.653 . . . . 0.0 109.636 -178.348 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -137.54 165.17 26.95 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -175.479 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 64' ' ' HIS . . . . . 0.561 ' CE1' ' CD ' ' A' ' 68' ' ' GLU . 0.0 OUTLIER -143.25 153.01 59.08 Favored Pre-proline 0 N--CA 1.495 1.79 0 N-CA-C 106.942 -1.503 . . . . 0.0 106.942 173.967 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.25 3.08 7.96 Favored 'Trans proline' 0 C--N 1.278 -3.17 0 C-N-CA 120.841 1.027 . . . . 0.0 114.61 -175.432 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 148.14 52.0 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 68' ' ' GLU . . . . . 0.74 ' HB3' HD23 ' A' ' 124' ' ' LEU . 18.0 pt-20 -136.76 135.93 38.48 Favored 'General case' 0 N--CA 1.468 0.457 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 176.473 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -106.18 124.79 50.13 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 -177.833 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 70' ' ' TYR . . . . . 0.685 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 101' ' ' ILE . . . . . 0.422 ' HB ' ' HG2' ' A' ' 68' ' ' GLU . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 119.42 22.54 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 107' ' ' HIS . . . . . 0.685 ' CE1' ' OH ' ' A' ' 70' ' ' TYR . 3.7 p80 -150.77 172.2 15.99 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 122.184 0.992 . . . . 0.0 112.514 -177.549 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 108' ' ' CYS . . . . . 0.614 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -170.01 168.43 8.55 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 174.154 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 118' ' ' SER . . . . . 0.481 ' O ' HD12 ' A' ' 50' ' ' LEU . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.53 38.21 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -117.01 120.38 4.79 Favored Glycine 0 N--CA 1.447 -0.627 0 N-CA-C 105.094 -3.202 . . . . 0.0 105.094 176.992 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.96 111.31 34.51 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.924 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 124' ' ' LEU . . . . . 0.74 HD23 ' HB3' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 202' ' ' TRP . . . . . 0.447 ' CE2' ' HA2' ' A' ' 47' ' ' GLY . 8.7 m0 . . . . . 0 N--CA 1.49 1.531 0 CA-C-O 117.146 -1.407 . . . . 0.0 109.176 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.62 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.53 126.1 74.5 Favored Pre-proline 0 N--CA 1.489 1.511 0 C-N-CA 123.453 0.701 . . . . 0.0 110.821 -178.14 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.59 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.806 0 C-N-CA 121.775 1.65 . . . . 0.0 112.97 -175.369 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.642 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' GLN . . . . . 0.642 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.61 13.0 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -139.24 155.23 47.92 Favored 'General case' 0 CA--C 1.49 -1.346 0 N-CA-C 109.438 -0.578 . . . . 0.0 109.438 -179.313 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.41 -163.43 35.04 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 118.072 -2.013 . . . . 0.0 113.208 -179.736 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.38 179.97 46.24 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 119.724 -1.227 . . . . 0.0 113.298 -176.946 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 132.62 35.08 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . 0.266 0.3 OUTLIER -114.64 20.48 15.26 Favored 'General case' 0 C--N 1.317 -0.822 0 O-C-N 117.791 -3.068 . . . . 0.0 114.69 -176.029 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -55.34 -32.2 62.34 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 117.275 -1.77 . . . . 0.0 111.328 174.525 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.15 54.46 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -104.46 15.98 27.04 Favored 'General case' 0 N--CA 1.487 1.383 0 N-CA-C 114.49 1.293 . . . . 0.0 114.49 -176.45 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.01 124.19 22.96 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.484 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.45 16.11 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 2.5 m -84.81 -13.74 11.31 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.753 0 CA-C-N 118.634 0.652 . . . . 0.0 112.657 179.072 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.77 160.55 43.12 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.246 0.93 . . . . 0.0 112.471 -178.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 128.65 29.56 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -145.15 174.91 10.66 Favored 'General case' 0 CA--C 1.518 -0.285 0 CA-C-N 114.765 -1.107 . . . . 0.0 109.705 -175.92 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -135.01 165.06 26.22 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -179.46 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' HIS . . . . . 0.507 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.0 OUTLIER -144.47 154.15 56.27 Favored Pre-proline 0 N--CA 1.483 1.184 0 N-CA-C 106.993 -1.484 . . . . 0.0 106.993 172.714 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.29 3.08 7.97 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 C-N-CA 121.065 1.177 . . . . 0.0 114.61 -173.819 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 145.9 54.6 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . 0.472 ' HB2' HD23 ' A' ' 124' ' ' LEU . 4.3 tt0 -128.62 128.11 43.53 Favored 'General case' 0 N--CA 1.479 1.011 0 O-C-N 124.479 1.112 . . . . 0.0 110.497 179.738 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -104.38 124.79 49.83 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.649 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . 0.676 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 118.59 21.58 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 107' ' ' HIS . . . . . 0.677 ' ND1' ' C ' ' A' ' 107' ' ' HIS . 1.2 p80 -149.42 170.24 19.02 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.949 0.88 . . . . 0.0 112.773 -176.889 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 108' ' ' CYS . . . . . 0.652 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -168.78 168.43 10.56 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 173.457 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.53 38.21 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -117.04 120.26 4.75 Favored Glycine 0 C--N 1.316 -0.569 0 N-CA-C 105.112 -3.195 . . . . 0.0 105.112 176.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.87 111.31 34.46 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 124' ' ' LEU . . . . . 0.472 HD23 ' HB2' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.76 126.17 73.78 Favored Pre-proline 0 N--CA 1.489 1.483 0 C-N-CA 123.322 0.649 . . . . 0.0 110.881 -178.12 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.178 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.642 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' GLN . . . . . 0.642 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.44 12.88 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.93 154.89 48.38 Favored 'General case' 0 CA--C 1.49 -1.346 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 -179.235 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.59 -163.4 35.13 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 118.059 -2.02 . . . . 0.0 113.208 -179.847 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.35 179.94 46.2 Favored Glycine 0 N--CA 1.444 -0.774 0 C-N-CA 119.67 -1.252 . . . . 0.0 113.27 -176.916 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.1 35.05 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . 0.479 ' H ' HD12 ' A' ' 50' ' ' LEU . 0.0 OUTLIER -108.97 14.24 24.21 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 119.579 -1.95 . . . . 0.0 115.235 -175.545 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.28 -32.2 66.39 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.778 -1.969 . . . . 0.0 111.328 178.741 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.13 54.45 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.2 mp -104.32 15.75 27.62 Favored 'General case' 0 N--CA 1.486 1.371 0 N-CA-C 114.494 1.294 . . . . 0.0 114.494 -176.292 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.1 124.19 23.08 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.329 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.47 16.12 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 2.3 m -84.89 -13.68 11.29 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.781 0 O-C-N 123.766 0.667 . . . . 0.0 112.758 179.132 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.83 160.55 43.09 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.191 0.905 . . . . 0.0 112.471 -179.045 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 129.57 33.62 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' HIS . . . . . 0.612 ' CE1' ' HE2' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -147.89 175.47 10.93 Favored 'General case' 0 N--CA 1.446 -0.625 0 CA-C-N 114.785 -1.098 . . . . 0.0 110.259 -176.62 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . 0.544 ' C ' ' ND1' ' A' ' 64' ' ' HIS . 28.7 p -134.83 163.2 30.35 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -177.49 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' HIS . . . . . 0.878 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -135.22 147.17 61.18 Favored Pre-proline 0 N--CA 1.492 1.641 0 C-N-CA 123.984 0.914 . . . . 0.0 108.876 177.864 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -79.32 3.08 7.79 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 N-CA-C 114.61 0.966 . . . . 0.0 114.61 178.869 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 144.69 55.67 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . 0.436 ' HB2' HD23 ' A' ' 124' ' ' LEU . 6.9 tt0 -126.49 125.0 41.35 Favored 'General case' 0 CA--C 1.553 1.081 0 O-C-N 124.891 1.37 . . . . 0.0 110.378 -178.93 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.06 124.79 49.19 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.179 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . 0.761 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 116.53 19.86 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 107' ' ' HIS . . . . . 0.761 ' CE1' ' OH ' ' A' ' 70' ' ' TYR . 0.0 OUTLIER -144.39 164.67 30.15 Favored 'General case' 0 C--N 1.341 0.222 0 N-CA-C 114.273 1.212 . . . . 0.0 114.273 -175.004 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 108' ' ' CYS . . . . . 0.637 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -166.16 168.43 15.35 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 170.626 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 118' ' ' SER . . . . . 0.467 ' O ' HD12 ' A' ' 50' ' ' LEU . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 150.93 39.24 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.35 120.15 4.77 Favored Glycine 0 N--CA 1.448 -0.505 0 N-CA-C 104.911 -3.276 . . . . 0.0 104.911 176.911 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.6 111.31 34.31 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -179.104 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 124' ' ' LEU . . . . . 0.436 HD23 ' HB2' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.7 126.18 73.9 Favored Pre-proline 0 N--CA 1.489 1.477 0 C-N-CA 123.359 0.664 . . . . 0.0 110.852 -178.126 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.57 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.778 0 C-N-CA 121.855 1.704 . . . . 0.0 112.97 -175.232 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.642 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' GLN . . . . . 0.642 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.49 12.91 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.96 154.88 48.35 Favored 'General case' 0 CA--C 1.491 -1.301 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 -179.187 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.55 -163.4 35.1 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 118.014 -2.041 . . . . 0.0 113.208 -179.88 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.35 179.94 46.2 Favored Glycine 0 N--CA 1.444 -0.774 0 C-N-CA 119.67 -1.252 . . . . 0.0 113.27 -176.916 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.1 35.05 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . 0.475 ' H ' HD12 ' A' ' 50' ' ' LEU . 0.0 OUTLIER -108.94 14.17 24.29 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 119.579 -1.95 . . . . 0.0 115.225 -175.501 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.29 -32.2 66.4 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.811 -1.955 . . . . 0.0 111.328 178.783 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.13 54.44 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.3 mp -104.25 15.71 27.75 Favored 'General case' 0 N--CA 1.486 1.351 0 N-CA-C 114.467 1.284 . . . . 0.0 114.467 -176.254 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.18 124.19 23.18 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.274 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.42 16.08 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 2.6 m -85.1 -13.47 11.26 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.829 0 CA-C-N 118.66 0.664 . . . . 0.0 112.707 179.222 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.74 160.55 43.13 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.205 0.911 . . . . 0.0 112.471 -179.195 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 129.64 33.92 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' HIS . . . . . 0.605 ' CE1' ' HE2' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -148.02 175.52 10.93 Favored 'General case' 0 N--CA 1.446 -0.655 0 CA-C-N 114.8 -1.091 . . . . 0.0 110.305 -176.644 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . 0.547 ' C ' ' ND1' ' A' ' 64' ' ' HIS . 28.7 p -134.85 163.14 30.5 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -177.416 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' HIS . . . . . 0.877 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -135.11 147.06 60.95 Favored Pre-proline 0 N--CA 1.493 1.692 0 C-N-CA 123.985 0.914 . . . . 0.0 108.875 177.891 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -79.25 3.08 7.77 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 N-CA-C 114.61 0.966 . . . . 0.0 114.61 178.826 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 144.74 55.64 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . 0.438 ' HB2' HD23 ' A' ' 124' ' ' LEU . 6.6 tt0 -126.52 124.88 41.04 Favored 'General case' 0 CA--C 1.553 1.096 0 O-C-N 124.936 1.398 . . . . 0.0 110.433 -178.862 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.06 124.79 49.2 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.214 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . 0.762 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 116.41 19.78 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 107' ' ' HIS . . . . . 0.762 ' CE1' ' OH ' ' A' ' 70' ' ' TYR . 0.0 OUTLIER -144.15 164.28 31.14 Favored 'General case' 0 C--N 1.342 0.246 0 N-CA-C 114.291 1.219 . . . . 0.0 114.291 -174.882 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 108' ' ' CYS . . . . . 0.634 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -165.96 168.43 15.73 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 170.501 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 118' ' ' SER . . . . . 0.464 ' O ' HD12 ' A' ' 50' ' ' LEU . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.02 39.1 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.6 120.41 4.84 Favored Glycine 0 N--CA 1.448 -0.525 0 N-CA-C 104.938 -3.265 . . . . 0.0 104.938 176.782 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.66 111.31 34.34 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -179.002 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 124' ' ' LEU . . . . . 0.438 HD23 ' HB2' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.76 126.17 73.78 Favored Pre-proline 0 N--CA 1.489 1.483 0 C-N-CA 123.322 0.649 . . . . 0.0 110.881 -178.12 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.178 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.642 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' GLN . . . . . 0.642 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.44 12.88 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.93 154.89 48.38 Favored 'General case' 0 CA--C 1.49 -1.346 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 -179.235 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.59 -163.4 35.13 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 118.059 -2.02 . . . . 0.0 113.208 -179.847 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.35 179.94 46.2 Favored Glycine 0 N--CA 1.444 -0.774 0 C-N-CA 119.67 -1.252 . . . . 0.0 113.27 -176.916 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.15 35.05 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . 0.48 ' H ' HD12 ' A' ' 50' ' ' LEU . 0.0 OUTLIER -109.05 14.23 24.13 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 119.538 -1.976 . . . . 0.0 115.281 -175.559 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.24 -32.2 66.3 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.773 -1.971 . . . . 0.0 111.328 178.73 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.13 54.45 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.1 mp -104.41 15.88 27.29 Favored 'General case' 0 N--CA 1.487 1.386 0 N-CA-C 114.465 1.283 . . . . 0.0 114.465 -176.273 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.14 124.19 23.13 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.395 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.51 16.15 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 2.1 m -84.96 -13.72 11.26 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.794 0 CA-C-N 118.613 0.642 . . . . 0.0 112.707 179.16 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.74 160.55 43.13 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.166 0.893 . . . . 0.0 112.471 -179.025 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 129.57 33.62 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' HIS . . . . . 0.608 ' CE1' ' HE2' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -147.89 175.4 10.99 Favored 'General case' 0 N--CA 1.447 -0.596 0 CA-C-N 114.785 -1.098 . . . . 0.0 110.256 -176.587 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . 0.546 ' C ' ' ND1' ' A' ' 64' ' ' HIS . 28.7 p -134.79 163.16 30.42 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -177.495 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' HIS . . . . . 0.878 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -135.19 147.04 60.69 Favored Pre-proline 0 N--CA 1.492 1.671 0 C-N-CA 123.987 0.915 . . . . 0.0 108.842 177.932 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -79.24 3.08 7.77 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 N-CA-C 114.61 0.966 . . . . 0.0 114.61 178.861 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 144.74 55.64 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . 0.434 ' HB2' HD23 ' A' ' 124' ' ' LEU . 6.5 tt0 -126.45 124.88 41.13 Favored 'General case' 0 CA--C 1.553 1.096 0 O-C-N 124.917 1.385 . . . . 0.0 110.428 -178.854 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.09 124.79 49.21 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.157 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . 0.763 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 116.51 19.84 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 107' ' ' HIS . . . . . 0.763 ' CE1' ' OH ' ' A' ' 70' ' ' TYR . 0.0 OUTLIER -144.35 164.57 30.41 Favored 'General case' 0 C--N 1.341 0.2 0 N-CA-C 114.23 1.196 . . . . 0.0 114.23 -174.956 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 108' ' ' CYS . . . . . 0.637 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -166.11 168.43 15.44 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 170.599 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 118' ' ' SER . . . . . 0.468 ' O ' HD12 ' A' ' 50' ' ' LEU . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 150.93 39.24 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.35 120.15 4.77 Favored Glycine 0 N--CA 1.448 -0.505 0 N-CA-C 104.911 -3.276 . . . . 0.0 104.911 176.911 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.6 111.31 34.31 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -179.104 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 124' ' ' LEU . . . . . 0.434 HD23 ' HB2' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.56 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.66 126.16 74.06 Favored Pre-proline 0 N--CA 1.488 1.469 0 C-N-CA 123.413 0.685 . . . . 0.0 110.925 -178.224 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.56 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.766 0 C-N-CA 121.759 1.639 . . . . 0.0 112.97 -175.215 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.642 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' GLN . . . . . 0.642 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 125.24 11.94 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -135.8 152.1 50.75 Favored 'General case' 0 CA--C 1.494 -1.209 0 O-C-N 123.894 0.746 . . . . 0.0 110.059 -178.241 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 163.81 -163.46 35.82 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.502 -2.285 . . . . 0.0 113.208 178.453 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.43 179.98 46.29 Favored Glycine 0 N--CA 1.443 -0.886 0 C-N-CA 119.784 -1.198 . . . . 0.0 113.381 -176.95 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.28 35.04 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.532 -1.834 . . . . 0.0 107.908 -177.641 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . 0.46 ' H ' HD12 ' A' ' 50' ' ' LEU . 0.0 OUTLIER -110.42 15.4 22.22 Favored 'General case' 0 N--CA 1.482 1.168 0 O-C-N 119.602 -1.936 . . . . 0.0 115.515 -175.456 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -56.98 -32.2 65.84 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 117.354 -1.739 . . . . 0.0 111.328 177.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.2 54.51 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.3 mp -104.69 16.06 26.76 Favored 'General case' 0 N--CA 1.486 1.337 0 N-CA-C 114.475 1.287 . . . . 0.0 114.475 -176.289 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.02 124.19 22.98 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.536 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.23 15.95 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 2.4 m -85.05 -13.51 11.27 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.906 0 CA-C-N 118.754 0.706 . . . . 0.0 112.498 179.237 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.48 160.55 43.24 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.402 1.001 . . . . 0.0 112.471 -179.223 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 126.35 21.06 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' HIS . . . . . 0.433 ' CE1' ' CD2' ' A' ' 64' ' ' HIS . 0.0 OUTLIER -139.94 169.29 17.99 Favored 'General case' 0 C--N 1.352 0.702 0 CA-C-N 113.504 -1.68 . . . . 0.0 110.459 -174.069 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -131.98 164.84 25.28 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 177.307 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' HIS . . . . . 0.572 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.0 OUTLIER -143.24 153.95 60.31 Favored Pre-proline 0 N--CA 1.485 1.312 0 N-CA-C 107.184 -1.413 . . . . 0.0 107.184 173.142 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.57 3.08 8.02 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 C-N-CA 120.772 0.981 . . . . 0.0 114.61 -174.869 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 145.15 55.36 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . 0.554 ' OE2' ' CE2' ' A' ' 70' ' ' TYR . 6.0 tt0 -127.92 128.01 44.36 Favored 'General case' 0 N--CA 1.485 1.304 0 O-C-N 124.277 0.985 . . . . 0.0 109.613 179.932 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.97 124.79 49.64 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.127 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . 0.654 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 119.21 22.24 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 107' ' ' HIS . . . . . 0.685 ' ND1' ' C ' ' A' ' 107' ' ' HIS . 1.5 p80 -150.74 171.43 17.18 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 122.148 0.975 . . . . 0.0 112.529 -177.37 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 108' ' ' CYS . . . . . 0.658 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -169.38 168.43 9.55 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 174.213 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 118' ' ' SER . . . . . 0.44 ' O ' HD12 ' A' ' 50' ' ' LEU . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 120' ' ' CYS . . . . . 0.407 ' HB3' HD21 ' A' ' 50' ' ' LEU . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.44 38.35 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.96 120.32 4.77 Favored Glycine 0 N--CA 1.447 -0.608 0 N-CA-C 105.19 -3.164 . . . . 0.0 105.19 176.9 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.88 111.31 34.46 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.856 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.63 126.28 73.84 Favored Pre-proline 0 N--CA 1.489 1.476 0 C-N-CA 123.354 0.662 . . . . 0.0 110.86 -178.172 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.65 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.801 0 C-N-CA 121.832 1.688 . . . . 0.0 112.97 -175.286 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.642 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' GLN . . . . . 0.642 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 125.51 12.15 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -136.69 152.67 50.64 Favored 'General case' 0 CA--C 1.492 -1.258 0 O-C-N 123.741 0.651 . . . . 0.0 109.9 -178.447 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 163.62 -163.43 35.7 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.728 -2.177 . . . . 0.0 113.208 178.978 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.38 179.97 46.24 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 119.724 -1.227 . . . . 0.0 113.298 -176.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 132.74 35.07 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . 0.263 0.3 OUTLIER -114.71 20.36 15.3 Favored 'General case' 0 N--CA 1.477 0.908 0 O-C-N 117.712 -3.117 . . . . 0.0 114.69 -176.107 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -55.24 -32.2 62.11 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 117.133 -1.827 . . . . 0.0 111.328 174.548 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 -0.15 54.19 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -103.1 14.9 30.76 Favored 'General case' 0 N--CA 1.49 1.565 0 N-CA-C 114.478 1.288 . . . . 0.0 114.478 -176.366 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.44 124.19 23.5 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -177.753 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.79 16.34 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.457 HG22 ' H ' ' A' ' 58' ' ' VAL . 0.1 OUTLIER -81.43 -17.27 11.98 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.906 0 O-C-N 125.025 1.453 . . . . 0.0 112.908 178.981 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -154.67 160.55 41.47 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 118.659 0.663 . . . . 0.0 112.471 -176.632 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 131.26 41.5 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -151.13 -179.79 7.62 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.784 -0.644 . . . . 0.0 109.575 -178.404 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -137.62 164.42 28.83 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -175.411 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' HIS . . . . . 0.579 ' CE1' ' CD ' ' A' ' 68' ' ' GLU . 0.0 OUTLIER -141.47 151.93 62.22 Favored Pre-proline 0 N--CA 1.496 1.835 0 N-CA-C 106.959 -1.497 . . . . 0.0 106.959 174.678 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -79.88 3.08 7.89 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 C-N-CA 120.77 0.98 . . . . 0.0 114.61 -176.587 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 147.9 52.31 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . 0.762 ' HB3' HD23 ' A' ' 124' ' ' LEU . 14.0 pt-20 -136.06 135.12 39.12 Favored 'General case' 0 N--CA 1.47 0.554 0 N-CA-C 108.909 -0.775 . . . . 0.0 108.909 176.664 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -105.76 124.79 50.13 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 -178.162 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . 0.715 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 119.79 23.05 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 107' ' ' HIS . . . . . 0.715 ' CE1' ' OH ' ' A' ' 70' ' ' TYR . 3.4 p80 -151.82 172.51 16.05 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-O 122.15 0.976 . . . . 0.0 112.223 -177.616 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 108' ' ' CYS . . . . . 0.605 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -170.04 168.43 8.49 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 174.755 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.78 37.78 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -117.98 121.23 5.0 Favored Glycine 0 C--N 1.313 -0.737 0 N-CA-C 104.952 -3.259 . . . . 0.0 104.952 176.712 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -106.09 111.31 34.59 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.607 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 124' ' ' LEU . . . . . 0.762 HD23 ' HB3' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.76 126.17 73.78 Favored Pre-proline 0 N--CA 1.489 1.483 0 C-N-CA 123.322 0.649 . . . . 0.0 110.881 -178.12 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.178 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.642 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' GLN . . . . . 0.642 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.46 12.89 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.93 154.93 48.39 Favored 'General case' 0 CA--C 1.491 -1.316 0 N-CA-C 109.571 -0.529 . . . . 0.0 109.571 -179.235 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.55 -163.43 35.12 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 118.07 -2.014 . . . . 0.0 113.208 -179.851 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.38 179.97 46.24 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 119.724 -1.227 . . . . 0.0 113.298 -176.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.15 35.05 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . 0.481 ' H ' HD12 ' A' ' 50' ' ' LEU . 0.0 OUTLIER -109.14 14.34 23.96 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 119.504 -1.998 . . . . 0.0 115.235 -175.56 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.24 -32.2 66.3 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.773 -1.971 . . . . 0.0 111.328 178.645 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.1 54.42 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.2 mp -104.3 15.8 27.52 Favored 'General case' 0 N--CA 1.486 1.339 0 N-CA-C 114.497 1.295 . . . . 0.0 114.497 -176.321 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.12 124.19 23.11 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.343 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.48 16.13 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 2.2 m -84.94 -13.64 11.29 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.777 0 CA-C-N 118.631 0.651 . . . . 0.0 112.719 179.124 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.83 160.55 43.09 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.183 0.901 . . . . 0.0 112.471 -179.052 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 129.6 33.75 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' HIS . . . . . 0.61 ' CE1' ' HE2' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -147.97 175.5 10.93 Favored 'General case' 0 N--CA 1.446 -0.655 0 CA-C-N 114.811 -1.086 . . . . 0.0 110.263 -176.649 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . 0.546 ' C ' ' ND1' ' A' ' 64' ' ' HIS . 28.7 p -134.83 163.15 30.46 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -177.435 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' HIS . . . . . 0.877 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -135.09 147.05 60.92 Favored Pre-proline 0 N--CA 1.493 1.676 0 C-N-CA 123.965 0.906 . . . . 0.0 108.857 177.954 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -79.28 3.08 7.78 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 N-CA-C 114.61 0.966 . . . . 0.0 114.61 178.782 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 144.74 55.64 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . 0.436 ' HB2' HD23 ' A' ' 124' ' ' LEU . 6.7 tt0 -126.52 124.92 41.14 Favored 'General case' 0 CA--C 1.553 1.073 0 O-C-N 124.917 1.385 . . . . 0.0 110.392 -178.869 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.06 124.79 49.19 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.179 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . 0.763 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 116.53 19.86 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 107' ' ' HIS . . . . . 0.763 ' CE1' ' OH ' ' A' ' 70' ' ' TYR . 0.0 OUTLIER -144.43 164.59 30.39 Favored 'General case' 0 C--N 1.341 0.222 0 N-CA-C 114.194 1.183 . . . . 0.0 114.194 -174.946 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 108' ' ' CYS . . . . . 0.637 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -166.11 168.43 15.44 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 170.633 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 118' ' ' SER . . . . . 0.466 ' O ' HD12 ' A' ' 50' ' ' LEU . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 150.93 39.24 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.36 120.17 4.77 Favored Glycine 0 N--CA 1.448 -0.543 0 N-CA-C 104.982 -3.247 . . . . 0.0 104.982 176.852 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.6 111.31 34.31 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -179.057 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 124' ' ' LEU . . . . . 0.436 HD23 ' HB2' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.56 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.67 126.1 74.18 Favored Pre-proline 0 N--CA 1.489 1.521 0 C-N-CA 123.428 0.691 . . . . 0.0 110.853 -178.135 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.234 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.642 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' GLN . . . . . 0.642 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.32 12.78 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.68 154.7 48.62 Favored 'General case' 0 CA--C 1.491 -1.295 0 N-CA-C 109.524 -0.547 . . . . 0.0 109.524 -179.151 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.69 -163.39 35.18 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 118.029 -2.034 . . . . 0.0 113.208 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.34 -179.94 46.27 Favored Glycine 0 N--CA 1.445 -0.703 0 C-N-CA 119.668 -1.254 . . . . 0.0 113.289 -176.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.22 133.29 35.01 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.48 -1.86 . . . . 0.0 107.908 -177.599 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . 0.52 ' H ' HD12 ' A' ' 50' ' ' LEU . 0.0 OUTLIER -109.08 14.05 24.2 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 119.618 -1.926 . . . . 0.0 115.383 -175.627 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.18 -32.2 66.2 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.782 -1.967 . . . . 0.0 111.328 178.775 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.19 54.5 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.2 mp -104.59 15.98 26.96 Favored 'General case' 0 N--CA 1.486 1.353 0 N-CA-C 114.488 1.292 . . . . 0.0 114.488 -176.284 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.06 124.19 23.03 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.468 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.54 16.17 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.418 ' H ' HG22 ' A' ' 58' ' ' VAL . 2.1 m -85.07 -13.58 11.25 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.793 0 N-CA-C 112.816 0.673 . . . . 0.0 112.816 179.223 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.91 160.55 43.06 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.094 0.861 . . . . 0.0 112.471 -179.176 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 128.06 27.25 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -143.66 173.57 11.55 Favored 'General case' 0 CA--C 1.513 -0.471 0 CA-C-N 114.44 -1.255 . . . . 0.0 109.906 -175.516 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -134.3 165.5 24.98 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 179.569 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' HIS . . . . . 0.578 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.0 OUTLIER -145.43 154.39 52.98 Favored Pre-proline 0 N--CA 1.481 1.099 0 N-CA-C 107.255 -1.387 . . . . 0.0 107.255 172.404 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.33 3.08 7.97 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 C-N-CA 120.946 1.097 . . . . 0.0 114.61 -173.161 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 145.02 55.49 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . 0.42 ' HB2' HD23 ' A' ' 124' ' ' LEU . 40.1 tt0 -128.36 128.5 44.64 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 123.766 0.666 . . . . 0.0 109.463 179.311 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.58 124.79 49.45 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.315 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . 0.725 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 118.75 21.72 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 107' ' ' HIS . . . . . 0.725 ' CE1' ' OH ' ' A' ' 70' ' ' TYR . 1.0 OUTLIER -149.16 170.15 19.1 Favored 'General case' 0 CA--C 1.518 -0.252 0 CA-C-O 122.108 0.956 . . . . 0.0 113.213 -176.9 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 108' ' ' CYS . . . . . 0.654 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -168.97 168.43 10.21 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 173.215 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 118' ' ' SER . . . . . 0.503 ' O ' HD12 ' A' ' 50' ' ' LEU . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 120' ' ' CYS . . . . . 0.409 ' CB ' HD21 ' A' ' 50' ' ' LEU . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.05 39.04 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.48 119.89 4.67 Favored Glycine 0 N--CA 1.451 -0.357 0 N-CA-C 104.924 -3.27 . . . . 0.0 104.924 176.915 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.33 111.31 34.15 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -179.104 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 124' ' ' LEU . . . . . 0.42 HD23 ' HB2' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.76 126.17 73.78 Favored Pre-proline 0 N--CA 1.489 1.483 0 C-N-CA 123.322 0.649 . . . . 0.0 110.881 -178.12 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.178 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.642 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' GLN . . . . . 0.642 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 125.59 12.22 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -136.81 152.82 50.72 Favored 'General case' 0 CA--C 1.493 -1.239 0 O-C-N 123.731 0.644 . . . . 0.0 109.904 -178.486 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 163.51 -163.43 35.64 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.685 -2.198 . . . . 0.0 113.208 179.012 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.4 179.94 46.25 Favored Glycine 0 N--CA 1.444 -0.812 0 C-N-CA 119.745 -1.217 . . . . 0.0 113.343 -176.912 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.15 35.05 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.506 -1.847 . . . . 0.0 107.908 -177.646 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . 0.48 ' H ' HD12 ' A' ' 50' ' ' LEU . 0.0 OUTLIER -109.06 14.27 24.09 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 119.573 -1.955 . . . . 0.0 115.238 -175.519 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.28 -32.2 66.39 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.778 -1.969 . . . . 0.0 111.328 178.731 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 -0.04 54.29 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -103.75 15.44 28.77 Favored 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 114.438 1.273 . . . . 0.0 114.438 -176.428 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.15 124.19 23.14 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.135 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.61 16.22 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.46 HG22 ' H ' ' A' ' 58' ' ' VAL . 0.3 OUTLIER -82.23 -16.41 11.8 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.923 0 O-C-N 124.729 1.268 . . . . 0.0 112.874 179.103 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -154.24 160.55 41.86 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 118.833 0.742 . . . . 0.0 112.471 -177.258 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 128.09 27.37 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -143.84 173.58 11.57 Favored 'General case' 0 CA--C 1.516 -0.347 0 CA-C-N 114.512 -1.222 . . . . 0.0 109.911 -175.468 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -134.3 164.67 26.88 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 179.701 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' HIS . . . . . 0.536 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.0 OUTLIER -143.77 153.54 57.93 Favored Pre-proline 0 N--CA 1.484 1.272 0 N-CA-C 106.906 -1.516 . . . . 0.0 106.906 173.051 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -79.96 3.08 7.9 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 C-N-CA 121.104 1.203 . . . . 0.0 114.61 -174.226 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 143.61 56.24 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . 0.511 ' HB3' ' HB ' ' A' ' 101' ' ' ILE . 0.1 OUTLIER -120.15 120.81 37.26 Favored 'General case' 0 N--CA 1.506 2.342 0 O-C-N 125.931 2.019 . . . . 0.0 111.397 -178.3 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -102.4 124.79 48.6 Favored 'General case' 0 N--CA 1.498 1.961 0 CA-C-N 120.735 1.607 . . . . 0.0 107.536 175.528 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . 0.65 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . 0.511 ' HB ' ' HB3' ' A' ' 68' ' ' GLU . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 118.89 21.85 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 107' ' ' HIS . . . . . 0.678 ' ND1' ' C ' ' A' ' 107' ' ' HIS . 1.4 p80 -150.2 170.72 18.3 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 121.961 0.886 . . . . 0.0 112.554 -177.01 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 108' ' ' CYS . . . . . 0.65 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -168.97 168.43 10.21 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 173.904 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 118' ' ' SER . . . . . 0.469 ' O ' HD12 ' A' ' 50' ' ' LEU . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.6 38.08 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -117.43 120.76 4.89 Favored Glycine 0 C--N 1.315 -0.629 0 N-CA-C 105.009 -3.236 . . . . 0.0 105.009 176.833 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.97 111.31 34.52 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.793 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.56 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.82 126.18 73.62 Favored Pre-proline 0 N--CA 1.489 1.484 0 C-N-CA 123.354 0.661 . . . . 0.0 110.825 -178.075 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.171 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.642 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' GLN . . . . . 0.642 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.09 12.6 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.11 154.15 49.23 Favored 'General case' 0 CA--C 1.492 -1.281 0 N-CA-C 109.654 -0.498 . . . . 0.0 109.654 -178.96 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.94 -163.4 35.32 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.941 -2.076 . . . . 0.0 113.208 179.714 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.35 179.94 46.2 Favored Glycine 0 N--CA 1.444 -0.774 0 C-N-CA 119.67 -1.252 . . . . 0.0 113.27 -176.916 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.08 35.05 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . 0.479 ' H ' HD12 ' A' ' 50' ' ' LEU . 0.0 OUTLIER -108.89 14.16 24.37 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 119.555 -1.966 . . . . 0.0 115.229 -175.541 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.28 -32.2 66.39 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.778 -1.969 . . . . 0.0 111.328 178.794 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.16 54.47 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.3 mp -104.44 15.87 27.29 Favored 'General case' 0 N--CA 1.486 1.354 0 N-CA-C 114.482 1.29 . . . . 0.0 114.482 -176.296 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.1 124.19 23.08 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.397 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.56 16.18 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 2.4 m -85.24 -13.51 11.2 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.816 0 CA-C-N 118.648 0.658 . . . . 0.0 112.73 179.236 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.71 160.55 43.14 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.153 0.888 . . . . 0.0 112.471 -179.217 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 129.84 34.88 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -148.38 177.23 9.62 Favored 'General case' 0 CA--C 1.515 -0.366 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.712 -177.238 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -135.89 164.81 27.09 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -177.116 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -142.68 153.29 61.41 Favored Pre-proline 0 N--CA 1.495 1.808 0 N-CA-C 106.896 -1.52 . . . . 0.0 106.896 173.65 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.28 3.08 7.97 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 C-N-CA 120.818 1.012 . . . . 0.0 114.61 -175.614 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 145.11 55.39 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . 0.427 ' HG3' HD23 ' A' ' 124' ' ' LEU . 0.3 OUTLIER -121.19 122.63 40.4 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 126.751 2.532 . . . . 0.0 112.971 -178.906 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -104.57 124.79 49.93 Favored 'General case' 0 N--CA 1.498 1.961 0 CA-C-N 120.444 1.475 . . . . 0.0 107.536 176.102 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . 0.704 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 118.97 21.93 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 107' ' ' HIS . . . . . 0.704 ' CE1' ' OH ' ' A' ' 70' ' ' TYR . 2.0 p80 -150.04 171.35 16.99 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 122.181 0.991 . . . . 0.0 112.555 -177.34 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 108' ' ' CYS . . . . . 0.663 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -169.44 168.43 9.46 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 173.792 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 118' ' ' SER . . . . . 0.47 ' O ' HD12 ' A' ' 50' ' ' LEU . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.23 38.73 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.69 120.21 4.76 Favored Glycine 0 N--CA 1.448 -0.539 0 N-CA-C 105.034 -3.226 . . . . 0.0 105.034 176.925 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.71 111.31 34.37 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 124' ' ' LEU . . . . . 0.427 HD23 ' HG3' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.7 126.13 74.03 Favored Pre-proline 0 N--CA 1.489 1.477 0 C-N-CA 123.359 0.664 . . . . 0.0 110.886 -178.126 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.2 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.642 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' GLN . . . . . 0.642 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.64 13.03 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -139.18 155.29 47.94 Favored 'General case' 0 CA--C 1.49 -1.356 0 N-CA-C 109.514 -0.551 . . . . 0.0 109.514 -179.329 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.33 -163.43 35.0 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 118.037 -2.03 . . . . 0.0 113.208 -179.801 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.4 179.93 46.24 Favored Glycine 0 N--CA 1.444 -0.812 0 C-N-CA 119.745 -1.217 . . . . 0.0 113.368 -176.912 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.14 132.47 35.09 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.514 -1.843 . . . . 0.0 107.908 -177.643 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . 0.263 0.3 OUTLIER -114.5 20.2 15.57 Favored 'General case' 0 C--N 1.312 -1.04 0 O-C-N 117.72 -3.112 . . . . 0.0 114.683 -175.974 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -55.07 -32.2 61.75 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 117.366 -1.734 . . . . 0.0 111.328 174.57 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 6.42 49.09 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . 0.424 ' HA ' HD12 ' A' ' 53' ' ' LEU . 1.0 OUTLIER -111.5 10.79 21.33 Favored 'General case' 2 N--CA 1.62 8.062 0 O-C-N 124.811 1.319 . . . . 0.0 111.199 -170.476 . . . . . . . . 4 4 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.04 124.19 23.01 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.244 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.34 16.03 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.432 ' H ' HG22 ' A' ' 58' ' ' VAL . 1.9 m -83.93 -14.51 11.51 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.919 0 O-C-N 124.134 0.896 . . . . 0.0 112.816 179.222 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -153.33 160.55 42.71 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.095 0.861 . . . . 0.0 112.471 -178.52 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 128.37 28.47 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -144.64 174.11 11.25 Favored 'General case' 0 CA--C 1.518 -0.274 0 CA-C-N 114.684 -1.144 . . . . 0.0 109.829 -175.619 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -134.54 164.89 26.46 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -179.772 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' HIS . . . . . 0.468 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.0 OUTLIER -144.39 154.07 56.44 Favored Pre-proline 0 N--CA 1.484 1.254 0 N-CA-C 106.895 -1.52 . . . . 0.0 106.895 172.617 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.09 3.08 7.93 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 C-N-CA 121.146 1.231 . . . . 0.0 114.61 -173.75 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 145.68 54.82 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . 0.483 ' HB2' HD23 ' A' ' 124' ' ' LEU . 23.6 tt0 -128.93 128.44 43.76 Favored 'General case' 0 N--CA 1.478 0.945 0 O-C-N 124.052 0.845 . . . . 0.0 110.103 179.599 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -104.22 124.79 49.75 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.742 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . 0.695 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 142.11 29.27 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 14.6 tp -132.36 121.37 23.39 Favored 'General case' 2 C--N 1.468 5.722 0 N-CA-C 102.143 -3.28 . . . . 0.0 102.143 179.921 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 118.46 21.46 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 107' ' ' HIS . . . . . 0.695 ' CE1' ' OH ' ' A' ' 70' ' ' TYR . 0.7 OUTLIER -148.91 169.35 20.75 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 122.042 0.925 . . . . 0.0 113.172 -176.556 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 108' ' ' CYS . . . . . 0.645 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -168.41 168.43 11.25 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 173.111 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.49 38.28 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -117.19 120.96 4.98 Favored Glycine 0 N--CA 1.446 -0.684 0 N-CA-C 104.99 -3.244 . . . . 0.0 104.99 176.779 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -106.12 111.31 34.6 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.882 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 124' ' ' LEU . . . . . 0.483 HD23 ' HB2' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.56 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.73 126.13 73.94 Favored Pre-proline 0 N--CA 1.489 1.477 0 C-N-CA 123.386 0.674 . . . . 0.0 110.882 -178.127 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.178 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.642 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' GLN . . . . . 0.642 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.48 12.9 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.96 154.88 48.35 Favored 'General case' 0 CA--C 1.491 -1.316 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 -179.202 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.58 -163.43 35.14 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 118.041 -2.028 . . . . 0.0 113.208 -179.852 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.38 179.97 46.24 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 119.724 -1.227 . . . . 0.0 113.298 -176.946 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.1 35.05 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . 0.48 HD12 ' O ' ' A' ' 118' ' ' SER . 0.0 OUTLIER -108.52 13.92 25.0 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 119.751 -1.843 . . . . 0.0 115.39 -175.544 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.57 -32.2 66.9 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.774 -1.97 . . . . 0.0 111.328 179.044 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.19 54.5 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.6 mp -103.85 15.22 29.2 Favored 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 114.517 1.303 . . . . 0.0 114.517 -176.223 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.35 124.19 23.39 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -177.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.47 16.12 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 2.2 m -84.85 -13.76 11.29 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.812 0 O-C-N 123.766 0.667 . . . . 0.0 112.705 179.169 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.83 160.55 43.09 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.198 0.908 . . . . 0.0 112.471 -178.996 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 129.44 33.01 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' HIS . . . . . 0.615 ' CE1' ' HE2' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -147.65 175.15 11.11 Favored 'General case' 0 N--CA 1.447 -0.607 0 CA-C-N 114.756 -1.111 . . . . 0.0 110.303 -176.527 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . 0.553 ' C ' ' ND1' ' A' ' 64' ' ' HIS . 28.7 p -134.64 163.1 30.51 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -177.615 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' HIS . . . . . 0.878 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -135.12 147.07 60.94 Favored Pre-proline 0 N--CA 1.492 1.666 0 C-N-CA 123.931 0.892 . . . . 0.0 108.831 177.9 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -79.23 3.08 7.77 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 CA-C-N 119.819 0.971 . . . . 0.0 114.61 178.861 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 144.74 55.64 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . 0.44 ' HB2' HD23 ' A' ' 124' ' ' LEU . 6.9 tt0 -126.59 125.11 41.42 Favored 'General case' 0 CA--C 1.553 1.088 0 O-C-N 124.879 1.362 . . . . 0.0 110.342 -178.928 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.13 124.79 49.23 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.18 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . 0.762 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 116.39 19.77 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 107' ' ' HIS . . . . . 0.762 ' CE1' ' OH ' ' A' ' 70' ' ' TYR . 0.0 OUTLIER -144.06 164.24 31.21 Favored 'General case' 0 C--N 1.341 0.224 0 N-CA-C 114.331 1.234 . . . . 0.0 114.331 -174.866 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 108' ' ' CYS . . . . . 0.634 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -165.96 168.43 15.73 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 170.457 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 118' ' ' SER . . . . . 0.48 ' O ' HD12 ' A' ' 50' ' ' LEU . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 150.81 39.44 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.25 120.12 4.77 Favored Glycine 0 N--CA 1.448 -0.509 0 N-CA-C 104.894 -3.282 . . . . 0.0 104.894 176.863 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.52 111.31 34.26 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -179.107 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 124' ' ' LEU . . . . . 0.44 HD23 ' HB2' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.61 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.8 126.03 74.01 Favored Pre-proline 0 N--CA 1.488 1.428 0 C-N-CA 123.358 0.663 . . . . 0.0 110.963 -178.117 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.46 107.32 2.36 Favored 'Trans proline' 0 C--N 1.323 -0.799 0 C-N-CA 121.836 1.691 . . . . 0.0 112.97 -175.1 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.642 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' GLN . . . . . 0.642 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.13 12.63 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.2 153.95 49.14 Favored 'General case' 0 CA--C 1.493 -1.233 0 O-C-N 123.524 0.515 . . . . 0.0 109.729 -178.841 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.99 -163.46 35.39 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.965 -2.064 . . . . 0.0 113.208 179.792 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.45 179.97 46.3 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 119.699 -1.239 . . . . 0.0 113.319 -176.95 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 132.53 35.08 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.506 -1.847 . . . . 0.0 107.908 -177.646 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . 0.266 0.3 OUTLIER -114.53 20.49 15.32 Favored 'General case' 0 C--N 1.316 -0.849 0 O-C-N 117.804 -3.06 . . . . 0.0 114.774 -175.974 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -55.47 -32.2 62.62 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 117.33 -1.748 . . . . 0.0 111.328 174.542 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.2 54.51 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.2 mp -104.2 15.71 27.79 Favored 'General case' 0 N--CA 1.488 1.448 0 N-CA-C 114.529 1.307 . . . . 0.0 114.529 -176.419 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.17 124.19 23.17 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.249 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.71 16.28 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.418 ' H ' HG22 ' A' ' 58' ' ' VAL . 1.6 m -84.97 -13.94 11.21 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.668 0 CA-C-N 118.669 0.668 . . . . 0.0 112.787 179.043 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.69 160.55 43.15 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.086 0.857 . . . . 0.0 112.471 -178.93 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 127.14 23.68 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -141.7 171.22 14.36 Favored 'General case' 0 C--N 1.351 0.634 0 CA-C-N 114.027 -1.442 . . . . 0.0 110.184 -174.718 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -133.0 165.53 24.52 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 178.347 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' HIS . . . . . 0.604 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.0 OUTLIER -145.55 154.04 52.07 Favored Pre-proline 0 N--CA 1.48 1.052 0 N-CA-C 107.208 -1.404 . . . . 0.0 107.208 172.63 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.17 3.08 7.94 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 C-N-CA 121.04 1.16 . . . . 0.0 114.61 -173.122 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 144.3 55.87 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 33.1 tt0 -126.3 127.34 45.42 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 124.286 0.991 . . . . 0.0 109.456 179.857 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.4 124.79 49.36 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 177.428 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . 0.713 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 119.08 22.07 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 107' ' ' HIS . . . . . 0.713 ' CE1' ' OH ' ' A' ' 70' ' ' TYR . 1.0 OUTLIER -150.21 171.04 17.58 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 122.16 0.981 . . . . 0.0 112.737 -177.18 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 108' ' ' CYS . . . . . 0.669 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -169.29 168.43 9.69 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 173.848 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 150.76 39.53 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.2 120.04 4.74 Favored Glycine 0 N--CA 1.448 -0.509 0 N-CA-C 104.947 -3.261 . . . . 0.0 104.947 176.857 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.46 111.31 34.22 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -179.058 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.76 126.17 73.78 Favored Pre-proline 0 N--CA 1.489 1.483 0 C-N-CA 123.322 0.649 . . . . 0.0 110.881 -178.12 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.178 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.642 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' GLN . . . . . 0.642 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.44 12.88 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.93 154.89 48.38 Favored 'General case' 0 CA--C 1.49 -1.346 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 -179.235 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.59 -163.4 35.13 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 118.059 -2.02 . . . . 0.0 113.208 -179.847 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.35 179.94 46.2 Favored Glycine 0 N--CA 1.444 -0.774 0 C-N-CA 119.67 -1.252 . . . . 0.0 113.27 -176.916 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 132.59 35.08 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . . . . . . . . 0.268 0.3 OUTLIER -114.57 20.43 15.34 Favored 'General case' 0 C--N 1.316 -0.869 0 O-C-N 117.821 -3.049 . . . . 0.0 114.791 -176.067 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -55.34 -32.2 62.34 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 117.275 -1.77 . . . . 0.0 111.328 174.557 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.09 54.41 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.2 mp -104.13 15.67 27.92 Favored 'General case' 0 N--CA 1.486 1.357 0 N-CA-C 114.559 1.318 . . . . 0.0 114.559 -176.327 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.23 124.19 23.24 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.237 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.51 16.15 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 2.2 m -84.97 -13.68 11.27 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.781 0 CA-C-N 118.613 0.642 . . . . 0.0 112.73 179.168 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.8 160.55 43.11 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.161 0.892 . . . . 0.0 112.471 -179.046 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 129.57 33.62 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' HIS . . . . . 0.609 ' CE1' ' HE2' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -147.89 175.47 10.93 Favored 'General case' 0 N--CA 1.446 -0.625 0 CA-C-N 114.785 -1.098 . . . . 0.0 110.259 -176.62 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . 0.546 ' C ' ' ND1' ' A' ' 64' ' ' HIS . 28.7 p -134.83 163.16 30.44 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -177.49 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' HIS . . . . . 0.877 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -135.18 147.04 60.72 Favored Pre-proline 0 N--CA 1.492 1.646 0 C-N-CA 124.013 0.925 . . . . 0.0 108.925 177.879 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -79.24 3.08 7.77 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 CA-C-N 119.809 0.968 . . . . 0.0 114.61 178.894 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 144.74 55.64 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . 0.436 ' HB2' HD23 ' A' ' 124' ' ' LEU . 6.7 tt0 -126.52 124.92 41.14 Favored 'General case' 0 CA--C 1.553 1.073 0 O-C-N 124.917 1.385 . . . . 0.0 110.392 -178.869 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.06 124.79 49.19 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.179 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . 0.762 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 116.51 19.84 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 107' ' ' HIS . . . . . 0.762 ' CE1' ' OH ' ' A' ' 70' ' ' TYR . 0.0 OUTLIER -144.39 164.61 30.32 Favored 'General case' 0 C--N 1.341 0.2 0 N-CA-C 114.211 1.189 . . . . 0.0 114.211 -174.976 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 108' ' ' CYS . . . . . 0.636 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -166.11 168.43 15.44 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 170.633 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 150.93 39.24 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.34 120.12 4.76 Favored Glycine 0 N--CA 1.447 -0.596 0 N-CA-C 104.976 -3.249 . . . . 0.0 104.976 176.901 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.6 111.31 34.31 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -179.055 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 124' ' ' LEU . . . . . 0.436 HD23 ' HB2' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.75 126.23 73.65 Favored Pre-proline 0 N--CA 1.489 1.483 0 C-N-CA 123.322 0.649 . . . . 0.0 110.847 -178.12 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.57 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.778 0 C-N-CA 121.855 1.704 . . . . 0.0 112.97 -175.211 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.642 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' GLN . . . . . 0.642 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 125.32 12.0 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -136.32 152.39 50.62 Favored 'General case' 0 CA--C 1.497 -1.084 0 O-C-N 123.731 0.644 . . . . 0.0 109.833 -178.296 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 163.75 -163.4 35.75 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.651 -2.214 . . . . 0.0 113.208 178.775 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.35 179.94 46.2 Favored Glycine 0 N--CA 1.444 -0.774 0 C-N-CA 119.67 -1.252 . . . . 0.0 113.27 -176.916 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 132.45 35.08 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . 0.577 HD12 ' O ' ' A' ' 118' ' ' SER . 0.0 OUTLIER -106.74 13.12 28.36 Favored 'General case' 0 N--CA 1.492 1.664 0 N-CA-C 115.597 1.702 . . . . 0.0 115.597 -175.034 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -58.91 -32.2 69.32 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 117.26 -1.776 . . . . 0.0 111.328 179.714 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 -0.23 54.12 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 47.9 mt -104.23 16.42 26.23 Favored 'General case' 0 C--N 1.364 1.224 0 N-CA-C 114.879 1.437 . . . . 0.0 114.879 -177.065 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -67.69 124.19 22.56 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.726 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.93 16.44 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -86.5 -12.96 10.91 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.621 0 CA-C-N 119.548 1.067 . . . . 0.0 112.281 178.766 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -151.41 160.55 43.69 Favored 'General case' 0 C--O 1.281 2.733 0 C-N-CA 119.023 -1.071 . . . . 0.0 112.471 -179.581 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 130.62 38.49 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -150.02 178.87 8.54 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.613 -0.721 . . . . 0.0 109.6 -177.933 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -136.78 164.82 27.38 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -176.04 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' HIS . . . . . 0.58 ' CE1' ' CD ' ' A' ' 68' ' ' GLU . 0.0 OUTLIER -142.21 152.38 61.0 Favored Pre-proline 0 N--CA 1.495 1.78 0 N-CA-C 107.12 -1.437 . . . . 0.0 107.12 174.393 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.1 3.08 7.93 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 N-CA-C 114.61 0.966 . . . . 0.0 114.61 -176.145 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 148.11 52.04 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . 0.744 ' HB3' HD23 ' A' ' 124' ' ' LEU . 16.9 pt-20 -136.47 136.21 39.26 Favored 'General case' 0 CA--C 1.517 -0.304 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 176.452 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -106.53 124.79 50.13 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 -177.955 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . 0.71 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 119.69 22.91 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 107' ' ' HIS . . . . . 0.71 ' CE1' ' OH ' ' A' ' 70' ' ' TYR . 3.5 p80 -151.42 172.49 15.86 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 122.176 0.988 . . . . 0.0 112.399 -177.665 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 108' ' ' CYS . . . . . 0.61 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -170.1 168.43 8.39 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 174.521 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 118' ' ' SER . . . . . 0.577 ' O ' HD12 ' A' ' 50' ' ' LEU . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 120' ' ' CYS . . . . . 0.57 ' HB2' HD21 ' A' ' 50' ' ' LEU . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.5 38.26 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -117.01 120.25 4.75 Favored Glycine 0 N--CA 1.447 -0.627 0 N-CA-C 105.152 -3.179 . . . . 0.0 105.152 176.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.85 111.31 34.45 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.856 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 124' ' ' LEU . . . . . 0.744 HD23 ' HB3' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.56 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.73 126.13 73.94 Favored Pre-proline 0 N--CA 1.489 1.477 0 C-N-CA 123.386 0.674 . . . . 0.0 110.882 -178.127 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.178 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.642 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' GLN . . . . . 0.642 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 125.55 12.18 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -136.67 152.65 50.64 Favored 'General case' 0 CA--C 1.493 -1.217 0 O-C-N 123.773 0.67 . . . . 0.0 109.94 -178.401 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 163.58 -163.46 35.7 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.683 -2.198 . . . . 0.0 113.208 178.939 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.45 179.97 46.3 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 119.699 -1.239 . . . . 0.0 113.319 -176.95 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.12 35.05 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.506 -1.847 . . . . 0.0 107.908 -177.646 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . 0.478 ' H ' HD12 ' A' ' 50' ' ' LEU . 0.0 OUTLIER -108.96 14.19 24.26 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 119.604 -1.935 . . . . 0.0 115.302 -175.559 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.27 -32.2 66.37 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.805 -1.958 . . . . 0.0 111.328 178.773 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 -0.02 54.31 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -103.65 15.28 29.23 Favored 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 114.449 1.278 . . . . 0.0 114.449 -176.38 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.21 124.19 23.22 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.031 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.64 16.24 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.464 HG22 ' H ' ' A' ' 58' ' ' VAL . 0.2 OUTLIER -81.89 -16.77 11.88 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.958 0 O-C-N 124.906 1.379 . . . . 0.0 112.928 179.114 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -154.43 160.55 41.69 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 118.758 0.708 . . . . 0.0 112.471 -177.057 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 128.2 27.82 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -144.13 173.83 11.4 Favored 'General case' 0 CA--C 1.516 -0.334 0 CA-C-N 114.575 -1.193 . . . . 0.0 109.86 -175.556 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -134.43 164.77 26.69 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 179.886 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' HIS . . . . . 0.538 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.0 OUTLIER -143.85 153.6 57.73 Favored Pre-proline 0 N--CA 1.483 1.182 0 N-CA-C 106.989 -1.486 . . . . 0.0 106.989 173.042 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.04 3.08 7.92 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 C-N-CA 121.075 1.183 . . . . 0.0 114.61 -174.215 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 143.69 56.19 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . 0.495 ' HB3' ' HB ' ' A' ' 101' ' ' ILE . 0.1 OUTLIER -120.08 120.78 37.25 Favored 'General case' 0 N--CA 1.507 2.385 0 O-C-N 125.999 2.062 . . . . 0.0 111.502 -178.315 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -102.49 124.79 48.68 Favored 'General case' 0 N--CA 1.498 1.961 0 CA-C-N 120.76 1.618 . . . . 0.0 107.536 175.493 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . 0.653 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . 0.495 ' HB ' ' HB3' ' A' ' 68' ' ' GLU . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 118.89 21.85 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 107' ' ' HIS . . . . . 0.677 ' ND1' ' C ' ' A' ' 107' ' ' HIS . 1.4 p80 -150.23 170.75 18.23 Favored 'General case' 0 C--N 1.322 -0.597 0 C-N-CA 119.462 -0.895 . . . . 0.0 112.54 -177.031 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 108' ' ' CYS . . . . . 0.65 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -168.96 168.43 10.23 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 173.932 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 118' ' ' SER . . . . . 0.468 ' O ' HD12 ' A' ' 50' ' ' LEU . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.6 38.08 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -117.43 120.76 4.89 Favored Glycine 0 C--N 1.315 -0.629 0 N-CA-C 105.009 -3.236 . . . . 0.0 105.009 176.833 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.97 111.31 34.52 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.793 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.76 126.17 73.78 Favored Pre-proline 0 N--CA 1.489 1.483 0 C-N-CA 123.322 0.649 . . . . 0.0 110.881 -178.12 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.178 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.642 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' GLN . . . . . 0.642 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.44 12.88 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.93 154.88 48.38 Favored 'General case' 0 CA--C 1.49 -1.33 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 -179.204 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.59 -163.43 35.14 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 118.059 -2.02 . . . . 0.0 113.208 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.38 179.97 46.24 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 119.724 -1.227 . . . . 0.0 113.298 -176.946 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 132.99 35.06 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . 0.478 ' H ' HD12 ' A' ' 50' ' ' LEU . 0.0 OUTLIER -108.8 14.19 24.46 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 119.569 -1.957 . . . . 0.0 115.265 -175.538 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.35 -32.2 66.5 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.789 -1.965 . . . . 0.0 111.328 178.784 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.08 54.4 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.2 mp -104.43 15.98 27.07 Favored 'General case' 0 N--CA 1.487 1.389 0 N-CA-C 114.396 1.258 . . . . 0.0 114.396 -176.322 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.06 124.19 23.03 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.467 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.53 16.16 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 2.5 m -85.06 -13.6 11.25 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.787 0 O-C-N 123.801 0.688 . . . . 0.0 112.737 179.241 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.86 160.55 43.08 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.187 0.903 . . . . 0.0 112.471 -179.11 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 129.64 33.92 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' HIS . . . . . 0.606 ' CE1' ' HE2' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -148.05 175.55 10.91 Favored 'General case' 0 N--CA 1.447 -0.601 0 CA-C-N 114.8 -1.091 . . . . 0.0 110.244 -176.666 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . 0.544 ' C ' ' ND1' ' A' ' 64' ' ' HIS . 28.7 p -134.85 163.16 30.44 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -177.385 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' HIS . . . . . 0.875 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -135.14 147.03 60.76 Favored Pre-proline 0 N--CA 1.492 1.631 0 C-N-CA 124.031 0.932 . . . . 0.0 108.869 177.939 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -79.27 3.08 7.78 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 N-CA-C 114.61 0.966 . . . . 0.0 114.61 178.825 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 144.74 55.64 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . 0.437 ' HB2' HD23 ' A' ' 124' ' ' LEU . 6.7 tt0 -126.52 124.92 41.14 Favored 'General case' 0 CA--C 1.553 1.073 0 O-C-N 124.917 1.385 . . . . 0.0 110.392 -178.869 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.06 124.79 49.19 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.179 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . 0.763 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 116.51 19.84 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 107' ' ' HIS . . . . . 0.763 ' CE1' ' OH ' ' A' ' 70' ' ' TYR . 0.0 OUTLIER -144.35 164.57 30.41 Favored 'General case' 0 C--N 1.341 0.2 0 N-CA-C 114.23 1.196 . . . . 0.0 114.23 -174.956 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 108' ' ' CYS . . . . . 0.637 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -166.11 168.43 15.44 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 170.599 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 118' ' ' SER . . . . . 0.466 ' O ' HD12 ' A' ' 50' ' ' LEU . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 120' ' ' CYS . . . . . 0.4 ' CB ' HD21 ' A' ' 50' ' ' LEU . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 150.99 39.15 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.52 120.47 4.86 Favored Glycine 0 N--CA 1.447 -0.616 0 N-CA-C 104.946 -3.261 . . . . 0.0 104.946 176.766 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.72 111.31 34.37 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -179.023 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 124' ' ' LEU . . . . . 0.437 HD23 ' HB2' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.77 126.21 73.66 Favored Pre-proline 0 N--CA 1.49 1.534 0 C-N-CA 123.364 0.665 . . . . 0.0 110.762 -178.076 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.261 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.642 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' GLN . . . . . 0.642 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.24 12.72 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.28 154.41 49.04 Favored 'General case' 0 CA--C 1.488 -1.434 0 N-CA-C 109.662 -0.496 . . . . 0.0 109.662 -179.056 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.76 -163.46 35.26 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.972 -2.061 . . . . 0.0 113.208 179.738 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.47 179.82 46.22 Favored Glycine 0 N--CA 1.444 -0.785 0 C-N-CA 119.66 -1.257 . . . . 0.0 113.27 -176.858 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.07 133.07 35.09 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.494 -1.853 . . . . 0.0 107.908 -177.692 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . 0.624 ' HB3' HD12 ' A' ' 53' ' ' LEU 0.286 0.3 OUTLIER -114.63 20.64 15.15 Favored 'General case' 0 N--CA 1.473 0.716 0 O-C-N 118.281 -2.762 . . . . 0.0 115.226 -176.201 . . . . . . . . 4 4 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -56.19 -32.2 64.14 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 117.243 -1.783 . . . . 0.0 111.328 174.709 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 -1.17 53.11 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . 0.624 HD12 ' HB3' ' A' ' 50' ' ' LEU . 59.6 mt -102.74 15.85 28.16 Favored 'General case' 0 CA--C 1.558 1.278 0 N-CA-C 114.876 1.436 . . . . 0.0 114.876 -176.903 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.13 124.19 23.12 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.321 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.76 16.32 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -86.07 -13.03 11.04 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.535 0 CA-C-N 119.284 0.947 . . . . 0.0 112.389 178.863 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -151.82 160.55 43.52 Favored 'General case' 0 C--O 1.281 2.733 0 C-N-CA 119.206 -0.998 . . . . 0.0 112.471 -179.452 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 128.16 27.67 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -144.0 173.81 11.39 Favored 'General case' 0 CA--C 1.519 -0.235 0 CA-C-N 114.543 -1.208 . . . . 0.0 109.778 -175.395 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -134.5 165.14 25.88 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 179.752 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' HIS . . . . . 0.543 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.0 OUTLIER -144.3 154.34 57.08 Favored Pre-proline 0 N--CA 1.484 1.248 0 N-CA-C 107.151 -1.425 . . . . 0.0 107.151 172.704 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.53 3.08 8.01 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 C-N-CA 120.901 1.068 . . . . 0.0 114.61 -174.026 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 145.57 54.93 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . 0.438 ' HB2' HD23 ' A' ' 124' ' ' LEU . 33.2 tt0 -128.57 128.22 43.82 Favored 'General case' 0 N--CA 1.486 1.372 0 O-C-N 124.232 0.958 . . . . 0.0 110.037 179.554 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.93 124.79 49.62 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.509 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . 0.694 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 118.88 21.84 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 107' ' ' HIS . . . . . 0.694 ' CE1' ' OH ' ' A' ' 70' ' ' TYR . 1.0 OUTLIER -150.11 170.67 18.35 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 121.949 0.88 . . . . 0.0 112.691 -177.034 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 108' ' ' CYS . . . . . 0.652 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -168.98 168.43 10.2 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 173.863 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.49 38.28 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -117.11 120.24 4.74 Favored Glycine 0 N--CA 1.448 -0.562 0 N-CA-C 105.047 -3.221 . . . . 0.0 105.047 177.018 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.77 111.31 34.4 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.86 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 124' ' ' LEU . . . . . 0.438 HD23 ' HB2' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.76 126.17 73.78 Favored Pre-proline 0 N--CA 1.489 1.483 0 C-N-CA 123.322 0.649 . . . . 0.0 110.881 -178.12 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.178 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.642 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' GLN . . . . . 0.642 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 125.51 12.15 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -136.66 152.8 50.81 Favored 'General case' 0 CA--C 1.493 -1.213 0 O-C-N 123.686 0.616 . . . . 0.0 109.894 -178.491 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 163.54 -163.43 35.66 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.694 -2.193 . . . . 0.0 113.208 178.947 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.4 179.94 46.25 Favored Glycine 0 N--CA 1.444 -0.812 0 C-N-CA 119.745 -1.217 . . . . 0.0 113.343 -176.912 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.25 35.05 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.506 -1.847 . . . . 0.0 107.908 -177.646 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . 0.485 HD12 ' O ' ' A' ' 118' ' ' SER . 0.0 OUTLIER -108.54 13.92 24.97 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 119.879 -1.763 . . . . 0.0 115.585 -175.579 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.79 -32.2 67.3 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.792 -1.963 . . . . 0.0 111.328 179.09 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.15 54.46 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 22.9 mt -104.76 16.14 26.57 Favored 'General case' 0 N--CA 1.484 1.251 0 N-CA-C 114.602 1.334 . . . . 0.0 114.602 -176.64 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -67.5 124.19 22.34 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.652 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.8 16.35 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -86.39 -12.79 10.97 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 CA-C-N 119.446 1.021 . . . . 0.0 112.251 178.85 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -151.62 160.55 43.6 Favored 'General case' 0 C--O 1.281 2.733 0 C-N-CA 119.128 -1.029 . . . . 0.0 112.471 -179.574 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 130.57 38.27 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -149.99 178.85 8.55 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.541 -177.928 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -136.76 164.81 27.4 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -176.03 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' HIS . . . . . 0.582 ' CE1' ' CD ' ' A' ' 68' ' ' GLU . 0.0 OUTLIER -142.03 152.23 61.21 Favored Pre-proline 0 N--CA 1.495 1.807 0 N-CA-C 107.161 -1.422 . . . . 0.0 107.161 174.534 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.1 3.08 7.93 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 N-CA-C 114.61 0.966 . . . . 0.0 114.61 -176.321 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 148.0 52.18 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . 0.744 ' HB3' HD23 ' A' ' 124' ' ' LEU . 17.1 pt-20 -136.31 135.83 39.23 Favored 'General case' 0 N--CA 1.465 0.319 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 176.593 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -106.28 124.79 50.13 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 -178.014 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . 0.709 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 119.69 22.91 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 107' ' ' HIS . . . . . 0.709 ' CE1' ' OH ' ' A' ' 70' ' ' TYR . 3.5 p80 -151.3 172.43 15.89 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 122.202 1.001 . . . . 0.0 112.503 -177.633 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 108' ' ' CYS . . . . . 0.603 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -170.13 168.43 8.35 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 174.428 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 118' ' ' SER . . . . . 0.485 ' O ' HD12 ' A' ' 50' ' ' LEU . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 120' ' ' CYS . . . . . 0.402 ' CB ' HD21 ' A' ' 50' ' ' LEU . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.41 38.42 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.93 120.24 4.75 Favored Glycine 0 N--CA 1.448 -0.535 0 N-CA-C 105.058 -3.217 . . . . 0.0 105.058 176.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.79 111.31 34.42 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.931 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 124' ' ' LEU . . . . . 0.744 HD23 ' HB3' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.56 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.48 126.15 74.53 Favored Pre-proline 0 N--CA 1.489 1.511 0 C-N-CA 123.444 0.698 . . . . 0.0 110.821 -178.148 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.65 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.801 0 C-N-CA 121.832 1.688 . . . . 0.0 112.97 -175.364 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' ALA . . . . . 0.642 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' GLN . . . . . 0.642 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 125.25 11.95 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -136.03 152.2 50.66 Favored 'General case' 0 CA--C 1.494 -1.177 0 O-C-N 123.809 0.693 . . . . 0.0 109.948 -178.28 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 163.82 -163.43 35.81 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.594 -2.241 . . . . 0.0 113.208 178.618 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.4 179.94 46.25 Favored Glycine 0 N--CA 1.444 -0.812 0 C-N-CA 119.745 -1.217 . . . . 0.0 113.343 -176.912 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.42 35.04 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.506 -1.847 . . . . 0.0 107.908 -177.646 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . 0.481 HD12 ' O ' ' A' ' 118' ' ' SER . 0.0 OUTLIER -108.8 14.11 24.51 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 119.907 -1.746 . . . . 0.0 115.637 -175.622 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.87 -32.2 67.44 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.796 -1.962 . . . . 0.0 111.328 178.98 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 -0.38 54.0 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 67.1 mt -104.03 16.1 27.03 Favored 'General case' 0 C--N 1.363 1.188 0 N-CA-C 114.868 1.433 . . . . 0.0 114.868 -177.309 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -67.16 124.19 21.91 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.773 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.89 16.41 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -86.37 -13.02 10.94 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.765 0 CA-C-N 119.652 1.115 . . . . 0.0 112.087 178.734 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -151.4 160.55 43.69 Favored 'General case' 0 C--O 1.281 2.733 0 C-N-CA 118.903 -1.119 . . . . 0.0 112.471 -179.428 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 131.24 41.38 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -151.05 -179.95 7.74 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.762 -0.653 . . . . 0.0 109.636 -178.348 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -137.54 165.17 26.95 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -175.479 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' HIS . . . . . 0.561 ' CE1' ' CD ' ' A' ' 68' ' ' GLU . 0.0 OUTLIER -143.25 153.01 59.08 Favored Pre-proline 0 N--CA 1.495 1.79 0 N-CA-C 106.942 -1.503 . . . . 0.0 106.942 173.967 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.25 3.08 7.96 Favored 'Trans proline' 0 C--N 1.278 -3.17 0 C-N-CA 120.841 1.027 . . . . 0.0 114.61 -175.432 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 148.14 52.0 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' GLU . . . . . 0.74 ' HB3' HD23 ' A' ' 124' ' ' LEU . 18.0 pt-20 -136.76 135.93 38.48 Favored 'General case' 0 N--CA 1.468 0.457 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 176.473 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -106.18 124.79 50.13 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 -177.833 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' TYR . . . . . 0.685 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 101' ' ' ILE . . . . . 0.422 ' HB ' ' HG2' ' A' ' 68' ' ' GLU . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 119.42 22.54 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 107' ' ' HIS . . . . . 0.685 ' CE1' ' OH ' ' A' ' 70' ' ' TYR . 3.7 p80 -150.77 172.2 15.99 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 122.184 0.992 . . . . 0.0 112.514 -177.549 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 108' ' ' CYS . . . . . 0.614 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -170.01 168.43 8.55 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 174.154 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 118' ' ' SER . . . . . 0.481 ' O ' HD12 ' A' ' 50' ' ' LEU . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.53 38.21 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -117.01 120.38 4.79 Favored Glycine 0 N--CA 1.447 -0.627 0 N-CA-C 105.094 -3.202 . . . . 0.0 105.094 176.992 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.96 111.31 34.51 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.924 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 124' ' ' LEU . . . . . 0.74 HD23 ' HB3' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.62 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.53 126.1 74.5 Favored Pre-proline 0 N--CA 1.489 1.511 0 C-N-CA 123.453 0.701 . . . . 0.0 110.821 -178.14 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.59 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.806 0 C-N-CA 121.775 1.65 . . . . 0.0 112.97 -175.369 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.642 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . 0.642 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.61 13.0 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -139.24 155.23 47.92 Favored 'General case' 0 CA--C 1.49 -1.346 0 N-CA-C 109.438 -0.578 . . . . 0.0 109.438 -179.313 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.41 -163.43 35.04 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 118.072 -2.013 . . . . 0.0 113.208 -179.736 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.38 179.97 46.24 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 119.724 -1.227 . . . . 0.0 113.298 -176.946 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 132.62 35.08 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . 0.266 0.3 OUTLIER -114.64 20.48 15.26 Favored 'General case' 0 C--N 1.317 -0.822 0 O-C-N 117.791 -3.068 . . . . 0.0 114.69 -176.029 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -55.34 -32.2 62.34 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 117.275 -1.77 . . . . 0.0 111.328 174.525 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.15 54.46 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -104.46 15.98 27.04 Favored 'General case' 0 N--CA 1.487 1.383 0 N-CA-C 114.49 1.293 . . . . 0.0 114.49 -176.45 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.01 124.19 22.96 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.484 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.45 16.11 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 2.5 m -84.81 -13.74 11.31 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.753 0 CA-C-N 118.634 0.652 . . . . 0.0 112.657 179.072 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.77 160.55 43.12 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.246 0.93 . . . . 0.0 112.471 -178.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 128.65 29.56 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -145.15 174.91 10.66 Favored 'General case' 0 CA--C 1.518 -0.285 0 CA-C-N 114.765 -1.107 . . . . 0.0 109.705 -175.92 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -135.01 165.06 26.22 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -179.46 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' HIS . . . . . 0.507 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.0 OUTLIER -144.47 154.15 56.27 Favored Pre-proline 0 N--CA 1.483 1.184 0 N-CA-C 106.993 -1.484 . . . . 0.0 106.993 172.714 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.29 3.08 7.97 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 C-N-CA 121.065 1.177 . . . . 0.0 114.61 -173.819 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 145.9 54.6 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.472 ' HB2' HD23 ' A' ' 124' ' ' LEU . 4.3 tt0 -128.62 128.11 43.53 Favored 'General case' 0 N--CA 1.479 1.011 0 O-C-N 124.479 1.112 . . . . 0.0 110.497 179.738 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -104.38 124.79 49.83 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.649 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . 0.676 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 118.59 21.58 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' HIS . . . . . 0.677 ' ND1' ' C ' ' A' ' 107' ' ' HIS . 1.2 p80 -149.42 170.24 19.02 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.949 0.88 . . . . 0.0 112.773 -176.889 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' CYS . . . . . 0.652 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -168.78 168.43 10.56 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 173.457 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.53 38.21 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -117.04 120.26 4.75 Favored Glycine 0 C--N 1.316 -0.569 0 N-CA-C 105.112 -3.195 . . . . 0.0 105.112 176.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.87 111.31 34.46 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' LEU . . . . . 0.472 HD23 ' HB2' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 202' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.68 0 CA-C-O 117.878 -1.058 . . . . 0.0 108.451 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.76 126.17 73.78 Favored Pre-proline 0 N--CA 1.489 1.483 0 C-N-CA 123.322 0.649 . . . . 0.0 110.881 -178.12 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.178 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.642 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . 0.642 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.44 12.88 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.93 154.89 48.38 Favored 'General case' 0 CA--C 1.49 -1.346 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 -179.235 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.59 -163.4 35.13 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 118.059 -2.02 . . . . 0.0 113.208 -179.847 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.35 179.94 46.2 Favored Glycine 0 N--CA 1.444 -0.774 0 C-N-CA 119.67 -1.252 . . . . 0.0 113.27 -176.916 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.1 35.05 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.479 ' H ' HD12 ' A' ' 50' ' ' LEU . 0.0 OUTLIER -108.97 14.24 24.21 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 119.579 -1.95 . . . . 0.0 115.235 -175.545 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.28 -32.2 66.39 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.778 -1.969 . . . . 0.0 111.328 178.741 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.13 54.45 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.2 mp -104.32 15.75 27.62 Favored 'General case' 0 N--CA 1.486 1.371 0 N-CA-C 114.494 1.294 . . . . 0.0 114.494 -176.292 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.1 124.19 23.08 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.329 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.47 16.12 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.425 HG11 ' CZ3' ' A' ' 202' ' ' TRP . 2.3 m -84.89 -13.68 11.29 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.781 0 O-C-N 123.766 0.667 . . . . 0.0 112.758 179.132 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.83 160.55 43.09 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.191 0.905 . . . . 0.0 112.471 -179.045 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 129.57 33.62 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' HIS . . . . . 0.455 ' CE1' ' NE2' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -147.89 175.47 10.93 Favored 'General case' 0 N--CA 1.446 -0.625 0 CA-C-N 114.785 -1.098 . . . . 0.0 110.259 -176.62 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . 0.544 ' C ' ' ND1' ' A' ' 64' ' ' HIS . 28.7 p -134.83 163.2 30.35 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -177.49 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' HIS . . . . . 0.878 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -135.22 147.17 61.18 Favored Pre-proline 0 N--CA 1.492 1.641 0 C-N-CA 123.984 0.914 . . . . 0.0 108.876 177.864 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -79.32 3.08 7.79 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 N-CA-C 114.61 0.966 . . . . 0.0 114.61 178.869 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 144.69 55.67 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.436 ' HB2' HD23 ' A' ' 124' ' ' LEU . 6.9 tt0 -126.49 125.0 41.35 Favored 'General case' 0 CA--C 1.553 1.081 0 O-C-N 124.891 1.37 . . . . 0.0 110.378 -178.93 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.06 124.79 49.19 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.179 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . 0.761 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 116.53 19.86 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' HIS . . . . . 0.796 ' HD1' ' N ' ' A' ' 108' ' ' CYS . 0.0 OUTLIER -144.39 164.67 30.15 Favored 'General case' 0 C--N 1.341 0.222 0 N-CA-C 114.273 1.212 . . . . 0.0 114.273 -175.004 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' CYS . . . . . 0.796 ' N ' ' HD1' ' A' ' 107' ' ' HIS . 7.3 p -166.16 168.43 15.35 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 170.626 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' SER . . . . . 0.467 ' O ' HD12 ' A' ' 50' ' ' LEU . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 150.93 39.24 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.35 120.15 4.77 Favored Glycine 0 N--CA 1.448 -0.505 0 N-CA-C 104.911 -3.276 . . . . 0.0 104.911 176.911 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.6 111.31 34.31 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -179.104 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 124' ' ' LEU . . . . . 0.436 HD23 ' HB2' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 202' ' ' TRP . . . . . 0.425 ' CZ3' HG11 ' A' ' 58' ' ' VAL . 1.3 m0 . . . . . 0 N--CA 1.49 1.561 0 CA-C-O 118.158 -0.925 . . . . 0.0 109.388 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.7 126.18 73.9 Favored Pre-proline 0 N--CA 1.489 1.477 0 C-N-CA 123.359 0.664 . . . . 0.0 110.852 -178.126 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.57 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.778 0 C-N-CA 121.855 1.704 . . . . 0.0 112.97 -175.232 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.642 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . 0.642 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.49 12.91 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.96 154.88 48.35 Favored 'General case' 0 CA--C 1.491 -1.301 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 -179.187 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.55 -163.4 35.1 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 118.014 -2.041 . . . . 0.0 113.208 -179.88 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.35 179.94 46.2 Favored Glycine 0 N--CA 1.444 -0.774 0 C-N-CA 119.67 -1.252 . . . . 0.0 113.27 -176.916 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.1 35.05 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.475 ' H ' HD12 ' A' ' 50' ' ' LEU . 0.0 OUTLIER -108.94 14.17 24.29 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 119.579 -1.95 . . . . 0.0 115.225 -175.501 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.29 -32.2 66.4 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.811 -1.955 . . . . 0.0 111.328 178.783 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.13 54.44 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.3 mp -104.25 15.71 27.75 Favored 'General case' 0 N--CA 1.486 1.351 0 N-CA-C 114.467 1.284 . . . . 0.0 114.467 -176.254 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.18 124.19 23.18 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.274 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.42 16.08 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 2.6 m -85.1 -13.47 11.26 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.829 0 CA-C-N 118.66 0.664 . . . . 0.0 112.707 179.222 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.74 160.55 43.13 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.205 0.911 . . . . 0.0 112.471 -179.195 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 129.64 33.92 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' HIS . . . . . 0.455 ' CE1' ' NE2' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -148.02 175.52 10.93 Favored 'General case' 0 N--CA 1.446 -0.655 0 CA-C-N 114.8 -1.091 . . . . 0.0 110.305 -176.644 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . 0.547 ' C ' ' ND1' ' A' ' 64' ' ' HIS . 28.7 p -134.85 163.14 30.5 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -177.416 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' HIS . . . . . 0.877 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -135.11 147.06 60.95 Favored Pre-proline 0 N--CA 1.493 1.692 0 C-N-CA 123.985 0.914 . . . . 0.0 108.875 177.891 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -79.25 3.08 7.77 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 N-CA-C 114.61 0.966 . . . . 0.0 114.61 178.826 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 144.74 55.64 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.438 ' HB2' HD23 ' A' ' 124' ' ' LEU . 6.6 tt0 -126.52 124.88 41.04 Favored 'General case' 0 CA--C 1.553 1.096 0 O-C-N 124.936 1.398 . . . . 0.0 110.433 -178.862 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.06 124.79 49.2 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.214 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . 0.762 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 116.41 19.78 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' HIS . . . . . 0.798 ' HD1' ' N ' ' A' ' 108' ' ' CYS . 0.0 OUTLIER -144.15 164.28 31.14 Favored 'General case' 0 C--N 1.342 0.246 0 N-CA-C 114.291 1.219 . . . . 0.0 114.291 -174.882 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' CYS . . . . . 0.798 ' N ' ' HD1' ' A' ' 107' ' ' HIS . 7.3 p -165.96 168.43 15.73 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 170.501 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' SER . . . . . 0.464 ' O ' HD12 ' A' ' 50' ' ' LEU . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.02 39.1 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.6 120.41 4.84 Favored Glycine 0 N--CA 1.448 -0.525 0 N-CA-C 104.938 -3.265 . . . . 0.0 104.938 176.782 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.66 111.31 34.34 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -179.002 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 124' ' ' LEU . . . . . 0.438 HD23 ' HB2' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 202' ' ' TRP . . . . . . . . . . . . . 1.5 m0 . . . . . 0 N--CA 1.488 1.436 0 CA-C-O 118.168 -0.92 . . . . 0.0 109.424 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.76 126.17 73.78 Favored Pre-proline 0 N--CA 1.489 1.483 0 C-N-CA 123.322 0.649 . . . . 0.0 110.881 -178.12 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.178 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.642 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . 0.642 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.44 12.88 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.93 154.89 48.38 Favored 'General case' 0 CA--C 1.49 -1.346 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 -179.235 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.59 -163.4 35.13 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 118.059 -2.02 . . . . 0.0 113.208 -179.847 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.35 179.94 46.2 Favored Glycine 0 N--CA 1.444 -0.774 0 C-N-CA 119.67 -1.252 . . . . 0.0 113.27 -176.916 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.15 35.05 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.48 ' H ' HD12 ' A' ' 50' ' ' LEU . 0.0 OUTLIER -109.05 14.23 24.13 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 119.538 -1.976 . . . . 0.0 115.281 -175.559 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.24 -32.2 66.3 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.773 -1.971 . . . . 0.0 111.328 178.73 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.13 54.45 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.1 mp -104.41 15.88 27.29 Favored 'General case' 0 N--CA 1.487 1.386 0 N-CA-C 114.465 1.283 . . . . 0.0 114.465 -176.273 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.14 124.19 23.13 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.395 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.51 16.15 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.447 HG11 ' CZ3' ' A' ' 202' ' ' TRP . 2.1 m -84.96 -13.72 11.26 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.794 0 CA-C-N 118.613 0.642 . . . . 0.0 112.707 179.16 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.74 160.55 43.13 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.166 0.893 . . . . 0.0 112.471 -179.025 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 129.57 33.62 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' HIS . . . . . 0.457 ' CE1' ' NE2' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -147.89 175.4 10.99 Favored 'General case' 0 N--CA 1.447 -0.596 0 CA-C-N 114.785 -1.098 . . . . 0.0 110.256 -176.587 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . 0.546 ' C ' ' ND1' ' A' ' 64' ' ' HIS . 28.7 p -134.79 163.16 30.42 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -177.495 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' HIS . . . . . 0.878 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -135.19 147.04 60.69 Favored Pre-proline 0 N--CA 1.492 1.671 0 C-N-CA 123.987 0.915 . . . . 0.0 108.842 177.932 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -79.24 3.08 7.77 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 N-CA-C 114.61 0.966 . . . . 0.0 114.61 178.861 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 144.74 55.64 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.434 ' HB2' HD23 ' A' ' 124' ' ' LEU . 6.5 tt0 -126.45 124.88 41.13 Favored 'General case' 0 CA--C 1.553 1.096 0 O-C-N 124.917 1.385 . . . . 0.0 110.428 -178.854 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.09 124.79 49.21 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.157 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . 0.763 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 116.51 19.84 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' HIS . . . . . 0.797 ' HD1' ' N ' ' A' ' 108' ' ' CYS . 0.0 OUTLIER -144.35 164.57 30.41 Favored 'General case' 0 C--N 1.341 0.2 0 N-CA-C 114.23 1.196 . . . . 0.0 114.23 -174.956 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' CYS . . . . . 0.797 ' N ' ' HD1' ' A' ' 107' ' ' HIS . 7.3 p -166.11 168.43 15.44 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 170.599 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 118' ' ' SER . . . . . 0.468 ' O ' HD12 ' A' ' 50' ' ' LEU . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 150.93 39.24 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.35 120.15 4.77 Favored Glycine 0 N--CA 1.448 -0.505 0 N-CA-C 104.911 -3.276 . . . . 0.0 104.911 176.911 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.6 111.31 34.31 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -179.104 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 124' ' ' LEU . . . . . 0.434 HD23 ' HB2' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 202' ' ' TRP . . . . . 0.447 ' CZ3' HG11 ' A' ' 58' ' ' VAL . 1.2 m0 . . . . . 0 N--CA 1.489 1.525 0 CA-C-O 118.193 -0.908 . . . . 0.0 109.332 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.56 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.66 126.16 74.06 Favored Pre-proline 0 N--CA 1.488 1.469 0 C-N-CA 123.413 0.685 . . . . 0.0 110.925 -178.224 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.56 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.766 0 C-N-CA 121.759 1.639 . . . . 0.0 112.97 -175.215 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.642 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . 0.642 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 125.24 11.94 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -135.8 152.1 50.75 Favored 'General case' 0 CA--C 1.494 -1.209 0 O-C-N 123.894 0.746 . . . . 0.0 110.059 -178.241 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 163.81 -163.46 35.82 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.502 -2.285 . . . . 0.0 113.208 178.453 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.43 179.98 46.29 Favored Glycine 0 N--CA 1.443 -0.886 0 C-N-CA 119.784 -1.198 . . . . 0.0 113.381 -176.95 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.28 35.04 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.532 -1.834 . . . . 0.0 107.908 -177.641 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.46 ' H ' HD12 ' A' ' 50' ' ' LEU . 0.0 OUTLIER -110.42 15.4 22.22 Favored 'General case' 0 N--CA 1.482 1.168 0 O-C-N 119.602 -1.936 . . . . 0.0 115.515 -175.456 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -56.98 -32.2 65.84 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 117.354 -1.739 . . . . 0.0 111.328 177.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.2 54.51 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.3 mp -104.69 16.06 26.76 Favored 'General case' 0 N--CA 1.486 1.337 0 N-CA-C 114.475 1.287 . . . . 0.0 114.475 -176.289 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.02 124.19 22.98 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.536 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.23 15.95 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 2.4 m -85.05 -13.51 11.27 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.906 0 CA-C-N 118.754 0.706 . . . . 0.0 112.498 179.237 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.48 160.55 43.24 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.402 1.001 . . . . 0.0 112.471 -179.223 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 126.35 21.06 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' HIS . . . . . 0.433 ' CE1' ' CD2' ' A' ' 64' ' ' HIS . 0.0 OUTLIER -139.94 169.29 17.99 Favored 'General case' 0 C--N 1.352 0.702 0 CA-C-N 113.504 -1.68 . . . . 0.0 110.459 -174.069 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -131.98 164.84 25.28 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 177.307 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' HIS . . . . . 0.572 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.0 OUTLIER -143.24 153.95 60.31 Favored Pre-proline 0 N--CA 1.485 1.312 0 N-CA-C 107.184 -1.413 . . . . 0.0 107.184 173.142 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.57 3.08 8.02 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 C-N-CA 120.772 0.981 . . . . 0.0 114.61 -174.869 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 145.15 55.36 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.554 ' OE2' ' CE2' ' A' ' 70' ' ' TYR . 6.0 tt0 -127.92 128.01 44.36 Favored 'General case' 0 N--CA 1.485 1.304 0 O-C-N 124.277 0.985 . . . . 0.0 109.613 179.932 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.97 124.79 49.64 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.127 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . 0.654 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 119.21 22.24 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' HIS . . . . . 0.685 ' ND1' ' C ' ' A' ' 107' ' ' HIS . 1.5 p80 -150.74 171.43 17.18 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 122.148 0.975 . . . . 0.0 112.529 -177.37 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' CYS . . . . . 0.658 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -169.38 168.43 9.55 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 174.213 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 118' ' ' SER . . . . . 0.44 ' O ' HD12 ' A' ' 50' ' ' LEU . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 120' ' ' CYS . . . . . 0.407 ' HB3' HD21 ' A' ' 50' ' ' LEU . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.44 38.35 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.96 120.32 4.77 Favored Glycine 0 N--CA 1.447 -0.608 0 N-CA-C 105.19 -3.164 . . . . 0.0 105.19 176.9 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.88 111.31 34.46 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.856 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 202' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.558 0 CA-C-O 117.596 -1.192 . . . . 0.0 108.238 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.63 126.28 73.84 Favored Pre-proline 0 N--CA 1.489 1.476 0 C-N-CA 123.354 0.662 . . . . 0.0 110.86 -178.172 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.65 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.801 0 C-N-CA 121.832 1.688 . . . . 0.0 112.97 -175.286 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.642 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . 0.642 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 125.51 12.15 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -136.69 152.67 50.64 Favored 'General case' 0 CA--C 1.492 -1.258 0 O-C-N 123.741 0.651 . . . . 0.0 109.9 -178.447 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 163.62 -163.43 35.7 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.728 -2.177 . . . . 0.0 113.208 178.978 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.38 179.97 46.24 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 119.724 -1.227 . . . . 0.0 113.298 -176.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 132.74 35.07 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . 0.263 0.3 OUTLIER -114.71 20.36 15.3 Favored 'General case' 0 N--CA 1.477 0.908 0 O-C-N 117.712 -3.117 . . . . 0.0 114.69 -176.107 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -55.24 -32.2 62.11 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 117.133 -1.827 . . . . 0.0 111.328 174.548 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 -0.15 54.19 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -103.1 14.9 30.76 Favored 'General case' 0 N--CA 1.49 1.565 0 N-CA-C 114.478 1.288 . . . . 0.0 114.478 -176.366 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.44 124.19 23.5 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -177.753 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.79 16.34 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.576 HG11 ' CZ3' ' A' ' 202' ' ' TRP . 0.1 OUTLIER -81.43 -17.27 11.98 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.906 0 O-C-N 125.025 1.453 . . . . 0.0 112.908 178.981 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -154.67 160.55 41.47 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 118.659 0.663 . . . . 0.0 112.471 -176.632 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 131.26 41.5 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -151.13 -179.79 7.62 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.784 -0.644 . . . . 0.0 109.575 -178.404 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -137.62 164.42 28.83 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -175.411 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' HIS . . . . . 0.579 ' CE1' ' CD ' ' A' ' 68' ' ' GLU . 0.0 OUTLIER -141.47 151.93 62.22 Favored Pre-proline 0 N--CA 1.496 1.835 0 N-CA-C 106.959 -1.497 . . . . 0.0 106.959 174.678 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -79.88 3.08 7.89 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 C-N-CA 120.77 0.98 . . . . 0.0 114.61 -176.587 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 147.9 52.31 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.762 ' HB3' HD23 ' A' ' 124' ' ' LEU . 14.0 pt-20 -136.06 135.12 39.12 Favored 'General case' 0 N--CA 1.47 0.554 0 N-CA-C 108.909 -0.775 . . . . 0.0 108.909 176.664 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -105.76 124.79 50.13 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 -178.162 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . 0.715 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 119.79 23.05 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' HIS . . . . . 0.715 ' CE1' ' OH ' ' A' ' 70' ' ' TYR . 3.4 p80 -151.82 172.51 16.05 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-O 122.15 0.976 . . . . 0.0 112.223 -177.616 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' CYS . . . . . 0.605 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -170.04 168.43 8.49 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 174.755 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.78 37.78 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -117.98 121.23 5.0 Favored Glycine 0 C--N 1.313 -0.737 0 N-CA-C 104.952 -3.259 . . . . 0.0 104.952 176.712 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -106.09 111.31 34.59 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.607 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 124' ' ' LEU . . . . . 0.762 HD23 ' HB3' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 202' ' ' TRP . . . . . 0.576 ' CZ3' HG11 ' A' ' 58' ' ' VAL . 40.8 m0 . . . . . 0 N--CA 1.49 1.553 0 CA-C-O 117.123 -1.417 . . . . 0.0 109.469 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.76 126.17 73.78 Favored Pre-proline 0 N--CA 1.489 1.483 0 C-N-CA 123.322 0.649 . . . . 0.0 110.881 -178.12 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.178 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.642 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . 0.642 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.46 12.89 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.93 154.93 48.39 Favored 'General case' 0 CA--C 1.491 -1.316 0 N-CA-C 109.571 -0.529 . . . . 0.0 109.571 -179.235 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.55 -163.43 35.12 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 118.07 -2.014 . . . . 0.0 113.208 -179.851 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.38 179.97 46.24 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 119.724 -1.227 . . . . 0.0 113.298 -176.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.15 35.05 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.481 ' H ' HD12 ' A' ' 50' ' ' LEU . 0.0 OUTLIER -109.14 14.34 23.96 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 119.504 -1.998 . . . . 0.0 115.235 -175.56 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.24 -32.2 66.3 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.773 -1.971 . . . . 0.0 111.328 178.645 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.1 54.42 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.2 mp -104.3 15.8 27.52 Favored 'General case' 0 N--CA 1.486 1.339 0 N-CA-C 114.497 1.295 . . . . 0.0 114.497 -176.321 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.12 124.19 23.11 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.343 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.48 16.13 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.462 HG11 ' CZ3' ' A' ' 202' ' ' TRP . 2.2 m -84.94 -13.64 11.29 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.777 0 CA-C-N 118.631 0.651 . . . . 0.0 112.719 179.124 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.83 160.55 43.09 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.183 0.901 . . . . 0.0 112.471 -179.052 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 129.6 33.75 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' HIS . . . . . 0.456 ' CE1' ' NE2' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -147.97 175.5 10.93 Favored 'General case' 0 N--CA 1.446 -0.655 0 CA-C-N 114.811 -1.086 . . . . 0.0 110.263 -176.649 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . 0.546 ' C ' ' ND1' ' A' ' 64' ' ' HIS . 28.7 p -134.83 163.15 30.46 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -177.435 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' HIS . . . . . 0.877 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -135.09 147.05 60.92 Favored Pre-proline 0 N--CA 1.493 1.676 0 C-N-CA 123.965 0.906 . . . . 0.0 108.857 177.954 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -79.28 3.08 7.78 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 N-CA-C 114.61 0.966 . . . . 0.0 114.61 178.782 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 144.74 55.64 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.436 ' HB2' HD23 ' A' ' 124' ' ' LEU . 6.7 tt0 -126.52 124.92 41.14 Favored 'General case' 0 CA--C 1.553 1.073 0 O-C-N 124.917 1.385 . . . . 0.0 110.392 -178.869 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.06 124.79 49.19 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.179 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . 0.763 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 116.53 19.86 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' HIS . . . . . 0.797 ' HD1' ' N ' ' A' ' 108' ' ' CYS . 0.0 OUTLIER -144.43 164.59 30.39 Favored 'General case' 0 C--N 1.341 0.222 0 N-CA-C 114.194 1.183 . . . . 0.0 114.194 -174.946 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' CYS . . . . . 0.797 ' N ' ' HD1' ' A' ' 107' ' ' HIS . 7.3 p -166.11 168.43 15.44 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 170.633 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 118' ' ' SER . . . . . 0.466 ' O ' HD12 ' A' ' 50' ' ' LEU . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 150.93 39.24 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.36 120.17 4.77 Favored Glycine 0 N--CA 1.448 -0.543 0 N-CA-C 104.982 -3.247 . . . . 0.0 104.982 176.852 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.6 111.31 34.31 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -179.057 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 124' ' ' LEU . . . . . 0.436 HD23 ' HB2' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 202' ' ' TRP . . . . . 0.462 ' CZ3' HG11 ' A' ' 58' ' ' VAL . 1.2 m0 . . . . . 0 N--CA 1.49 1.529 0 CA-C-O 118.114 -0.946 . . . . 0.0 109.31 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.56 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.67 126.1 74.18 Favored Pre-proline 0 N--CA 1.489 1.521 0 C-N-CA 123.428 0.691 . . . . 0.0 110.853 -178.135 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.234 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.642 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . 0.642 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.32 12.78 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.68 154.7 48.62 Favored 'General case' 0 CA--C 1.491 -1.295 0 N-CA-C 109.524 -0.547 . . . . 0.0 109.524 -179.151 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.69 -163.39 35.18 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 118.029 -2.034 . . . . 0.0 113.208 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.34 -179.94 46.27 Favored Glycine 0 N--CA 1.445 -0.703 0 C-N-CA 119.668 -1.254 . . . . 0.0 113.289 -176.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.22 133.29 35.01 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.48 -1.86 . . . . 0.0 107.908 -177.599 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.52 ' H ' HD12 ' A' ' 50' ' ' LEU . 0.0 OUTLIER -109.08 14.05 24.2 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 119.618 -1.926 . . . . 0.0 115.383 -175.627 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.18 -32.2 66.2 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.782 -1.967 . . . . 0.0 111.328 178.775 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.19 54.5 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.2 mp -104.59 15.98 26.96 Favored 'General case' 0 N--CA 1.486 1.353 0 N-CA-C 114.488 1.292 . . . . 0.0 114.488 -176.284 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.06 124.19 23.03 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.468 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.54 16.17 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.666 HG11 ' CZ3' ' A' ' 202' ' ' TRP . 2.1 m -85.07 -13.58 11.25 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.793 0 N-CA-C 112.816 0.673 . . . . 0.0 112.816 179.223 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.91 160.55 43.06 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.094 0.861 . . . . 0.0 112.471 -179.176 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 128.06 27.25 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -143.66 173.57 11.55 Favored 'General case' 0 CA--C 1.513 -0.471 0 CA-C-N 114.44 -1.255 . . . . 0.0 109.906 -175.516 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -134.3 165.5 24.98 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 179.569 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' HIS . . . . . 0.578 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.0 OUTLIER -145.43 154.39 52.98 Favored Pre-proline 0 N--CA 1.481 1.099 0 N-CA-C 107.255 -1.387 . . . . 0.0 107.255 172.404 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.33 3.08 7.97 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 C-N-CA 120.946 1.097 . . . . 0.0 114.61 -173.161 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 145.02 55.49 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.42 ' HB2' HD23 ' A' ' 124' ' ' LEU . 40.1 tt0 -128.36 128.5 44.64 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 123.766 0.666 . . . . 0.0 109.463 179.311 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.58 124.79 49.45 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.315 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . 0.725 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 118.75 21.72 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' HIS . . . . . 0.725 ' CE1' ' OH ' ' A' ' 70' ' ' TYR . 1.0 OUTLIER -149.16 170.15 19.1 Favored 'General case' 0 CA--C 1.518 -0.252 0 CA-C-O 122.108 0.956 . . . . 0.0 113.213 -176.9 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' CYS . . . . . 0.666 ' N ' ' HD1' ' A' ' 107' ' ' HIS . 7.3 p -168.97 168.43 10.21 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 173.215 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 118' ' ' SER . . . . . 0.503 ' O ' HD12 ' A' ' 50' ' ' LEU . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 120' ' ' CYS . . . . . 0.409 ' CB ' HD21 ' A' ' 50' ' ' LEU . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.05 39.04 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.48 119.89 4.67 Favored Glycine 0 N--CA 1.451 -0.357 0 N-CA-C 104.924 -3.27 . . . . 0.0 104.924 176.915 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.33 111.31 34.15 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -179.104 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 124' ' ' LEU . . . . . 0.42 HD23 ' HB2' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 202' ' ' TRP . . . . . 0.666 ' CZ3' HG11 ' A' ' 58' ' ' VAL . 8.6 m0 . . . . . 0 N--CA 1.489 1.507 0 CA-C-O 118.571 -0.728 . . . . 0.0 110.004 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.76 126.17 73.78 Favored Pre-proline 0 N--CA 1.489 1.483 0 C-N-CA 123.322 0.649 . . . . 0.0 110.881 -178.12 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.178 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.642 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . 0.642 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 125.59 12.22 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -136.81 152.82 50.72 Favored 'General case' 0 CA--C 1.493 -1.239 0 O-C-N 123.731 0.644 . . . . 0.0 109.904 -178.486 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 163.51 -163.43 35.64 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.685 -2.198 . . . . 0.0 113.208 179.012 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.4 179.94 46.25 Favored Glycine 0 N--CA 1.444 -0.812 0 C-N-CA 119.745 -1.217 . . . . 0.0 113.343 -176.912 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.15 35.05 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.506 -1.847 . . . . 0.0 107.908 -177.646 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.48 ' H ' HD12 ' A' ' 50' ' ' LEU . 0.0 OUTLIER -109.06 14.27 24.09 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 119.573 -1.955 . . . . 0.0 115.238 -175.519 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.28 -32.2 66.39 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.778 -1.969 . . . . 0.0 111.328 178.731 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 -0.04 54.29 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -103.75 15.44 28.77 Favored 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 114.438 1.273 . . . . 0.0 114.438 -176.428 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.15 124.19 23.14 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.135 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.61 16.22 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.601 HG11 ' CZ3' ' A' ' 202' ' ' TRP . 0.3 OUTLIER -82.23 -16.41 11.8 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.923 0 O-C-N 124.729 1.268 . . . . 0.0 112.874 179.103 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -154.24 160.55 41.86 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 118.833 0.742 . . . . 0.0 112.471 -177.258 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 128.09 27.37 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -143.84 173.58 11.57 Favored 'General case' 0 CA--C 1.516 -0.347 0 CA-C-N 114.512 -1.222 . . . . 0.0 109.911 -175.468 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -134.3 164.67 26.88 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 179.701 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' HIS . . . . . 0.536 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.0 OUTLIER -143.77 153.54 57.93 Favored Pre-proline 0 N--CA 1.484 1.272 0 N-CA-C 106.906 -1.516 . . . . 0.0 106.906 173.051 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -79.96 3.08 7.9 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 C-N-CA 121.104 1.203 . . . . 0.0 114.61 -174.226 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 143.61 56.24 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.511 ' HB3' ' HB ' ' A' ' 101' ' ' ILE . 0.1 OUTLIER -120.15 120.81 37.26 Favored 'General case' 0 N--CA 1.506 2.342 0 O-C-N 125.931 2.019 . . . . 0.0 111.397 -178.3 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -102.4 124.79 48.6 Favored 'General case' 0 N--CA 1.498 1.961 0 CA-C-N 120.735 1.607 . . . . 0.0 107.536 175.528 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . 0.65 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . 0.511 ' HB ' ' HB3' ' A' ' 68' ' ' GLU . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 118.89 21.85 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' HIS . . . . . 0.678 ' ND1' ' C ' ' A' ' 107' ' ' HIS . 1.4 p80 -150.2 170.72 18.3 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 121.961 0.886 . . . . 0.0 112.554 -177.01 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' CYS . . . . . 0.65 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -168.97 168.43 10.21 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 173.904 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 118' ' ' SER . . . . . 0.469 ' O ' HD12 ' A' ' 50' ' ' LEU . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.6 38.08 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -117.43 120.76 4.89 Favored Glycine 0 C--N 1.315 -0.629 0 N-CA-C 105.009 -3.236 . . . . 0.0 105.009 176.833 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.97 111.31 34.52 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.793 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 202' ' ' TRP . . . . . 0.601 ' CZ3' HG11 ' A' ' 58' ' ' VAL . 41.0 m0 . . . . . 0 N--CA 1.491 1.59 0 CA-C-O 117.526 -1.226 . . . . 0.0 109.664 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.56 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.82 126.18 73.62 Favored Pre-proline 0 N--CA 1.489 1.484 0 C-N-CA 123.354 0.661 . . . . 0.0 110.825 -178.075 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.171 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.642 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . 0.642 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.09 12.6 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.11 154.15 49.23 Favored 'General case' 0 CA--C 1.492 -1.281 0 N-CA-C 109.654 -0.498 . . . . 0.0 109.654 -178.96 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . 0.429 ' HA2' ' CE2' ' A' ' 202' ' ' TRP . . . 162.94 -163.4 35.32 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.941 -2.076 . . . . 0.0 113.208 179.714 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.35 179.94 46.2 Favored Glycine 0 N--CA 1.444 -0.774 0 C-N-CA 119.67 -1.252 . . . . 0.0 113.27 -176.916 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.08 35.05 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.479 ' H ' HD12 ' A' ' 50' ' ' LEU . 0.0 OUTLIER -108.89 14.16 24.37 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 119.555 -1.966 . . . . 0.0 115.229 -175.541 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.28 -32.2 66.39 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.778 -1.969 . . . . 0.0 111.328 178.794 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.16 54.47 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.3 mp -104.44 15.87 27.29 Favored 'General case' 0 N--CA 1.486 1.354 0 N-CA-C 114.482 1.29 . . . . 0.0 114.482 -176.296 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.1 124.19 23.08 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.397 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.56 16.18 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 2.4 m -85.24 -13.51 11.2 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.816 0 CA-C-N 118.648 0.658 . . . . 0.0 112.73 179.236 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.71 160.55 43.14 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.153 0.888 . . . . 0.0 112.471 -179.217 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 129.84 34.88 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -148.38 177.23 9.62 Favored 'General case' 0 CA--C 1.515 -0.366 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.712 -177.238 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -135.89 164.81 27.09 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -177.116 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -142.68 153.29 61.41 Favored Pre-proline 0 N--CA 1.495 1.808 0 N-CA-C 106.896 -1.52 . . . . 0.0 106.896 173.65 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.28 3.08 7.97 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 C-N-CA 120.818 1.012 . . . . 0.0 114.61 -175.614 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 145.11 55.39 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.427 ' HG3' HD23 ' A' ' 124' ' ' LEU . 0.3 OUTLIER -121.19 122.63 40.4 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 126.751 2.532 . . . . 0.0 112.971 -178.906 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -104.57 124.79 49.93 Favored 'General case' 0 N--CA 1.498 1.961 0 CA-C-N 120.444 1.475 . . . . 0.0 107.536 176.102 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . 0.704 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 118.97 21.93 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' HIS . . . . . 0.704 ' CE1' ' OH ' ' A' ' 70' ' ' TYR . 2.0 p80 -150.04 171.35 16.99 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 122.181 0.991 . . . . 0.0 112.555 -177.34 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' CYS . . . . . 0.663 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -169.44 168.43 9.46 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 173.792 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 118' ' ' SER . . . . . 0.47 ' O ' HD12 ' A' ' 50' ' ' LEU . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.23 38.73 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.69 120.21 4.76 Favored Glycine 0 N--CA 1.448 -0.539 0 N-CA-C 105.034 -3.226 . . . . 0.0 105.034 176.925 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.71 111.31 34.37 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 124' ' ' LEU . . . . . 0.427 HD23 ' HG3' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 202' ' ' TRP . . . . . 0.429 ' CE2' ' HA2' ' A' ' 47' ' ' GLY . 13.1 m0 . . . . . 0 N--CA 1.491 1.575 0 CA-C-O 117.229 -1.367 . . . . 0.0 109.439 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.7 126.13 74.03 Favored Pre-proline 0 N--CA 1.489 1.477 0 C-N-CA 123.359 0.664 . . . . 0.0 110.886 -178.126 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.2 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.642 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . 0.642 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.64 13.03 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -139.18 155.29 47.94 Favored 'General case' 0 CA--C 1.49 -1.356 0 N-CA-C 109.514 -0.551 . . . . 0.0 109.514 -179.329 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.33 -163.43 35.0 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 118.037 -2.03 . . . . 0.0 113.208 -179.801 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.4 179.93 46.24 Favored Glycine 0 N--CA 1.444 -0.812 0 C-N-CA 119.745 -1.217 . . . . 0.0 113.368 -176.912 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.14 132.47 35.09 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.514 -1.843 . . . . 0.0 107.908 -177.643 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . 0.263 0.3 OUTLIER -114.5 20.2 15.57 Favored 'General case' 0 C--N 1.312 -1.04 0 O-C-N 117.72 -3.112 . . . . 0.0 114.683 -175.974 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -55.07 -32.2 61.75 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 117.366 -1.734 . . . . 0.0 111.328 174.57 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 6.42 49.09 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . 0.424 ' HA ' HD12 ' A' ' 53' ' ' LEU . 1.0 OUTLIER -111.5 10.79 21.33 Favored 'General case' 2 N--CA 1.62 8.062 0 O-C-N 124.811 1.319 . . . . 0.0 111.199 -170.476 . . . . . . . . 4 4 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.04 124.19 23.01 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.244 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.34 16.03 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.594 HG11 ' CZ3' ' A' ' 202' ' ' TRP . 1.9 m -83.93 -14.51 11.51 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.919 0 O-C-N 124.134 0.896 . . . . 0.0 112.816 179.222 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -153.33 160.55 42.71 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.095 0.861 . . . . 0.0 112.471 -178.52 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 128.37 28.47 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -144.64 174.11 11.25 Favored 'General case' 0 CA--C 1.518 -0.274 0 CA-C-N 114.684 -1.144 . . . . 0.0 109.829 -175.619 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -134.54 164.89 26.46 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -179.772 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' HIS . . . . . 0.468 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.0 OUTLIER -144.39 154.07 56.44 Favored Pre-proline 0 N--CA 1.484 1.254 0 N-CA-C 106.895 -1.52 . . . . 0.0 106.895 172.617 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.09 3.08 7.93 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 C-N-CA 121.146 1.231 . . . . 0.0 114.61 -173.75 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 145.68 54.82 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.483 ' HB2' HD23 ' A' ' 124' ' ' LEU . 23.6 tt0 -128.93 128.44 43.76 Favored 'General case' 0 N--CA 1.478 0.945 0 O-C-N 124.052 0.845 . . . . 0.0 110.103 179.599 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -104.22 124.79 49.75 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.742 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . 0.695 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 142.11 29.27 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 14.6 tp -132.36 121.37 23.39 Favored 'General case' 2 C--N 1.468 5.722 0 N-CA-C 102.143 -3.28 . . . . 0.0 102.143 179.921 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 118.46 21.46 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' HIS . . . . . 0.695 ' CE1' ' OH ' ' A' ' 70' ' ' TYR . 0.7 OUTLIER -148.91 169.35 20.75 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 122.042 0.925 . . . . 0.0 113.172 -176.556 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' CYS . . . . . 0.645 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -168.41 168.43 11.25 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 173.111 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.49 38.28 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -117.19 120.96 4.98 Favored Glycine 0 N--CA 1.446 -0.684 0 N-CA-C 104.99 -3.244 . . . . 0.0 104.99 176.779 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -106.12 111.31 34.6 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.882 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 124' ' ' LEU . . . . . 0.483 HD23 ' HB2' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 202' ' ' TRP . . . . . 0.594 ' CZ3' HG11 ' A' ' 58' ' ' VAL . 3.3 m0 . . . . . 0 N--CA 1.487 1.386 0 CA-C-O 118.209 -0.901 . . . . 0.0 109.111 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.56 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.73 126.13 73.94 Favored Pre-proline 0 N--CA 1.489 1.477 0 C-N-CA 123.386 0.674 . . . . 0.0 110.882 -178.127 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.178 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.642 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . 0.642 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.48 12.9 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.96 154.88 48.35 Favored 'General case' 0 CA--C 1.491 -1.316 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 -179.202 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.58 -163.43 35.14 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 118.041 -2.028 . . . . 0.0 113.208 -179.852 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.38 179.97 46.24 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 119.724 -1.227 . . . . 0.0 113.298 -176.946 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.1 35.05 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.48 HD12 ' O ' ' A' ' 118' ' ' SER . 0.0 OUTLIER -108.52 13.92 25.0 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 119.751 -1.843 . . . . 0.0 115.39 -175.544 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.57 -32.2 66.9 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.774 -1.97 . . . . 0.0 111.328 179.044 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.19 54.5 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.6 mp -103.85 15.22 29.2 Favored 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 114.517 1.303 . . . . 0.0 114.517 -176.223 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.35 124.19 23.39 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -177.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.47 16.12 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.463 HG11 ' CZ3' ' A' ' 202' ' ' TRP . 2.2 m -84.85 -13.76 11.29 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.812 0 O-C-N 123.766 0.667 . . . . 0.0 112.705 179.169 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.83 160.55 43.09 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.198 0.908 . . . . 0.0 112.471 -178.996 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 129.44 33.01 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' HIS . . . . . 0.469 ' CE1' ' NE2' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -147.65 175.15 11.11 Favored 'General case' 0 N--CA 1.447 -0.607 0 CA-C-N 114.756 -1.111 . . . . 0.0 110.303 -176.527 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . 0.553 ' C ' ' ND1' ' A' ' 64' ' ' HIS . 28.7 p -134.64 163.1 30.51 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -177.615 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' HIS . . . . . 0.878 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -135.12 147.07 60.94 Favored Pre-proline 0 N--CA 1.492 1.666 0 C-N-CA 123.931 0.892 . . . . 0.0 108.831 177.9 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -79.23 3.08 7.77 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 CA-C-N 119.819 0.971 . . . . 0.0 114.61 178.861 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 144.74 55.64 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.44 ' HB2' HD23 ' A' ' 124' ' ' LEU . 6.9 tt0 -126.59 125.11 41.42 Favored 'General case' 0 CA--C 1.553 1.088 0 O-C-N 124.879 1.362 . . . . 0.0 110.342 -178.928 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.13 124.79 49.23 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.18 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . 0.762 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 116.39 19.77 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' HIS . . . . . 0.8 ' HD1' ' N ' ' A' ' 108' ' ' CYS . 0.0 OUTLIER -144.06 164.24 31.21 Favored 'General case' 0 C--N 1.341 0.224 0 N-CA-C 114.331 1.234 . . . . 0.0 114.331 -174.866 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' CYS . . . . . 0.8 ' N ' ' HD1' ' A' ' 107' ' ' HIS . 7.3 p -165.96 168.43 15.73 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 170.457 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 118' ' ' SER . . . . . 0.48 ' O ' HD12 ' A' ' 50' ' ' LEU . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 150.81 39.44 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.25 120.12 4.77 Favored Glycine 0 N--CA 1.448 -0.509 0 N-CA-C 104.894 -3.282 . . . . 0.0 104.894 176.863 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.52 111.31 34.26 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -179.107 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 124' ' ' LEU . . . . . 0.44 HD23 ' HB2' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 202' ' ' TRP . . . . . 0.463 ' CZ3' HG11 ' A' ' 58' ' ' VAL . 1.3 m0 . . . . . 0 N--CA 1.489 1.501 0 CA-C-O 118.272 -0.87 . . . . 0.0 109.396 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.61 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.8 126.03 74.01 Favored Pre-proline 0 N--CA 1.488 1.428 0 C-N-CA 123.358 0.663 . . . . 0.0 110.963 -178.117 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.46 107.32 2.36 Favored 'Trans proline' 0 C--N 1.323 -0.799 0 C-N-CA 121.836 1.691 . . . . 0.0 112.97 -175.1 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.642 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . 0.642 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.13 12.63 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.2 153.95 49.14 Favored 'General case' 0 CA--C 1.493 -1.233 0 O-C-N 123.524 0.515 . . . . 0.0 109.729 -178.841 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.99 -163.46 35.39 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.965 -2.064 . . . . 0.0 113.208 179.792 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.45 179.97 46.3 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 119.699 -1.239 . . . . 0.0 113.319 -176.95 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 132.53 35.08 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.506 -1.847 . . . . 0.0 107.908 -177.646 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . 0.266 0.3 OUTLIER -114.53 20.49 15.32 Favored 'General case' 0 C--N 1.316 -0.849 0 O-C-N 117.804 -3.06 . . . . 0.0 114.774 -175.974 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -55.47 -32.2 62.62 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 117.33 -1.748 . . . . 0.0 111.328 174.542 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.2 54.51 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.2 mp -104.2 15.71 27.79 Favored 'General case' 0 N--CA 1.488 1.448 0 N-CA-C 114.529 1.307 . . . . 0.0 114.529 -176.419 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.17 124.19 23.17 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.249 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.71 16.28 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.678 HG11 ' CZ3' ' A' ' 202' ' ' TRP . 1.6 m -84.97 -13.94 11.21 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.668 0 CA-C-N 118.669 0.668 . . . . 0.0 112.787 179.043 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.69 160.55 43.15 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.086 0.857 . . . . 0.0 112.471 -178.93 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 127.14 23.68 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -141.7 171.22 14.36 Favored 'General case' 0 C--N 1.351 0.634 0 CA-C-N 114.027 -1.442 . . . . 0.0 110.184 -174.718 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -133.0 165.53 24.52 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 178.347 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' HIS . . . . . 0.604 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.0 OUTLIER -145.55 154.04 52.07 Favored Pre-proline 0 N--CA 1.48 1.052 0 N-CA-C 107.208 -1.404 . . . . 0.0 107.208 172.63 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.17 3.08 7.94 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 C-N-CA 121.04 1.16 . . . . 0.0 114.61 -173.122 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 144.3 55.87 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 33.1 tt0 -126.3 127.34 45.42 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 124.286 0.991 . . . . 0.0 109.456 179.857 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.4 124.79 49.36 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 177.428 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . 0.713 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 119.08 22.07 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' HIS . . . . . 0.713 ' CE1' ' OH ' ' A' ' 70' ' ' TYR . 1.0 OUTLIER -150.21 171.04 17.58 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 122.16 0.981 . . . . 0.0 112.737 -177.18 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' CYS . . . . . 0.669 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -169.29 168.43 9.69 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 173.848 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 150.76 39.53 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.2 120.04 4.74 Favored Glycine 0 N--CA 1.448 -0.509 0 N-CA-C 104.947 -3.261 . . . . 0.0 104.947 176.857 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.46 111.31 34.22 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -179.058 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 202' ' ' TRP . . . . . 0.678 ' CZ3' HG11 ' A' ' 58' ' ' VAL . 11.6 m0 . . . . . 0 N--CA 1.488 1.449 0 CA-C-O 118.012 -0.994 . . . . 0.0 109.683 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.76 126.17 73.78 Favored Pre-proline 0 N--CA 1.489 1.483 0 C-N-CA 123.322 0.649 . . . . 0.0 110.881 -178.12 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.178 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.642 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . 0.642 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.44 12.88 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.93 154.89 48.38 Favored 'General case' 0 CA--C 1.49 -1.346 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 -179.235 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.59 -163.4 35.13 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 118.059 -2.02 . . . . 0.0 113.208 -179.847 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.35 179.94 46.2 Favored Glycine 0 N--CA 1.444 -0.774 0 C-N-CA 119.67 -1.252 . . . . 0.0 113.27 -176.916 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 132.59 35.08 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . . . . . . . . 0.268 0.3 OUTLIER -114.57 20.43 15.34 Favored 'General case' 0 C--N 1.316 -0.869 0 O-C-N 117.821 -3.049 . . . . 0.0 114.791 -176.067 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -55.34 -32.2 62.34 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 117.275 -1.77 . . . . 0.0 111.328 174.557 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.09 54.41 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.2 mp -104.13 15.67 27.92 Favored 'General case' 0 N--CA 1.486 1.357 0 N-CA-C 114.559 1.318 . . . . 0.0 114.559 -176.327 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.23 124.19 23.24 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.237 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.51 16.15 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.442 HG11 ' CZ3' ' A' ' 202' ' ' TRP . 2.2 m -84.97 -13.68 11.27 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.781 0 CA-C-N 118.613 0.642 . . . . 0.0 112.73 179.168 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.8 160.55 43.11 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.161 0.892 . . . . 0.0 112.471 -179.046 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 129.57 33.62 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' HIS . . . . . 0.456 ' CE1' ' NE2' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -147.89 175.47 10.93 Favored 'General case' 0 N--CA 1.446 -0.625 0 CA-C-N 114.785 -1.098 . . . . 0.0 110.259 -176.62 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . 0.546 ' C ' ' ND1' ' A' ' 64' ' ' HIS . 28.7 p -134.83 163.16 30.44 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -177.49 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' HIS . . . . . 0.877 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -135.18 147.04 60.72 Favored Pre-proline 0 N--CA 1.492 1.646 0 C-N-CA 124.013 0.925 . . . . 0.0 108.925 177.879 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -79.24 3.08 7.77 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 CA-C-N 119.809 0.968 . . . . 0.0 114.61 178.894 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 144.74 55.64 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.436 ' HB2' HD23 ' A' ' 124' ' ' LEU . 6.7 tt0 -126.52 124.92 41.14 Favored 'General case' 0 CA--C 1.553 1.073 0 O-C-N 124.917 1.385 . . . . 0.0 110.392 -178.869 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.06 124.79 49.19 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.179 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . 0.762 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 116.51 19.84 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' HIS . . . . . 0.796 ' HD1' ' N ' ' A' ' 108' ' ' CYS . 0.0 OUTLIER -144.39 164.61 30.32 Favored 'General case' 0 C--N 1.341 0.2 0 N-CA-C 114.211 1.189 . . . . 0.0 114.211 -174.976 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' CYS . . . . . 0.796 ' N ' ' HD1' ' A' ' 107' ' ' HIS . 7.3 p -166.11 168.43 15.44 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 170.633 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 150.93 39.24 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.34 120.12 4.76 Favored Glycine 0 N--CA 1.447 -0.596 0 N-CA-C 104.976 -3.249 . . . . 0.0 104.976 176.901 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.6 111.31 34.31 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -179.055 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 124' ' ' LEU . . . . . 0.436 HD23 ' HB2' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 202' ' ' TRP . . . . . 0.442 ' CZ3' HG11 ' A' ' 58' ' ' VAL . 1.3 m0 . . . . . 0 N--CA 1.49 1.557 0 CA-C-O 118.232 -0.89 . . . . 0.0 109.367 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.75 126.23 73.65 Favored Pre-proline 0 N--CA 1.489 1.483 0 C-N-CA 123.322 0.649 . . . . 0.0 110.847 -178.12 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.57 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.778 0 C-N-CA 121.855 1.704 . . . . 0.0 112.97 -175.211 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.642 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . 0.642 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 125.32 12.0 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -136.32 152.39 50.62 Favored 'General case' 0 CA--C 1.497 -1.084 0 O-C-N 123.731 0.644 . . . . 0.0 109.833 -178.296 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . 0.456 ' HA2' ' CE2' ' A' ' 202' ' ' TRP . . . 163.75 -163.4 35.75 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.651 -2.214 . . . . 0.0 113.208 178.775 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.35 179.94 46.2 Favored Glycine 0 N--CA 1.444 -0.774 0 C-N-CA 119.67 -1.252 . . . . 0.0 113.27 -176.916 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 132.45 35.08 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.577 HD12 ' O ' ' A' ' 118' ' ' SER . 0.0 OUTLIER -106.74 13.12 28.36 Favored 'General case' 0 N--CA 1.492 1.664 0 N-CA-C 115.597 1.702 . . . . 0.0 115.597 -175.034 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -58.91 -32.2 69.32 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 117.26 -1.776 . . . . 0.0 111.328 179.714 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 -0.23 54.12 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 47.9 mt -104.23 16.42 26.23 Favored 'General case' 0 C--N 1.364 1.224 0 N-CA-C 114.879 1.437 . . . . 0.0 114.879 -177.065 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -67.69 124.19 22.56 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.726 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.93 16.44 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.404 HG21 ' CZ3' ' A' ' 202' ' ' TRP . 0.1 OUTLIER -86.5 -12.96 10.91 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.621 0 CA-C-N 119.548 1.067 . . . . 0.0 112.281 178.766 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -151.41 160.55 43.69 Favored 'General case' 0 C--O 1.281 2.733 0 C-N-CA 119.023 -1.071 . . . . 0.0 112.471 -179.581 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 130.62 38.49 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -150.02 178.87 8.54 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.613 -0.721 . . . . 0.0 109.6 -177.933 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -136.78 164.82 27.38 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -176.04 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' HIS . . . . . 0.58 ' CE1' ' CD ' ' A' ' 68' ' ' GLU . 0.0 OUTLIER -142.21 152.38 61.0 Favored Pre-proline 0 N--CA 1.495 1.78 0 N-CA-C 107.12 -1.437 . . . . 0.0 107.12 174.393 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.1 3.08 7.93 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 N-CA-C 114.61 0.966 . . . . 0.0 114.61 -176.145 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 148.11 52.04 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.744 ' HB3' HD23 ' A' ' 124' ' ' LEU . 16.9 pt-20 -136.47 136.21 39.26 Favored 'General case' 0 CA--C 1.517 -0.304 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 176.452 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -106.53 124.79 50.13 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 -177.955 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . 0.71 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 119.69 22.91 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' HIS . . . . . 0.71 ' CE1' ' OH ' ' A' ' 70' ' ' TYR . 3.5 p80 -151.42 172.49 15.86 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 122.176 0.988 . . . . 0.0 112.399 -177.665 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' CYS . . . . . 0.61 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -170.1 168.43 8.39 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 174.521 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 118' ' ' SER . . . . . 0.577 ' O ' HD12 ' A' ' 50' ' ' LEU . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 120' ' ' CYS . . . . . 0.57 ' HB2' HD21 ' A' ' 50' ' ' LEU . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.5 38.26 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -117.01 120.25 4.75 Favored Glycine 0 N--CA 1.447 -0.627 0 N-CA-C 105.152 -3.179 . . . . 0.0 105.152 176.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.85 111.31 34.45 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.856 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 124' ' ' LEU . . . . . 0.744 HD23 ' HB3' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 202' ' ' TRP . . . . . 0.456 ' CE2' ' HA2' ' A' ' 47' ' ' GLY . 9.5 m0 . . . . . 0 N--CA 1.49 1.542 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.289 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.56 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.73 126.13 73.94 Favored Pre-proline 0 N--CA 1.489 1.477 0 C-N-CA 123.386 0.674 . . . . 0.0 110.882 -178.127 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.178 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.642 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . 0.642 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 125.55 12.18 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -136.67 152.65 50.64 Favored 'General case' 0 CA--C 1.493 -1.217 0 O-C-N 123.773 0.67 . . . . 0.0 109.94 -178.401 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 163.58 -163.46 35.7 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.683 -2.198 . . . . 0.0 113.208 178.939 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.45 179.97 46.3 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 119.699 -1.239 . . . . 0.0 113.319 -176.95 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.12 35.05 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.506 -1.847 . . . . 0.0 107.908 -177.646 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.478 ' H ' HD12 ' A' ' 50' ' ' LEU . 0.0 OUTLIER -108.96 14.19 24.26 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 119.604 -1.935 . . . . 0.0 115.302 -175.559 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.27 -32.2 66.37 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.805 -1.958 . . . . 0.0 111.328 178.773 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 -0.02 54.31 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -103.65 15.28 29.23 Favored 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 114.449 1.278 . . . . 0.0 114.449 -176.38 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.21 124.19 23.22 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.031 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.64 16.24 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.636 HG11 ' CZ3' ' A' ' 202' ' ' TRP . 0.2 OUTLIER -81.89 -16.77 11.88 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.958 0 O-C-N 124.906 1.379 . . . . 0.0 112.928 179.114 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -154.43 160.55 41.69 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 118.758 0.708 . . . . 0.0 112.471 -177.057 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 128.2 27.82 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -144.13 173.83 11.4 Favored 'General case' 0 CA--C 1.516 -0.334 0 CA-C-N 114.575 -1.193 . . . . 0.0 109.86 -175.556 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -134.43 164.77 26.69 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 179.886 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' HIS . . . . . 0.538 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.0 OUTLIER -143.85 153.6 57.73 Favored Pre-proline 0 N--CA 1.483 1.182 0 N-CA-C 106.989 -1.486 . . . . 0.0 106.989 173.042 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.04 3.08 7.92 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 C-N-CA 121.075 1.183 . . . . 0.0 114.61 -174.215 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 143.69 56.19 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.495 ' HB3' ' HB ' ' A' ' 101' ' ' ILE . 0.1 OUTLIER -120.08 120.78 37.25 Favored 'General case' 0 N--CA 1.507 2.385 0 O-C-N 125.999 2.062 . . . . 0.0 111.502 -178.315 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -102.49 124.79 48.68 Favored 'General case' 0 N--CA 1.498 1.961 0 CA-C-N 120.76 1.618 . . . . 0.0 107.536 175.493 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . 0.653 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . 0.495 ' HB ' ' HB3' ' A' ' 68' ' ' GLU . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 118.89 21.85 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' HIS . . . . . 0.677 ' ND1' ' C ' ' A' ' 107' ' ' HIS . 1.4 p80 -150.23 170.75 18.23 Favored 'General case' 0 C--N 1.322 -0.597 0 C-N-CA 119.462 -0.895 . . . . 0.0 112.54 -177.031 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' CYS . . . . . 0.65 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -168.96 168.43 10.23 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 173.932 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 118' ' ' SER . . . . . 0.468 ' O ' HD12 ' A' ' 50' ' ' LEU . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.6 38.08 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -117.43 120.76 4.89 Favored Glycine 0 C--N 1.315 -0.629 0 N-CA-C 105.009 -3.236 . . . . 0.0 105.009 176.833 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.97 111.31 34.52 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.793 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 124' ' ' LEU . . . . . . . . . . . . . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 202' ' ' TRP . . . . . 0.636 ' CZ3' HG11 ' A' ' 58' ' ' VAL . 41.6 m0 . . . . . 0 N--CA 1.491 1.586 0 CA-C-O 117.459 -1.258 . . . . 0.0 109.754 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.76 126.17 73.78 Favored Pre-proline 0 N--CA 1.489 1.483 0 C-N-CA 123.322 0.649 . . . . 0.0 110.881 -178.12 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.178 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.642 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . 0.642 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.44 12.88 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.93 154.88 48.38 Favored 'General case' 0 CA--C 1.49 -1.33 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 -179.204 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.59 -163.43 35.14 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 118.059 -2.02 . . . . 0.0 113.208 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.38 179.97 46.24 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 119.724 -1.227 . . . . 0.0 113.298 -176.946 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 132.99 35.06 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.485 -1.857 . . . . 0.0 107.908 -177.617 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.478 ' H ' HD12 ' A' ' 50' ' ' LEU . 0.0 OUTLIER -108.8 14.19 24.46 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 119.569 -1.957 . . . . 0.0 115.265 -175.538 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.35 -32.2 66.5 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.789 -1.965 . . . . 0.0 111.328 178.784 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.08 54.4 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 1.2 mp -104.43 15.98 27.07 Favored 'General case' 0 N--CA 1.487 1.389 0 N-CA-C 114.396 1.258 . . . . 0.0 114.396 -176.322 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.06 124.19 23.03 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.467 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.53 16.16 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.4 HG11 ' CZ3' ' A' ' 202' ' ' TRP . 2.5 m -85.06 -13.6 11.25 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.787 0 O-C-N 123.801 0.688 . . . . 0.0 112.737 179.241 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -152.86 160.55 43.08 Favored 'General case' 0 C--O 1.281 2.733 0 CA-C-N 119.187 0.903 . . . . 0.0 112.471 -179.11 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 129.64 33.92 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' HIS . . . . . 0.452 ' CE1' ' NE2' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -148.05 175.55 10.91 Favored 'General case' 0 N--CA 1.447 -0.601 0 CA-C-N 114.8 -1.091 . . . . 0.0 110.244 -176.666 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . 0.544 ' C ' ' ND1' ' A' ' 64' ' ' HIS . 28.7 p -134.85 163.16 30.44 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -177.385 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' HIS . . . . . 0.875 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.1 OUTLIER -135.14 147.03 60.76 Favored Pre-proline 0 N--CA 1.492 1.631 0 C-N-CA 124.031 0.932 . . . . 0.0 108.869 177.939 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -79.27 3.08 7.78 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 N-CA-C 114.61 0.966 . . . . 0.0 114.61 178.825 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 144.74 55.64 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.437 ' HB2' HD23 ' A' ' 124' ' ' LEU . 6.7 tt0 -126.52 124.92 41.14 Favored 'General case' 0 CA--C 1.553 1.073 0 O-C-N 124.917 1.385 . . . . 0.0 110.392 -178.869 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.06 124.79 49.19 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.179 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . 0.763 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 116.51 19.84 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 107' ' ' HIS . . . . . 0.797 ' HD1' ' N ' ' A' ' 108' ' ' CYS . 0.0 OUTLIER -144.35 164.57 30.41 Favored 'General case' 0 C--N 1.341 0.2 0 N-CA-C 114.23 1.196 . . . . 0.0 114.23 -174.956 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 108' ' ' CYS . . . . . 0.797 ' N ' ' HD1' ' A' ' 107' ' ' HIS . 7.3 p -166.11 168.43 15.44 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 170.599 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 118' ' ' SER . . . . . 0.466 ' O ' HD12 ' A' ' 50' ' ' LEU . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 120' ' ' CYS . . . . . 0.4 ' CB ' HD21 ' A' ' 50' ' ' LEU . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 150.99 39.15 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.52 120.47 4.86 Favored Glycine 0 N--CA 1.447 -0.616 0 N-CA-C 104.946 -3.261 . . . . 0.0 104.946 176.766 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.72 111.31 34.37 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -179.023 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 124' ' ' LEU . . . . . 0.437 HD23 ' HB2' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 202' ' ' TRP . . . . . 0.4 ' CZ3' HG11 ' A' ' 58' ' ' VAL . 1.7 m0 . . . . . 0 N--CA 1.487 1.416 0 CA-C-O 118.167 -0.921 . . . . 0.0 109.419 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.77 126.21 73.66 Favored Pre-proline 0 N--CA 1.49 1.534 0 C-N-CA 123.364 0.665 . . . . 0.0 110.762 -178.076 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.261 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.642 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . 0.642 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 126.24 12.72 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -138.28 154.41 49.04 Favored 'General case' 0 CA--C 1.488 -1.434 0 N-CA-C 109.662 -0.496 . . . . 0.0 109.662 -179.056 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 162.76 -163.46 35.26 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.972 -2.061 . . . . 0.0 113.208 179.738 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.47 179.82 46.22 Favored Glycine 0 N--CA 1.444 -0.785 0 C-N-CA 119.66 -1.257 . . . . 0.0 113.27 -176.858 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.07 133.07 35.09 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.494 -1.853 . . . . 0.0 107.908 -177.692 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.624 ' HB3' HD12 ' A' ' 53' ' ' LEU 0.286 0.3 OUTLIER -114.63 20.64 15.15 Favored 'General case' 0 N--CA 1.473 0.716 0 O-C-N 118.281 -2.762 . . . . 0.0 115.226 -176.201 . . . . . . . . 4 4 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -56.19 -32.2 64.14 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 117.243 -1.783 . . . . 0.0 111.328 174.709 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 -1.17 53.11 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . 0.624 HD12 ' HB3' ' A' ' 50' ' ' LEU . 59.6 mt -102.74 15.85 28.16 Favored 'General case' 0 CA--C 1.558 1.278 0 N-CA-C 114.876 1.436 . . . . 0.0 114.876 -176.903 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -68.13 124.19 23.12 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.321 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.76 16.32 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -86.07 -13.03 11.04 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.535 0 CA-C-N 119.284 0.947 . . . . 0.0 112.389 178.863 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -151.82 160.55 43.52 Favored 'General case' 0 C--O 1.281 2.733 0 C-N-CA 119.206 -0.998 . . . . 0.0 112.471 -179.452 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 128.16 27.67 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -144.0 173.81 11.39 Favored 'General case' 0 CA--C 1.519 -0.235 0 CA-C-N 114.543 -1.208 . . . . 0.0 109.778 -175.395 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -134.5 165.14 25.88 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 179.752 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' HIS . . . . . 0.543 ' N ' ' ND1' ' A' ' 64' ' ' HIS . 0.0 OUTLIER -144.3 154.34 57.08 Favored Pre-proline 0 N--CA 1.484 1.248 0 N-CA-C 107.151 -1.425 . . . . 0.0 107.151 172.704 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.53 3.08 8.01 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 C-N-CA 120.901 1.068 . . . . 0.0 114.61 -174.026 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 145.57 54.93 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.438 ' HB2' HD23 ' A' ' 124' ' ' LEU . 33.2 tt0 -128.57 128.22 43.82 Favored 'General case' 0 N--CA 1.486 1.372 0 O-C-N 124.232 0.958 . . . . 0.0 110.037 179.554 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -103.93 124.79 49.62 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 178.509 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . 0.694 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 118.88 21.84 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 107' ' ' HIS . . . . . 0.694 ' CE1' ' OH ' ' A' ' 70' ' ' TYR . 1.0 OUTLIER -150.11 170.67 18.35 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 121.949 0.88 . . . . 0.0 112.691 -177.034 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 108' ' ' CYS . . . . . 0.652 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -168.98 168.43 10.2 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 173.863 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 118' ' ' SER . . . . . . . . . . . . . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.49 38.28 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -117.11 120.24 4.74 Favored Glycine 0 N--CA 1.448 -0.562 0 N-CA-C 105.047 -3.221 . . . . 0.0 105.047 177.018 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.77 111.31 34.4 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.86 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 124' ' ' LEU . . . . . 0.438 HD23 ' HB2' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 202' ' ' TRP . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.488 1.45 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.57 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.76 126.17 73.78 Favored Pre-proline 0 N--CA 1.489 1.483 0 C-N-CA 123.322 0.649 . . . . 0.0 110.881 -178.12 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.52 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 121.854 1.702 . . . . 0.0 112.97 -175.178 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.642 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . 0.642 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 125.51 12.15 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -136.66 152.8 50.81 Favored 'General case' 0 CA--C 1.493 -1.213 0 O-C-N 123.686 0.616 . . . . 0.0 109.894 -178.491 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . 0.466 ' HA2' ' CE2' ' A' ' 202' ' ' TRP . . . 163.54 -163.43 35.66 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.694 -2.193 . . . . 0.0 113.208 178.947 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.4 179.94 46.25 Favored Glycine 0 N--CA 1.444 -0.812 0 C-N-CA 119.745 -1.217 . . . . 0.0 113.343 -176.912 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.25 35.05 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.506 -1.847 . . . . 0.0 107.908 -177.646 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.485 HD12 ' O ' ' A' ' 118' ' ' SER . 0.0 OUTLIER -108.54 13.92 24.97 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 119.879 -1.763 . . . . 0.0 115.585 -175.579 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.79 -32.2 67.3 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.792 -1.963 . . . . 0.0 111.328 179.09 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 0.15 54.46 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 22.9 mt -104.76 16.14 26.57 Favored 'General case' 0 N--CA 1.484 1.251 0 N-CA-C 114.602 1.334 . . . . 0.0 114.602 -176.64 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -67.5 124.19 22.34 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.652 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.8 16.35 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.406 HG21 ' CZ3' ' A' ' 202' ' ' TRP . 0.0 OUTLIER -86.39 -12.79 10.97 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 CA-C-N 119.446 1.021 . . . . 0.0 112.251 178.85 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -151.62 160.55 43.6 Favored 'General case' 0 C--O 1.281 2.733 0 C-N-CA 119.128 -1.029 . . . . 0.0 112.471 -179.574 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 130.57 38.27 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -149.99 178.85 8.55 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.541 -177.928 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -136.76 164.81 27.4 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -176.03 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' HIS . . . . . 0.582 ' CE1' ' CD ' ' A' ' 68' ' ' GLU . 0.0 OUTLIER -142.03 152.23 61.21 Favored Pre-proline 0 N--CA 1.495 1.807 0 N-CA-C 107.161 -1.422 . . . . 0.0 107.161 174.534 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.1 3.08 7.93 Favored 'Trans proline' 0 N--CA 1.414 -3.147 0 N-CA-C 114.61 0.966 . . . . 0.0 114.61 -176.321 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 148.0 52.18 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.744 ' HB3' HD23 ' A' ' 124' ' ' LEU . 17.1 pt-20 -136.31 135.83 39.23 Favored 'General case' 0 N--CA 1.465 0.319 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 176.593 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -106.28 124.79 50.13 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 -178.014 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . 0.709 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . . . . . . . . . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 119.69 22.91 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 107' ' ' HIS . . . . . 0.709 ' CE1' ' OH ' ' A' ' 70' ' ' TYR . 3.5 p80 -151.3 172.43 15.89 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 122.202 1.001 . . . . 0.0 112.503 -177.633 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 108' ' ' CYS . . . . . 0.603 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -170.13 168.43 8.35 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 174.428 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 118' ' ' SER . . . . . 0.485 ' O ' HD12 ' A' ' 50' ' ' LEU . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 120' ' ' CYS . . . . . 0.402 ' CB ' HD21 ' A' ' 50' ' ' LEU . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.41 38.42 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -116.93 120.24 4.75 Favored Glycine 0 N--CA 1.448 -0.535 0 N-CA-C 105.058 -3.217 . . . . 0.0 105.058 176.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.79 111.31 34.42 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.931 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 124' ' ' LEU . . . . . 0.744 HD23 ' HB3' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 202' ' ' TRP . . . . . 0.466 ' CE2' ' HA2' ' A' ' 47' ' ' GLY . 11.4 m0 . . . . . 0 N--CA 1.49 1.554 0 CA-C-O 117.175 -1.393 . . . . 0.0 109.408 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -2.542 0 CA-C-O 118.503 -0.707 . . . . 0.0 112.711 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -70.61 134.25 47.43 Favored 'General case' 0 N--CA 1.492 1.654 0 CA-C-N 121.984 2.175 . . . . 0.0 105.93 166.086 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 16.5 t0 -105.53 127.05 29.3 Favored Pre-proline 0 C--O 1.274 2.389 0 N-CA-C 103.932 -2.618 . . . . 0.0 103.932 -175.463 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.89 -18.95 58.53 Favored 'Trans proline' 0 CA--C 1.55 1.318 0 CA-C-N 119.718 0.935 . . . . 0.0 113.715 -173.685 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.4 mm-40 -85.84 -4.96 59.3 Favored 'General case' 0 CA--C 1.56 1.363 0 CA-C-O 117.597 -1.192 . . . . 0.0 112.454 -179.517 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 89.3 mt -125.83 132.52 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.521 3.078 0 N-CA-C 105.15 -2.167 . . . . 0.0 105.15 -170.396 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 70.6 t -118.53 115.74 49.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.225 0 CA-C-O 122.653 1.216 . . . . 0.0 107.746 169.378 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 25.2 mm-40 -104.02 -13.57 16.25 Favored 'General case' 0 N--CA 1.5 2.07 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.861 177.605 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' GLY . . . . . . . . . . . . . . . -82.12 72.09 2.86 Favored Glycine 0 CA--C 1.536 1.354 0 CA-C-O 122.769 1.205 . . . . 0.0 113.957 -177.383 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 96.8 mt -136.62 151.87 73.52 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 113.122 -1.539 . . . . 0.0 110.44 -166.679 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -70.96 170.26 64.49 Favored 'Cis proline' 0 C--O 1.267 1.947 0 CA-C-O 122.05 0.771 . . . . 0.0 112.765 -9.189 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 27.8 mt -105.97 105.88 54.93 Favored Pre-proline 0 C--N 1.296 -1.75 0 N-CA-C 106.135 -1.802 . . . . 0.0 106.135 176.192 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -84.99 118.04 1.99 Allowed 'Trans proline' 0 N--CA 1.432 -2.111 0 CA-C-O 122.214 0.839 . . . . 0.0 110.121 -175.19 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.46 137.82 51.0 Favored 'General case' 0 N--CA 1.427 -1.594 0 C-N-CA 124.232 1.013 . . . . 0.0 112.185 -177.409 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -66.22 126.33 28.36 Favored 'General case' 0 C--O 1.272 2.274 0 C-N-CA 119.031 -1.068 . . . . 0.0 111.884 174.241 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 87.6 t -131.31 137.52 55.34 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.392 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 -176.789 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.89 141.37 57.23 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 123.957 1.837 . . . . 0.0 111.568 -179.95 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 91.13 -21.43 34.44 Favored Glycine 0 CA--C 1.525 0.66 0 CA-C-N 114.27 -1.332 . . . . 0.0 115.934 -178.347 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -88.74 152.16 21.96 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 125.298 1.439 . . . . 0.0 108.569 -176.137 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -108.54 -6.93 15.86 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 115.02 1.489 . . . . 0.0 115.02 177.672 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -133.91 164.44 43.97 Favored Pre-proline 0 C--O 1.184 -2.392 0 N-CA-C 104.764 -2.309 . . . . 0.0 104.764 163.71 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -64.26 147.56 91.08 Favored 'Trans proline' 0 C--N 1.307 -1.606 0 C-N-CA 117.182 -1.412 . . . . 0.0 110.139 -176.692 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.48 126.15 74.53 Favored Pre-proline 0 N--CA 1.489 1.511 0 C-N-CA 123.444 0.698 . . . . 0.0 110.821 -178.148 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -73.65 107.32 2.37 Favored 'Trans proline' 0 C--N 1.323 -0.801 0 C-N-CA 121.832 1.688 . . . . 0.0 112.97 -175.364 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -94.58 141.42 28.62 Favored 'General case' 0 CA--C 1.511 -0.546 0 CA-C-O 125.038 2.351 . . . . 0.0 110.476 177.38 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.81 -32.41 7.63 Favored 'General case' 0 CA--C 1.487 -1.464 0 CA-C-N 112.941 -1.936 . . . . 0.0 112.929 170.061 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 82.8 mt -118.83 128.33 54.36 Favored 'General case' 0 C--O 1.274 2.345 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 170.02 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' THR . . . . . . . . . . . . . 68.1 p -121.53 158.11 29.22 Favored 'General case' 0 C--O 1.257 1.45 0 O-C-N 120.69 -1.256 . . . . 0.0 110.345 174.443 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' ALA . . . . . 0.642 ' H ' HE21 ' A' ' 44' ' ' GLN . . . -62.1 -23.37 66.49 Favored 'General case' 0 C--O 1.269 2.084 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -172.898 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.4 p-10 -90.72 -3.09 57.72 Favored 'General case' 0 C--O 1.272 2.282 0 N-CA-C 114.648 1.351 . . . . 0.0 114.648 -175.38 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' MET . . . . . . . . . . . . . 28.8 mtt -75.14 147.93 40.08 Favored 'General case' 0 C--O 1.255 1.349 0 N-CA-C 114.008 1.114 . . . . 0.0 114.008 176.69 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 52.27 39.7 27.62 Favored 'General case' 0 C--O 1.262 1.722 0 CA-C-N 114.439 -1.255 . . . . 0.0 113.001 173.266 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.19 0.11 81.68 Favored Glycine 0 C--O 1.284 3.223 0 N-CA-C 119.087 2.395 . . . . 0.0 119.087 179.944 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 127.64 120.31 2.31 Favored Glycine 1 N--CA 1.367 -5.902 0 O-C-N 120.715 -1.462 . . . . 0.0 112.394 179.717 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 78.8 mt -111.94 151.25 43.4 Favored Pre-proline 0 CA--C 1.487 -1.472 0 N-CA-C 114.158 1.17 . . . . 0.0 114.158 175.698 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -88.17 -1.9 7.01 Favored 'Trans proline' 0 N--CA 1.489 1.22 0 O-C-N 124.003 1.528 . . . . 0.0 115.863 -176.81 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 35.9 m -144.87 162.05 13.73 Favored 'Isoleucine or valine' 0 C--O 1.252 1.187 0 N-CA-C 107.762 -1.199 . . . . 0.0 107.762 -179.713 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' GLN . . . . . 0.642 HE21 ' H ' ' A' ' 35' ' ' ALA . 36.1 mt-30 -124.86 160.78 28.01 Favored 'General case' 0 C--O 1.248 1.023 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 172.238 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' LEU . . . . . . . . . . . . . 9.2 tt -147.38 125.25 11.95 Favored 'General case' 0 CA--C 1.48 -1.731 0 CA-C-O 118.794 -0.622 . . . . 0.0 110.59 -175.743 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -136.03 152.2 50.66 Favored 'General case' 0 CA--C 1.494 -1.177 0 O-C-N 123.809 0.693 . . . . 0.0 109.948 -178.28 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . 0.447 ' HA2' ' CE2' ' A' ' 202' ' ' TRP . . . 163.82 -163.43 35.81 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.594 -2.241 . . . . 0.0 113.208 178.618 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 175.4 179.94 46.25 Favored Glycine 0 N--CA 1.444 -0.812 0 C-N-CA 119.745 -1.217 . . . . 0.0 113.343 -176.912 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.9 tm-20 -83.15 133.42 35.04 Favored 'General case' 0 N--CA 1.43 -1.453 0 CA-C-N 112.506 -1.847 . . . . 0.0 107.908 -177.646 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.481 HD12 ' O ' ' A' ' 118' ' ' SER . 0.0 OUTLIER -108.8 14.11 24.51 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 119.907 -1.746 . . . . 0.0 115.637 -175.622 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 95.7 p -57.87 -32.2 67.44 Favored 'General case' 0 C--O 1.293 3.392 0 C-N-CA 116.796 -1.962 . . . . 0.0 111.328 178.98 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . . . . . . . . . 47.9 p -94.93 -0.38 54.0 Favored 'General case' 0 C--O 1.282 2.774 0 CA-C-N 120.191 1.36 . . . . 0.0 114.376 179.792 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 67.1 mt -104.03 16.1 27.03 Favored 'General case' 0 C--N 1.363 1.188 0 N-CA-C 114.868 1.433 . . . . 0.0 114.868 -177.309 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 73.8 t -67.16 124.19 21.91 Favored 'Isoleucine or valine' 0 C--O 1.265 1.905 0 N-CA-C 105.215 -2.143 . . . . 0.0 105.215 -178.773 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.46 8.36 87.82 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 117.843 -1.532 . . . . 0.0 114.252 -179.422 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 33.3 mttm -129.71 101.75 18.4 Favored Pre-proline 0 N--CA 1.491 1.624 0 CA-C-N 119.037 1.419 . . . . 0.0 110.465 -173.988 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 89.8 Cg_endo -80.05 143.89 16.41 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 CA-C-N 120.244 1.123 . . . . 0.0 111.246 -173.643 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -86.37 -13.02 10.94 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.765 0 CA-C-N 119.652 1.115 . . . . 0.0 112.087 178.734 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -151.4 160.55 43.69 Favored 'General case' 0 C--O 1.281 2.733 0 C-N-CA 118.903 -1.119 . . . . 0.0 112.471 -179.428 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -85.29 170.07 14.32 Favored Pre-proline 0 C--N 1.292 -1.917 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 168.354 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -52.9 131.24 41.38 Favored 'Trans proline' 0 CA--C 1.474 -2.502 0 O-C-N 122.217 0.588 . . . . 0.0 111.159 174.234 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -151.05 -179.95 7.74 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 115.762 -0.653 . . . . 0.0 109.636 -178.348 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 28.7 p -137.54 165.17 26.95 Favored 'General case' 0 C--O 1.271 2.232 0 N-CA-C 113.374 0.879 . . . . 0.0 113.374 -175.479 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' HIS . . . . . 0.561 ' CE1' ' CD ' ' A' ' 68' ' ' GLU . 0.0 OUTLIER -143.25 153.01 59.08 Favored Pre-proline 0 N--CA 1.495 1.79 0 N-CA-C 106.942 -1.503 . . . . 0.0 106.942 173.967 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -80.25 3.08 7.96 Favored 'Trans proline' 0 C--N 1.278 -3.17 0 C-N-CA 120.841 1.027 . . . . 0.0 114.61 -175.432 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 30.5 m -132.18 160.71 42.3 Favored 'Isoleucine or valine' 0 C--O 1.171 -3.034 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -178.433 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 95.7 m-20 -67.38 148.14 52.0 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 126.774 2.546 . . . . 0.0 108.704 175.212 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . 0.74 ' HB3' HD23 ' A' ' 124' ' ' LEU . 18.0 pt-20 -136.76 135.93 38.48 Favored 'General case' 0 N--CA 1.468 0.457 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 176.473 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 50.9 mt -106.18 124.79 50.13 Favored 'General case' 0 N--CA 1.498 1.961 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 -177.833 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' TYR . . . . . 0.685 ' OH ' ' CE1' ' A' ' 107' ' ' HIS . 11.5 m-85 -85.69 135.16 33.88 Favored 'General case' 0 N--CA 1.425 -1.714 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 170.321 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 30.2 tp -121.47 122.13 39.05 Favored 'General case' 0 CA--C 1.497 -1.067 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 171.988 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 96' ' ' PRO . 48.4 tp -116.67 122.67 45.23 Favored 'General case' 0 C--O 1.26 1.61 0 N-CA-C 107.445 -1.317 . . . . 0.0 107.445 -177.136 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . . . . . . . . . 27.5 m -132.64 156.57 42.48 Favored 'Isoleucine or valine' 0 C--O 1.257 1.481 0 O-C-N 122.044 -0.41 . . . . 0.0 110.376 179.045 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.9 t -157.67 153.22 22.35 Favored Pre-proline 0 N--CA 1.412 -2.363 0 O-C-N 121.072 -1.018 . . . . 0.0 109.344 174.194 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 89.0 Cg_exo -60.59 -35.93 87.83 Favored 'Trans proline' 0 C--O 1.261 1.667 0 C-N-CA 114.893 -2.938 . . . . 0.0 114.452 -173.914 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 -98.2 141.14 31.49 Favored 'General case' 0 C--N 1.288 -2.068 0 O-C-N 124.369 1.043 . . . . 0.0 110.356 173.269 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . . . . . . . . . 54.4 tttp -52.88 127.93 25.24 Favored 'General case' 0 C--O 1.261 1.677 0 N-CA-C 108.887 -0.783 . . . . 0.0 108.887 171.667 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 69.1 15.33 69.57 Favored Glycine 0 C--N 1.351 1.367 0 N-CA-C 117.168 1.627 . . . . 0.0 117.168 -177.417 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.6 -17.63 73.04 Favored Glycine 0 C--O 1.182 -3.112 0 N-CA-C 118.399 2.119 . . . . 0.0 118.399 177.737 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -133.77 144.88 49.31 Favored 'General case' 0 CA--C 1.481 -1.691 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 177.628 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 49.4 ttm-85 -137.62 135.83 36.95 Favored 'General case' 0 CA--C 1.481 -1.687 0 CA-C-O 117.088 -1.434 . . . . 0.0 109.886 176.801 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 17.9 pt -127.98 148.79 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 CA-C-N 120.839 1.654 . . . . 0.0 108.795 175.169 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . 0.493 ' OE2' ' NE2' ' A' ' 85' ' ' GLN . 49.0 tt0 -94.7 129.52 41.57 Favored 'General case' 0 CA--C 1.483 -1.63 0 O-C-N 125.564 1.79 . . . . 0.0 108.959 166.337 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -115.88 125.28 72.96 Favored 'Isoleucine or valine' 0 C--O 1.181 -2.519 0 CA-C-O 118.452 -0.785 . . . . 0.0 109.855 171.969 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' GLN . . . . . 0.493 ' NE2' ' OE2' ' A' ' 83' ' ' GLU . 86.2 mm-40 -88.17 124.0 33.38 Favored 'General case' 0 CA--C 1.481 -1.683 0 O-C-N 123.794 0.684 . . . . 0.0 111.021 168.134 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . 0.409 ' CD1' ' OG ' ' A' ' 105' ' ' SER . 6.1 tp -120.36 108.8 14.58 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 106.598 -1.631 . . . . 0.0 106.598 179.329 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 56.3 m-20 40.04 52.4 2.68 Favored 'General case' 0 N--CA 1.497 1.882 0 CA-C-O 124.811 2.244 . . . . 0.0 111.645 -174.376 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 79.31 1.23 85.62 Favored Glycine 0 N--CA 1.425 -2.097 0 N-CA-C 120.621 3.008 . . . . 0.0 120.621 178.35 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' ARG . . . . . . . . . . . . . 14.1 tpt180 -108.92 125.47 52.05 Favored 'General case' 0 N--CA 1.416 -2.134 0 CA-C-N 119.384 1.592 . . . . 0.0 108.367 -178.131 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 2.9 ttm-85 -71.62 133.08 45.47 Favored 'General case' 0 N--CA 1.478 0.928 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.117 179.336 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' HIS . . . . . . . . . . . . . 60.6 m80 -127.87 152.54 47.7 Favored 'General case' 0 C--O 1.192 -1.938 0 C-N-CA 126.302 1.841 . . . . 0.0 109.292 172.348 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -129.08 145.25 51.32 Favored 'General case' 0 C--N 1.29 -2.01 0 CA-C-O 121.653 0.739 . . . . 0.0 110.517 174.365 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' LEU . . . . . . . . . . . . . 36.9 mt -122.0 133.8 54.81 Favored 'General case' 0 N--CA 1.429 -1.481 0 C-N-CA 125.35 1.46 . . . . 0.0 110.443 176.716 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 54.0 tp -112.15 126.5 55.26 Favored 'General case' 0 C--O 1.25 1.105 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.991 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 94.2 p -64.1 145.97 97.71 Favored Pre-proline 0 N--CA 1.481 1.114 0 C-N-CA 118.43 -1.308 . . . . 0.0 111.662 -174.283 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . 0.409 ' HA ' ' O ' ' A' ' 72' ' ' LEU . 77.0 Cg_endo -80.73 141.63 55.64 Favored 'Cis proline' 0 N--CA 1.507 2.284 0 C-N-CA 128.565 0.652 . . . . 0.0 111.4 -9.745 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' ALA . . . . . . . . . . . . . . . -154.52 159.33 40.89 Favored 'General case' 0 C--N 1.362 1.14 0 CA-C-N 114.409 -1.269 . . . . 0.0 111.339 -179.677 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 70' ' ' TYR . 25.4 t -133.68 134.79 56.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 125.846 1.658 . . . . 0.0 108.533 174.684 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 28.2 ttt -131.14 131.4 44.07 Favored 'General case' 0 C--O 1.209 -1.069 0 CA-C-O 122.257 1.027 . . . . 0.0 110.035 176.711 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' ARG . . . . . . . . . . . . . 69.4 ttt-85 -83.19 132.75 35.05 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 114.078 -1.419 . . . . 0.0 113.022 174.441 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' ILE . . . . . 0.422 ' HB ' ' HG2' ' A' ' 68' ' ' GLU . 43.0 mm -116.57 103.02 53.11 Favored Pre-proline 0 C--O 1.265 1.909 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 176.446 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -57.37 147.23 78.76 Favored 'Trans proline' 0 C--O 1.201 -1.362 0 C-N-CA 121.08 1.187 . . . . 0.0 113.448 -177.88 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 103' ' ' ALA . . . . . . . . . . . . . . . -52.73 132.47 36.35 Favored 'General case' 0 N--CA 1.5 2.064 0 N-CA-C 106.702 -1.592 . . . . 0.0 106.702 175.191 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 104' ' ' GLY . . . . . . . . . . . . . . . 89.14 -16.93 54.46 Favored Glycine 0 C--O 1.262 1.861 0 O-C-N 125.714 1.883 . . . . 0.0 116.821 179.552 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.409 ' OG ' ' CD1' ' A' ' 86' ' ' LEU . 41.0 t -69.51 131.68 45.1 Favored 'General case' 0 CA--C 1.556 1.204 0 CA-C-O 117.54 -1.219 . . . . 0.0 108.965 -177.7 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -79.6 119.42 22.54 Favored 'General case' 0 C--O 1.249 1.031 0 N-CA-C 105.074 -2.195 . . . . 0.0 105.074 177.215 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 107' ' ' HIS . . . . . 0.685 ' CE1' ' OH ' ' A' ' 70' ' ' TYR . 3.7 p80 -150.77 172.2 15.99 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 122.184 0.992 . . . . 0.0 112.514 -177.549 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 108' ' ' CYS . . . . . 0.614 ' N ' ' ND1' ' A' ' 107' ' ' HIS . 7.3 p -170.01 168.43 8.55 Favored 'General case' 0 C--O 1.275 2.411 0 N-CA-C 105.705 -1.961 . . . . 0.0 105.705 174.154 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 12.1 p90 -129.77 158.13 40.28 Favored 'General case' 0 C--O 1.276 2.485 0 CA-C-O 122.487 1.137 . . . . 0.0 110.27 174.847 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 110' ' ' LEU . . . . . . . . . . . . . 53.0 tp -132.1 128.49 38.27 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-N 113.386 -1.734 . . . . 0.0 109.044 177.135 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 111' ' ' THR . . . . . . . . . . . . . 27.7 m -73.79 114.81 12.5 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-O 117.438 -1.268 . . . . 0.0 112.789 172.944 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 60.2 mt -96.78 -23.77 16.24 Favored 'General case' 0 N--CA 1.503 2.211 0 O-C-N 124.103 0.877 . . . . 0.0 112.944 177.277 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 113' ' ' GLU . . . . . . . . . . . . . 12.9 tp10 -153.52 143.25 21.89 Favored 'General case' 0 C--O 1.255 1.38 0 N-CA-C 106.186 -1.783 . . . . 0.0 106.186 177.809 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 114' ' ' ALA . . . . . . . . . . . . . . . -161.23 145.21 13.19 Favored 'General case' 0 C--O 1.254 1.339 0 CA-C-O 121.949 0.881 . . . . 0.0 108.681 175.203 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 115' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -107.54 173.02 6.5 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 114.216 -1.356 . . . . 0.0 110.086 168.636 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.2 t -60.26 126.58 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 CA-C-O 123.726 1.727 . . . . 0.0 106.74 171.773 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 117' ' ' GLY . . . . . . . . . . . . . . . 96.08 -3.58 64.57 Favored Glycine 1 N--CA 1.393 -4.189 0 N-CA-C 118.639 2.215 . . . . 0.0 118.639 -176.579 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 118' ' ' SER . . . . . 0.481 ' O ' HD12 ' A' ' 50' ' ' LEU . 61.2 m -70.61 136.3 49.08 Favored 'General case' 0 CA--C 1.498 -1.049 0 N-CA-C 107.316 -1.365 . . . . 0.0 107.316 173.572 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 119' ' ' TYR . . . . . . . . . . . . . 54.8 m-85 -130.63 142.89 50.45 Favored 'General case' 0 N--CA 1.48 1.035 0 C-N-CA 123.955 0.902 . . . . 0.0 110.931 175.646 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 43.6 t -121.94 129.58 52.64 Favored 'General case' 0 C--O 1.252 1.201 0 N-CA-C 106.881 -1.526 . . . . 0.0 106.881 163.709 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 121' ' ' PHE . . . . . . . . . . . . . 81.1 m-85 -119.21 151.53 38.21 Favored 'General case' 0 C--O 1.246 0.915 0 C-N-CA 125.188 1.395 . . . . 0.0 111.039 172.296 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 122' ' ' GLY . . . . . . . . . . . . . . . -117.01 120.38 4.79 Favored Glycine 0 N--CA 1.447 -0.627 0 N-CA-C 105.094 -3.202 . . . . 0.0 105.094 176.992 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 4.6 mp -105.96 111.31 34.51 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.039 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -178.924 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 124' ' ' LEU . . . . . 0.74 HD23 ' HB3' ' A' ' 68' ' ' GLU . 7.4 mt -92.66 122.45 35.09 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 -174.956 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 125' ' ' LEU . . . . . . . . . . . . . 91.1 mt -88.58 66.45 8.18 Favored 'General case' 0 N--CA 1.433 -1.288 0 CA-C-O 122.545 1.164 . . . . 0.0 110.607 -169.578 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 164.86 173.52 33.58 Favored Glycine 0 CA--C 1.473 -2.569 0 N-CA-C 109.551 -1.42 . . . . 0.0 109.551 -177.284 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 127' ' ' ASP . . . . . . . . . . . . . 41.3 p30 -102.32 6.25 40.31 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 179.571 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 128' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.3 153.65 26.88 Favored 'General case' 0 C--O 1.253 1.252 0 CA-C-N 119.835 1.198 . . . . 0.0 112.292 173.839 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 129' ' ' LEU . . . . . . . . . . . . . 91.3 mt . . . . . 0 CA--C 1.549 0.909 0 CA-C-N 113.83 -1.532 . . . . 0.0 108.448 168.255 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 201' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 202' ' ' TRP . . . . . 0.447 ' CE2' ' HA2' ' A' ' 47' ' ' GLY . 8.7 m0 . . . . . 0 N--CA 1.49 1.531 0 CA-C-O 117.146 -1.407 . . . . 0.0 109.176 . . . . . . . . . 1 1 . 1 stop_ save_